





The authors will present a comprehensive account of  the neurological aspects of  SARS-CoV-2 
infection. The aim is to provide a practical clinical book which will serve as a guide for clinicians 
from all specialties involved in the management of  COVID-19 patients. The authors share the 
extensive clinical experience gained in major hospitals in Lombardy, the first European region to 
face the COVID-19 emergency in 2020.  All are recognized international experts in their respective 
fields and have been involved in the management of  COVID-19 cases from the very beginning 
of  the Italian SARS-CoV-2 outbreak. The text begins with a description of  pathobiological and 
pathophysiological aspects related to the involvement of  the nervous system, moving on to the 
discussion of  the neurological complications observed in COVID-19 patients; these range from 
central to peripheral symptoms, and can occur in the acute or post-acute phases of  the disease. 
Further topics are: neuropathology, seizures and EEG, neuroimaging, delirium, encephalomyelitis, 
stroke, psychopathology and psychiatry, neuropsychology and cognitive impairment, neuromuscu-
lar disorders, and the impact of  COVID-19 on other pre-existing neurological disorders. In addi-
tion, the book will discuss the new developments in teleneurology approaches, which have been a 
direct response to the ongoing pandemic. Finally, the possible neurological complications of  the 
COVID-19 vaccines and the neurological complications in children will be considered.
Each chapter will present a critical review of  the existing literature concerning the specific subject 
matter, followed by practical clinical recommendations, as well as personal considerations based 
on the experience gained by each author during the course of  the COVID-19 pandemic.
“Neurology of  COVID-19” will be an original and innovative reference book for clinicians 
of  all the specialties involved in the management of  patients with SARS-CoV-2 infection.





































Neurology of  COVID-19 / Alberto Priori. Milano: Milano University Press, 2021.
ISBN 979-12-80325-33-4 (print)
ISBN 979-12-80325-35-8 (PDF)
ISBN 979-12-80325 37-2 (EPUB)
DOI 10.54103/milanoup.57
This volume, and Milano University Press publications in general, unless otherwise 
specified, are submitted to an external refereeing process under the responsibility of  
the Milano University Press Editorial Board. The works published are evaluated and 
approved by the Editorial Board of  the publishing house, and must be compliant with 
the Peer review policy, the Open Access, Copyright and Licensing policy and the Pub-
lication Ethics and Complaint policy as reflected in MilanoUP publishing guidelines 
(Linee Guida per pubblicare su MilanoUP).
The present work is released under Creative Commons Attribution 4.0 - CC-BY-ND, 
the full text of  which is available at the URL: https://creativecommons.org/licenses/
by-nd/4.0/deed.it.
 
 This and other volumes of  Milano University Press are available in open access at: 
https://libri.unimi.it/index.php/milanoup 
© Alberto Priori 
© Milano University Press 
Published by: 
Milano University Press




The print edition of  this volume can be ordered from all physical and online book-
stores, and is distributed by Ledizioni (www.ledizioni.it)
With the patronage of  the Società Italiana di Neurologia  
 
The book has been partly supported by “Aldo Ravelli” Research Center for Neurotech-
nology and Experimental Brain Therapeutics, University of  Milan, Italy.
Table of  contents
I. List of  Contributors XIII
II. Preface by Silvio Brusaferro XIX
III. Foreword by Gioacchino Tedeschi XXIII
IV. Introduction by Alberto Priori XXV
Chapter 1. SARS-CoV-2 and the nervous system: review  
on pathogenesis of  nervous system SARS-CoV-2 damage 1
SARS-CoV-2 and the nervous system: pathogenetic aspects 2
CNS impairment as a consequence of  a direct viral effect  4
Indirect CNS damage in the course of  SARS-CoV-2 infection:  
non-specific complications of  systemic disease  11
Indirect CNS damage during SARS-CoV-2 infection: para-infectious 
 and post-infectious immune-mediated disease 12
Brain regions affected by SARS-CoV-2 infection 13
Neuropathological findings of  COVID-19 patients 13
Conclusions 14
References 15
Chapter 2. The lung-brain axis 21
Introduction  21
Neurobiology and pathophysiology 21
Respiratory dysfunction and brainstem viral infections 22
Respiratory clinical physiology  24
Dyspnea: a complex symptom  25
Respiratory failure in COVID-19 26
Post-COVID clinical sequelae 27
Practical recommendations for the clinician 27
References 30
Chapter 3. Does the COVID-19 related respiratory failure have  
a neurogenic component? 33
Pathological pathways  33
Clinical features and possible treatments 36
Conclusions 40
References 41
Chapter 4. Neurological manifestations: an overview 45
Introduction 45
Neurological manifestations of  COVID-19 47
References 51
Chapter 5. Neuroimaging in COVID-19 55
Introduction 55
Prevalence of  abnormal neuroimaging findings 55
Macrovascular pathology 56
White matter abnormalities 59
Diffusion abnormalities 59
Susceptibility weighted imaging abnormalities 59
Perfusion abnormalities 60
Pathological contrast-enhancement 61
Encephalitis and encephalitis-like abnormalities 61
Practical implications in neuroimaging of  COVID-19 neuropathology 63
References 64
Chapter 6. Neuropathology 67
The state of  the art 67
Autopsy, biopsy, fixation and gross pathology 68
Neuronal, glial and vascular histological damages 72
Viral entry pathways into the CNS 77
Conclusions 77
References 80
Chapter 7. Encephalomyelitis in COVID-19 83
Introduction 83
Encephalitis and myelitis as a possible manifestation of  the disease 84
Mechanisms of  COVID-19-related encephalomyelitis 89
Conclusive remarks 91
References 93
Chapter 8. Stroke 97
Introduction 97
Epidemiology 97
COVID-19 and cerebral vascular disease: pathophysiological mechanisms 99
Risk factor of  stroke in COVID-19 patients 101
COVID-19 and stroke characteristics 102
Stroke therapy in COVID-19 patients 103
Outcome 104
COVID-19 and hemorrhagic stroke 105
Niguarda Hospital, Milan: the COVID-19 experience 105
Stroke care and assisting patients with COVID-19 infection 106
References 107
Chapter 9. Seizures and EEG 113
Introduction 113
EEG findings 113
Technical recommendations for EEG 115
Mechanisms of  seizures in SARS-CoV-2 116
Seizures and SARS-CoV-2 119




Chapter 10. Delirium 129
Background and epidemiology 129
Pathogenesis 130
Clinical features and implications 132
Potential factors contributing to delirium during the COVID-19 pandemic 133
Diagnostic work-up 135
Treatment strategies 138
Outcome and long-term complications 139
References 142




Obsessive-compulsive disorder  152
Eating disorders 155
Autism spectrum disorders  159
Somatic symptom and related disorders 162
References 169
Chapter 12. Cognitive dysfunction and rehabilitation 177
Introduction 177
Rationale for cognitive dysfunction in COVID-19 178




Chapter 13. Disorders of  cranial and spinal nerves 195
Non-length dependent neuropathies: Guillain-Barré-Strohl syndrome  
and COVID-19  195
Length-dependent neuropathies 196
Isolated involvement of  the cranial nerves 198
Practical recommendations for clinicians and personal experience 201
References 202
Chapter 14. COVID-19-related myopathy 207
Introduction 207









Teleneurology for long-term care facilities 229
Telerehabilitation 230
New digital technologies  230
Training and educational teleneurology 231
Practical implications and future directions  232
References  234
Chapter 16. Impact of  COVID-19 on pre-existing neurological diseases 243
Introduction 243
Neuroinflammatory and neuro-oncological diseases 243
Cerebrovascular diseases 247
Epilepsy 248
Dementia and movement disorders 249
Reflections on COVID-19 vaccination in frail neurological patient 255
References 257
Chapter 17. Neurological complications of  vaccines for COVID-19 265
Safety definitions 266
Neurological complications of  COVID-19 vaccines in clinical trials 267
Post-marketing surveillance of  neurological complications of  




Chapter 18. Neuro-COVID in children 281
Introduction 281
Neurological manifestations of  COVID-19 in children 282
Neurological manifestations in Multisystem Inflammatory Syndrome 
in Children  291
Conclusions and clinical work-up   292
Therapeutic recommendation and prognosis 293
References  295
General note on figures and tables
Unless otherwise indicated, figures and tables have been prepared by the au-
thor(s) of  the chapter in question. 
The Editor is committed to striving to satisfy all copyright requirements con-
cerning graphics, images and tables for which it has not been possible to iden-





Professor of  Neurology
Director of  “Aldo Ravelli” Research Center for Neurotechnology and Experi-
mental Brain Therapeutics, Department of  Health Sciences, University of  Mi-
lan, Milan, Italy;
Director of  Neurology Unit I, San Paolo University Hospital, ASST Santi Paolo 




“Aldo Ravelli” Research Center for Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health Sciences, University of  Milan, Milan, Italy. 

List of  Contributors
Elio Agostoni
Director of  Neuroscience Department and 
Niguarda Neuro Center, Milan, Italy; 
Director of  Neurology and Stroke Unit, ASST 





School of  Medicine and Surgery, University 
of  Milano-Bicocca, Monza, Italy; 
NeuroMI (Milan Center for Neuroscience), 
Milan, Italy; 
San Gerardo Hospital, ASST Monza, Monza, Italy. 
Email: paola.alberti@unimib.it
Francesca Bai
Clinic of  Infectious Diseases, Department of  
Health Sciences, ASST Santi Paolo e Carlo, 
University of  Milan, Milan, Italy. 
Email: francesca.bai@unimi.it
Beatrice Benatti
Luigi Sacco University Hospital, Psychiatry 2 
Unit, University of  Milan, Milan, Italy; 
“Aldo Ravelli” Center for Neurotechnology 
and Experimental Brain Therapeutics, 
Department of  Health Sciences, University 
of  Milan, Milan, Italy. 
Email: beatrice.benatti@unimi.it
Maria Donata Benedetti
Neurology Unit, Department of  
Neuroscience, Biomedicine and Movement 
Sciences, University of  Verona, Verona, Italy. 
Email: mariadonata.benedetti@univr.it
Alberto Benussi
Neurology Unit, Department of  Clinical and 
Experimental Sciences, ASST Spedali Civili of  
Brescia and University of  Brescia, Brescia, Italy.
email: alberto.benussi@unibs.it
Simone Beretta 
School of Medicine and Surgery, University of  
Milano-Bicocca, Monza, Italy; 
NeuroMI (Milan Center for Neuroscience), Milan, 
Italy; 
San Gerardo Hospital, ASST Monza, Monza, Italy. 
Email: beretta.simone@gmail.com
Elisabetta Bernardi
Neurology Unit I, San Paolo University 
Hospital, ASST Santi Paolo e Carlo, 
University of  Milan, Milan, Italy. 
Email: elisabetta.bernardi@unimi.it
Laura Bertolasi
Neurology Unit, Department of  
Neuroscience, Biomedicine and Movement 
Sciences, University of  Verona, Verona, Italy. 
Email: laura.bertolasi@aovr.veneto.it
Tommaso Bocci
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health 
Sciences, University of  Milan, Milan, Italy;
Neurology Unit I, San Paolo University 




Department of  Anesthesia and Intensive 
Care, ASST Santi Paolo e Carlo, San Paolo 
University Hospital, Milan, Italy. 
Email: matteo.bonifazi@unimi.it
Laura Brighina
NeuroMI (Milan Center for Neuroscience), 
Milan, Italy; 
San Gerardo Hospital, ASST Monza, Monza, 
Italy. 
Email: brighina.laura@asst-monza.it
XIV Neurology of  COVID-19
Silvio Brusaferro
President of  the Italian National Institute of  
Health, Rome, Italy;
Full Professor of  Hygiene and Public Health, 
University of  Udine, Udine, Italy.
Email: presidenza@iss.it
Gaetano Pietro Bulfamante
Professor of  Pathological Anatomy 
Pathological Anatomy Unit, Department of  
Health Sciences, University of  Milan, Milan, 
Italy; 
Human Pathology Unit, ASST Santi Paolo e 




Neurology Unit I, San Paolo University 




Professor of  Child Neurology 
Epilepsy Center – Sleep Medicine Center, 
Childhood and Adolescence Neuropsychiatry 
Unit, ASST Santi Paolo e Carlo, San Paolo 
University Hospital, Milan, Italy; 
Department of  Health Sciences, University 
of  Milan, Milan, Italy. 
Email: mariapaola.canevini@unimi.it 
Laura Carpenito




Department of  Neurology and Stroke Unit, 
ASST Grande Ospedale Metropolitano 
Niguarda, Milan, Italy. 
Email: angelo.casciorizzo@ospedaleniguarda.it
Stefano Centanni
Professor of  Respiratory Medicine 
Respiratory Unit, ASST Santi Paolo e Carlo, 
San Paolo University Hospital, Department 




Epilepsy Center, ASST Santi Paolo e Carlo, 
San Paolo University Hospital, Milan, Italy. 
Email: valentina.chiesa@asst-santipaolocarlo.it
Davide Chiumello
Associate Professor of  Anesthesiology 
Department of  Anesthesia and Intensive 
Care, ASST Santi Paolo e Carlo, San Paolo 
University Hospital, Milan, Italy. 
Email: davide.chiumello@unimi.it
Giacomo Pietro Comi
Professor of  Neurology 
Dino Ferrari Centre, Neuroscience Section, 
Department of  Pathophysiology and 
Transplantation (DEPT), University of  Milan, 
Milan, Italy; 
Neurology Unit, Foundation IRCCS Ca’ 




Dino Ferrari Centre, Neuroscience Section, 
Department of  Pathophysiology and 




Professor of  Infectious Diseases 
Clinic of  Infectious Diseases, Department of  
Health Sciences, ASST Santi Paolo e Carlo, 
University of  Milan, Milan, Italy. 
Email: antonella.darminio@unimi.it
XVList of  Contributors
Bernardo Dell’Osso
Associate Professor of  Psychiatry 
Luigi Sacco University Hospital, Psychiatry 2 
Unit, University of  Milan, Milan, Italy; 
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health Sciences, 
University of  Milan, Milan, Italy; 
Department of  Psychiatry and Behavioral 
Sciences, Stanford University, Stanford, 
California, USA; 
Centro per lo studio dei meccanismi molecolari 
alla base delle patologie neuro-psicogeriatriche”, 
University of  Milan, Milan, Italy. 
Email: bernardo.dellosso@unimi.it
Benedetta Demartini
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health 
Sciences, University of  Milan, Milan, Italy; 
Psychiatry 52 Unit, ASST Santi Paolo e Carlo, 
San Paolo University Hospital, Milan, Italy. 
Email: benedetta.demartini@unimi.it
Michelangelo Dini
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health 




School of Medicine and Surgery, University of  
Milano-Bicocca, Monza, Italy; 
NeuroMI (Milan Center for Neuroscience), Milan, 
Italy; 
San Gerardo Hospital, ASST Monza, Monza, Italy. 
Email: carlo.ferrarese@unimib.it
Roberta Ferrucci
Associate Professor of  Psychology.
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health 
Sciences, University of  Milan, Milan, Italy;
Neurology Unit I, San Paolo University 
Hospital, ASST Santi Paolo e Carlo, Milan, Italy. 
Email: roberta.ferrucci@unimi.it
Orsola Gambini
Professor of  Psychiatry 
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health 
Sciences, University of  Milan, Milan, Italy; 
Psychiatry 52 Unit, ASST Santi Paolo e Carlo, 
San Paolo University Hospital, Milan, Italy. 
Email: orsola.gambini@unimi.it
Nicolaja Girone
Luigi Sacco University Hospital, Psychiatry 2 
Unit, University of  Milan, Milan, Italy.
Email: girone.nicolaja@asst-fbf-sacco.it
Giuditta Giussani
Department of  Neurology and Stroke Unit, 




Department of  Neurology and Stroke Unit, 





School of  Medicine and Surgery, University 
of  Milano-Bicocca, Monza, Italy; 




Department of  Neurology and Stroke Unit, 




Neurology Unit I, San Paolo University 
Hospital, ASST Santi Paolo e Carlo, 
University of  Milan, Milan, Italy. 
Email: fabrizio.luiso@unimi.it
XVI Neurology of  COVID-19
Chiara Manfredi
Neurology Unit I, San Paolo University 




Associate Professor of  Infectious Diseases 
Clinic of  Infectious Diseases, Department of  
Health Sciences, ASST Santi Paolo e Carlo, 
University of  Milan, Milan, Italy. 
Email: giulia.marchetti@unimi.it
Sara Meoni
Université Grenoble Alpes, Inserm, 
CHU Grenoble Alpes, Grenoble Institut 
Neurosciences, Grenoble, France; 
Movement Disorders Unit, Division of  
Neurology, CHU Grenoble Alpes, Grenoble, 
France; 
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health 
Sciences, University of  Milan, Milan, Italy. 
Email: smeoni@chu-grenoble.fr 
Elena Moro
Professor of  Neurology 
Université Grenoble Alpes, Inserm, 
CHU Grenoble Alpes, Grenoble Institut 
Neurosciences, Grenoble, France; 
Movement Disorders Unit, Division of  
Neurology, CHU Grenoble Alpes, Grenoble, 
France; 
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health 
Sciences, University of  Milan, Milan, Italy. 
Email: emoro@chu-grenoble.fr
Veronica Nisticò
“Aldo Ravelli” Research Center for 
Neurotechnology and Experimental Brain 
Therapeutics, Department of  Health 
Sciences, University of  Milan, Milan, Italy. 
Email: veronica.nistico@unimi.it
Alessandro Padovani
Professor of  Neurology 
Neurology Unit, Department of  Clinical and 
Experimental Sciences, ASST Spedali Civili 




Department of  Health Sciences, University 
of  Milan, Milan, Italy; 
Casa di Cura del Policlinico, Department of  
Neurorehabilitation Sciences, Milan, Italy.
Email: g.pellegrino@ccppdezza.it
Alessandro Pezzini
Neurology Unit, Department of  Clinical and 
Experimental Sciences, ASST Spedali Civili 




Neurology Unit, Department of  Clinical and 
Experimental Sciences, ASST Spedali Civili 




Professor of  Neurology 
Director of  “Aldo Ravelli” Research Center 
for Neurotechnology and Experimental 
Brain Therapeutics, Department of  Health 
Sciences, University of  Milan, Milan, Italy;
Director of  Neurology Unit I, San Paolo 
University Hospital, ASST Santi Paolo e 
Carlo, Milan, Italy.  
Email: alberto.priori@unimi.it
Roberta Rovito
Clinic of  Infectious Diseases, Department of  
Health Sciences, ASST Santi Paolo e Carlo, 
University of  Milan, Milan, Italy. 
Email: roberta.rovito@unimi.it
XVIIList of  Contributors
Marco Scarabello
Diagnostic and Interventional 
Neuroradiology Department, ASST Santi 





Neurology Unit I, San Paolo University 
Hospital, ASST Santi Paolo e Carlo, Milan, 
Italy.  
Email: emma.scelzo@asst-santipaolocarlo.it
Giuseppe Francesco Sferrazza 
Papa
Department of  Health Sciences, University 
of  Milan, Milan, Italy; 
Casa di Cura del Policlinico, Department of  
Neurorehabilitation Sciences, Milan, Italy. 
Email: giuseppe.sferrazza@unimi.it
Vincenzo Silani
Professor of  Neurology 
Department of  Neurology and Laboratory 
of  Neuroscience, Istituto Auxologico 
Italiano, Istituto di Ricovero e Cura a 
Carattere Scientifico (IRCCS), Department 
of  Pathophysiology and Transplantation, 
University of  Milan, Milan, Italy; 
“Aldo Ravelli” Center for Neurotechnology 
and Experimental Brain Therapeutics, 
Department of  Health Sciences, University 
of  Milan, Milan, Italy. 
Email: vincenzo.silani@unimi.it
Gioacchino Tedeschi
President of  the Italian Society of  Neurology;
Professor of  Neurology, Campania University 
“L. Vanvitelli”, Naples, Italy.
Email: gioacchino.tedeschi@unicampania.it
Delfina Tosi
Pathological Anatomy Unit, Department of  




Human Pathology Unit, ASST Santi Paolo e 
Carlo, San Paolo University Hospital, Milan, 
Italy.
Gemma Tumminelli
Epilepsy Center, ASST Santi Paolo e Carlo, 




Diagnostic and Interventional 
Neuroradiology Department, ASST Santi 




Diagnostic and Interventional 
Neuroradiology Department, ASST Santi 




Child Neuropsychiatry and Epilepsy Center, 
ASST Santi Paolo e Carlo, Milan, Italy. 
Email: chiara.vannicola@asst-santipaolocarlo.it
Daniele Velardo
Neurology Unit, Foundation IRCCS Ca’ 




Child Neuropsychiatry and Epilepsy Center, 
ASST Santi Paolo e Carlo, San Paolo 




In December 2019, a novel coronavirus, designated as “severe acute res-
piratory syndrome coronavirus 2” (SARS-CoV-2), was identified as the cause 
of  a disease that was named COVID-19 (coronavirus disease 2019). The virus 
rapidly spread worldwide and it was declared a pandemic by the World Health 
Organization on March 11, 2020. 
At the very early stages of  the pandemic, it became increasingly evident that 
COVID-19 is not limited to the respiratory system, and that other organs can 
be affected. In particular, virus-related neurological manifestations were fre-
quently reported in COVID-19 patients all over the world.  
Neurological complications are common in patients during acute infection as 
well as in the long term. They are particularly frequent in hospitalized patients, 
among whom more than 80% may develop neurological symptoms at some 
point during their disease course, and in patients with severe COVID-19. There 
is also increasing recognition that psychiatric manifestations represent possible 
complications of  infection.
Over the last year, the scientific literature on nervous system-related manifes-
tation of  COVID-19 has continued to grow, producing over 4,500 publications, 
including over 700 reviews and close to 40 systematic reviews (available from: 
www. https://pubmed.ncbi.nlm.nih.gov/).
Despite this rapidly expanding scientific literature, the mechanisms contrib-
uting to neurological and psychiatric symptoms of  COVID-19 are still not fully 
understood and more pathogenetic studies are needed to shed light on this top-
ic. An understanding of  the mechanisms underlying such manifestations will be 
essential to promote optimal use of  targeted therapeutic strategies.
The book edited by Alberto Priori and Michelangelo Dini brings together the 
contributions of  a group of  internationally renowned experts who have gained 
extensive clinical experience in major hospitals in the northern Italian region 
of  Lombardy,  the first European region to face the COVID-19 emergency in 
2020. It offers a comprehensive and updated account of  the neurological as-
pects of  SARS-CoV-2 infection. The aim of  the authors is to provide practical 
clinical insights for clinicians of  all specialties involved in the management of  
COVID-19 patients. Each chapter presents a critical review of  the existing lit-
erature, followed by practical clinical considerations  based on the lessons learnt 
by each author during the course of  the COVID-19 pandemic. 
The urgent need for solid and timely scientific information has been evi-
dent since the early phases of  this unprecedented health emergency. The Italian 
Istituto Superiore di Sanità (ISS), in its dual capacity of  research institution and 
technical-scientific body of  the Italian National Health System, has put in place 
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several strategies to meet this need. Among them, the ISS COVID-19 reports 
(“Rapporti ISS COVID-19”), written by over 400 ISS and external experts or-
ganized into 22 Working Groups,  have covered a broad spectrum of  operation-
al indications: from the management of  SARS-CoV-2 cases to the reopening of  
commercial and tourist activities, to the outbreaks in schools and other educa-
tion institutes, to mention only a few.  These reports, freely available from the 
official ISS website, have also been translated into English and Spanish at the 
request of  several foreign organizations; a testimony to the Italian leadership 
demonstrated during the pandemic.
The first three chapters of  the book define the landscape of  SARS-CoV-2 in-
fection and the nervous system. Chapter 1 reviews the pathogenesis of  SARS-
CoV-2-related brain damage, while Chapter 2, after a brief  overview of  the 
lung-brain axis, offers a detailed account of  dyspnea and respiratory failure in 
COVID-19, and of  post-COVID-19 sequelae. The neurogenic component of  
COVID-19-related respiratory failure is then explored in Chapter 3. 
The book then deals more specifically with the “neurology of  COVID-19”, 
starting with an overview of  the neurological manifestations and two method-
ological chapters on neuroimaging and neuropathology.  
The following chapters illustrate specific neurological manifestations, includ-
ing encephalomyelitis, stroke, seizures, delirium, as well as psychiatric condi-
tions, such as mood disorders, psychotic disorders, anxiety disorders, obses-
sive-compulsive disorders, eating disorders, autism spectrum disorders, somatic 
symptoms and related disorders. Cognitive dysfunction in COVID-19 as a key 
factor in determining the functional outcome for a large number of  patients is 
also discussed, highlighting the importance of   including cognitive rehabilita-
tion in multidisciplinary rehabilitation programs. Similarly, the authors highlight 
the need for observational, multicenter studies to better understand the impact 
of  COVID-19 on patients with pre-existing neurological diseases, such as neu-
roinflammatory and neuro-oncological diseases, who represent a particularly 
vulnerable and frail population. The related chapter addresses some topics of  
high potential interest and provides some considerations on COVID-19 vacci-
nation in these frail neurological categories.
Further issues presented in specific chapters are the COVID-19-related dis-
orders of  the peripheral nervous system and the muscular system, and the neu-
rological manifestations in children. Although relatively rare, there is an increas-
ing number of  reports of  cases of  neurological symptoms, such as seizures, 
encephalitis, stroke or neuropathies, in a small proportion of  children affected 
by SARS-CoV-2 suggesting a possibly greater neurological involvement in the 
pediatric population affected by SARS-CoV-2 than in those affected by other 
human coronaviruses. 
Finally, the book covers two major areas of  interest for the management 
of  the COVID-19 pandemic: vaccines and telemedicine. In particular, the 
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advantages and limitations, clinical implications, and future challenges of  “tele-
neurology” (a word used to indicate the application of  telemedicine to neurolo-
gy) are comprehensively discussed. Telemedicine is the delivery of  medical care 
by electronic communication between a health care professional and a patient at 
different locations. It is no surprise that the pandemic has greatly pushed tele-
medicine and teleneurology forward, with the double aim of  reducing exposure 
to SARS-CoV-2 infection while ensuring patients receive all the assistance they 
need. In addition, during the pandemic, the use of  virtual communication for 
seminars, webinars, educational training and teaching courses has greatly helped 
health operators and scientific communities. To give an example, in 2020, the 
ISS hosted weekly scientific meetings on  “COVID-19 - the state of  the art” by 
teleconference, with insights and comparisons by leading epidemiological and 
clinical experts and provided courses in distance learning methods aimed at all 
health professionals and socio workers, and school and support staff. These 
events were followed by over 500,000 registered users.
All the changes imposed by the pandemic have happened very fast, in days 
or weeks, requiring the availability of  adequate equipment and the rapid de-
velopment of  a technology infrastructure to support them. Telemedicine and 
teleneurology expand access and availability from outpatient to acute care and 
rehabilitation. While, still  in their infancy, there are, as pointed out by the au-
thors, considerable possibilities for improvement. 
In conclusion, “Neurology of  COVID-19” is an innovative reference book 
for clinicians of  all specialties involved in the management of  patients with 
SARS-CoV-2 infection, presenting “the state of  the art” in the field, but also 
offering food for thought about present limitations and future challenges.
Public health policies at international, national and regional levels will cer-
tainly benefit from this book and we should be grateful to the authors for their 
efforts.  I also hope that, starting from this experience, other similar contribu-
tions covering all clinical aspects of  COVID-19 can be made available to public 
health bodies and to the scientific community at large. 
Silvio Brusaferro




Neurology of  COVID-19 deals with a recent disease that has deeply changed 
the practice of  neurologists worldwide, and as such it represents an important 
novelty in the scenario of  neurological textbooks. COVID-19 had a double 
impact on neurologists. First, at the onset of  the pandemic, neurologists were 
required to help colleagues of  other medical specialties (respiratory medicine, 
infectious diseases, intensive care, emergency departments) thus going back 
to being medical doctors. Many neurologists had to update their knowledge 
of  using ventilators and of  internal medicine. A further important issue was 
the description and discovery of  the effect of  SARS-CoV-2 infection on the 
nervous system. Neurology of  COVID-19 deals with the pathophysiology, neu-
ropathology, neuroimaging, neurological, and psychopathological and cogni-
tive manifestations of  SARS-CoV-2 in adults and children. Italy was the first 
European country to face the pandemic, and Italian neurologists immediately 
began to study their patients and to report their observations. This, in several 
cases, opened up new avenues towards improving the understanding and man-
agement of  COVID-19 that were then replicated and expanded by colleagues 
in other countries. As President of  the Italian Neurological Society, I am, there-
fore, proud and honored to introduce Neurology of  COVID-19. I believe it will 
become a reference book in its field. The efforts of  Professor Alberto Priori 
who edited the book and of  all the contributors will certainly draw the atten-
tion of  other specialists to the neurological aspects of  this novel condition. 
Notably, all the contributors and the editors were dealing with COVID-19 on 
the front-line and had a direct experience with the many faces of  the neurolog-
ical aspects of  SARS-Cov-2 infection.
Gioacchino Tedeschi
President of  the Italian Neurological Society

Introduction
Our neurological department came face to face with COVID-19 suddenly 
in February 2020 when a 63-year-old colleague was admitted for focal motor 
seizures. Brain neuroimaging showed only a mild leukoaraiosis without focal 
lesions. Two days later, fever, cough, and interstitial pneumonia developed, his 
general medical condition rapidly worsened, and he later died. Just one month 
later, in March 2020, northern Italy became the second country most affected 
by COVID-19 in the world, and the national death toll overtook that in China. 
Hospital staff  soon realized that COVID-19 was far more severe than they had 
expected from the few data available at that time (mostly from the daily news-
papers and media channels, which in January 2020 represented the only source 
of  information). 
Restoring the balance
The COVID-19 pandemic has forced hospitals to adjust to rapidly changing 
circumstances. Since March 8, 2020, health authorities have transformed the 
regional public health system. Within days, the number of  patients accessing 
emergency departments (ED) for COVID-19 dramatically increased, requiring 
hospital managements to reorganize all their wards. Within a week, most hos-
pital beds were dedicated to COVID patients and, COVID aside, most other 
routine clinical activities were gradually reduced and eventually stopped. Events 
escalated so suddenly that even departments not usually in the first line of  
defense against COVID-19 had to deal with the prevailing circumstances. The 
decision to transform most operating theaters into intensive care units (ICU) 
meant redefining surgical guidelines. Surgeons generally accepted this ‘revo-
lution’ in their daily activity without any complaints. The number of  people, 
contacts, friends and relatives who fell ill, many of  whom later died, of  COVID, 
had “cooled down the sacred fire of  surgery”. And everybody learnt to do na-
sopharyngeal swabs (NPS). 
COVID teams
To address the urgent need for physicians and to reallocate unemployed health 
specialists, the hospital assigned all physicians to “COVID teams”. Each team 
was made up of  a specialist in infectious diseases (ID), respiratory medicine, 
internal medicine, and other specialties (including ophthalmology, pathology, 
maxillofacial surgery, ear-nose-and throat [ENT], neurology, general surgery, 
orthopedic surgery, urology). With this approach, teams were created in which 
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non-COVID-related specialists could train others to treat patients on their own 
in case the epidemiologic situation worsened or any doctors fell ill. Because 
most COVID-19 patients are elderly, and have comorbidities, a further advan-
tage was that the multidisciplinary teams worked well together and were rela-
tively autonomous. This meant that external consultations were not required, 
thus reducing the number of  contacts and, therefore, the risk of  infection.
Hubs & Spokes
On March 8, 2020, the Lombardy region instituted a regional healthcare 
system to assist patients with acute illnesses including cardiovascular disease, 
stroke, oncology, and surgery during the COVID-19 epidemic (Deliberation 
of  the Lombardy Region n. XI/2906). To manage these diseases, the territorial 
emergency medical system (EMS) in Lombardy identified and linked together 
13 central hospitals (Hubs) and 42 peripheral hospitals (Spokes). The main aim 
of  this was to enable hospitals to create a well-organized territorial network, 
with well-trained operators and shared protocols that would guarantee appro-
priate and timely medical assistance, and ensure patients’ safety.
Personal protective equipment (PPE) 
The Covid-19 outbreak meant that hospital managements suddenly had to 
to devise new specific procedures. One of  these was that the use of  personal 
protective equipment (PPE) was required on all the wards. The fear of  infection 
and the need to respect the new rules generated tensions that proved difficult 
to de-escalate. Watching doctors tying up the lab coat on support workers and 
vice versa may, at times, have been amusing, but keeping the department up and 
running meant implementing strong preventive measures also for patients and 
instructing them on the importance of  self-care (e.g., wearing surgical masks at 
all times, frequent hand washing, etc.). 
From mid-February 2020, the authorities limited hospital access only to pa-
tients. Everyone had to have their temperature measured and undergo careful 
questioning about any fever or respiratory symptoms at home. Since then, pa-
tients have had to use gloves and face masks. In a delicate setting such as psychi-
atry, where patients are often in a confusional state and experiencing delirium, 
compulsory face masks interfered with the therapeutic relationship. In addition, 
for patients without cognitive and psychiatric disturbances, the mask became 
an emotional obstacle to smiling, a potent ’drug‘. No relatives could enter the 
wards, causing many patients to experience significant psychological distress, 
which, in turn, also affected doctors and all other healthcare workers. 
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Teaching: students and residents 
During the Covid-19 outbreak, academic staff  made a great effort to contin-
ue teaching by rapidly activating online lessons, seminars, webinars and exami-
nations for medical students and in-house consultants. Those involved needed 
to have an open mind about these new modalities in order to adapt to these 
individual teaching methods. Some of  us will always remember the video medi-
cal graduation examination sessions we attended as members of  the exam com-
mission. A medical degree is arguably the most important event in any student’s 
career, and one which they look forward to. We had to watch our students on 
a computer screen as they defended the results of  their thesis, sitting alone in 
their bedrooms without the comfort of  cheering relatives and friends, but still 
wearing their best clothes, as if  participating in the real ceremony. 
Residents no longer worked a rotating shift system but were integrated into 
the COVID units, working on the internal medicine and respiratory medicine 
wards. They were re-located around the hospital according to their exper-
tise. Final year ID, respiratory medicine, internal medicine and anesthesiology 
students were recruited as part of  the medical team and allowed to treat pa-
tients. Others (from pathologists to ENT and many other specialties) worked 
in COVID teams, volunteered to work in the emergency network, and some 
worked in the occupational health service.
Work overload
The upheaval caused by the pandemic has also led to an increased the work 
load; many operators had to prolong their working hours and skip their day off  
to allow the hospitals to adjust to the new organizational model that had been 
designed. To mitigate the daily stress and emotional burden, our hospital pro-
vided a ‘decompression room’ and psychological support group sessions. The 
decompression room is a physical and mental space where staff  can go to relax 
to help them relieve work pressures. The small group sessions help the doctors 
and nurses to develop inter-professional group thinking. A theme which was 
addressed right at the start was moral distress, while the focus later switched to a 
more closely related intervention to prevent post-traumatic stress disorder. The 
rehabilitation team has also created a ’muscle reconditioning‘ space intended for 
workers who complain of  muscle tension.
Tele(phone)medicine
A powerful tool that is easily accessible to the whole population (from chil-
dren to the elderly) ensures assistance at home for many patients, and reduces 
the danger of  infection, is an internet video meeting or a telephone call. On 
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most wards, the hospital set up a call center, often managed by residents or 
medical students, to answer patients’ phone calls and e-mails and reschedule 
medical appointments. Outpatient activities were limited to urgent cases for all 
specialties and were mainly telephone consultations. Patients who could not go 
to the hospital because of  the lockdown restrictions could reach the rehabili-
tation team by phone or videocalls. The rehabilitation team also created video 
tutorials that allowed patients to continue their exercises at home. 
A lesson on empathy
Apart from the purely medical response, a major issue in dealing with 
COVID-19 is the human aspect. All the physicians and nurses involved are 
facing difficult moment in their professional lives, especially when they rep-
resent the only link between COVID patients, who cannot receive visits, and 
their families. Our hearts and minds will forever remember some extraordi-
nary and extremely difficult medical conversations with patients passing away. 
Solidarity, empathy and compassion are cardinal points in the work that we do. 
We feel helpless, and at times in despair, when facing the silent yet deafening 
plea for oxygen that patients about to die convey through their terrified eyes. 
Nonetheless, a smile and  a caress can transmit incredible power and strength 
to our patients. Each of  us, at least once over the past months, has felt human-
kind’s vulnerability in this massive global crisis. 
Nurses, close to the patients
Nurses are on the frontline. Since the COVID-19 outbreak began, day after 
day they have been facing difficult and stressful situations. For example, patients 
complaining of  mild respiratory difficulties enter the emergency department 
unaided, then rapidly evolve into severely distressed persons needing mechani-
cal ventilation (either invasive or non-invasive), and several later die. Nurses are 
put under extreme psychological pressure. What is more, seeing the eyes of  a 
patient in sudden need for oxygen, clenching the nurse’s hand in the desperate 
effort to breathe, reminds us that such patients are facing this situation alone. 
As infection prevention policies forbid relatives to enter the wards, nurses fully 
realize that, as the patient’s situation worsens and their fears increase, they have 
no support from their loved ones. Given that nurses are often the last people a 
dying patient sees, patients tend to share with them their most intimate feelings 
and life stories. When their shift ends, nurses find it tremendously difficult to 
leave all of  this behind. Moreover, upon returning home, nurses cannot even 
embrace their own loved ones because of  the risk of  transmitting the disease. 
Hence, they face a high risk of  experiencing psychological scars that will be 
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hard to heal. Research already shows that both patients who survived and hos-
pital workers are at an increased risk of  long-term psychological distress, and 
possibly even trauma. 
Neurology
Within a week of  Lombardy’s COVID-19 catastrophic outbreak erupting, 
the hospital directors transformed the neurology unit into a COVID ward. All 
the neurological subspecialty outpatient clinics provided phone or internet con-
sultations for patients or their general practitioner. Surprisingly, for the first two 
weeks, no patients with acute neurological problems presented to the emer-
gency department. Three weeks later, neurological non-COVID patients pro-
gressively began attending the emergency department again.  During the sec-
ond and third wave of  pandemic (after the summer of  2020) several hospitals 
created a Neuro-Covid ward for patients either with pre-existing neurological 
disorders who were infected by SARS-CoV-2, or COVID-19 cases with neuro-
logical complications. By the autumn of  2020, we had realized that COVID-19 
patients infected during the winter or spring of  2020 often had neurological 
sequelae.
This book reports how several neurological departments located in large 
hospitals in the most affected area in Italy experienced the COVID-19 outbreak 
and its neurological manifestations. We believe that a pandemic event of  this 
magnitude implies a multidisciplinary response, so we include chapters from 
all the main neurological subspecialties, along with those from infectivologists, 
pneumologists, pathologists and several other colleagues, in a single reference 
book. Despite the tragedy, we feel that the COVID-19 pandemic has offered a 
unique opportunity to develop a new healthcare management model as a trigger 
for future innovation in medical and neurological practice. This book witnesses 
the tremendous vitality of  Italian neurology in response to a novel disease that 
is likely to add a new chapter to the neurology textbooks. Lastly, the issue of  
how some COVID-19 complications (e.g., the development of  long-term cog-
nitive impairment) will evolve in the future is still unknown and this will require 
close neurological follow-up for which this book will represent both a starting 
point and a guide. 
Alberto Priori
Professor of  Neurology
University of  Milan
San Paolo University Hospital
Italy

Chapter 1. SARS-CoV-2 and the nervous 
system: review on pathogenesis of  nervous 
system SARS-CoV-2 damage
Francesca Bai, Roberta Rovito, Giulia Marchetti,  
Antonella d’Arminio Monforte
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a 
newly emerged enveloped virus, positive-sense single-stranded RNA, of  the 
Coronaviridae family, belonging to the genus of  all highly pathogenic coronavi-
ruses, i.e., Betacoronavirus1. After SARS-CoV and the Middle Eastern respira-
tory syndrome coronavirus (MERS-CoV), SARS-CoV-2 is the third coronavi-
rus to have caused a large outbreak in humans. SARS-CoV emerged in South 
China in 20022, MERS-CoV in Saudi Arabi in 20123, and SARS-CoV-2 in the 
Hubei province of  China in 2019 most likely due to species barrier spillover, 
making the One Health approach a worldwide priority. 
SARS-CoV-2 genome is more closely related to the genome of  SARS-CoV 
than to MERS-CoV (80% and 50% identity, respectively)4-6. Overall, SARS-
CoV-2 appears to be less lethal than SARS-CoV and MERS-CoV but is more 
highly transmissible. The main cellular target of  SARS-CoV-2 is the angioten-
sin converting enzyme 2 (ACE2), a cell surface carboxypeptidase that is part 
of  the renin-angiotensin system (RAS)7. SARS-CoV-2 has a strong affinity for 
ACE27,8. Two-thirds of  the SARS-CoV-2 genome encodes for non-structural 
proteins necessary for the replicase complex, whereas the remaining genome 
encodes for accessory and structural proteins4,5,9; the latter include spike (S), 
envelope (E), membrane (M), and nucleocapsid (N) proteins. The S protein is 
composed of  two domains, one containing the receptor binding domain (RBD) 
and the other the membrane fusion domain, i.e., S1 and S2, respectively. The 
RBD of  the S protein mediates viral entry by binding to the human ACE2. The 
binding is followed by proteolytic activation between S1/S2 at the plasma mem-
brane by the transmembrane protease serine 2 (TMPRSS2) or at the endosomal 
membrane by cathepsin L10. The genome is then released in the cytosol where it 
is translated in viral proteins that form the RNA-dependent RNA polymerase. 
The genomic and sub-genomic RNAs are replicated, with the latter translated 
in accessory and structural proteins used for virion assembly. Finally, the viral 
RNA genomes are incorporated into the virions which are released from the 
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plasma membrane9,11,12. ACE2 is expressed by the respiratory tract, and, after 
having entered the host via epithelial cells, the vascular endothelial cells and 
macrophages may be the first targets13-15.
SARS-CoV-2 is the etiologic agent of  coronavirus disease 2019 (Covid-19) 
which is characterized by severe ‘flu’-like symptoms that can progress to 
life-threatening systemic inflammation and multiorgan dysfunction16. Severe 
COVID-19 is observed in about 20% of  patients infected with SARS-CoV-2, 
and the factors that dictate whether or not a patient develops the severe form 
are not yet known, although older age is one of  the main known risk factors 
associated with severity together with obesity, cardiovascular diseases and male 
gender. One of  the hallmarks of  COVID-19 severity is the ‘cytokine storm’17-19, 
i.e., an uncontrolled increase in pro-inflammatory mediators following innate 
immune activation. The increased cytokine and chemokine concentration 
further amplifies the tissue damage by means of  endothelial dysfunction and 
vasodilatation, eventually creating a hypoxic environment and organ failure20. 
Clinical aggravation occurs approximately one week after the onset of  symp-
toms17,21,22, which roughly corresponds to the temporal bridging of  the innate 
and adaptive immune response. Once the disease becomes systemic, the disease 
will involve other organs and systems. 
SARS-CoV-2 and the nervous system: pathogenetic aspects
Central nervous system and peripheral nervous system manifestations in 
COVID-19 disease
Central nervous system (CNS) and peripheral nervous system (PNS) involve-
ment were described following SARS and MERS, even if  these involved only 
a small proportion of  cases: in fact, the prevalence of  CNS and PNS compli-
cations ranged from 0.04% for SARS to 0.20% for MERS, and from 0.05% 
for SARS to 0.16% for MERS, respectively23. As the COVID-19 pandemic 
progressed, neurological manifestations increased. These included neurological 
symptoms that are present at the time of  COVID-19 diagnosis in a considerable 
number of  patients, and neurological complications that could appear later24-26. 
The neurological manifestations in COVID-19 disease have been catego-
rized in three groups: (i) CNS involvement, characterized by dizziness, head-
ache, impaired consciousness, acute cerebrovascular disease and epilepsy; (ii) 
PNS involvement, including anosmia, hypogeusia, visual impairment and neu-
ralgia; and (iii) skeletal muscle impairment27. Neurological symptoms, such as 
loss of  the sense of  smell and taste, headache, fatigue, nausea and vomiting, 
dizziness, are reported in more than one-third of  COVID-19 patients17,28; but 
more severe manifestations, as well as encephalopathy, stroke, Guillain-Barré 
syndrome, acute hemorrhagic necrotizing encephalitis, and acute disseminated 
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encephalomyelitis seem to be less common23,29. However, the prevalence of  
neurological manifestations associated with COVID-19 varies widely among 
the different studies, ranging from 7% to over 84%27,30.
Given the high prevalence of  COVID-19 disease worldwide, and the 
non-specificity of  neurological symptoms associated with SARS-CoV-2 infec-
tion, that are, in fact, described also in the course of  other viral infections, 
experts advise caution in attributing any specific causal links between SARS-
CoV-2 and neurological symptoms27. The pathogenesis of  CNS infection by 
SARS-CoV-2 and the neurological complications are still poorly understood 
and more pathogenetic studies are needed to shed light on this topic.
ACE2 receptors are expressed in different brain regions
ACE2 receptors are widely expressed in human organs, including in mul-
tiple CNS structures, such as brainstem, cortex, striatum and hypothalamus, 
and in several cell types, such as neurons and glia26,31,32; recently, ACE2 has also 
been found in the human cerebral vasculature in postmortem brain samples 
and appears to be upregulated in brain tissues by oxidative stress, apoptosis and 
neuroinflammation that characterize several neurological diseases or hyperten-
sion31,32. ACE2 in brain was also found in the neurons of  the subfornical organ, 
where the virus could more easily find a means of  entering the CNS, thanks to 
the lack of  a blood brain barrier (BBB)7. Additional receptors may play a role in 
SARS-CoV-2 invasion of  the brain: CD147 (or basigin, BSG) and Neuropilin1 
(NRP1), to which the spike protein is capable of  binding. Recently, a furin-like 
cleavage site on the spike protein of  SARS-CoV-2 was demonstrated to be 
specific for this virus; the association between the furin-like cleavage site and 
its protease in host has been demonstrated to be critical for the neurotropism 
of  the Coronaviridae family and thus the presence of  this site could explain the 
ability of  SARS-CoV-2 to invade the CNS33.
Possible mechanisms of  neurotropism and neurovirulence of  SARS-CoV-2
Neurological manifestations could be caused by SARS-CoV-2 through a 
direct or indirect mechanism. The possible mechanisms of  neurological im-
pairment that have been identified so far are: (i) a direct effect of  the virus 
entry into the CNS; (ii) para-infectious or post-infectious immune-mediated 
disease; (iii) a secondary involvement of  the CNS following the systemic effects 
of  COVID-19, such as systemic inflammatory response syndrome, sepsis and 
multiorgan failure23,24. The different mechanisms are not mutually exclusive and 
might co-exist. Similarly, Neuro-COVID has also been described as a process in 
three phases: (i) neuroinvasion; (ii) CNS clearance; and (iii) immune response. 
In the first phase, the virus reaches the CNS through the systemic circulation 
and/or through the trans-cribriform route along the olfactory nerve; it seems 
that the viral load in the CSF gradually increases until the second phase. In the 
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second phase, the interaction between the subunit S1 of  the spike protein and 
the ACE2 receptor allows viral entry into the neuronal cells with subsequent 
neuronal damage; early after the infection, neuronal damage leads to the onset 
of  anosmia and/or dysgeusia, while later the involvement of  the nucleus of  
the solitary tract may cause severe respiratory impairment. During the second 
phase, the viral load starts to decrease until SARS-CoV-2 indirectly affects the 
CNS. In the third and last phases, the viral infection causes immune-mediat-
ed CNS impairment. The virus could stimulate the production of  antibodies 
against glial cells, as a para- or post-infective mechanism, similar to that ob-
served after other viral infections. In this phase, the respiratory symptoms may 
become even more severe, leading to neurotoxic hypoxia and brain damage34.
CNS impairment as a consequence of  a direct viral effect 
Different experimental models were used to study the presence and the con-
sequences of  SARS-CoV-2 in the CNS: neural cell lines, animal models and brain 
organoids35,36. Published studies have shown that SARS-CoV-2 can infect and 
replicate in induced pluripotent stem cell (iPSCs)-derived human neural progen-
itor cells (hNPCs) and in neurospheres or brain organoids produced from these 
cells25,32. Animal experiments have provided information as to the neuroinvasive 
potential of  SARS-CoV-2: the presence of  the virus was found in neurons of  dif-
ferent brain areas, and this was later compared with the pulmonary involvement. 
Interestingly, not all infected animals showed neurological symptoms or signs of  
CNS infection24. The neurotropism and neurovirulence of  SARS-CoV-2 have 
also been demonstrated by the finding of  viral acid nucleic in the cerebrospinal 
fluid (CSF) and in brain tissue samples26, even if  with a low frequency.
Detection of  SARS-CoV-2 in cerebrospinal fluid
Neurotropism is a common characteristic of  human coronaviruses (HCoVs) 
and several studies have demonstrated that SARS-CoV-2 is able to invade the 
CNS33,37. The detection of  the viral RNA in the cerebrospinal fluid (CSF) by 
Real-Time Reverse Transcription PCR (RT-PCR) has been described by differ-
ent authors in some cases of  encephalopathy with a prevalence of  6.4%38-43. 
However, in the majority of  patients diagnosed with encephalopathy, SARS-
CoV-2 RNA was not detected in the CSF41,42,44,45. A possible explanation for this 
could be that the virus is cell-bound and spreads from cell to cell and does not 
transit freely in the CSF. Alternatively, the viral concentrations in the CSF could 
be below the level of  detection of  the test or the PCR reaction is inhibited by 
the presence of  hemoglobin products for the breakdown of  erythrocytes. The 
detection rate is also highly dependent on the type of  neurological disease and 
the time of  sample collection41. Finally, the absence of  the virus in the CSF 
despite inflammation (confirmed by high levels of  CSF white blood cells and 
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protein levels described in some patients with encephalitis) suggests that the 
encephalitis could be the result of  systemic immune-mediated inflammation 
and is not driven only by a direct neuroinvasion of  SARS-CoV-227,42,46. 
The detection rate of  SARS-CoV-2 RNA in the CSF was generally higher in 
patients diagnosed with encephalitis and much lower in patients with encephalop-
athy, cerebrovascular accidents or Guillain-Barré syndrome. Interestingly, patients 
without neurological manifestations were all negative for CSF SARS-CoV-2 RNA41. 
Moreover, almost half  the patients with a negative test for SARS-CoV-2 in the CSF 
showed the presence in the CSF of  antibodies specific for SARS-CoV-2, and, ac-
cording to available data, 23.3% of  tested patients present intrathecal antibody syn-
thesis41 that could suggest the invasion of  the virus into the CNS47.
Detection of  SARS-CoV-2 in brain tissue samples
Postmortem examination is the definitive means of  assessing viral neuroinva-
sion, in addition to that of  the CSF, and previous studies have investigated the 
detection of  SARS-CoV-2 in postmortem human brain samples, but so far with 
contrasting results. Some authors, in fact, reported the detection of  the virus in 
brain autopsies (even though the viral load was low), by PCR and quantitative 
PCR (qPCR), or of  viral nucleocapsid and/or spike proteins by immunohisto-
chemistry1,46,48. Conversely, in other studies, the virus was not detected in brain 
cells. Thus, the hypothesis that the virus is intrinsically neuroinvasive and is able to 
create a persistent infection in the CNS requires clarification27,49,50. SARS-CoV-2 
was detected in different cell types as well as frontal lobe neurons, glial cells, en-
dothelial cells, pericytes of  brain capillaries and vagus nerve fibers45,51-53, and viral 
proteins were found in a smaller proportion of  patients in different brain regions, 
as well as brainstem, cerebellum, cerebrum and the olfactory system41. The high-
est detection rate of  SARS-CoV-2 RNA was found in brainstem, as well as the 
most severe microgliosis and lymphocytic infiltration, suggesting that the brain-
stem could be a major target of  SARS-CoV-2 in the CNS41.
The most common findings in the CNS of  patients who died from COVID-19 
are hypoxic injury and vascular accidents41 and microglial activation was found 
in the compromised brain areas in more than half  the patients. The detection 
rate of  SARS-CoV-2 was higher in regions with microgliosis and lymphocytic 
infiltration than in areas with hypoxic injury and vascular impairment41.
Routes of  neuroinvasion
Coronaviruses may reach the CNS through any of  three different path-
ways: (i) hematogenous dissemination; (ii) the “Trojan horse” mechanism; and 
(iii) neuronal retrograde propagation27,28,54,55. In the first case, after a phase of  
viremia, the virus can cross the BBB and enter the CNS.
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Figure 1.1: Possible SARS-CoV-2 entry to the central nervous system (CNS)  
via blood circulation
Passage of  SARS-CoV-2 from the upper respiratory tract and the alveolar epithelial 
cells to the blood circulation; crossing of  the Blood Brain Barrier (BBB) and inva-
sion of  the CNS. Reproduced from 25 with permission.
The passage of  the virus to the blood circulation may follow the infection 
of  type II alveolar epithelial cells, which highly express ACE2, and the epithelial 
cells of  the gastrointestinal tract, which also express ACE2 receptors and can be 
infected by SARS-CoV-253. The most plausible scenario is that of  access through 
the respiratory tract: the damage to lung blood vessels following SARS-CoV-2 
infection, including endothelial necrosis and capillary injury, has been demon-
strated in postmortem analyses, and suggests that the virus can translocate from 
the lungs to the pulmonary microcirculation and then spread to other organs25,56.
The “Trojan horse” mechanism is the process by which the virus infects lympho-
cytes and monocytes, and the latter, activated by the infection, can disseminate and 
cross the BBB; infected macrophages have been described in COVID-19, suggest-
ing that latent SARS-CoV-2 infection can establish in immune cells25,56. Finally, the 
trans-synaptic dissemination can be retrograde or antegrade and use an exocytosis/
endocytosis mechanism or the rapid axonal transport; it could be facilitated by pro-
teins called dinein and kinesin, both possible targets of  the virus57,58. 
The virus can either infect endothelial cells of  the BBB or epithelial cells of  
the blood-CSF barrier in the choroid plexus to enter the CNS.
71. SARS-CoV-2 and the nervous system




SARS-CoV-2 infection of  microglia and neurons triggers an inflammatory cascade 
with release of  pro-inflammatory cytokines and chemokines in the Central Nervous 
System (CNS). b) These pro-inflammatory cytokines and chemokines, in turn, reduce 
the integrity of  the Blood Brain Barrier (BBB) and allow the entry of  other viruses 
and mediators of  inflammation into the CNS. This neuroinflammation process even-
tually causes neurotoxicity and neuronal death. Reproduced from 65 with permission.
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During transcellular migration, the virus invades host endothelial cells to 
cross the BBB, while during paracellular migration, the virus invades the tight 
junctions formed by the endothelial cells59. ACE2 and NRP1 have been found 
in human brain microvascular endothelial cells (BMVECs) and may allow viral 
entry to the CNS; the examination of  postmortem brain samples by transmis-
sion electron microscopy has found the presence of  viral-like proteins inside 
BMVECs in the frontal lobe45. Human choroid plexus expresses ACE2 and, 
thanks to its greater permeability compared to BBB, it could provide a second 
entry route to the CNS25,60; on the other hand, the low viral load in the blood 
makes this an unlikely means of  entry to the CSN25.
BBB is negatively affected by viral infections, not only thanks to the pro-
ductive or non-productive infection of  endothelial cells, but also by the host 
immune response that stimulate the release of  pro-inflammatory cytokines, 
chemokines and cell adhesion molecules, finally leading to changes in the struc-
tural and functional integrity of  the BBB31. The inflammatory mediators could 
break down the BBB by reducing the integrity of  the tight junction proteins61. 
In turn, BBB dysfunction creates a vicious circle, allowing the passage of  other 
free viral particles and infected immune cells to the CNS.
The increase in BBB permeability has been described in COVID-19 patients 
with neurological symptoms62 and, recently, a possible direct role for SARS-
CoV-2 in modifying BBB properties has been reported. In a BBB-on-a-chip 
in vitro model of  the human BBB, the subunits S1, S2 and RBD of  the spike 
protein are able to promote a loss of  barrier integrity, triggering a proinflam-
matory response on brain endothelial cells that includes upregulation of  Matrix 
Metalloproteinases (MMP), cell adhesion molecules (ICAM-1 and VCAM-1), 
leukocyte chemotaxis factors (CXCL10 and RANTES) and cytokines (IL-1b 
and IL-6), and may finally contribute to a destabilization of  BBB function31.
On entry into the CNS, SARS-CoV-2 may cause active infection of  resident 
cells, thanks to the presence of  its receptors, such as ACE2, NRP1 and BSG)45. 
Furthermore, the virus or infected lymphocytes could stimulate the production 
of  pro-inflammatory cytokines, such as TNF-α and IL-6, and chemokines, such 
as CCL5, CXCL10 and CXCL11, that can induce chemoattraction of  other acti-
vated T cells in the CNS. Activated astrocytes can, in turn, produce chemokines 
and participate in the recruitment of  leukocytes. This process, for which the 
viral infection is the first trigger, finally causes neuroinflammation and neuro-
toxicity, damaging oligodendrocytes and neurons63. 
The presence of  SARS-CoV-2 in the brain was not always associated with 
the severity of  neuroinflammation and immune-activation, probably underlin-
ing the fact that the virus can hide in neurons and elude the surveillance of  the 
immune system, or that the immune response is not effectively activated in the 
infected areas unless the neurons that were infected first have been significantly 
impaired41.
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As regards peripheral nerve dissemination, coronaviruses are known to invade 
peripheral nerve terminals and spread retrogradely across nerve synapses, reach-
ing the CNS. Several viruses may spread to the peripheral nerves by binding to 
specific receptors on the axons or dendrites of  the neurons64. Once the neu-
rons are infected, the viruses reside in endosomal vesicles, resulting from the 
cytomembrane during viral entry, and use dinein to transport the vesicles along 
the microtubule to the centrosome beside the nucleus. Gradually, the viral capsid 
disassembles, according to the change in pH in the endosomal vesicle, and the 
viral nucleic acids are then released to the cytoplasm, allowing viral replication. 
Finally, viral nucleic acids and viral proteins are transported to synaptic membrane 
for further assembly and transmission to the next neuron and to the CNS7.
Recently, a rapid accumulation of  SARS-CoV-2 in the brain was reported after 
intranasal injection using a new humanized ACE knock-in-mouse model56. The 
most likely way of  entering the CNS following intranasal infection is through the 
olfactory receptor neurons, also known as olfactory sensory neurons27,29.
Figure 1.3: Possible SARS-CoV-2 entry to the central nervous system (CNS)  
via the olfactory nerve
SARS-CoV-2 entry through the olfactory nerve. SARS-CoV-2 can infect the ol-
factory epithelium thanks to the ACE2 receptor expressed by the horizontal basal 
cells. Horizontal basal cells can mature in infected olfactory neurons that are con-
nected with neurons in the olfactory bulb; these neurons allow the viral spread 
to other areas in the CNS. Furthermore, the infected olfactory epithelial cells can 
release the virus at the cribriform plate. Reproduced from 25 with permission.
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The virus can pass the neuroepithelium of  the olfactory mucosa and reach 
the olfactory bulb, the olfactory nerve, and, from there, eventually spread to 
the hippocampus or other brain structures27,32. The ability to enter the olfactory 
bulb was reported for SARS and another coronavirus, OC43, using murine 
models of  human coronavirus infection65, and several studies have recently pro-
posed this process in the context of  SARS-CoV-225,33,56,59,66,67. Figure 1.3 shows 
the proposed mechanism for SARS-CoV-2 entry into the CNS through the 
olfactory receptor neurons25. Given that SARS-CoV-2 spreads through the res-
piratory tracts, the olfactory nerve may serve as a major retrograde route for 
the spread of  the virus to the CNS7,68. Furthermore, the proximity of  the cribri-
form plate to the infected nasal epithelium, possible traumas due to sneezing, 
and the detection of  the highest SARS-CoV-2 viral load in nasal swabs com-
pared to bronchoalveolar lavage or pharyngeal swabs, all seem to confirm the 
different means of  entry into the CNS through this route25,32.
SARS-CoV-2 could infect the olfactory neurons thanks to its binding to 
NRP1 and BSG. In fact, both these proteins are expressed in the olfactory bulb 
at higher levels than ACE2 or TMPRSS2; NRP1 is also expressed in the olfac-
tory epithelium69-73. In contrast, in another model, the first target of  the virus 
could be the sustentacular cells (SUSs) thanks to their expression of  ACE2 and 
TMPRSS2; the infection of  these cells triggers a cascade of  events leading to 
anosmia and eventually allows access of  the virus to the CNS.
The possible entry through olfactory receptor neurons has also been hy-
pothesized after the detection of  SARS-CoV-2 RNA and viral proteins, with 
associated microgliosis and/or lymphocytic infiltrations, in the olfactory mu-
cosa of  most of  the autopsies that have been carried out41. In animal models, 
immunostaining for SARS-CoV-2 revealed extensive staining in secondary and 
tertiary brain regions connected with the olfactory bulb, and the possibility of  
invasion of  the brain in a retrograde manner along gustatory and trigeminal 
pathways at the early stage of  infection was shown24.
Other potential routes of  brain infection through nerve dissemination could 
be possible, as well as via vagus, trigeminal and nasopharyngeal nerves; in 
fact, ACE2 and NRP1 are expressed in the vagus nerve in animal models, and 
trigeminal and nasopharyngeal nerves are easily exposed to SARS-CoV-225,53. 
SARS-CoV-2 fragments have been found in a patient’s conjunctiva, where the 
sensory nerve endings of  the trigeminal nerve are found. In addition, local 
peripheral nerves of  the gastrointestinal tract may play a role in the retrograde 
penetration of  SARS-CoV-2 to the CNS53.
However, additional data on humans are needed to understand if  these 
mechanisms are likely to produce CNS infection25.
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Indirect CNS damage in the course of  SARS-CoV-2 in-
fection: non-specific complications of  systemic disease 
The CNS could also be damaged by hyperinflammation syndrome and the 
“cytokine storm” that is triggered outside the brain by SARS-CoV-2, or by the 
severe effects of  systemic disorders, such as sepsis, hyperpyrexia, hypoxia, hy-
percoagulability and critical illness with multiorgan failure25,32,74,75.
The excessive levels of  proinflammatory cytokines and chemokines in the 
systemic circulation, caused by a maladaptive innate immunity, may increase 
the permeability of  the BBB; the passive flow of  cytokines/chemokines to 
the CNS, together with infected immune cells, could damage the brain58,61. 
Furthermore, IL-6, IL-1 and TNF-a are all upregulated in the brain of  infected 
animal models and are produced in the human CNS following brain injuries37. 
In fact, sepsis and the subsequent inflammatory “cytokine storm” has been 
implicated in cases of  an altered state of  consciousness37. Increased levels of  
pro-inflammatory cytokines in the CNS could also persist for a lengthy period 
of  time, leading to a post-infectious proinflammatory state that may contribute 
to possible long-term neuroinflammation61.
Metabolic imbalances, including disorders of  blood calcium, sodium and glu-
cose, and renal and/or liver dysfunction, may have secondary negative effects 
on CSN function56.
Systemic factors could also be responsible for the increased risk of  cerebro-
vascular disease in COVID-19 patients. The SARS-CoV-2 binding to the ACE2 
receptor on endothelial cells may result in increased blood pressure. Arterial 
hypertension can also complicate severe or critical COVID-19 as consequence 
of  the viral infection or kidney damage, and can result in ischemic or cere-
bral bleeding74. Together with an increase in blood pressure, thrombocytopenia 
and thrombus formation due to hypercoagulability in the brain or in peripheral 
veins could finally lead to stroke. Indeed, the marked systemic inflammation 
and hypercoagulability that characterize severely affected patients are associat-
ed with increased risk of  thrombotic events and stroke. Cases of  myocarditis 
associated with SARS-CoV-2 have also been described and can lead to ischem-
ic stroke through heart failure, with a reduction in the cerebral blood supply, 
or supra- and ventricular arrhythmias causing intra-ventricular thrombus for-
mation. Finally, systemic and CNS inflammatory vasculitis have been reported 
from autopsies of  COVID-19 patients56.
Severe COVID-19 with acute respiratory failure, severe acute respiratory dis-
tress syndrome (ARDS), or even cardiac arrest can be associated with cerebral 
hypoxia32,74. Hypoxia may cause indirect neuronal damage56. There is, however, 
some evidence that the possible hypoxic injury is not an underlining mechanism 
of  CNS impairment in COVID-19. In fact, hypoxia causes specific features on 
cerebral imaging: (i) the localization of  lesions in grey matter; (ii) the edema, loss 
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of  grey/white matter differentiation, reversal sign, white cerebellum sign, linear 
hyperdensity outlining the cortex and pseudo-subarachnoid bleeding on a CT 
scan; or (iii) cytotoxic edema within the first 24 hours with T2-hyperintensity 
of  the lesions, subsequent pseudo-normalization of  the lesions after 1 week 
and T1-hyperintensity after 1-2 weeks suggesting cortical laminar necrosis on 
MRI76. The evolution of  these lesions has not been described in COVID-19 
patients. Moreover, most patients are intubated and on mechanical ventilation 
before they develop cerebral hypoxia74.
It has been hypothesized that the gut-brain axis could also be responsible 
for the CNS impairment during the clinical course of  SARS-CoV-2 infection; 
however, the actual impact of  SARS-CoV-2 on gut microbiota has yet to be 
established. The possible relationships between gut and brain could be due to 
a direct viral invasion of  the CNS through systemic circulation or the vagal 
nerve after entry from the gut, or the disruption of  the homeostasis of  mucosal 
immunity and gut microbiota with repercussions on the CNS. In fact, a gut 
dysbiosis induced by the virus could make the CNS even more susceptible to 
harmful agents including pathogens and SARS-CoV-2 itself77.
One last mechanism of  possible CNS damage is the effect of  empiric treat-
ments for COVID-19; rhabdomyolisis was sometimes described after treatment 
with antivirals, such as remdesivir and lopinavir/ritonavir, while toxic myopathy 
can be caused by chloroquine or some antibiotics74. Finally, a myasthenic syn-
drome was reported after treatment with chloroquine. However, we must con-
sider that most of  these therapies are no longer recommended in the guidelines 
for COVID-19 treatment, and this mechanism could explain only a small part 
of  the neurological complications associated with COVID-1978,79. A possible 
alteration of  the adaptive cellular immune response to viruses could be caused 
by the use of  steroids, even if  their role in switching off  the inflammatory re-
sponse seems to be more important than any possible negative effects46.
Indirect CNS damage during SARS-CoV-2 infection: pa-
ra-infectious and post-infectious immune-mediated disease
SARS-CoV-2 could cause indirect damage to the CNS because of  an in-
fection-triggered excessive and detrimental immune activation47. Autoimmune 
responses to the virus have also been proposed as para- or post-infectious 
mechanism of  CNS damage and could explain some neurological manifesta-
tions, such as Guillain-Barré syndrome, acute necrotizing encephalopathy, and 
acute disseminated encephalomyelitis, that have been described in COVID-19 
patients26,37,43.
As regards immune-mediated process, SARS-CoV-2 infection may be asso-
ciated with a process of  neuroinflammation, similar to that described in other 
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viral infections and in neurological diseases, such as Alzheimer’s and Parkinson’s 
disease. SARS-CoV-2 could escape from the immune system and spread to all 
CNS tissue, causing increased viral replication or over-reactive innate immune 
responses61. The activation of  glial cells by SARS-CoV-2 could result in further 
production of  cytokines/chemokines that ultimately damage neurons61.
The neuroinflammation could also be associated with cellular senescence 
and a state of  cell proliferative arrest, as an adaptive response to the viral infec-
tion, eventually resulting in neurodegenerative processes. The possibility that 
neurodegenerative diseases could follow the viral infection in certain patients 
as long-term consequences is still under investigation32,58. The possible causes 
could be the establishment of  a latent reservoir of  SARS-CoV-2 in the CNS 
and long-term neuroinflammation26,61. Following latent viral infection, vascu-
lar endothelium dysfunction and oxidative stress could persist, and both these 
processes have been well described as determinants of  neurodegeneration61,80.
Immune-mediated demyelinating diseases have been described for other 
coronaviruses, following the virus-induced inflammation and activation of  gli-
al cells; the same mechanism could lead do demyelinating diseases also after 
SARS-CoV-2 infection67.
Brain regions affected by SARS-CoV-2 infection
Brainstem could be one of  the major areas affected by SARS-CoV-2 infec-
tion in the CNS; one hypothesis is that the infection of  respiratory centers in 
the medulla oblongata and the pons could contribute partially to the respiratory 
breakdown of  COVID-19 patients. The spread via synapse-connected route 
into the brainstem cardiorespiratory centers of  the medulla oblongata has been 
demonstrated for other coronaviruses and is thus likely also for SARS-CoV-28. 
Grey matter could be directly impacted by the infection as demonstrated by 
edema and partial neuronal degeneration observed in autopsies. Finally, demy-
elinating lesions have been described in the white matter and the spine8.
Neuropathological findings of  COVID-19 patients
Histological findings described in COVID-19 patients are heterogeneous81. 
The most frequent are: (i) microglial activation, mostly confined to the brain-
stem, the cerebellum, the frontal lobe and meninges; (ii) lymphoid inflamma-
tion including perivascular lymphocytosis, parenchymal lymphocytic infiltration 
and leptomeningeal lymphocytic inflammation with a prevalence of  infiltration 
of  CD8+ cytotoxic T lymphocytes; (iii) hypoxic-ischemic changes; (iv) variable 
degrees of  astrogliosis in all brain regions; (v) myelin loss; (vi) acute/subacute 
brain infarcts; and (vii) primary hemorrhage and microthrombi48,81,82.
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Conclusions
SARS-CoV-2 may be neurotropic and it has been demonstrated that it can 
reach the CNS. The exact mechanisms of  neuropathogenesis of  SARS-CoV-2 
infection are still unknown and are likely to be multifactorial. It is likely that 
the virus could harm the CNS both directly, entering the CNS and triggering a 
process of  neuroinflammation, and indirectly, thanks to systemic inflammation 
and immune-mediated processes. Viral entry to the CNS is under investigation: 
similar to other viruses and coronaviruses, SARS-CoV-2 could enter the CNS 
through the systemic circulation crossing the BBB, through the infection of  
immune cells, such as lymphocytes and monocytes (the “Trojan horse” mecha-
nism) or through a neuronal retrograde dissemination, via olfactory mucosa or 
gastrointestinal tract. Future studies will promote a better understanding of  the 
real neurovirulence of  SARS-CoV-2.
Take-home message
 – SARS-CoV-2 infection can involve the Central Nervous System (CNS) 
causing neurological symptoms at the time of  the diagnosis or neurolog-
ical complications that could appear later, defined as “Neuro-COVID”.
 – SARS-CoV-2 could determine neurological impairment directly invading 
the CNS or indirectly by para/post-infectious immune-mediated disease 
or by a secondary involvement of  the CNS in the course of  systemic 
COVID-19 disease. 
 – The virus reaches the CNS through the blood circulation crossing the 
Blood Brain Barrier (BBB) and/or through the olfactory nerve. The 
exact mechanisms of  viral entry into the CNS are still not completely 
understood. 
 – SARS-CoV-2 can infect the microglia and neuronal cells and the viral 
presence in the CNS triggers an inflammatory cascade; pro-inflammatory 
cytokines and chemokines increase the permeability of  the BBB, allow-
ing the arrival of  new viral particles, as well as immune system cells and 
inflammatory mediators, in the CNS. A process of  neuroinflammation is 
then established which ultimately causes neurotoxicity.
 – The long-term consequences of  “Neuro-COVID” and the possibili-
ty of  establishing a latent viral reservoir in the CNS or developing neu-
rodegenerative diseases following the acute viral infection is still under 
investigation.
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Chapter 2. The lung-brain axis
Giuseppe Francesco Sferrazza Papa, Giulia Michela Pellegrino, 
Stefano Centanni
Introduction 
There is an intrinsic connection between neurological and respiratory func-
tions both in conditions of  health and of  disease. Over the past decades, it has 
become increasingly acknowledged that lung and brain represent an integrated 
physiological ensemble such that insults involving one organ will necessarily af-
fect the other. For instance, it has been shown that neurological conditions such 
as brain death1, traumatic brain injury2, or status epilepticus3 may cause pulmo-
nary edema and lung injury, thus further worsening clinical outcomes4,5. On 
the other hand, severe respiratory disorders such as acute respiratory distress 
syndrome (ARDS) may be responsible for poor neurocognitive outcomes6. 
After a brief  overview of  neurobiology and physiology, this chapter will in-
troduce the concepts of  dyspnea and respiratory failure in COVID-19, and 
then focus on post-COVID sequelae with a special focus on the respiratory 
and neurological aspects. Finally, we will provide some practical recommenda-
tions for the clinician caring for patients post COVID. Further insights into the 
neurogenic component of  COVID-19-related respiratory failure are discussed 
elsewhere in the book.
Neurobiology and pathophysiology
Breathing is a key homeostatic function that regulates gas exchanges of  ox-
ygen (O2) and carbon dioxide (CO2) in the lung in order to stabilize pH and 
support metabolism. Ventilation is the result of  the integrated actions between 
the mechanical properties of  the airways, lungs, respiratory muscles, and the 
chest wall, while gas exchanges are due to the capacity of  the lung to exchange 
gases across the alveolar–capillary membrane.
Respiratory movements occur automatically and continuously, and are driven 
by the rhythmic motor activity generated within neural circuits in the brain-
stem and spinal cord7. The underlying neural machinery is not a simple trigger, 
but rather a complex flexible system that provides physiological and behavioral 
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integration.  Recent research showed that the brainstem respiratory network 
works at multiple hierarchical levels, which allows flexible expression of  dif-
ferent rhythmogenic mechanisms under different physiological conditions and 
enables a wide repertoire of  respiratory patterns8. The core circuit components 
of  the neural machinery that generates the rhythm and shapes the inspirato-
ry and expiratory motor patterns are located within three adjacent structural 
compartments in the ventrolateral medulla: the Bötzinger complex (BötC), pre-
Bötzinger complex (pre-BötC), and rostral ventral respiratory group (rVRG)8. 
Recent experiments showed that, in adult mammals, the rhythm is dominated 
by the pre-BötC9 which seems to work as a self-organized group-pacemaker10.
The respiratory rhythm should then be modulated to satisfy the body’s met-
abolic demand and transformed into an efficient pattern of  movement. To reg-
ulate this task, the brain links sensory information to the motor output, the 
respiratory muscles. To provide this regulation, carotid bodies and brainstem 
chemosensory organs monitor blood O2 and CO2 levels. The carotid bodies are 
located at the bifurcation of  the carotid arteries and produce signals that relate 
mostly to O2 levels in arterial blood
10,11. Although lung and cardiac diseases 
are the main causes of  breathing disorders, dysfunctions of  the neural control 
of  breathing may play a role in some diseases such as sudden infant death 
syndrome (SIDS)12,13. Several genetic disorders cause abnormal respiration, in-
cluding Rett syndrome14 and congenital central hypoventilation syndrome (also 
known as Ondine’s curse)15. Death due to progressive respiratory failure occurs 
in neurodegenerative diseases such as amyotrophic lateral sclerosis, and may 
play a role in some cases of  Parkinson’s disease16 and multiple system atrophy 
(MSA).
Respiratory dysfunction and brainstem viral infections
The relationship between respiratory alterations and brainstem viral infec-
tions has long been studied and appears to stem from both primary respiratory 
and brainstem affections. 
A) Primary respiratory affections - changes in primary afferent neurosensors sub-
sequent to respiratory viral infections may alter the synaptic integration of  pe-
ripheral inputs at the brainstem level. The most frequent consequence is cough 
hypersensitivity following an acute respiratory viral infection. Studies employ-
ing capsaicin inhalation challenge to measure cough reflex sensitivity have doc-
umented a transient tussive hyper-responsiveness induced by upper respiratory 
infections (URI) that reverts to normal values by 4-8 weeks post infection. An 
underlying hypersensitivity of  the cough reflex potentiates the effect of  the 
exogenous stimulus, resulting in refractory, chronic cough in a particular sub-
group of  individuals17. 
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Numerous mechanisms have been proposed to explain the transient cough 
and enhancement of  cough reflex sensitivity associated with acute viral URI. 
Direct effects of  the viral infection on airway epithelium include inflamma-
tion and cytokine release which stimulate sensory afferent nerves. Other airway 
effects of  URI include increase in neurotransmitter levels, such as Substance 
P, reduced activity of  neutral endopeptidases, increased neural receptor levels 
(NK-1), and transient modulation of  airway neural activity. Increased leukot-
riene production and mucus hypersecretion are likely additional contributors 
to cough induction. Many patients experience cough during acute COVID-19 
pneumonia, and less frequently report cough as a symptom of  long COVID. 
The latter might result from the invasion of  vagal sensory neurons by SARS-
CoV-2 or a neuroinflammatory response, or both, leading to peripheral and 
central hypersensitivity of  cough pathways similar to that of  the cough hyper-
sensitivity syndrome.
B) Brainstem affections - brainstem viral infections can cause respiratory com-
plications, both by direct pulmonary involvement and respiratory muscle failure.
Most tumoral and infectious causes of  brainstem encephalitis (BE) deter-
mine ventilatory failure by compromising the central ventilatory control, as is 
the case of  Listeria Monocitogenes, herpes simplex virus (HSV) 1 and 2, and 
human herpes virus 6 (HHV6); some may affect respiratory muscles as well, 
such as the Epstein-Barr virus (EBV)-related overlapping of  BE and Guillain-
Barré syndrome, while others primarily determine bulbar muscle impairment 
and subsequent respiratory failure, such as the progressive multifocal leukoen-
cephalopathy (PML) caused by the JC polyomavirus18. 
Brain stem encephalitis caused by enterovirus 71 determines a release of  cy-
tokines and chemokines which may induce secondary pulmonary edema (PE). 
The disease is a hyperinflammatory syndrome resulting from hypercytokinemia 
and central nervous system inflammation of  various inflammatory mediators. 
Some studies have shown that proinflammatory cytokines (interleukin [IL]-6, 
tumor necrosis factor [TNF]-α, and IL-1β) are associated with brainstem en-
cephalitis that is complicated by PE19.  
Recent reports have provided some evidence of  the occurrence of  acute res-
piratory failure in COVID-19 due to neurotropism of  the brainstem by SARS-
CoV-2, which may contribute to the pulmonary damage. SARS-CoV-2 proba-
bly invades the brain via axonal transport and transneuronal spread from the 
olfactory nerves on to the rhinencephalon, finally reaching the brainstem and 
causing the irreversible respiratory failure seen in severe COVID-19, typically 
characterized by lack of  dyspnea20.
Patients with COVID-19 often develop respiratory failure 8-14 days after 
symptom onset, with “silent hypoxemia” and a high respiratory rate, resulting 
in hypocapnia. The hypoxia in COVID-19 leading to stimulation of  the pre-
BÖTC via the chemoreceptor area is expected to cause an increased respiratory 
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rate and depth that has often been reported in COVID-19 patients. On the 
contrary, the patients with profound hypoxia seemingly appear to be asymp-
tomatic, though respiratory failure is expected to occur quite soon. Damage to 
vagal receptors of  the lungs, and perhaps mechanoreceptors of  the respiratory 
muscles, might explain the lack of  dyspnea, along with a possible defective cen-
tral neural system processing of  the respiratory signals21. 
Respiratory clinical physiology 
Patients with persistent respiratory symptoms after COVID-19 need to be 
thoroughly examined to assess the presence of  disease sequelae. Outside the 
emergency setting, pulmonary function testing (PFTs) is part of  the key investi-
gations, and this must be performed before any invasive or second-line imaging 
tests such as computed tomography.
As the COVID-19 infection quite often affects lung parenchyma, spirome-
try and lung volume measurements may be of  help to detect the lung disease. 
This is strongly suggested by a decrease in total lung capacity (TLC), forced 
vital capacity (FVC), and the forced expiratory volume in 1 s (FEV1) below the 
threshold of  natural variability22 (Figure 2.1). 
Figure 2.1: Lung volumes
VT: tidal volume; RV: residual volume; FRC: functional residual capacity;  
VC: expiratory vital capacity; TLC: total lung capacity. 
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Measurement of  lung gas exchange is also part of  the clinical evaluation of  
the patients affected by COVID-19 infection. For instance, a decrease in dif-
fusing capacity for carbon monoxide is an index of  alveolar inflammation or 
pulmonary fibrosis. Similarly, a decrease in arterial oxygen tension will indicate 
an important gas exchange impairment22. In contrast, an increase in arterial CO2 
tension is consistent with an impairment in ventilation as a result of  the inability 
of  the inspiratory muscles to maintain the minute ventilation required to satis-
fy metabolic requirements. Under these conditions, measuring the inspiratory 
muscle force and diaphragm activity with ultrasound will help estimate the se-
verity of  the respiratory muscle defect.
Dyspnea: a complex symptom 
The American Thoracic Society defines dyspnea as a “subjective experience 
of  breathing discomfort that consists of  qualitatively distinct sensations that 
vary in intensity. The experience derives from interactions among multiple 
physiological, psychological, social, and environmental factors, and may induce 
secondary physiological and behavioral responses”23. There are numerous sen-
sory receptors located throughout the respiratory system that send afferent in-
formation to the central nervous system.  It is widely accepted that there are at 
least three main dyspnea components, depending on quality of  the symptom, 
the generating stimuli, and the pathways involved: 1) air hunger; 2) work/effort; 
and 3) chest tightness. 
1) Air hunger is a primordial sensation that signals the urgency to breathe 
and correlates with the failure of  pulmonary ventilation in maintaining gas ex-
changes. It is strongly linked to the development of  hypercapnia, and, to a lesser 
extent, of  hypoxia. To the best of  our practical daily experience, this is the prin-
cipal component of  the dyspnea experienced during COVID-19. 
2) Respiratory effort arises when the work of  breathing or the required mo-
tor command is increased by high minute ventilation, by impedance to inspira-
tion, by weakness of  respiratory muscles, or by placing inspiratory muscles at a 
disadvantageous length.
3) Chest tightness appears to be specific to bronchoconstriction and is the 
earliest symptom of  asthma. It arises from the activation of  rapidly adapting 
stretch receptors (RARs) and C-fiber receptors in the lungs. 
Given the different mechanisms underlying dyspnea, it is of  practical help to 
assess not only the presence and intensity, but also the different qualitative com-
ponents. The widely used one-dimensional scales (such as the BORG scale24, 
the Visual Analog Scale [VAS]25, or the Medical Research Council [MRC] scale26) 
adequately measure the intensity of  the perceived dyspnea but cannot charac-
terize its different components. In the past years, there has been great interest 
in the development of  novel tools that capture the different, multidimensional 
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qualities of  dyspnea such as the Multidimensional Dyspnea Profile (MDP) and 
the Dyspnea-12 Questionnaire (D12)27. 
Respiratory failure in COVID-19
The clinical spectrum of  COVID-19 is quite heterogeneous. In a recent 
study, severity of  the respiratory infection, older age, and renal impairment, and 
absence of  any comorbidities were predictors of  28-day mortality in patients 
affected by COVID-1928. Respiratory failure due to interstitial pneumonia, de-
creased lung compliance, and hypoxemia are the most critical features of  the 
disease28,29. Examining a series of  ventilatory features such as lung elastance, 
ventilation-to-perfusion ratio, lung weight and lung volume recruitability, 
Gattinoni et al. were able to identify patterns with different combinations of  
the lung function/imaging parameters possibly explaining the changes in the 
severity of  the disease over time and its susceptibility to different treatments30.
In addition, disproportionate endothelial damage may disrupt pulmonary 
vasoregulation, thus promoting ventilation-perfusion mismatch and fostering 
thrombogenesis. Finally, remarkably increased respiratory drive could potential-
ly increase tidal strain and energy loads to highly vulnerable tissue, thus adding 
patient self-inflicted lung injury31 to the mix of  the lung’s inflammatory assault32. 
Mechanical ventilation support keeps patients alive until their own biological 
mechanisms are able to outwit the coronavirus33. The best way to minimize 
ventilator-associated complications is to avoid intubation unless it is absolutely 
necessary34,35. In a cohort of  64 patients, Brusasco et al.36 reported successful 
treatment of  severe COVID-19 pneumonia by CPAP ventilation in 83% of  the 
cases, with only four deaths and seven patients requiring subsequent intubation. 
In a multicenter study performed on 175 patients, Aliberti et al.37 reported only 
a 55% efficacy of  helmet CPAP in treating severe COVID-19 pneumonia, with 
higher rates of  CPAP failure occurring in patients with more severe pneumonia 
upon admission and higher IL6 levels. 
Even though there is no consensus as to the best length of  time for me-
chanical ventilation, most of  the studies agree on the concept of  stopping the 
treatment as soon as possible to avoid risks of  infection and death38. 
It has been documented that, whereas the most severe and critical COVID-19 
patients have no significant long-term sequelae, a substantial proportion suffers 
from long-lasting symptoms and respiratory impairment. In a study performed 
on severe and critical COVID-19 patients, about 25% of  patients complained 
of  persistent fatigue at the 3-month follow-up. Twenty percent of  the patients 
exhibited signs of  fibrosis on lung HRCT, and this was somewhat correlated 
with length of  stay in the intensive care unit (ICU) and mechanical ventilation.
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Post-COVID clinical sequelae
COVID-19 infection has been shown to frequently cause complications that 
last weeks to months after recovery. This has been named Long COVID and 
defined as a post-viral illness that can affect survivors of  COVID-19 regardless 
of  the initial disease severity or patient age, with a prevalence in the female sex 
and in those patients exhibiting more than five early COVID-19 symptoms or 
early dyspnea39.
Clinical manifestations are quite heterogenous and fluctuate over time, 
with the most common symptoms being fatigue and dyspnea that can last for 
months after acute COVID-19. Other persistent symptoms may include cogni-
tive and mental impairment, chest and joint pains, palpitations, myalgia, smell 
and taste dysfunctions, cough, headache, and gastrointestinal and heart prob-
lems. Possible pathophysiologic mechanisms are persisting tissue damage with-
in the lung, brain, and heart, and/or exaggerated inflammatory processes as a 
result of  viral persistence, immune dysregulation, or autoimmunity. 
Interestingly, many of  the above mentioned respiratory, cardiovascular, gas-
trointestinal, and neurological problems that follow the COVID-19 infection 
have also been reported in other chronic diseases involving the neural system, 
such as chronic pain, migraine and myalgic encephalomyelitis or chronic fatigue 
syndrome. Whether this could be explained by neural mechanisms activated 
independently of  the underlying diseases is an interesting hypothesis that, how-
ever, still has to be demonstrated.
Practical recommendations for the clinician
Patients recovering from COVID-19 pneumonia frequently report symp-
toms such as dyspnea, cough, asthenia, and general malaise even some time 
after the initial infection.
In view of  possible further pharmacological or physical treatments, the pa-
tient should be carefully evaluated according to different criteria (Table 2.1). In 
chronological order, there has been a tentative suggestion to first review the 
clinical history of  the patient along with the time course and duration of  the 
COVID-19 disease and consider any other associated diseases that could po-
tentially interfere with recovery. Measuring dyspnea with the VAS scale should 
be performed with current scales such as the MRC or multidimensional tools. 
Measuring oxygen saturation at rest and during walking is another simple and 
effective way of  evaluating the patient’s clinical condition and excluding severe 
diseases such as persistence of  pulmonary thromboembolism. Routine blood 
tests are then recommended along with pulmonary function testing inclusive 
of  spirometry, measurement of  lung volumes, DLCO, assessment of  the res-
piratory muscle force, and blood gas analysis. Based on these findings, CT scans 
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will then be recommended to provide support to steroid therapy in case of  
persistence of  interstitial lung disease.
Finally, a cardiopulmonary exercise test could be indicated in case the dysp-
nea cannot be explained on the grounds of  the above mentioned clinical, 
functional, and radiological tests. This can identify the presence of  anomalous 
respiratory or cardiovascular adaptations to exercise and/or locomotor muscle 
deconditioning. In the opposite case, the hypothesis of  psychogenic dyspnea 
could find substantial support40.
Table 2.1: Practical issues in managing patients after COVID-19 
 pneumonia or post-COVID syndrome
Assessment Treatment
SYMPTOMS AND LUNG FUNCTION
• Check adherence to therapy and other 
coexisting medical conditions
• Avoid empiric use of  bronchodilators 
(indicated only for obstructive pulmonary diseases)
• Vaccines (SARS-CoV-2, pneumococcal, flu)
• Rehabilitation for selected patients
• Consider enrolling in clinical trials
• Assess dyspnea (exertional), cough and fatigue 
(consider referral to neurologist)
• Spirometry and DLCO
• Consider ABG if  SpO2<92% in room air or 
suspected chronic respiratory failure
      In selected patients*:
• full PFTs with body plethysmography
• respiratory muscle testing (e.g., MIP/MEP, 
SNIP)
• Perform CPET 
IMAGING
• Follow up ground glass areas/lung nodules 
(e.g., high-risk patients such as smokers)
• Avoid unjustified use of  CT scan
• Consider use of  lung and diaphragm 
ultrasound
ABG: arterial blood gas; COPD: chronic obstructive pulmonary disease;  
CT: computed tomography; PFT: pulmonary function tests; CPET: cardiopulmonary 
exercise testing; DLCO: diffusing capacity of  the carbon monoxide; MEP: maximum 
expiratory pressure; MIP: maximum inspiratory pressure; SNIP: sniff  nasal inspiratory 
pressure. * Particularly for patients who underwent long term invasive ventilation.
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Take-home message
 – SARS-CoV-2 induces a wide spectrum of  neurological and respiratory 
manifestations that may co-exist with and complicate the clinical course 
of  the disease.
 – Respiratory failure due to interstitial pneumonia is the dominant clinical 
issue and the main determinant for the prognosis in the acute care setting; 
assessing and monitoring its severity and minimizing invasive support may 
help to improve treatment efficacy.
 – Post-COVID syndrome is an intriguing clinical entity that is currently the 
subject of  much debate. Many survivors have been affected, with heterog-
enous clinical presentation often requiring a multidisciplinary diagnostic 
approach.
 – Given the complex interactions between lung, muscles, and brain after 
acute respiratory failure, not only due to SARS-CoV-2, clinical physiology 
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Chapter 3. Does the COVID-19 related 
respiratory failure have a neurogenic 
component?
Davide Chiumello, Matteo Bonifazi
Pathological pathways 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandem-
ic has pushed the response of  health systems to maximum capacity. Worldwide 
the surge of  cases has overwhelmed the facilities and human resources avail-
able1-4. Intensive care units have found themselves with no available beds due 
to the huge influx of  severe cases over just a few weeks, with acute respirato-
ry distress syndrome (ARDS) as the main reason for admission1-4. Indeed, its 
structure and mechanism of  transmission and replication make SARS-CoV-2 
highly infectious5-9.
One widely reported phenomenon is the presence of  a profoundly hypox-
emic patient with the slightest, or no, dyspnea, out of  proportion to the extent 
of  radiographic abnormalities and changes in lung compliance. This clinical 
manifestation has been called “happy hypoxemia or hypoxia” but has been bet-
ter described as “silent hypoxemia”. This has led to speculation that there are 
underlying pathophysiologic differences between lung injury due to COVID-19 
and ARDS from other causes10-14. 
Histological SARS-CoV-2 has been established as a cause of  severe alveolar 
damage and pneumonia. The consolidation of  lung parenchyma precipitates 
the alterations in blood gases in COVID-19 patients that are known to compli-
cate and cause hypoxemic respiratory failure15,16. Indeed, the damage caused by 
SARS-CoV-2 at the level of  gaseous exchange in the lungs causes exudative and 
organized diffuse alveolar damage. It has been reported that severely hypox-
emic COVID-19 patients may present quite different characteristics: 1) normal 
breathing (“silent” hypoxemia) or remarkably dyspneic; 2) quite responsive to 
nitric oxide or unresponsive; 3) deeply hypocapnic or normo/hypercapnic; and 
4) responsive to a prone position or not responsive. Therefore, the same disease 
presents itself  with notable heterogeneity. The ongoing exudation and fibrosis 
in the terminal bronchioles and alveolar walls thicken the gaseous barrier leading 
34 Neurology of  COVID-19
to profound hypoxia and the risk of  hypoxemic-respiratory failure. Many pa-
tients with a severe drop in partial alveolar (pa)O2 remain asymptomatic, initially 
due to possible compensation by an increase in the rate of  breathing that comes 
into play through the neurogenic mechanism against hypoxia resulting from a 
poor diffusion of  O2 across the alveolar barrier
15-17. A possible explanation for 
such severe hypoxemia occurring in a compliant lung is the possible loss of  lung 
perfusion and hypoxic vasoconstriction10-13.
However, the alteration of  paO2 and paCO2 in COVID-19 is complex and 
difficult to understand when compared to conventional viral cases of  pneumo-
nia. The reason for this added complexity is the concurrent renal, gastrointes-
tinal, and adrenal damage, coagulation abnormalities, and metabolic derange-
ments like lactate production from cellular damage that are known contributors 
to the maintenance of  blood pH and blood gases, and act as buffers to combat 
any alteration that may occur in these parameters.
An alarming but yet unexplored component in COVID-19 is the damage 
to the neurons in the central nervous system (CNS) that has been reported to 
start during the disease course in some patients. Emerging data on COVID-19 
cases from hospitals and autopsies in the last few months have helped in un-
derstanding the pathogenesis of  respiratory failures in COVID-1918-21. Recent 
reports have provided overwhelming evidence of  the occurrence of  acute res-
piratory failure in COVID-19 due to neurotropism of  the brainstem by SARS-
CoV-222-26. It is easy to compute the complexity that ongoing damage to res-
piratory regulating neurons in CNS would add to the pulmonary damage in 
COVID-19. Knowledge of  the circuit of  neural projections and synapses that 
regulate the breathing process is essential to understanding respiratory failure in 
general and that seen in COVID-19.
The breathing process carried forward by the CNS under physiological con-
ditions is an involuntary (autonomous) process enforced by pacemaker cells in 
the pre-Bötzinger complex (pre-BÖTC) on either side of  the medulla oblon-
gata in the brainstem. These neurons produce rhythmic discharges that reach 
the phrenic nerve motor neurons. In addition, dorsal (DRG) and ventral (VRG) 
groups of  respiratory neurons are present in the medulla, and they are known 
to project to the pre-BÖTC pacemaker neurons. The rhythmic discharges of  
the pre-BÖTC pacemaker neurons are modified by a pneumotaxic center (nu-
cleus parabrachialis), which may play a role in switching between inspiration and 
expiration in the pons and afferents in the vagus nerve from receptors in the 
airways and lungs. 
A rise in the paCO2 or H+ ion concentration of  arterial blood or a drop in 
its paO2 increases the rhythmic discharge in the medulla oblongata and vice 
versa22-28.
The effects of  variations in serum chemistry on the rhythmic discharge of  
pre-BÖTC are mediated via respiratory chemoreceptors: the carotid and aortic 
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bodies and the central chemoreceptor area in the medulla29.  Each carotid and 
aortic body contains isles of  two types of  cells, glomus type I and glomus type 
II cells (supporting cells), surrounded by fenestrated sinusoidal capillaries. 
The glomus type I is closely associated with glossopharyngeal nerve afferent 
nerve (CN-IX) endings and is stimulated by hypoxia-induced inhibition of  O2-
sensitive potassium K+ channels. The transmitter involved appears to be do-
pamine, which stimulates the nerve endings by way of  D2 dopaminergic recep-
tors. The glomus type I receptors in the carotid/aortic bodies are stimulated, 
with increased afferent nerve discharges, by a rise in the paCO2 or H+ concen-
tration of  arterial blood or a decline in its paO2 below 55-60 mmHg. Therefore, 
the stimulatory effects of  hypoxia on ventilation are not manifested until they 
become strong enough. In addition, even though spontaneous breathing is not 
usually a conscious phenomenon, both inspiration and expiration are under 
voluntary control. The pathways for voluntary control pass from the neocortex 
(Brodman’s area 4 neurons) to the motor neurons innervating the respiratory 
muscles, without influencing the medullary neurons20-30.
Invasion of  the CNS by SARS-CoV-2 has recently been shown in areas such 
as the brainstem that control the normal breathing process with nuclei like the 
pre-BÖTC. This may explain why some of  the patients with COVID-19 who 
have been reported to have recovered from pneumonia could not be weaned off  
invasive mechanical ventilation, and the occurrence of  acute respiratory arrests 
seen in COVID-19. This debate is important for many reasons, one of  which is 
the fact that permanent damage to the medullary respiratory centers by SARS-
CoV-2 would not benefit from mechanical ventilators, something which could 
be happening during the management of  COVID-19 patients20-31. Moreover, 
there have been reports of  acute respiratory failure in 45-65% of  cases of  
COVID-19 in which the patients lost spontaneous breathing, required mechan-
ical ventilation, and then later died. Some of  the patients with COVID-19 that 
have been reported to recover from pneumonia but could not be weaned off  
invasive mechanical ventilation need to be investigated for deteriorating SARS-
CoV-2 neurotropism that can prove fatal. The occurrence of  these spontane-
ous (autonomic) breathing control failures early in COVID-19 is alarming and 
possibly reflects the damaging effect of  SARS-CoV-2 on the CNS nuclei that 
control normal involuntary breathing mechanics18-30. 
SARS-CoV-2 probably invades the brain via axonal transport and transneu-
ronal spread from the olfactory nerves on to the rhinencephalon, ultimately 
reaching the brainstem and causing the irreversible respiratory failure seen in se-
vere COVID-19, typically characterized by lack of  dyspnea. Additionally, SARS-
CoV-2 has been isolated from the cerebrospinal fluid (CSF) of  COVID-19 pa-
tients and the hematogenous or lymphatic routes have been proposed as ways 
through which the virus may gain entry to the CNS20-30.
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It is more likely that the virus invades the brainstem in the early phases of  
COVID-19. Therefore, respiratory failure due to damage in respiratory regulat-
ing centers can occur long before the hypoxemic influence comes into effect, 
as has been reported recently, since severe respiratory distress is observed 8-14 
days after symptoms develop. In fact, even partial damage to the pacemak-
er neurons in the pre-BÖTC area can lead to intervals of  loss of  autonomic 
breathing and lead to the neurological manifestations reported in COVID-19. 
Moreover, the spinal motor neurons that act as a nuclear group for phrenic 
nerve, emerging as nerve roots, are located at cervical nerves 3, 4, and 5 (C3, 
C4, and C5) and could be involved, as has recently been reported, in affect-
ing the diaphragm and thoracic muscles, completely interrupting respiratory 
function21-31. 
Clinical features and possible treatments
Correlating the pulmonary sign and symptoms of  patients with COVID-19 
and the ongoing neurological deficits can help identify the possible regions of  
the CNS where SARS-CoV-2 impacts the breathing process. The ability of  
COVID-19 patients to retain control over voluntary breathing suggests that 
the neocortical projections of  the brain to the spinal motor neurons are spared. 
Moreover, the damage to both the pneumotaxic center and vagus nerves is 
also expected to result in inspiratory spasms as if  the patient was holding their 
breath in the inspiratory phase of  breathing (apneusis), as has been reported. 
Damage to the central chemoreceptor can strongly affect breathing rate and 
depth. Partial neurotoxicity of  the neurons in the pre-BÖTC region which nor-
mally generates pacemaker impulses for autonomic breathing appears to be the 
most likely explanation for the patient having a sensation of  losing the ability 
to breathe spontaneously, while a complete or substantial loss of  the neurons 
in this region would induce neurogenic acute respiratory arrest despite the pres-
ence of  moderate hypoxia and hypocapnia. 
The question of  survival in COVID-19 patients could also be best explained 
by the degree of  the quantitative loss of  neurons in the pre-BÖTC region and 
the ability of  the neurons to compensate for a partial loss in those patients who 
survive the episode of  medullary neurotoxicity in COVID-19. Paralysis of  the 
diaphragm and damage to spinal motor neurons below C5 segments, or a com-
bination of  these, can contribute to syndromic respiratory failure21-33. 
All these signs could, therefore, be explained by the concept of  central neu-
rogenic respiratory failure. Given this, it is important to mention that, in a severe 
case of  COVID-19, distinguishing hypoxemic respiratory failure from exclusive 
respiratory arrest due to damage to the brainstem pre-BÖTC and phrenic nerve 
nuclear group at C3-C5 is difficult if  not impossible. A respiratory arrest that 
cannot be explained by the extent of  lung damage in early onset COVID-19 
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and abnormal breathing patterns should undergo thorough clinical investiga-
tion, since, as previously mentioned, neuro-invasiveness by SARS-CoV-2 can 
occur early during COVID-19 and could be missed.
Moreover, the decline in arterial O2 tension is normally detected by O2-
sensing cells in the carotid body (CB), the main arterial chemoreceptor, which 
rapidly activates sensory fibers impinging on neurons in the brainstem to in-
duce compensatory hyperventilation and increase the heart rate. In this way, 
both O2 uptake and its distribution to the tissues are enhanced. Indeed, bilateral 
removal of  the CB in humans leaves individuals unaware of  hypoxemia, with 
complete abolition of  the hypoxic ventilatory response. Therefore, inhibition 
of  CB responsiveness to hypoxia could be a plausible explanation for the im-
paired respiratory drive and reduced dyspnea that characterizes the “silent hy-
poxemia” observed in COVID-19 patients. The CB parenchyma is organized 
into clusters of  cells called glomeruli. Each glomerulus is composed of  4-8 
neuron-like glomus or Type I cells, which are in close contact with a network 
of  fenestrated capillaries and are richly innervated by afferent sensory fibers of  
the petrosal ganglion. Glomus cells, the O2-sensing elements in the CB, contain 
abundant synaptic vesicles with neurotransmitters that are rapidly released in 
response to hypoxia to activate the sensory fibers that connect the brainstem 
respiratory and autonomic centers. In addition, the CB glomeruli also contain 
a smaller number of  glial-like, Type II or sustentacular cells with interdigitat-
ing processes that envelop the glomus cells. Type II cells are multipotent stem 
cells that can differentiate into O2 sensitive glomus cells to support CB growth 
under sustained hypoxia. Although acute O2-sensing is an intrinsic property of  
CB glomus cells, the functional responses of  these cells are modulated by nu-
merous auto- and paracrine signals generated within the organ. In this regard, 
a local renin-angiotensin system (RAS) and its principal components (angioten-
sinogen, angiotensin-converting enzyme, and angiotensin receptors) have been 
described in the CB. Indeed angiotensin-converting enzyme 2 (ACE2) has an 
important regulatory role in the RAS and it has been identified as the functional 
receptor by which severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) enters human cells. 
Based on the high ACE2 expression found in human CB, it is plausible that 
infection of  chemosensory glomus cells by SARS-CoV-2 could alter their ability 
to detect changes in arterial O2 tension. This could mask the hypoxemia, as oc-
curs in cases of  “silent hypoxemia” in COVID-19 patients. Several studies show 
a highly individual variability of  ACE2 expression in human CB tissue, which 
could explain why there appears to be no explanation as to why any particular 
COVID-19 patient should experience “silent hypoxemia”. 
 Therefore, ventilation dysregulation and dyspnea add to an already injured 
lung, exacerbating the damage. In fact, breathing produces a phenomenon of  
continuous cyclic strain deformation, where the applied pressure is inspiratory 
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pressure. The overall strain for the whole lung can be defined as the ratio be-
tween the tidal volume (Vt) and a reference volume, usually the volume of  air at 
the end of  passive expiration, and the functional residual capacity (FRC). Stress, 
the force acting on a surface unit, produces its deformation. Transpulmonary 
pressure corresponds to the stress in the lung. Strain and stress in the lung tissue 
are closely related to each other through a constitutive relation (stress = tissue 
elastance*strain)34-44. Both play an important role in the onset and development 
of  ventilator-induced lung injury (VILI) and patient self-inflicted lung injury 
(P-SILI).
Figure 3.1: Patient self-inflicted lung injury cycle (PSILI) 
High values of  strain are known to be harmful to the lung and to increase 
mortality34-42.
Assisting ventilation both with non-invasive support and invasive mechanical 
ventilation can be used to minimize stress and strain when impending respira-
tory failure is recognized. 
Continuous positive airway pressure (CPAP) helmets and non-invasive venti-
lation (NIV) can prevent excessive respiratory effort. The latter can be assessed 
through monitoring esophageal pressure swings, a surrogate of  the transpul-
monary pressure in spontaneously breathing patients43-46. 
CPAP potentially modulates drive by improving oxygenation by means of  
positive airway pressure, optimized oxygen delivery, and improvement of  lung 
mechanics, while NIV may reduce respiratory drive by several mechanisms: 1) 
unloading respiratory muscles from inspiratory effort, which also reduces CO2 
production; and 2) improving oxygenation and lung mechanics through increas-
es in positive end-expiratory pressure (PEEP)43-46.
Despite respiratory support, the neurological involvement of  SARS-COV-2 
requires an additional strategy to control dyspnea in these patients. In fact, 
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respiratory drive and respiratory rate could be controlled through sedation to 
prevent and treat high respiratory frequencies along with respiratory support. 
Sedation also plays an important role in making patients comfortable and help-
ing them to cope with what could be several days of  non-invasive ventilation as 
compliance to treatment is fundamental given the lengthy course of  the disease. 
Indeed, measuring respiratory drive in patients with COVID-19 acute distress 
syndrome (CARDS) could be important when selecting the initial ventilato-
ry support and in deciding when to wean the patient off  mechanical ventila-
tion. Indeed, vigorous breathing efforts can amplify the severity of  lung injury, 
which in turn can influence the duration of  mechanical ventilation and impact 
patient outcome. 
The prone position has been widely adopted in COVID-19 patients to treat 
hypoxemia45. However, its role has been fundamental not only to restore gas 
exchange in both awake and sedated patients, but in particular to homogenize 
the lung and reduce unprotective lung ventilation, thus reducing lung injury48-50. 
Despite this, some patients will remain dyspneic, breathing spontaneously, 
with or without respiratory support. Vigorous and dysregulated respiratory ef-
fort, even if  under control in terms of  respiratory rate, may promote P-SILI, 
with generation of  high stress and strain, as shown by a high swing in esopha-
geal, thus transpulmonary, pressure.
Ultimately, this phenomenon worsens the respiratory failure; the patient 
must be intubated and mechanical ventilation is required in up to 20-30% of  
cases. When invasive mechanical ventilation is instituted, there is often an initial 
phase of  deep sedation, which may decrease the respiratory drive and, occa-
sionally, a period of  neuromuscular blockade, which eliminates breathing effort. 
Once assisted breathing is restored, uncontrolled high respiratory drive may 
also resume.
SARS-CoV-2 neurological involvement could also be seen during mechanical 
ventilation; an alteration of  the central nervous system with dyspnea and deliri-
um can promote the development of  asynchronies and VILI51,52.
Ventilator asynchronies have been associated with longer duration of  me-
chanical ventilation and increased mortality. In particular, reverse trigger is de-
fined as a dyssynchrony in which the patient starts to activate the inspiratory 
muscle during a passive insufflation of  the lung (i.e., in non-triggered breaths). 
The inspiratory muscle causes an increase in the inspiratory effort with larger 
Vt and double cycling (breath stacking) with increased stress and strain, leading 
to unprotective ventilation52-53.
Thus, in these patients, early detection of  the possible presence of  asynchro-
ny and reverse trigger is fundamental. Moreover, impaired respiratory drive and 
excessive inspiratory efforts represent a challenge during the weaning process 
from mechanical ventilation, leading to increased mortality and fewer days off  
mechanical ventilation. 
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As has been said, pharmacological intervention with opioids, drugs modulat-
ing agitation and anxiety like dexmedetomidine, as suggested in a recent study, 
and partial muscular paralysis by low-dose neuromuscular blocking agents 
could achieve protective Vts and inspiratory pressures in CARDS patients 
exhibiting uncontrolled high respiratory drive during assisted ventilation54,55. 
Non-pharmacological techniques, such as extracorporeal carbon dioxide re-
moval (ECCO2R) or venous-venous extracorporeal membrane oxygenation 
(ECMO), could also be applied in selected severe cases of  CARDS and refrac-
tory hypercapnia56-58.
Conclusions
With a rapid rise in mortality in patients with COVID-19 exhibiting extrapul-
monary manifestations, there is an urgent need to understand and diagnose the 
neurological symptoms early in the course of  this disease. Future research is 
needed to understand the route of  virus entry (neural or through the blood-
stream), the neuronal damage and the affected areas in the brain, including 
pathological assessment of  the respiratory center in the brainstem.
Take-home message
 – COVID-19 is a systemic disease with multiple organ involvement, espe-
cially the lung.
 – Respiratory failure is not only due to direct damage to the lung but is a 
consequence of  neurological involvement.
 – Respiratory effort and its neurological control play an important role in 
causing acure respiratory distress and lung damage.
 – Sedation together with lung ventilatory strategies to prevent VILI should 
be tailored based on pathophysiology assessment.
 – Understanding neural patterns can help identify phenotypes of  respirato-
ry efforts in COVID-19 patients.
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Chapter 4. Neurological manifestations: an 
overview
Chiara Manfredi, Emma Scelzo, Vincenzo Silani, Carlo Ferrarese, 
Alberto Priori
Introduction
Coronaviruses are enveloped, positive stranded RNA viruses which repre-
sent important human and animal pathogens, predominantly causing respirato-
ry and gastrointestinal tract infections1. However, neurological symptoms have 
been reported in COVID-19 patients from all over the world (Table 4.1)2-4.
Mao et al.5, in the first retrospective study on neurological manifestations, 
estimated that more than one-third (36.4%) of  patients with COVID-19 devel-
op neuropsychiatric symptoms, out of  which the most common were central 
nervous system (CNS) manifestations followed by peripheral nervous system 
(PNS) involvement5.
Table 4.1: Summary of  the neurological manifestations of  COVID-19


























CNS: Central Nervous System; PNS: Peripheral Nervous System; TIA: Transient 
Ischemic Aattack; ADEM: Acute Disseminated Encephalomyelitis; GBS: Guillain-
Barré Syndrome; MFS: Miller-Fisher Syndrome.
Neurological complications appear to be even more common in hospitalized 
patients. It has been reported that over 80% of  COVID-19 patients who re-
quire hospitalization may develop neurological symptoms at some point during 
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their disease course6. Moreover, it seems that patients with a severe course of  
COVID-19 are more likely to develop neurological complications5.
Rates of  symptoms vary by geographical location and patient characteris-
tics. Overall, the most common neurological manifestations reported in Asia, 
Europe and the US were smell and taste disturbances, myalgia, headache, en-
cephalopathy, and dizziness. Cerebrovascular events, movement disorders, mo-
tor and sensory deficits, ataxia, and seizures are not common2,5,6-8.
The EAN survey and the Global Consortium Study of  Neurological 
Dysfunction in COVID-19
In April 2020, the European Academy of  Neurology (EAN) core COVID-19 
Task Force conducted a survey on neurological symptoms observed in patients 
with SARS-CoV-2 infection to assess their incidence and characteristics. They 
distributed a 17-question online survey to EAN members and other physicians 
worldwide, collecting data from a total of  2,343 responders (82% neurologists), 
mostly from Europe. According to the survey, the most frequent neurological 
symptoms were headache (61.9%), myalgia (50.4%), smell and taste disturbanc-
es (particularly anosmia, 49.2%, and ageusia, 39.8%), impaired consciousness 
(29.3%), and psychomotor agitation (26.7%). Other reported neurological 
symptoms were encephalopathy and acute cerebrovascular disorders (21%). 
The results of  the survey, in agreement with the data available in the liter-
ature, showed that neurological symptoms occurred predominantly in hospi-
talized patients and appeared at various times during the infection course. As 
expected, the most severe neurological features were reported by physicians in 
the Intensive Care Units (ICUs). Moreover, despite some observed differences, 
which could be attributable to the setting and the degree of  involvement of  the 
responders during the outbreak, there was no great difference in neurological 
manifestations between countries or continents9.
From March to October 2020, the Global Consortium Study of  Neurologic 
Dysfunction in COVID-19 (GCS-NeuroCOVID) and the EAN Neuro-COVID 
Registry (ENERGY) performed a multicohort study including COVID-19 pa-
tients from 13 countries and 4 continents. The study aimed to determine neu-
rological phenotypes, incidence, and outcomes among hospitalized patients. 
This study showed that approximately 80% of  the patients had neurological 
manifestations (both self-reported symptoms and/or neurological signs or 
syndrome). In particular, the most common self-reported symptoms included 
headache (37%) and smell or taste disturbances (26%), while the most prevalent 
neurological signs and/or syndromes were acute encephalopathy (49%), coma 
(17%), and stroke (6%). Moreover, the presence of  any neurological sign was 
associated with higher in-hospital mortality, even after adjusting for age, sex, 
race, and ethnicity10.
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Non-specific symptoms
SARS-CoV-2 can potentially present with several non-specific neurological 
symptoms. In the case series of  Mao et al., the most common neurological 
symptoms were dizziness (16.8%), headache (13.1%), myalgia (10.7%), and al-
tered mental status (14.8%)5. 
These data appear also to be in line with the results of  the EAN survey. 
Interestingly, Favas et al. found that, in health care workers, the incidence of  
non-specific symptoms was higher compared with the general population4. 
Smell and taste disturbances
Smell and taste disturbances have been reported as common early symp-
toms in patients with COVID-19, and were rarely the only manifestation. 
Interestingly, they can be a sign of  a milder form of  infection and can occur 
both during and after presentation of  general symptoms11.  Early data suggested 
that smell and taste disturbances are due to the direct effects of  the virus on the 
olfactory system and gustatory receptors12, since the SARS-CoV-2 could enter 
the brain through the olfactory epithelium and the neural-mucosal interface13. 
Magnetic resonance imaging (MRI) signal abnormalities in one or both olfacto-
ry bulbs have been described in patients with COVID-19, sometimes resolved 
on follow-up imaging14,15. In an autoptic study, pathologic findings demonstrat-
ed severe and widespread tissue damage involving the olfactory nerve, the gyrus 
rectus, and the brainstem, along with numerous particles referable to virions of  
SARS-CoV-216.  According to a systematic review of  212 studies conducted by 
Favas et al., the most common smell disturbance was anosmia; other symptoms 
reported were hyposmia, phantosmia and parosmia. Among taste disturbances, 
the most commonly reported were dysgeusia and ageusia. Overall, the incidence 
of  smell disturbances ranged from 4.9% to 85.6%, while incidence of  taste dis-
turbances varied from 0.3% to 88.8%2. Nevertheless, further data on long-term 
prognosis are needed. In one series, 72.6% of  affected patients recovered their 
olfactory function within the first week after resolution of  the disease11, while 
in a survey of  non-hospitalized patients with olfactory or gustatory dysfunction 
from Northern Italy, resolution rates after nearly a month from symptom onset 
were 87% and 82%, respectively17.
CNS manifestations 
Cerebrovascular diseases (CVD) were reported in 0.5-5.9% of  COVID-19 
patients and, of  these, the most common type was acute ischemic stroke 
(0.4-4.9%) followed by hemorrhagic stroke (0.2-0.9%) and cerebral venous 
thrombosis4.  
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These rates of  cerebrovascular events associated with COVID-19 are mostly 
based on observational cohort studies on hospitalized COVID-19 patients from 
different epicenters around the world, mainly in China, Europe, and the US5,18-21. 
These reports reflect a wide variety of  populations in terms of  disease severity, 
comorbidities, and follow-up, all of  which are likely to contribute to the rate of  
cerebrovascular events. Overall, the mean age of  patients with COVID-19 and 
stroke appears to be similar to those without COVID-19. But the relative risk of  
CVD may vary according to the severity of  the disease. In particular, early case 
series suggest that patients with a more severe illness could have a higher risk of  
developing an acute CVD22. These data are also supported by evidence that the 
incidence of  acute CVD was higher in ICU patients (0.8-9.8%)4. 
Several cases of  meningoencephalitis (both viral and apparently autoimmune) 
were reported in COVID-19 patients4.  Moriguchi et al. described the first case 
of  viral encephalitis with COVID-19, confirmed by cerebrospinal fluid (CSF) 
analysis23. Other cases of  meningoencephalitis have been reported in patients in 
whom CSF was either negative for SARS-CoV-2 or not tested. Isolated menin-
goencephalitis without any respiratory involvement has also been reported24,25. 
Incidence of  disturbances of  consciousness and delirium ranged from 
3.3% to 19.6% in retrospective studies4. Early studies indicate that 20-30% 
of  COVID-19 patients will present with/or develop delirium or mental status 
changes during their hospitalization, with rates of  60-70% in cases of  severe 
illness at all ages26. Encephalopathy is more common in critically ill patients 
with COVID-19. In a cohort study of  2,088 patients with COVID-19 admitted 
to an ICU, 55% presented delirium27 . 
A few retrospective studies have reported seizures, with an incidence ranging 
from 0.5% to 1.4%4.  
Posterior reversible encephalopathy syndrome (PRES) has also been reported 
and may be due to hypertension and renal failure in some patients28-30.  In one case 
series, neuroradiological findings consistent with PRES were seen in over 1%31. 
A few case reports have described patients with clinical and neuroimaging 
findings consistent with acute disseminated encephalomyelitis (ADEM)4. Some 
patients had myelitis with or without brain involvement. An additional case 
report describes a case of  acute necrotizing encephalopathy in a patient with 
COVID-1932.
Three cases of  generalized myoclonus were reported from Spain, with nor-
mal CSF and imaging findings. In all these patients, myoclonus could not be ex-
plained by hypoxia, metabolic cause, or drug effect, and the EEG showed mild 
diffuse slowing without any epileptic activity. Patients were treated symptomat-
ically with antiepileptic drugs (AEDs) and/or propofol sedation and appeared 
to recover gradually with immunotherapy33. 
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PNS manifestations
All variants of  Guillain-Barré syndrome (GBS) such as AIDP, AMAN, 
AMSAN have been reported in COVID-19 patients4. Cases of  Miller Fisher 
syndrome (MFS) were also described, one of  these being associated with serum 
GD1b-IgG antibodies34.  Both para- and post-infectious patterns are described. 
GBS was a presenting feature in one case report by Zhao et al.35. However, 
while Toscano et al. reported a series of  five patients with GBS, with an interval 
between COVID-19 onset and symptoms of  GBS ranging from 5 to 10 days36, 
a cohort study from the UK failed to show any specific association between 
GBS and COVID-19 infection37. Therefore, it is still not certain if  there is a 
potential causal association of  COVID-19 with the risk of  GBS. 
Several peripheral nerve and plexus syndromes have been reported in pa-
tients with COVID-19 including cranial neuropathies (facial nerve palsy, ocular 
motor neuropathies, Tapia syndrome), peripheral motor neuropathy, and neu-
ralgic amyotrophy38-40.
Since myalgia and fatigue are common symptoms in COVID-19, some spec-
ulate that COVID-19 may be associated with a viral myositis, although there is 
still no conclusive evidence for this41. Different studies have reported the inci-
dence of  rhabdomyolysis to be 0.2-2.6%4.
Long-term effects 
The issue of  the long-term effects of  the SARS-CoV-2 infection is much 
more complex. These have been described in various ways, including “Long 
COVID” and “post-COVID syndrome”. In particular, there is some evidence 
to suggest that both patients recovering from a severe illness and patients 
with milder symptoms who never required hospitalization may report pro-
longed neurological symptoms that persist for weeks to months after the acute 
infection42-44.
In a survey of  180 non-hospitalized COVID-19 patients, over 50% reported 
having at least one persistent symptom (most frequently fatigue and anosmia) 
approximately 4 months after the onset of  symptoms45. Moreover, preliminary 
data related to extrapyramidal disorders46 and cognitive disturbances47 are still 
coming in, but the whole picture of  the consequences of  the pandemic will 
only be clarified after longitudinal studies are completed.  
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Take-home message
 – Over one-third of  patients with COVID-19 develop neuropsychiatric 
symptoms.
 – Central nervous system manifestations are more common than peripheral 
nervous system symptoms.
 – The most common neurological manifestations are smell and taste distur-
bances, myalgia, headache, encephalopathy, and dizziness. 
 – Patients may report long-lasting neurological symptoms that persist for 
weeks to months after the acute infection.
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Chapter 5. Neuroimaging in COVID-19
Marco Scarabello, Carla Uggetti, Luca Valvassori
Introduction
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2). Human coronaviruses have neuroin-
vasive capacities and may be neurovirulent by two main mechanisms1–3: viral 
replication into glial or neuronal cells of  the brain or autoimmune reaction 
with a misdirected host immune response4. Prior to the current pandemic there 
were reports of  encephalitis-like syndromes caused by human coronaviruses5. 
Reports on central nervous system involvement during COVID-19 started early 
during the first wave6 and large multicenter studies were subsequently carried 
out7-17. These studies showed a number of  neuroradiological patterns, some of  
them similar to known disease entities or pathological conditions, with var-
ious frequencies and associated risk factors. The objective of  this section is 
to highlight the different imaging features that must be recognized, the tech-
niques to depict them and how to best interpret them with the current available 
knowledge.
Prevalence of  abnormal neuroimaging findings
One of  the earliest studies on neurological symptoms in patients with 
COVID-1914 showed an estimated overall prevalence of  36.4% in hospitalized 
patients. Twenty-four percent of  them had symptoms referred to the central 
nervous system. In another large retrospective cohort8 2,611 adults, 269 exam-
inations were performed in 185 patients. MRI and CT examinations were per-
formed and were available on 1.6% and 6.6% of  patients, showing a low preva-
lence of  neuroimaging studies in patients with COVID-19. Consecutive patients 
with neurological manifestations and brain magnetic resonance imaging (MRI) 
were selected among 16 French hospitals during 20207, excluding ischemic in-
farcts, cerebral venous thrombosis and previous chronic lesions. Among these 
37 highly selected patients there were various patterns that can be strictly related 
to neuroradiological findings during COVID-19. Interestingly, there were 16/37 
patients (43%) with unilateral fluid attenuation inversion recovery (FLAIR) and/
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or diffusion hyperintensities in mesial temporal lobe; 11 (30%) showed non-con-
fluent multifocal white matter hyperintense lesions on FLAIR/diffusion, with 
variable enhancement, associated with hemorrhagic lesions; 9 (24%) showed 
extensive and isolated white matter microhemorrhages; 4 (11%) showed exten-
sive and confluent supratentorial white matter FLAIR hyperintensities; 2 (5%) 
showed FLAIR and diffusion ovoid hyperintense lesion located in the central part 
of  the splenium of  the corpus callosum; 2 (5%) showed non-confluent multifocal 
white matter hyperintense lesions on FLAIR/diffusion with variable enhance-
ment; 2 (5%) showed acute necrotizing encephalopathy; 2 (5%) FLAIR or dif-
fusion hyperintense lesions involving both middle cerebellar peduncles. The ma-
jority of  the patients had one neuroimaging pattern (76%), with the rest multiple 
coexisting patterns. These patients underwent neuroimaging mainly because of  
alteration of  consciousness (73%), pathologic wakefulness after sedation (41%), 
confusion (32%), and agitation (19%). From the available evidence it appears that 
neurological manifestations severe enough to warrant advanced neuroimaging are 
relatively uncommon and have a plethora of  imaging patterns, some of  them are 
more frequent than others and the majority are fairly unspecific, similar to oth-
er neuroradiological patterns related to various inflammatory, microvascular, and 
immune-mediated disorders.18 Specific imaging patterns will be further discussed 
below.
Anosmia, usually associated to ageusia, is a frequent symptom in patients 
affected by COVID-19. MRI abnormalities of  the olfactory bulb of  these pa-
tients have been reported in several studies, with discordant results, also due to 
different technical approaches. A thinning and T2-hyperintensity of  the olfac-
tory bulbs can be sometimes detected with focused MRI studies.
Macrovascular pathology
There have been various reports of  ischemic and hemorragic stroke in pa-
tients with COVID-19. Klironomos et al.8 reported 8.6% of  patients having 
acute ischemic stroke and 6.3% having non-traumatic brain hemorrhage. One 
of  the early studies15 reported 4.6% incidence of  acute ischemic stroke among 
patients hospitalized for COVID-19. Later studies19,20 reported rates of  acute 
ischemic stroke between 0.9% to 3.3%. It has been shown that COVID-19 
increases stroke-related mortality19. Neuroimaging in acute stroke is fairly estab-
lished21 and presents no particular issue specific to COVID-19, except for the 
fact that a continuous flux of  potentially COVID-19 positive patients through 
the CT scanner located in the emergency department may contribute to the 
delay of  the first diagnostic step22. Brain hemorrhages have been reported, both 
as a presenting illness and as complications of  anticoagulant therapy.
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Table 5.1: Neuroimaging findings in COVID-19
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Figure 5.1: 52 yo female COVID-19 patient with anosmia
FLAIR coronal scan shows thinning and T2-hyperintensity in the bilateral olfactory 
bulbs (arrows)
Figure 5.2
A: FLAIR axial scan shows a small acute ischemic lesion (blue arrow) in the left 
insular cortex in a previously healthy 33 yo man. B: Sagittal contrast-enhanced CT 
of  the epiaortic vessels shows dissection (blue arrow) of  the cervical segment of  
the ipsilateral internal carotid.
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White matter abnormalities
Kremer et al.7 reported a prevalence of  30% (CI 15-45%) of  non-confluent 
multifocal white matter hyperintense lesions on FLAIR and diffusion-weighted 
images with variable enhancement associated with hemorrhagic lesions among 
patients with severe COVID-19, and 11% of  extensive and confluent supraten-
torial white matter FLAIR hyperintensities, making white matter one of  the 
main structures to be analyzed in severe COVID-19 with brain lesions. White 
matter changes can be in the form of  symmetrical, periventricular lesions8 lo-
cated posteriorly in the occipital and parietal lobes15 or even affect middle cere-
bellar peduncles. Ventricle size changes and dynamic evolution of  white matter 
lesions has also been reported, with improvement in a small percentage of  cas-
es (14%)23. White matter can also been affected by COVID-19-related diffuse 
posthypoxic leukoencephalopathy24. Isolated lesions of  the corpus callosum 
have been reported7 as well as lesions located on the midline in the splenium of  
the corpus callosum, which is a typical locations for toxic-metabolic damage25-27.
Diffusion abnormalities
Klironomos et al.8 reported 5/41 patients with acute ischemic infarcts and 
5/41 with acute lacunar infarcts. One patient from their series presented with 
restricted diffusion in the splenium of  corpus callosum. One patient had re-
stricted diffusion in the globus pallidus. Kremer et al.7, who decided to exclude 
patients with macrovascular pathology, reported diffusion weighted imaging 
(DWI) abnormalities in the form of  non-confluent white matter abnormalities 
(with corresponding FLAIR hyperintensities) both supra- and infratentorially, 
along with restricted diffusion in the middle cerebellar peduncles. If  we exclude 
DWI changes due to acute ischemic/cytotoxic damage from macrovascular or 
lacunar infarcts which are common in adult and elderly patients and not strictly 
related to COVID-19 effects, there are patterns resembling acute disseminated 
encephalomyelitis (ADEM)28, hypoxic damage (bilateral globus pallidus), tox-
ic-metabolic damage (splenium of  corpus callosum), which could be a conse-
quence of  microvascular damage, hypoxic ischemia during severe COVID-19 
pneumonia, and immune-mediated white matter lesions.
Susceptibility weighted imaging abnormalities
Susceptibility weighted imaging (SWI) abnormalities were reported as the 
most frequent finding in patient with central nervous system involvement by 
Klironomos et al.8 being found in 74% of  them (29/39). Interestingly, the 
shape of  susceptibility foci were reported as round or ovoid, the latter proba-
bly due to microscopic thrombi along small medullary veins with subsequent 
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microbleeds29. They were more frequently located in the splenium of  the 
corpus callosum, juxtacortical U-fibers, and main white matter tracts. Fifty-
nine percent of  patients had SWI abnormalities in the corpus callosum. Low 
signal intensity foci were also reported in subarachnoid and intraventricular 
location, as well as cortical superficial siderosis. There were reports of  sus-
ceptibility changes in patients with severe COVID-19 on mechanical ventila-
tion/oxygenation30-32, the pathophysiology of  which is the subject of  ongoing 
research, with some advocating possible COVID-19-mediated microvascular 
damage and thrombosis and others focusing on secondary effects induced by 
the severe illness and hypoxic-ischemic environment29,33. Generally, patients 
whose neuroimaging findings included susceptibility changes had worse clin-
ical conditions, worse prognosis, longer duration of  mechanical ventilation 
and worse laboratory profiles (high peak D-dimer, lower nadir platelet count, 
higher international normalized ratio)29. 
Perfusion abnormalities
Among the largest cohort of  patients with abnormal neuroimaging find-
ings there were reports describing no significant perfusion abnormalities8 us-
ing dynamic susceptibility contrast (DSC) technique (19/39 patients), with 
relative cerebral blood flow (rCBF) within normal range, but also studies 
highliting a significant proportion of  patients with perfusion-weighted ab-
normalities34-38. Chougar et al.34 performed three-dimensional pseudocontin-
uous arterial spin labeling (pCASL) on 46/73 patients in their neuroimag-
ing cohort, with roughly half  of  them belonging to the intensive care unit 
(ICU) subgroup. Twenty-two patients out of  46 had perfusion abnormalities, 
9 were seizure related, 4 secondary to ischemic lesions and 10 were isolat-
ed. The proportion of  patients with pCASL abnormal values were higher in 
the ICU group and more of  the latter had isolated perfusion abnormalities. 
Lambrecq et al. analyzed clinical, biological, brain MRI and electroencephalo-
graphic findings in patients with neurological symptoms during COVID-19. 
Half  of  the foty patients who underwent perfusion weighted imaging showed 
abnormal results: 19/20 of  them had hypoperfusion, especially in frontal 
and temporal lobes and a minority of  them showed hyperperfusion (4/20). 
Hypoperfusion seemed to represent an important feature in the radar chart 
of  what they described as COVID-19–related encephalopathy. Other studies 
reported a similar proportion of  perfusion abnormalities, with the temporal 
lobes often affected36-38. 
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Pathological contrast-enhancement
Enhancement in brain MRI after administration of  gadolinium-based con-
trast agents reflects disruption or abnormal permeability of  the blood-brain 
barrier. Several different mechanisms can lead to such effects and therefore 
there were different reports of  contrast-enhancing (CE) lesions associated 
with pathological CE. Kremer et al.7 reported variable CE in non-confluent 
white matter lesions, with superimposed hemorrhagic changes. Klironomos et 
al.8 reported pathological CE after ischemic, hemorrhagic and hypoxic insults 
in three patients, which are expected from the breakdown of  the blood brain 
barrier. Interestingly, they reported subtle leptomeningeal enhancement, most 
visible on contrast-enhanced T2-weighted FLAIR and they demonstrated 
progression of  the enhancement in one patient at follow-up although there 
was clinical improvement. Two patients in their series exhibited cranial nerve 
enhancement (bilateral facial nerve CE and vestibular nerve respectively) and 
two others showed pathological CE along the roots of  the cauda equina. The 
studies by Kandemirli10 and Chougar34 also showed variable leptomeninge-
al and perivascular white matter pathological CE in a small proportion of  
patients. 
Encephalitis and encephalitis-like abnormalities
There were several reports of  encephalitis and encephalitis-like syndromes 
in patients with COVID-19. Moriguchi et al.39 reported a case of  a 24-years 
old man who was found unconscious and had generalized seizures and neck 
stiffness at admission to the hospital. Cerebrospinal fluid analysis found 
SARS-CoV-2 RNA. Brain MRI showed signs of  ventriculitis along the right 
temporal horn, restricted diffusion and high FLAIR signal in the right hip-
pocampus. Hayashi et al.27 reported a case of  mild encephalitis/encephalopa-
thy with a reversible splenial lesion. 
Grimaldi et al.40 showed a peculiar case of  a man presented with subacute 
cerebellar syndrome and myoclonus several days after general infectious symp-
toms began. Of  note, brain MRI findings were normal and brain18F-FDG PET 
showed diffuse cortical hypometabolism associated with putaminal and cerebel-
lum hypermetabolism. Autoimmune limbic encephalitis was also described and 
reviewed by the group led by Pizzanelli41, with the usual brain MRI signature. 
Acute disseminated encephalomyelitis has also been reported, with the pattern 
of  abnormal neuroimaging findings, in adults and children42,43. Finally, in criti-
cally ill COVID-19 patients severe hypoxic, toxic and metabolic encephalopa-
thies may be found.
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Figure 5.3 
FLAIR scan (A) and Diffusion weighted image (DWI) show an alteration in the 
central aspect of  the splenium of  corpus callosum, consistent with the diagnosis of  
mild encephalopathy with a reversible splenial lesion (MERS).
Figure 5.4 
   
Diffusion weighted (A) and FLAIR (B) images show widespread gyral T2 hyperin-
tensity, swelling and restricted diffusion, consistent with extensive anoxic suffering 
in a 40 yo male patient with severe respiratory failure due to COVID-19.
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Practical implications in neuroimaging of  COVID-19 
neuropathology
Many retrospective studies and case reports have been published on neuro-
imaging during COVID-19.  Some patterns have emerged and there is evidence 
that more severe disease and the need for mechanical ventilation are risk factors 
for a positive brain MRI. Most of  the findings are not specific to COVID-19 
and are in fact common to other disease entities and etiologies. The majority of  
the findings are still being analyzed form the pathophysiological point of  view 
to ascertain the cause, mechanism and possible treatment. From the neurora-
diological perspective, since COVID-19 can have epidemic waves and variable 
disease course, it is important to note that SARS-CoV-2 positive patients can 
present with acute neurological emergencies unrelated to the viral illness and 
time-dependent imaging needs to be performed accordingly. This review can 
provide the necessary references to guide in the differential diagnosis of  central 
nervous system pathology in patients with COVID-19.
 
Take-home message
 – The majority of  patients with COVID-19 showed abnormal findings at 
CT and MRI caused by concurrent macrovascular pathology, mainly is-
chemic stroke.
 – Highly selective studies have shown a few neuroimaging patterns directly 
or indirectly related to the viral illness itself.
 – The most prevalent abnormalities were non-confluent and confluent white 
matter FLAIR hyperintensities with variable enhancement, leptomeninge-
al enhancement, small SWI susceptibility foci.
 – The neuroimaging patterns resemble known immune-mediated, toxic, hy-
poxic or severe illness-related abnormalities.
 – The prevalence of  abnormal CT and MRI findings increases with the se-
verity of  COVID-19.
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The state of  the art
Up to 1st of  June 2021 only 150 articles appeared in PubMed’s database using 
the search queries “SARS-CoV-2 Neuropathology” and “COVID-19”, an ex-
tremely low number compared with the 85,519 articles using a “SARS-CoV-19” 
entry and the 140,077 with the keyword “COVID-19”. Furthermore, the cases 
studied were extremely limited1. There are several reasons for this low number 
of  publications, and the difficulty in performing brain biopsies or autopsy on 
subjects infected with SARS-CoV-2 or affected by COVID-19 plays an impor-
tant role. To date, this explains how our knowledge of  the neuropathology of  
this infection is limited and sometimes contradictory. The poor understanding 
of  the neuropathology of  this infection and of  this disease is of  considerable 
concern considering that neurological complications of  COVID-192 have fre-
quently been observed, both in the acute and in the long-term phases of  the 
disease. Complications such as autoimmune encephalitis, memory loss, sleep 
disorders, severe mood disorders, and persistent headache can last for months 
and significantly affect the rehabilitation period that nowadays potentially in-
volves the millions of  COVID-19 patients and are expressed by the more than 
120 million subjects infected with SARS-CoV-21. Still today, in the scientific 
literature the prevailing thoughts are based on the following points: 1) SARS-
CoV-2 does not infect the central nervous system (CNS) directly; 2) theoret-
ically, the virus can infect the endothelial cells of  the CNS vessels since they 
express the ACE2 receptor; 3) the detectable damage to the CNS in people 
with COVID-19 is the result of  thrombotic microangiopathies3 and of  the local 
activation of  an inflammatory response supported by cytokines, including IL-2 
and IL-124-6. Despite this, recent observations suggest the presence of  SARS-
CoV-2 in the parenchymal tissue of  the brain7,8 and that suggests how the virus 
can enter the CNS in different pathways other than through the circulatory sys-
tem9,10. It is possible that the incongruity of  the immunohistochemical findings 
related to the presence of  the virus in the CNS depends on different factors 
such as the viral load at the time of  the biopsy / autopsy, the type and clone of  
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the antibody used for its recognition, and the time elapsed between death and 
carrying out the autopsy itself10-12.
Autopsy, biopsy, fixation and gross pathology
An adequate autopsy evaluation of  the CNS must be based both on its rapid 
evisceration from the body and on its adequate fixation. CNS biopsies also need 
an appropriate fixation procedure, although they have a simpler protocol of  ex-
ecution. The autopsy must be performed as soon as possible after the patient’s 
death due to the immediate onset of  the postmortal involutionary phenomena, 
which produces tissue alterations that can lead to misinterpretation of  the histo-
pathological findings, i.e., by reducing tissue immunoreactivity. In our practice, 
the evisceration of  the brain-brainstem-cerebellum block (B-BS-C block) was 
performed within three hours after death, through instrumental determination 
of  death by continuous electrocardiographic monitoring showing a flat trace 
for at least 20 minutes. Autopsy must be performed in a Biosafety Level 3 (BSL 
3) autopsy room according to the rules of  the Centers for Disease Control and 
Prevention (CDC) and the staff  must be adequately protected1. The removal of  
the skull cap must be carried out with an electric oscillating saw equipped with 
an aspiration system for the bone dust and for the blood and tissue micropar-
ticles that are produced during the cutting procedure. The epidural space, the 
dura mater, the dural venous sinuses opened in situ, the subdural space, the lep-
tomeninges must be examined and their characteristics must be recorded. The 
brainstem should be at best dissected at the level of  the junction with the spi-
nal cord, given the importance of  its examination in patients with COVID-19 
disease or infected with SARS-CoV-2. This procedure can be easily performed 
using a thin double-edged scalpel and a gouge. Once the B-BS-C block has been 
eviscerated, it must be quickly examined also on the lower surface, ensuring 
that the olfactory and optic nerves have also been removed. Then, it must be 
weighed. The entire visceral block must be suspended in abundant 10% buff-
ered formalin: that of  an adult must be completely immersed in at least 5 liters 
of  formalin, suspending it at the edges of  the vessel with a thin cord passing 
under the basilar artery of  the Circle of  Willis; the eyelet below the artery where 
the cord passes must be obtained with a thin scalpel blade while the artery is 
placed in traction with a small anatomical forceps, ensuring no damage to the 
underlying Varolius pons11 (Figure 6.1A). The fixation of  the brain suspended 
in formalin is crucial to avoid any anatomical artifacts to the B-BS-C block 
structures produced by the pressure against the walls of  the container. The 
macroscopic examination of  the inner part of  the B-BS-C block performed 
with parallel serial cuts immediately after its evisceration should be avoided as it 
irreparably damages the histological details. However, following evisceration, it 
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is recommended to quickly collect small tissue samples for electron microscopy 
and for molecular or microbiological /virological investigations. These samples 
must not compromise the visceral integrity of  the block. Moreover, it is impor-
tant to note the areas from which the samples are taken. It is also important to 
collect samples of  the corresponding contralateral areas in order to correlate 
the histopathological patterns to the molecular, ultrastructural or microbiologi-
cal / virological findings when the final sampling for histological examination 
is carried out. The complete or partial removal of  the spinal cord should be 
performed by removing the vertebral bodies that need to be examined, using 
an oscillating saw, a Brunetti’s chisel and a gouge. The spinal cord is removed 
inside the dural sac and, once eviscerated, it is stretched and fixed at the margins 
on a cork dissecting board, with pins set in the dura mater, before immersing 
it in abundant formalin. The B-BS-C block fixation lasts from 21 to 27 days, 
depending on its size. The fixation protocol requires the following essential 
steps: 1) a complete change of  formalin on the 2nd, 4th, 6th, 13th and 20th days; 2) 
a dissection of  the block into two parts on the 4th day through a full-thickness 
cut of  the brain. This procedure is performed to facilitate the entry of  the 
formalin into the ventricular cavities and to facilitate the fixation of  the deep 
structures; 3) immersion without suspension of  the two parts of  the block 
back in formalin. The first cut must be made according to the chosen section 
plane (coronal, sagittal or transverse). The subsequent cuts must be performed 
at the end of  the fixation on seriated planes approximately 1 cm apart. On the 
21st or 27th day, the B-BS-C block (according to the macroscopic assessment of  
adequate fixation also of  the deepest parenchymal areas) should be macroscop-
ically examined and sampled for histological examination. The serial sections 
are to be performed with a long Virchow brain sectioning knife. The blade must 
be wet with water after each cut to ensure it slides continuously in one direction 
to avoid sawing movements. For convenience, it may be useful to perform a 
macroscopic examination of  the parenchyma on serial macrosections after hav-
ing separated the brain from the brainstem and the latter from the cerebellum, 
first dissecting the midbrain at the level of  the cerebral peduncles and then the 
cerebellar peduncles (Figure 6.1B-F).
The fixation procedure of  the spinal cord should last from 8 to 10 days, de-
pending on its thickness and length, changing the formalin on the 2nd, 4th, 6th days. 
Biopsies performed in vivo on patients infected with or suspected of  infection 
with the SARS-CoV-2, including those of  the CNS, should be fixed for at least 24 
hours in formalin before processing them for paraffin embedding13,14. It is a good 
practice to process autopsy samples under vacuum, with three steps in Xylene or 
equivalent for at least 1 hour each. The procedures we performed have sometimes 
produced unexpected results when compared with the data published by other 
research groups. This suggests that, regardless of  the other variables already listed 
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in the previous paragraph, the SARS-CoV-2 virus is very labile after the patient’s 
death, most of  all in its identification with immunohistochemical methods.
Figure 6.1: Macroscopic examination of  the midbrain and brainstem
A. Anterior surface with some vessels of  the Circle of  Willis and the leptomeninges in 
place. The yellow arrowheads indicate the basilar artery, under which the string must be 
passed to suspend the brain in formalin after its evisceration, to allow a correct fixation. 
Red arrows: vertebral arteries. T = trigeminal nerve root (V cranial nerve). X: vagus 
nerve. XII: hypoglossal nerve. B. Midbrain and brainstem (pons and medulla oblon-
gata) after the removal of  the vessels of  the Circle of  Willis and the leptomeninges. 
Red dotted line = midbrain. CP = cerebral peduncle (lateral rotated in the picture). P = 
pons; Yellow arrowhead = interpeduncular fossa; MCP = middle cerebellar peduncle; 
T = trigeminal nerve root (V cranial nerve). Yellow dotted line = medulla oblongata; 
O = olives; Pi = pyramid; Ams = anterior median sulcus. C. Posterior surface of  the 
midbrain and brainstem, after the removal of  the cerebellum. The image highlights the 
anterior wall of  the IV ventricle where the medial eminence (ME), the locus coeroules 
(LC), the underlying vestibular area (VA) and several choroid plexus (yellow arrows) are 
observed. SC: superior colliculus. IC: inferior colliculus. Yellow dot: inferior cerebel-
lar peduncle. IX: glossopharyngeal nerve. X: vagus nerve. XII: hypoglossal nerve. GT: 
gracile tubercle. GF: gracile fasciculus. Pms: posterior median sulcus. D-F. Multiple 
midbrain and brainstem sections after section on transverse planes at a distance of  ap-
proximately 0.5 cm. In D in the leftmost section performed at the level of  the midbrain, 
the substantia nigra is clearly observed. NR: nucleus ruber. SC: superior colliculus. AM: 
aqueductus mesencephali (Silvius aqueductus).
716. Neuropathology
Damage to the meninges and choroid plexus
The presence of  the spike glycoprotein of  SARS-CoV-2 has been detected 
both in the leptomeninges and in the stroma of  the choroid plexus in patients 
affected by COVID-1915,16. The lesions described in association with the de-
tection of  the virus or in COVID-19 disease are inflammatory or thrombotic. 
The meningitis sustained by T lymphocytes with increased macrophages and, 
less frequently, with the detection of  vascular thrombosis has been observed in 
many patients, involving also the vessels of  the Circle of  Willis17,18. Subarachnoid 
hemorrhages are only occasionally described in the literature, mostly as small 
or punctate19,20. 
Figure 6.2: Leptomeninges and large intracranial vessels in patients 
 with COVID-19 disease
A. Large arterial vessel of  the Circle of  Willis subocluded by a thrombus in an acute 
phase of  evolution. The yellow arrows delimit the edges of  the thrombus which 
in the image appears attached to the highest part of  the vessel. B. Leptomeninges 
with moderate edema. The arachnoid vessels are not thrombosed. C. Leptomeninges 
with small subarachnoid hemorrhagic extravasations (arrows). Also in this image the 
arachnoid vessels are not thrombosed. D. Leptomeninges characterized by a few 
positive macrophages (dark brown cells) with the immunohistochemical staining for 
CD68 PGM1. Macrophages are mostly located perivascularly. Some isolated CD68 
PGM1 positive cells can also be observed in the underlying nervous parenchyma 
(cells most likely referable to microglia). E. Same area as the previous image, stained 
with immunohistochemical reaction for CD163. It can be seen that the number of  
CD163 + inflammatory cells are significantly higher than CD68 PGM1 + cells, al-
though they largely maintain the same arrangement. CD163 marks the activated mac-
rophages (M2) indicating the presence of  a local reactive / inflammatory state.
We have observed recent thrombosis of  a vessel of  the Circle of  Willis in 
only one patient (Figure 6.2A); leptomeninges mostly showed mild focal edema. 
We have only occasionally detected small subarachnoid hemorrhagic suffusions 
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(Figure 6.2C); on the contrary, we have almost always observed an increase in 
macrophages in the meninges (CD68 PGM1 + cells) and a very large popula-
tion of  M2 macrophages (CD163 + cells). This demonstrates the presence of  a 
leptomeningeal inflammatory state (Figure 6.2D and E).
Macroscopic parenchymal lesions
The frequency of  macroscopic lesions in the CNS changes significantly in 
the different case series that have been studied. In almost all cases, these lesions 
are ischemic or hemorrhagic, and involve also widespread cortical areas. They 
can affect either the brain, the cerebellum or the brainstem18. Cerebral edema is 
one of  the most reported alterations19,21 but its direct relationship with the viral 
infection appears difficult to define, given that this disease can be traced back to 
many other pathogenic causes during an autopsy. There were occasional macro-
scopic cerebral lesions (a small cerebral infarction occurring a few days before 
death in a single intubated and mechanically ventilated patient) and non-specific 
even in our autopsy experience, while diffuse cerebral edema was almost always 
detected, with from mild to moderate weight gain of  the B-BS-C block. 
Neuronal, glial and vascular histological damages
Several autopsy or biopsy studies have described alterations in single neurons 
or glial activation, as well as vascular thrombosis involving both major and minor 
intracranial vessels. However, the question as to whether the neuronal damage is 
directly caused by the virus or is the result of  hypoxic / ischemic mechanisms or 
immune-mediated processes remains unanswered1,22. The most frequent histolog-
ical damage described is: 1) sparse neuropil infiltration of  inflammatory cells (de-
pending on the case: T lymphocytes, B lymphocytes, microglia, neutrophil gran-
ulocytes. T lymphocytes are often arranged in a cap around small vessels, while 
B lymphocytes prevail within the parenchyma with more frequent distribution in 
single cells. Neutrophil granulocytes mostly characterize micro-areas of  ischemic 
necrosis); 2) acute hypoxic-ischemic neuronal changes, including perikaryal cyto-
plasmic eosinophilia and nuclear pyknosis (so-called “red neurons”); 3) microglial 
activation with microglial nodules, with or without neuronophagia features; 4) 
focal demyelination18,23; 5) localized axonal swellings, demonstrated with amyloid 
precursor protein (APP) immunostain, indicative of  subacute and acute axonal 
damage24-26. In our experience, we have observed neuronal histological alterations, 
particularly at the level of  the brainstem10. The altered neurons are distributed 
quantitatively in different ways at the different sites of  the B-BS-C block, resulting 
very high at the level of  the Varolius pons, the medulla oblongata and the basal 
fronto-temporal areas of  the brain, while they progressively decrease proceeding 
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from basal ganglia / thalamus to the cortex of  the latero-superior areas of  the 
brain (GP Bulfamante, unpublished data, 2021). 
Figure 6.3: Brainstem neurons in patients with COVID-19 disease;  
many of  them show evident structural alterations
A. The neurons indicated by the arrows show marked regressive morphological alter-
ations both nuclear and cytoplasmic. The nuclei are shrunken with heavily thickened 
chromatin and often have an angled profile. The cytoplasms are not red (as in the “red 
cells”) but equally have reduced volumes, asymmetric profiles and a hyperchromat-
ic halo at the outer membrane. These structural changes make these neurons clear-
ly different from morphologically normal ones. B-C. Neuronal alterations referable 
to different evolutionary stages, with Nissl staining. In the red box “B” and “C” two 
neurons are observed with marked compaction of  the pyrenephorus, which appears 
completely dark blue. In image “B” the two brown arrows indicate two neurons with 
swollen pyrenephorus and peripheral dispersion of  Nissl substance. D. Neurons posi-
tive with immunohistochemical staining for SARS-CoV-2 Nuclear Protein: staining was 
developed with red color. The arrows identify three neurons infected with the virus; the 
rightmost cell presents regressive alterations. Immunohistochemical positivity showes 
itself  as small red droplets (red arrowheads) in the cytoplasm; these droplets should not 
be confused with the irregular granules of  intracytoplasmic Nissl substance (yellow ar-
rowhead). Since in damaged neurons the substance of  Nissl can undergo modifications 
(compaction, loss of  volume of  the single granules) it is not advisable to develop im-
munohistochemical reactions for the detection of  SARS-CoV-2 on the central nervous 
system with brown tracer. E. Immunohistochemical stain for the SARS-CoV-2 Nuclear 
Protein: the stain was developed with red color. In this image there are two cells with 
cytoplasmic positivity. The one indicated by the red arrowhead clearly appears to be 
an endothelial cell. The other (yellow arrowhead) is difficult to attribute: it could be a 
perivascular cell in the Virchow-Robin space.
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Neuronal alterations may be similar to those described in shrunken cells 
caused by hypoxia / ischemia, but with no evidence of  red staining of  the cyto-
plasm (Figure 6.3A-C). Another type of  neuronal damage is represented by the 
presence of  cells with swollen pyrenephorus and peripheral dispersion of  Nissl 
substance (Figure 6.3B). Neurons were found to be infected by SARS-CoV-2 in 
several areas10 (Figure 6.3D) and the number of  infected neurons changes with-
in the brain following the neuronal alterations listed above (GP Bulfamante, 
unpublished data, 2021). The virus has also been observed in some endothelial 
and perivascular cells of  the Virchow-Robin space of  intraparenchymal vessels 
(Figure 6.3E).
Our experience of  the autopsy histopathological characteristics of  the CNS 
in COVID-19 patients also involved the glia. The most frequent finding that 
cannot be correlated with any pre-COVID-19 diseases regarded the activation 
state of  this cellular compartment. Immunohistochemical staining for CD68 
PGM1 highlighted the constant increase of  intraparenchymal cells, identifiable 
as microglia cells: these cells are almost always distributed as single cells, small, 
with no enlarged and vacuolated cytoplasm, a feature that makes them easily 
identifiable when they intervene in an area of  infarction. Some of  these cells are 
observed on the contour of  the intraparenchymal blood vessels (Figure 6.4A). 
Microglia represents the main innate immune system within the central nervous 
system and plays a fundamental role during inflammatory processes, traumatic 
events, and in the pathogenesis of  neurodegenerative disorders or in case of  ne-
oplasms27. This glial population has different embryological origins compared 
to monocytes / macrophages, which originate from the hematopoietic system, 
even if  it shares with them some surface antigens and some functions, such as 
phagocytosis and modulation of  the inflammatory process27,28. These cells do 
not only respond to a noxious stimulus or a pathological condition; they are also 
involved in the regulation of  neuronal development during the embryonic and 
fetal period, and in the regulation of  its homeostasis in adult life29,30. CD163 
immunohistochemical staining also demonstrates the presence of  a much larg-
er cell population than CD68 PGM1 positive cells and most CD163 positive 
cells do not co-express CD68 PGM1 (GP Bulfamante, unpublished data, 2021). 
(Figure 6.4B-D). 
Similarly to monocytes/macrophages, two activation states have also been 
recognized for microglia: the “classic” state, M1-like or pro-inflammatory, and 
the “alternative” state, M2-like or anti-inflammatory / protective marked by 
immunohistochemical positivity for CD163 protein. These two different micro-
glial activation states are expressed in different pathophysiological conditions. 
They are characterized by cytokine secretion that arranges the complex immune 
response in the tissue microenvironment. The ability of  the microglia to regu-
late and modulate its phagocytic capacities in response to an external stimulus is 
of  particular importance in this context; the precise regulation of  the microglial 
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activation state, therefore, ensures the control of  adverse events that would lead 
to irreversible and sometimes fatal tissue damage28.
Figure 6.4: Glial population of  the brainstem
A. Immunohistochemical staining for CD68 PGM1, developed in brown, shows the 
presence of  a sparse but widespread population of  positive cells. These are identifiable as 
microglia due to their morphology. B. Immunohistochemical staining for CD163 shows 
that the population of  CD163 + cells is clearly superior to CD68 PGM1 + ones. The red 
box is enlarged in the next image. C. At higher enlargement it is appreciated how many of  
the CD163 + cells are arranged in close contact with the intraparenchymal blood vessels. 
The black dotted box highlights the enlarged area in image “D”. The image does not have 
the scale bar because it is a digital enlargement of  the previous image. D. The high mag-
nification shows how many CD163 + cells have a glial dendritic appearance. The image 
does not have the scale bar because it is a digital magnification of  the image “B”.
Its ability to remove sialic acid residues from the neuronal cell surface, thus 
activating the complement cascade and its own phagocytic activity, appears to 
be particularly important to help understand its role during SARS-CoV-2 infec-
tion31: complement factors C1q and C3 can stimulate microglia in the phagocy-
tosis of  synapses and neurons through the complement receptor 3 (CR3), con-
sisting of  CD11b and CD18 subunits. It is also known that microglia can play a 
role as a viral “reservoir” in the course of  HIV1 infection, through mechanisms 
not yet fully understood, probably depending on specific immunophenotypic 
characteristics of  the cells themselves32. Sialic acid bound to glycoproteins and 
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gangliosides is used by several viruses as an entry receptor within human cells; 
SARS-CoV-2 itself  penetrates inside the cells through the spike glycoproteins. 
Our working group has recently used an immunohistochemical approach to 
demonstrate the presence of  this virus in the glial cells of  the brainstem10. This 
suggests a more important role of  microglia both in the acute phase and in 
the post-COVID-19 conditions. Our findings regarding the histopathology of  
the neuropil and white matter of  the CNS were also found to be only partially 
comparable to those of  the previous studies18,23-26. The rapid evisceration and 
fixation of  the B-BS-C block allowed us to recognize and adequately grade the 
distribution of  tissue edema as it avoided the well-known and frequent post-
mortal alterations of  the parenchymal tissue of  the brain, which can make rec-
ognition of  tissue edema extremely confusing (Figure 6.5A and B).  We found 
the damage to the myelin sheaths and subacute and acute axonal damage7,10. We 
also observed the widespread presence of  structures similar to the more recent-
ly formed (non-stratified) amylaceous corpora or to the Lewy bodies present in 
some neurodegenerative diseases10 (Figure 6.5B-D) in middle-aged patients not 
suffering from neurodegenerative diseases.
Figure 6.5: White matter of  the brain
A-B. Brain. The white matter appears edematous with the presence of  numerous 
small hollow halos on the contour of  the glial cells. Hollow halos are also observed 
between the myelin sheaths and their respective axons. In “B” the arrows identify 
some corpora amylacea. C-D. Olfactory nerve. This structure also appears mark-
edly damaged and it is characterized by the presence of  numerous corpora amyla-
cea in a middle-aged patient not suffering from neurological degenerative diseases, 
such as Alzheimer’s disease. In “C” the yellow box indicates the enlarged area in 
image “D”. In the latter, it is observed that the corpora amylacea can also be large 
reaching a diameter of  about 12 microns.
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These structures are particularly abundant both in the brainstem and in the 
basal areas of  the brain, particularly at the level of  the frontal and temporal 
lobes. It is not yet clear whether these findings are a consequence of  the 
involution of  single pyrenophores or axonal spheroids at points of  axonal 
distruption. However, in patients who died from COVID-19, the close quan-
titative correlation between the areas of  the greatest tissue damage and these 
amorphous structures suggests that the latter can be a prompt indicator in 
the routine histopathological examination of  tissue damage, which requires 
in-depth studies with histochemical and immunohistochemical methods for 
its identification.
Viral entry pathways into the CNS
To date, this topic is still one of  the most discussed, and several studies 
have not showed the presence of  SARS-CoV-2 in the brain of  patients with 
COVID-1923,33-37. It is reasonable to assume that this discrepancy is the result 
of  different factors, including the time elapsed between death and the eviscer-
ation of  the brain, the different viral load at the time of  death, and the viral 
detection methods (type and clone of  the antibody; in situ hybridization; qRT-
PCR). Theoretically speaking, the virus could infect the parenchymal tissue 
of  the brain either through the circulatory system (in this case, the role of  
endothelial and perivascular cells would be crucial)38, or by tracing back to the 
CNS via nerves connecting it to other organs typically infected by the virus, 
i.e., the lung10, or airborne, coming into contact with the nervous olfactory 
epithelium. The latter, through the cribriform plate of  the ethmoid, projects 
into the mucosa that covers some parts of  the nasal cavities39. The current 
state of  knowledge considers all these pathways to be potentially possible. It 
is not to be excluded that the virus could reach the CNS by several routes in 
single patients, and that, in different autopsy cases, the different geography 
of  the observed damage in the CNS may be an expression of  the type of  
route of  infection followed by the virus. Our impression and our current 
topic of  investigation is that there is quantitatively less damage resulting from 
the bloodstream infection, at least at the level of  cortical neurons, and that 
it occurs particularly in the areas of  the brain that are further from the basal 
cortex of  the frontal and temporal lobes.
Conclusions
It is undeniable that, still today, after over 4 million deaths from COVID-19 
and over 180 million people infected with SARS-CoV-2 worldwide, our 
knowledge of  the neuropathological characteristics of  this infection and 
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disease is limited. From a histopathological point of  view, it is difficult to de-
fine whether the observable neuronal or glial damage is a direct effect of  the 
viral infection or a secondary effect of  the disease rather than an expression 
or co-expression40-43 of  other previous diseases. Many patients are elderly and, 
therefore, their CNS is characterized by alterations due to aging, degenerative 
neurological diseases, or vascular diseases. It is, therefore, extremely difficult 
to decide which and how many of  the macroscopic or histological alterations 
highlighted are the expression of  previous diseases or, instead, the direct ef-
fect of  the viral infection in single cases8. Secondly, many patients affected 
by COVID-19 were hospitalized in intensive care units, sometimes for many 
days, and were mechanically ventilated before they died. These conditions 
could be the cause of  the hypoxic changes or of  the inflammatory state de-
tected during autopsy. Thirdly, it has been argued that the viral load in the 
brain can be reduced in the case of  prolonged illness39,44: this makes it difficult 
to detect the presence of  the virus in the CNS and removes an important 
correlative element with the pathological alterations eventually detected, even 
in patients without other previous diseases. Fourthly, the number of  patients 
dying from COVID-19 who underwent autopsy is unacceptably low, even 
in countries adequately equipped with autopsy rooms with a BLS 3. All this 
is of  particular concern if  we consider that, with the prolongation of  the 
pandemic, the weight of  the poor neurological outcomes of  this disease in 
survivors is becoming increasingly clear, with evident consequences on the 
health costs of  rehabilitation, on the social costs (also in terms of  work) and 
personal costs. Neuropathology studies on COVID-19 should address a large 
cohort of  patients and case-control series, and explore both the damage to 
the CNS that can lead to a patient’s death, such as those involving the primary 
respiratory and cardiovascular control center in the medulla oblongata9,10,17,39, 
and the damage to the brain or cerebellar areas capable of  worsening the 
quality of  life of  disease survivors. The SARS-CoV-2 pandemic, even after 
the number of  cases worldwide has significantly decreased, will continue to 
represent a health emergency for many years, and medical research must con-





 – The autopsy study of  the CNS is still fundamental to better understand 
the SARS-CoV-2 infection, its way of  transmission and spreading, and 
many clinical aspects of  the disease.
 – It is important to remove and fix the brain as soon as possible after the 
patient’s death.
 – In our experience, SARS-CoV-2 can directly damage neurons, glia and 
myelin contributing to the overall cerebral damage, potentially caused also 
by alterations in oxygenation from lung disease and/or mechanical venti-
lation during COVID-19.
 – The current state of  knowledge suggests that the virus can migrate via 
nerves, probably with a mechanism similar to the Herpesviruses.
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Chapter 7. Encephalomyelitis in COVID-19
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Introduction
After the first cases of  the novel coronavirus disease 2019 (COVID-19) were 
reported in Wuhan, China, in December 2019, the spread of  severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2) rapidly became a pandemic, 
forcing health-care systems and governments across the world to take measures 
to contain the infection, and simultaneously engaging the health community 
in a race against time to develop effective treatments1,2. The SARS-CoV-2 is 
a positive-sense, enveloped, single-stranded RNA virus that primarily affects 
the lungs, and the recent disease has been designated as COVID-19. As with 
many other flu-like syndromes, the most common symptoms of  COVID-19 are 
fever and dry cough, whereas other manifestations, including rhinorrhea and 
gastrointestinal symptoms, are much less frequent3. Reports from China at the 
beginning of  the outbreak, and from other countries afterwards, have clearly 
demonstrated that most patients (80%) have mild symptoms with no or mild 
pneumonia; among those patients with more significant symptoms, 15% have 
severe respiratory distress and 5% have respiratory failure, septic shock, and/
or multi- organ failure4,5. Although the scientific community is still trying to un-
derstand the syndromic complexity of  COVID-19, growing evidence indicates 
that the disease is not limited to the respiratory system and that SARS-CoV-2 
has an organotropism beyond the respiratory tract, including the kidneys, liver, 
heart, skin, and brain. COVID-19-associated neurological manifestations range 
from mild symptoms such as dizziness, headache, dysgeusia, or anosmia to se-
vere disorders such as stroke, Guillain-Barré syndrome (GBS), acute hemor-
rhagic necrotizing encephalopathy, meningoencephalitis, and cerebral venous 
thrombosis. The frequency of  reported neurological signs and symptoms is 
variable but, in spite of  this, substantial. In an early Chinese retrospective study, 
36.4% of  214 COVID-19 patients had neurological symptoms which included 
dizziness (16.8%), headache (13.1%), impaired consciousness (7.5%), dysgeusia 
(5.6%), and anosmia (5.1%)5. In Western studies, dysgeusia and anosmia are 
reported in many patients6,7. A French study reports that 49 out of  58 (84%) 
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COVID-19 intensive care unit (ICU) patients had neurological signs which in-
cluded agitation (69%), confusion (65%), corticospinal tract signs (67%), and 
dysexecutive syndrome (33%)8. A study from a British referral center described 
cases of  septic or para-infectious encephalopathy, autoimmune encephalitis in-
cluding acute disseminated encephalomyelitis (ADEM), and GBS9. An Italian 
study also reported a wide range of  encephalopathies during the first wave, in-
cluding ADEM, limbic encephalitis, necrotizing hemorrhagic encephalopathies 
and meningoencephalitis10. In general, neurological complications have been 
reported to be more common in older age groups and patients with pre-existing 
comorbidities, including diabetes mellitus, hypertension, malignancies, immu-
nological disorders, obesity, chronic respiratory disease, coronary artery disease, 
and liver failure11. Neurological abnormalities and manifestations have been de-
scribed as the presenting symptom of  SARS-CoV-2 in some patients, while in 
most cases the neurological onset followed the classical respiratory onset. More 
recently, there has been growing evidence favoring a relatively high neurolog-
ical involvement in the so-called Long COVID. In fact, viral infections can 
damage the structure and function of  the nervous system, manifesting as en-
cephalitis, toxic encephalopathy, and post-infectious demyelinating disease11,12. 
Coronaviruses can invade the nervous tissues involving immune-functioning 
macrophages, microglia, or astrocytes13 and cause nerve damage through direct 
infection pathways (circulatory and neuronal), hypoxia, immune injury, attack-
ing ACE2 enzymes, and other mechanisms14. The involvement of  the nervous 
system can be due to a direct action of  these viruses on the nervous tissue and/
or to an indirect action through the activation of  immune-mediated mecha-
nisms. While the first can be verified during the acute phase of  the disease, 
the second is mostly apparent only days, weeks, or even months after the acute 
phase. 
Encephalitis and myelitis as a possible manifestation of  
the disease
Different cases and reviews have consistently shown that patients with 
COVID-19 are at higher risk for developing CNS involvement, including men-
ingitis, encephalitis and myelitis. In most cases, case reports or limited series 
of  patients, it was not clear whether CNS involvement was secondary to direct 
infection or para-infectious immune-mediated disease. The description of  en-
cephalitis and myelitis syndromes seen with COVID-19 were, in fact, general-
ly highly heterogenous in their presentation9,10,15 suggesting varied underlying 
neuropathogenesis, and, in some instances, were not directly correlated with 
COVID-19. Acute presentations were potentially a consequence of  systemic 
pro-inflammatory cytokines transcending the blood-brain barrier (BBB) or, 
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more rarely, due to direct viral invasion of  the central nervous system (CNS)9,15. 
Later, post-infectious presentations were likely to be due to immune-mediated 
processes operating through cellular or antibody pathways9,10. 
The wide spectrum of  clinical presentation of  encephalomyelitis in patients 
with SARS-CoV-2 respiratory infection, however, closely resembles those phe-
notypes already associated with influenza and other corona-viruses15-18, indicat-
ing that SARS-CoV-2 behaves like other viruses.
Nevertheless, the neurological complications of  influenza have an estimated 
incidence of  between 0.21 and 12 cases per million and particularly affect chil-
dren18, whereas the incidence of  encephalomyelitis in COVID-19 is estimated to 
be at least 50 per 100,000 cases10,20. The trends in CNS complications in SARS-
CoV and MERS-CoV proposed by Ellul and co-authors15 had an estimated in-
cidence of  between 37 and 224 cases per 100,000 symptomatic patients. Several 
risk factors for encephalomyelitis as a complication of  COVID-19 have been 
elucidated. Demographic risk factors such as old age and underlying comor-
bidities increased risk of  complications from COVID-19 infection, including 
the development of  encephalitis. Additionally, patients who are severely ill with 
COVID-19 are at a much higher risk of  suffering from complications such as 
encephalitis and myelitis. This incidence as a complication of  COVID-19 was 
less than 1% in the general population of  COVID-19 patients but there is a no-
table rise to 6.7% in those who are severely ill. Although there are case reports 
of  several patients developing encephalomyelitis weeks after initial infection 
with COVID-1922, most patients develop both COVID-19 symptoms and CNS 
symptoms during the same period. Most often, patients present with respirato-
ry symptoms and develop encephalomyelitis an average 14.5 days later, during 
their hospital stay21,22.
Encephalitis
SARS-CoV-2 infection has been associated with a wide clinical spectrum 
of  encephalitis, characterized by heterogeneous clinical presentation and out-
comes. As far as encephalitis-related symptoms are concerned, the most com-
mon included loss or decreased level of  consciousness and altered mental state 
or delirium, while seizures, headaches, and limb weakness were reported in 15-
37% of  cases21,22; other less common symptoms were aphasia, ataxia, and myo-
clonus. Patients who suffer from encephalitis as a complication of  COVID-19 
had much poorer outcomes compared to the general population of  COVID-19 
patients, including admission to intensive care facilities, use of  ventilators, and a 
high rate of  mortality. Common magnetic resonance imaging (MRI) brain find-
ings include diffuse white matter hyperintensities and hemorrhagic lesions on 
fluid-attenuated inversion recovery and T2 sequences (see Figure 7.1) whereas 
other less common MRI findings include cerebral edema and venous throm-
bosis. Several cases with encephalitis as a complication of  COVID-19 showed 
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normal brain imaging results likely due to milder encephalitis or imaging con-
ducted before brain changes developed22. 
Figure 7.1: Brain Magnetic Resonance Imaging findings according  
to encephalitis phenotypes
A and B Case of  acute necrotizing encephalitis (ANE) characterized by FLAIR 
diffuse bilateral hyperintensities. B with linear Gadolinium-enhancement 
on coronal T1. C and D A case of  ADEM with T2 and FLAIR hyperintensi-
ties (involving corpus callosum, bilateral cerebellar peduncles and right thal-
amus) on axial (C) and coronal (D) plane. E and F A case of  limbic encepha-
litis (LE) characterized by increased T2-FLAIR signal within bilateral mesial 
temporal lobes and (E) and coronal (F) planes. G and H A case of  unspecific 
alterations defining the group of  E-MRI+: DWI hyperintensities on frontal su-
perior and medium gyrus and FLAIR hyperintensity on right cerebellar tonsil.  
ADEM: acute disseminated encephalomyelitis; ANE: acute necrotizing encephali-
tis; E-MRI+: encephalitis with MRI alterations; LE: limbic encephalitis. 
Electroencephalography (EEG) in some patients showed patterns of  general 
slowing while sharp waves and epileptiform activity were uncommon findings. 
Analyses of  cerebrospinal fluid (CSF) showed mild pleocytosis and/or hyperpro-
teinorrachia in almost all cases, whereas most COVID-19 studies failed to detect 
SARS-CoV-2 in the CSF samples of  the COVID-19 patients with neurological 
manifestations21.  To date, few cases of  encephalitis have showed the presence of  
SARS-CoV-2 in CSF, despite negative peripheral and respiratory findings23. There 
may be various reasons for this. The virus may be cell-bound without entering the 
CSF or have concentrations below the level of  detection of  the testing method. 
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In addition, the presence of  heme products owing to the breakdown of  erythro-
cytes in the CSF can interfere with the PCR tests used for detecting SARS-CoV-2. 
Viruses can be associated with limited viremia in blood and CSF. SARS-CoV-2 
RNA can only be detected from blood in 1% of  the actively infected cases. It is 
interesting to note that the absence of  the virus in the CSF could not definite-
ly exclude a direct viral invasion, as demonstrated for other infectious diseases 
such as West Nile virus or enterovirus infections24. However, the clinical courses 
and CSF alterations in most patients argue against any direct CNS damage and 
conversely make a claim for neuroinflammatory and, in rarer cases, autoimmune 
responses as major players in COVID-19 encephalitis. 
For these reasons, several authors have suggested the use of  high-dose ster-
oid treatment (such as methylprednisolone 1 g for 5 days) that has been demon-
strated to be effective in reducing the CSF markers of  inflammatory response22. 
Immunoglobulin administration or plasmapheresis are indicated, according to 
the current guidelines, in patients fulfilling criteria for autoimmune encephalitis, 
particularly in those rare cases presenting an antibody-mediated form of  dis-
ease24. This particular approach in COVID-19 disease is still much debated, as 
most cases did not present CSF alterations suggestive of  an immune-mediated 
inflammatory CNS response. 
Acute transverse myelitis 
Acute transverse myelitis is clinically characterized by sensorimotor distur-
bances, bladder/bowel dysfunction, and/or autonomic dysfunction attributable 
to the spinal cord. It typically manifests as a rapid disease progression from 
within a few hours to up to 21 days, with a sensory level, bilateral pyrami-
dal signs, and bladder/bowel dysfunction. Acute demyelinating diseases of  the 
CNS, such as multiple sclerosis, neuromyelitis optica spectrum disorder, and 
acute disseminated encephalomyelitis are other frequently encountered causes 
of  acute myelitis. There is evidence that inflammatory reactions to infectious 
disease might exacerbate autoimmune diseases, making diagnostic differentia-
tion difficult25,26. Many viruses can be directly implicated in the etiopathogenesis 
of  acute transverse myelitis, including varicella-zoster, herpes simplex, Epstein-
Barr, West Nile, Dengue, Japanese encephalitis, Zika, influenza, echovirus and 
hepatitis B, mumps, measles, and rubella viruses5.  However, it is usually difficult 
to differentiate between a viral-induced and an immune-mediated transverse 
myelitis. Not surprisingly, several reports have linked the SARS-CoV-2 virus to 
the pathogenesis of  acute transverse myelitis (ATM)27,31. Most patients had typ-
ical features of  ATM with acute onset of  paralysis, sensory level, and sphincter 
deficits due to spinal cord lesions demonstrated by imaging. Male and females 
were similarly affected, and mean age was 49 years, with two peaks at 29 and 58 
years, but pediatric cases were also described. The main clinical manifestations 
were quadriplegia and paraplegia. MRI showed localized ATM lesions affected 
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≤3 cord segments in one-third of  cases, whereas most patients had longitu-
dinally-extensive ATM (LEATM) involving ≥4 spinal cord segments31. Most 
cases had a latency of  10 days to 6 weeks that may indicate post-infectious 
neurological complications mediated by the host’s response to the virus, but 
in one-third a brief  latency (15 hours to 5 days) suggested a direct neurotropic 
effect of  SARS-CoV-2. 
Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis (ADEM) has also been described af-
ter SARS-CoV-2 as well as other coronavirus infections, including severe acute 
respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) 
coronaviruses32. ADEM affected predominantly women (2 out of  3) ranging in 
age from 27 to 64 years (mean age 43 years). The onset of  ADEM cases was 
delayed after the onset of  COVID-19 symptoms, which were more severe in 
terms of  respiratory function compared to other encephalitis. Lesions revealed 
by MRI included cervicothoracic spinal cord lesions down to the conus medul-
laris, lesions in pons and medulla-cord junction, multiple T1 post-Gd enhanc-
ing white matter lesions plus bilateral edema of  the optic nerves, hyperintense 
FLAIR lesions in the medial temporal lobe, bilateral lesions involving cerebral 
white matter, corpus callosum and brainstem. Indeed, immunomodulatory 
treatment showed high efficacy in the typical ADEM22. 
Acute necrotizing hemorrhagic encephalopathy
Acute necrotizing encephalopathy (ANE) is a rare neurological complication 
secondary to para-infectious and hyperimmune response to SARS-CoV-2 infec-
tion. This clinico-radiological syndrome affects patients with severe COVID-19 
infection and occurs between one to two weeks after the onset of  the upper res-
piratory tract infection33,34. The true incidence is unknown due to under-recog-
nition of  the syndrome and difficulties in obtaining timely neuroimaging stud-
ies due to patients’ disease severity. Neurological manifestations of  coma and 
persistent encephalopathy dominated clinical presentation, followed by seizures 
and focal deficits22,33,34. Neuroimaging findings in most patients showed patchy 
bilateral periventricular hypoattenuation on CT. MRI imaging showed multifo-
cal diffusion restriction, periventricular confluent T2/FLAIR hyperintensities, 
and diffuse microhemorrhages. The pathophysiology of  COVID-19-related 
ANE is unclear. Although the exact pathophysiology remains obscure, the lack 
of  the typical features of  viral and post-viral encephalitides in most ANE cases 
argues against the hypothesis that the virus directly damages the CNS and, as 
such, prompts speculation that, after a latent period following the infectious 
illness, SARS-CoV-2 might induce a secondary, parainfectious process that is 
responsible for many neurological manifestations. Several mechanisms were 
hypothesized, including hypercoagulable state from systemic inflammation, 
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the so-called “cytokine storm”, post-infectious immune-mediated responses, 
direct viral-induced endotheliopathy leading to angiopathy, and microthrombo-
sis. Viral particles have been isolated from the endothelium of  various tissues, 
including the brain. “Cytokine storm”-mediated immunoglobulin G (IgG) pro-
duction and breakdown of  the blood-brain-barrier (BBB) are likely contributo-
ry mechanisms22. 
Mechanisms of  COVID-19-related encephalomyelitis
There are three proposed mechanisms of  the pathophysiology of  enceph-
alomyelitis as a complication of  COVID-19 (Figure 7.2). The most important 
mechanism for the acute forms of  encephalomyelitis is the systemic inflamma-
tion caused by the SARS-CoV-2 virus36,38, which resembles Cytokine Release 
Syndrome (CRS). 
Figure 7.2: Main mechanisms involved in encephalomyelitis 
 
ADEM: acute disseminated encephalomyelitis; ANE: acute necrotizing encephali-
tis; CNS: central nervous system.
This is a potentially fatal complication of  various infectious (e.g., influenza, 
SARS, Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis) and 
non-infectious diseases (e.g., multiple organ dysfunction syndrome, multiple scle-
rosis). It is triggered by an initial release of  proinflammatory cytokines from ac-
tivated T and/or B cells37. The release of  cytokines activates bystander immune 
cells and endothelial cells to produce proinflammatory molecules. CRS-driven 
neurological disturbances have been described following CAR-T cell therapy and 
are termed immune effector cell-associated neurotoxicity syndrome (ICANS). 
There are various clinical manifestations of  ICANS and these include encepha-
lopathy (confusion or delirium), expressive aphasia or language disturbance, mo-
tor weakness, tremor, headache, seizures, depressed level of  consciousness, and, 
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more rarely, diffuse cerebral edema39,40. Some neurological signs/symptoms such 
as expressive aphasia appear to be very specific to ICANS. Symptoms may pro-
gress to seizures or depressed level of  consciousness/obtundation to the point 
of  requiring intubation for airway protection. There have been rare cases of  dif-
fuse cerebral edema, often developing rapidly over hours with few antecedent 
clinical warning signs. However, most ICANS symptoms are transient and can 
fully resolve within the first 3-4 weeks of  treatment; persistent abnormalities are 
uncommon39. Severe ICANS occurs almost exclusively in patients who develop 
CRS and almost always after the first fever. ICANS can occur at the same time as 
CRS or days later after CRS abates. Brain MRI in ICANS revealed the presence 
of  acute T2/FLAIR hyperintensities suggestive of  interstitial edema of  varying 
severity and small (mm-scale) ischemic strokes39. More importantly, proinflamma-
tory cytokines such as IL-6 have been shown to lead to endothelial damage and 
BBB dysfunction in this clinical entity and there is evidence that severe ICANS is 
associated with elevated CSF protein levels, likely reflecting increased blood-CSF 
barrier permeability. Accordingly, SARS-CoV-2 infection also activates the innate 
immune system, causing the release of  large amounts of  inflammatory cytokines. 
This causes the phenomenon known as “cytokine storm,” which results in sys-
temic inflammatory response syndrome41. Evidence to support this theory has 
been demonstrated by a recent study on CSF. Patients with encephalitis showed 
increased CSF levels of  IL-8, IL-6, TNF-α, and β2-macroglobulin42. A second 
mechanism is direct invasion of  the SARS-CoV-2 virus into the brain parenchyma 
that could cause the development of  encephalitis43,44. SARS-CoV-2 could enter 
the brain parenchyma via a trans-synaptic propagation or via hematogenous in-
vasion. In trans-synaptic propagation, SARS-CoV-2 binds to the angiotensin II 
(ACE-II) receptor on the cell membrane of  peripheral nerve cells and enters 
cells via receptor-mediated endocytosis. It then uses active axonal machinery to 
travel retrogradely to the CNS46. One such route is via the olfactory epithelium, 
where SARS-CoV-2 invades the olfactory primary sensory neurons and travels to 
the cribriform plate of  the ethmoid bone. From there, it crosses into the anterior 
cranial fossa and may later spread throughout the brain parenchyma to cause 
encephalitis45. 
During hematogenous invasion, SARS-CoV-2 crosses the BBB to enter the 
brain parenchyma. SARS-CoV-2 first invades vascular endothelial cells that ex-
press the ACE-II receptor2,32. It then interacts with ACE-II on surrounding 
neurons, glial cells, and other vascular cells, beginning a cycle of  viral budding. 
This causes damage to both vascular and neuronal tissue, compromising the 
BBB and allowing the SARS-CoV-2 virus to enter the CNS. 
Alternatively, hematogenous invasion could also occur through the infec-
tion of  leukocytes45. Lymphocytes, monocytes, and granulocytes all express 
the ACE-II receptor, making way for possible infection with SARS-CoV-2. 
Once infected, these leukocytes travel in the blood vessels and cross the BBB, 
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entering the CNS and taking the SARS-CoV-2 virus with them, where they can 
infect other cell types within the CNS to cause encephalitis. However, it has 
been suggested that direct invasion of  SARS-CoV-2 into the CNS may be less 
likely to be the main mechanism causing encephalomyelitis in COVID-19, as 
most of  these patients have had a negative CSF PCR against SARS-CoV-22,4,45. 
A third proposed mechanism for encephalomyelitis as a complication of  
COVID-19 is molecular mimicry46. In response to infection with SARS-CoV-2, 
there is an expansion of  host antibodies and lymphocytes. Although these im-
mune molecules are supposed to be specific for SARS-CoV-2 viral antigens, 
some of  them are cross-reactive and can attack self-antigens47. When cells in the 
vascular endothelium and brain parenchyma are affected, there is widespread 
damage to the CNS, which may cause the development of  encephalitis32,46. 
There have also been reports of  acute hemorrhagic necrotizing encephalopa-
thy which is known to develop via molecular mimicry, further supporting the 
theory of  molecular mimicry as the pathophysiology of  encephalitis as a com-
plication of  COVID-1932. 
Conclusive remarks
A variety of  neurological manifestations have been reported in COVID-19, 
which include encephalopathy, encephalitis, and myelitis. Various clinical presenta-
tions have been described among which altered mental state and delirium are the 
most frequent, though these are not always clearly detected. The incidence is rela-
tively low, but higher compared to other viral infections. Different mechanisms have 
been proposed according to onset and the relationship with COVID-19 symptoms. 
Most encephalitis, closely related to the onset of  respiratory problems were likely 
due to a cytokine release syndrome. Direct invasion of  SARS-CoV-2 is an unlikely 
mechanism but a few neuropathological studies have shown that this might happen 
in selected cases. Many cases of  encephalomyelitis have occurred after the onset of  
COVID-19 and were likely immune-mediated. Different mechanisms have been 
identified but the heterogenous clinical picture still needs to be better understood. 
A key challenge in any epidemiological investigation is the precise definition of  
patients’ clinical phenotypes. Clinicians should be aware that the diagnostic work-up 
should be as detailed and exhaustive as possible in order to rule out causes other 
than SARS-CoV-2 infection before including cases in epidemiological analyses. This 
requires, for example, a distinction between patients with clear evidence of  brain 
inflammation (encephalitis) and patients with encephalopathy, and a careful char-
acterization of  all patients with suspected disease of  the spinal cord by CSF exami-
nation, neurophysiological studies and, when needed, spinal imaging. Although this 
careful characterization is not always easy to achieve, especially in severely affected 
individuals, it should be noted that such a rigorous diagnostic approach was not 
applied in many of  the studies published to date, with the obvious consequence 
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of  phenotypic heterogeneity which compromised the reliability of  the findings. A 
useful experimental approach would be, at least, a large-scale case-control study to 
compare homogeneous groups of  patients with confirmed SARS-CoV-2 infection 
with non-infected individuals; however, this approach would present design chal-
lenges, as exposure to SARS-CoV-2 is high in the general population and wide-
spread antibody testing would be needed to ascertain seroprevalence. In addition, 
neuropathological examination of  patients with COVID-19 after death should be 
performed, as this approach might provide clues as to the mechanisms underly-
ing nervous system injury. Finally, although an emphasis has been put on recovery 
from the acute phase of  the infection, the potential long-term neurological effects 
of  COVID-19 should not be overlooked. If  SARS-CoV-2 invades the CNS, neu-
rological manifestations could recur in predisposed individuals after the virus has 
remained latent for a long time. Longitudinal neurological assessments of  patients 
after recovery will be crucial in understanding the natural history of  SARS-CoV-2 in 
the CNS and monitoring for potential neurological sequelae. Evidence from animal 
and human studies of  other coronaviruses suggests that, in some at-risk individuals, 
the inflammatory response elicited in acute or chronic infection might trigger or ac-
celerate subclinical mechanisms that underlie the earliest stages of  many neurolog-
ical diseases. Accordingly, longitudinal studies should include careful neurological, 
imaging, laboratory, and neuropsychological evaluation in order to determine the 
interplay between central and systemic infection driving CNS damage and neuro-
logical alterations.
Take-home message
 – COVID-19 infection is associated with increased risk of  encephalitis and 
myelitis through different mechanisms.
 – The spectrum of  SARS-CoV-2-related encephalitides includes inflamma-
tory-mediated and rare antibody-mediated forms.
 – A prompt diagnosis of  encephalitis and myelitis in COVID-19 is pivotal 
for early treatment.
 – High-dose steroid treatment should be discussed on the basis of  clinical 
and biological features as treatment options for non-infectious encephali-
tis/myelitis concomitant COVID-19 disease. 
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Chapter 8. Stroke
Angelo Cascio Rizzo, Alessandro Innocenti, Giuditta Giussani, 
Francesca Lanzani, Elio Clemente Agostoni
Introduction
Coronavirus disease 2019 (COVID-19) has been associated with an increased 
risk of  venous and arterial thromboembolic complications, including stroke. 
Patients affected by the illness may develop clinically significant coagulopathy 
probably mediated by several factors such as hyperinflammation, endotheli-
al dysfunction, thrombin generation and platelet activation. Since the spread 
of  the outbreak, a series of  early reports indicated an association between 
COVID-19 and cerebrovascular disease, particularly ischemic stroke. In a case 
series of  individuals admitted to a hospital in Wuhan, China, during the emer-
gency, six patients (3%) presented stroke; five out of  six strokes were ischemic 
and only one was hemorrhagic1. A series of  five cases of  severe large-vessel 
stroke (mean National Institutes of  Health Stroke Scale [NIHSS] score: 17) in 
patients under 50 years of  age was described in New York City2 drawing atten-
tion to the potential relationship between large-vessel stroke and COVID-19 in 
young patients. From then, several studies have been published showing that 
the COVID-19 outbreak has had a considerable impact on stroke incidence 
and etiology.
Epidemiology
Incidence of  ischemic stroke among COVID-19 admissions in clinical series 
is approximately 0.9-2.7%3-7. A lower incidence has been reported for intracranial 
hemorrhage (range 0.2-0.9%)8,9 and for cerebral venous thrombosis (0.08%)10. 
Moreover, there is a higher occurrence of  stroke among patients with COVID-19 
compared to patients with other viral respiratory infections (SARS-CoV-1 or 
Influenza)11. Although there is evidence to suggest a high rate of  cerebrovascular 
complications in patients with SARS-CoV-2 infection, the actual frequency of  
stroke among patients with COVID-19 has probably been underestimated be-
cause of  the phenomenon of  missed stroke diagnoses due to possible falling rates 
of  new ischemic stroke admissions. Patients have been less likely to go to hospital 
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to ask for medical assistance, especially in the presence of  mild symptoms. In 
addition, stroke diagnosis has been missed in those patients with severe respira-
tory involvement who were not extubated (thus clinical neurological symptoms 
could not be detected) or who did not survive mechanical ventilation. Finally, 
the number of  stroke cases were probably underestimated due to fewer MRIs 
being carried out. Stroke generally developed later, after a mean 1-2 weeks from 
onset of  COVID-19 symptoms. In a metanalysis, neurological symptoms related 
to stroke represented the reason for hospital admission in 37.7% and the median 
delay of  stroke from onset of  COVID-19 symptoms was 8.8 days12. In a UK 
study, fever, cough or dyspnea occurred a median 6 days before stroke onset13. 
This delay between stroke onset and COVID-19 infection is probably secondary 
to the development of  the increased hypercoagulable and inflammation state as 
trigger mechanisms of  cerebrovascular complications.
Figure 8.1: Pathophysiological processes related to stroke in patients  
with COVID-19 infection
HIF = hypoxia-inducible transcription factor; IL-6 = Interleukin 6.
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COVID-19 and cerebral vascular disease: pathophysio-
logical mechanisms
Various mechanisms can lead to involvement of  the nervous system in 
COVID-1914. Many reports demonstrated a link between COVID-19 and cer-
ebrovascular disease1,15, and a recent meta-analysis showed a 5-fold increase 
in stroke risk for patients with severe COVID-1912. COVID-19 patients with 
ischemic stroke frequently have large vessel occlusion due to either cryptogenic 
or cardioembolic strokes.  However, there is a higher risk even for minor or la-
cunar strokes. This clinical diversity probably also reflects    pathophysiological 
heterogeneity. Several pathophysiological processes seem to be related to stroke 
in patients with COVID-19:  a) an immunomediated thrombosis and hyper-
coagulopathy; b) direct invasion of  the nervous system; c) heart disease with 
increased cardioembolic risk; and d) the consequences of  systemic infection.
a) Immuno-mediated thrombosis and hypercoagulopathy state
S proteins are expressed on the surface of  SARS-CoV-2 that bind the recep-
tor for the enzyme that converts angiotensin (ACE2), also expressed in epithe-
lial alveolar cells and endothelial cells.
In the lung, the virus is recognized by Toll like receptor (TLR) and upregu-
lates pro-interleukin-1β expression of  macrophages16. Macrophages cause the 
release of  pro-inflammatory acute-response cytokines (tumor necrosis factor 
and IL-1β) and a sustained increase in IL-6. In turn, IL-6 supports the inflam-
matory process, similar to what happens in cytokine release syndrome17. During 
this hyper-inflammatory state, activated platelets induce the extrinsic coagula-
tion cascade, leading to thrombin formation. The cytokine storm also promotes 
expression of  plasminogen activator inhibitor-1 from the endothelium, thus 
inhibiting the formation of  plasmin inhibiting fibrinolysis18. Simultaneously, cir-
culating viruses, binding endothelial cells, facilitate endothelial and vascular in-
flammation (endothelitis)19. In turn, damaged endothelial cells also release Von 
Willebrand factor, causing platelet hyperactivation. The pro-inflammatory state, 
platelet and coagulation activation, and endothelitis result in hypercoagulability 
and microvascular immune-mediated thrombosis20. In some patients, hyperco-
agulopathy is also determined by the presence of  antiphospholipid antibodies 
or lupus anticoagulant21. High D-dimer levels and elevated fibrinogen without 
hypofibrinogenemia characterize COVID-19 hypercoagulopathy. Furthermore, 
prolonged inflammation determines oxidative stress with the production of  re-
active oxygen species (ROS) which in turn enhance the inflammatory response22.
b) Direct invasion and renin-angiotensin-aldosterone system
As mentioned above, S proteins on the surface of  SARS-CoV-2 bind ACE2, 
which is expressed not only in the lung and endothelium but also in the Central 
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Nervous System (CNS), especially in the olfactory bulb, in the cingulate cortex, 
the temporo-mesial lobe, the substantia nigra, in cerebral capillaries, smooth 
muscle cells, and microglia. Direct CNS invasion by a virus probably occurs 
in several ways, but mainly through the olfactory nerve and olfactory bulb23. 
The hematogenous spread of  a virus by crossing the blood-brain barrier could 
also cause direct damage. ACE2 counteracts the renin–angiotensin–aldoster-
one system by degrading angiotensin I and II and promoting vasodilating and 
an-inflammatory effects. By binding ACE2, SARS-CoV-2 downregulates ACE2 
expression and higher formation of  angiotensin II causes the migration of  leu-
kocytes into the tissues with a pro-inflammatory effect, promoting platelet ag-
gregation24. These effects, together with endothelitis, cytokine storm, comple-
ment, platelet and neutrophil activation, may affect both the stability of  already 
vulnerable atherosclerotic plaques and contribute to a hypercoagulable state 
and arterial embolism25.  In addition, direct infection of  the cerebrovascular 
endothelium and immune dysregulation could cause a viral cerebral vasculitis 
in the brain26. Direct (viral invasion) or indirect (inflammatory cytokine, pro-
thrombotic factors, activation of  coagulation cascades) endothelial damage in-
creases not only the thrombotic risk, but also contributes to vascular fragility. 
This, associated with blood brain barrier dysfunction, can result in a cerebral 
hemorrhage27.
c) Cardioembolism and COVID-19-associated cardiopathy
Pro-inflammatory pattern and cytokine storm may lead to myocardial injury, 
elevating microthrombi genesis28. In addition to vascular myocardial damage, 
several studies report an increased incidence of  myocarditis and Tako-tsubo 
syndrome in COVID-19 patients29,30. Myocardial damage, whether vascular or 
non-vascular, causes left ventricular dysfunction, which is a well-known cause 
of  embolic stroke. Furthermore, myocardial damage associated with a systemic 
infection can result in atrial fibrillation or in malignant ventricular arrhythmias, 
which in turn can be a potential cause of  cardioembolism.
d) Systemic infection
COVID-19 is known to be a systemic disease. Therefore, disease-related 
brain damage is also closely linked to the systemic alterations caused by the dis-
ease. Hypoxia due to cardio-respiratory distress increases the risk of  ischemic 
stroke. Furthermore, systemic hypoxia promotes the expression of  Hypoxia 
Inducible Factor (HIF), which in turn activates the coagulation cascade via ex-
trinsic coagulation pathway, maintaining hypercoagulability in hypoxic regions18. 
Sepsis with high D-dimer levels can result in sepsis-induced Disseminated 
Intravascular Coagulation. Furthermore, co-pathologies play an important role: 
severe disease is usually seen in older patients who often have comorbidities 
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that increase their risk of  stroke (diabetes, hypertension, obesity, smoking hab-
it), and these have a significant negative effect on prognosis. 
Risk factor of  stroke in COVID-19 patients
Some early reports observed that ischemic stroke frequently occurred in 
young patients with COVID-19. In a retrospective cohort study of  consecu-
tive patients with ischemic stroke who were hospitalized within a major health 
system in New York, among the 32 patients with COVID-19 and stroke, the 
median age was 62.5 years2,4. In a systematic review and metanalysis, patients 
with COVID-19 and stroke were younger than patients with stroke without 
infection with a pooled median difference for age of  6.0 years12. In the larg-
est study, comprehensively reporting the characteristics and subtypes of  stroke 
in SARS-CoV-2–infected patients from the Multinational COVID-19 Stroke 
Study Group, in a population of  323 patients with acute ischemic stroke, 36.2% 
were <55 years of  age31. However, these data have not been confirmed by sub-
sequent studies and systematic analysis which have shown a higher mean age of  
COVID-19 patients with stroke of  over 65 years7,32. In the Global COVID-19 
Stroke Registry study33, median age was 71.2 years. 
Male sex is more frequently associated with stroke and COVID-19 infec-
tion34 and in several studies the proportion of  Black people was higher32,35,36. 
Earlier observations from smaller case series also suggested that patients with 
COVID-19 who developed acute ischemic stroke did not have pre-existing car-
diovascular risk factors4.
However, subsequent studies and metanalysis showed stroke risk in Covid-19 
was higher in patients with cardiovascular risk factors, with patients developing 
cerebrovascular diseases having greater likelihood of  a smoking habit, hyper-
tension, diabetes mellitus, hyperlipidemia, atrial fibrillation, coronary artery dis-
ease, and congestive heart failure12,32.
Stroke in COVID-19 patients seems to be associated with more severe in-
fectious disease. In a retrospective study in patients admitted to the intensive 
care unit (ICU), incidence of  stroke was 5.7% compared to 0.8% of  patients 
with a non-severe disease course. Siepmann et al.37 conducted a meta-analysis 
of  741 patients showing severe COVID-19 infection was associated with an 
increased risk of  acute stroke. In a recent systematic review and meta-analysis 
of  5,266 patients, according to the severity of  the disease, patients with severe 
COVID-19 had an increased risk of  acute ischemic stroke compared with pa-
tients with non-severe disease: total stroke rate 3.37% and 0.61%, respectively38. 
Moreover, patients with severe manifestations of  COVID-19 have significantly 
more frequent ischemic strokes with multivascular territorial distribution, hem-
orrhagic transformation, and simultaneous infarction and intracranial hemor-
rhage36. Stroke in severe COVID-19 is also associated with significantly higher 
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C-reactive protein and ferritin levels, elevated D-dimer levels, and more fre-
quent lymphopenia and renal and hepatic injury, supporting the proposed path-
ogenic mechanisms of  hyperinflammation activating a prothrombotic state, 
particularly in those with severe disease36.
COVID-19 and stroke characteristics
Patients with COVID-19 and stroke have a higher prevalence of  moder-
ate-severe stroke with higher admission NIHSS score. In an early report from 
a hospital in New York, median NIHSS score was 19 in COVID-19 patients 
compared to 8 in patients not infected4. Sahajouel et al.31 reported that, in a 
population of  323 acute ischemic strokes, up to 74% of  patients had a NIHSS 
score ≥5. The high prevalence of  more severe strokes can be explained by a 
greater prevalence of  large vessel occlusions (LVO) that is twice as frequent as 
previously reported (up to 47%), with higher prevalence across all age groups, 
even in the absence of  risk factors or comorbidities7,31. Up to 68.8% of  young 
patients present a LVO7. Considering published data, young patients proba-
bly represent only a small proportion of  the entire population of  COVID-19 
stroke patients and show specific features with respect to older individuals, such 
as lower prevalence of  traditional vascular risk factors and higher incidence of  
LVO. 
In COVID-19 patients, strokes usually present cortical and lobar location and 
multiterritorial involvement, and associated brain hemorrhage (hemorrhagic 
transformation or simultaneous hemorrhage and infarction) is common39. With 
regards to stroke etiology, cryptogenic subtype is the most frequently reported 
from several studies with a prevalence of  50-63%4,40,41. Around 50% have no 
identifiable source and are categorized as embolic stroke of  unknown source 
(ESUS)42. In a recent metanalysis, patients infected by SARS-CoV-2 appear to 
have increased odds of  cryptogenic stroke when compared to contemporary or 
historical non-infected controls43. The higher incidence of  cryptogenic strokes 
and ESUS is probably due to blood hyperviscosity and a hypercoagulable state; 
these have been linked to an immune-mediated response following SARS-
CoV-2 infection. In fact, high levels of  biomarkers of  inflammatory response 
(neutrophils, C-reactive protein, IL-6) and coagulation defects (high level of  
D-Dimer, low platelet count, elevated PT and aPTT) were found in patients 
with cryptogenic strokes3,4,41, and significantly higher levels of  CRP and D-dimer 
were found in patients with more severe infection, suggestive of  an acquired 
thrombophilia36. Moreover, a temporal correlation has been identified between 
stroke onset and the peak of  acute phase reactants, including C-reactive protein, 
ferritin, and D-dimer, supporting the hypothesis that ischemic stroke is due 
to an underlying endotheliopathy and thrombosis44. An association with newly 
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positive antiphospholipid antibodies has also been observed although the cause 
of  this is uncertain21,35.
Other possible embolic sources are probably related to cardiac dysfunction 
associated with critical illness and prolonged stay in the ICU; hypotension and 
inadequate cerebral perfusion, septic embolization, atrial fibrillation, cardiac 
dysfunction, stress cardiomyopathy, myocarditis are sometimes underdiagnosed 
in severely compromised patients. Compared to SARS-CoV-2-negative patients, 
patients with COVID-19 infection more often have cardioembolism, especially 
related to atrial fibrillation, as the likely cause of  brain ischemia34. In fact, atrial 
arrhythmias have been associated with severe COVID-19 infection45. Patients 
with ischemic stroke under 50 years of  age frequently have elevated cardiac 
troponin, a marker of  acute or chronic myocardial injury strongly associated 
with the risk of  stroke and usually secondary to underlying heart disease at 
baseline or to a myocardial ischemia. In a cohort of  young stroke patients with 
COVID-19, 80% had high troponin. Considering that 44.8% of  them had no 
prior risk factors, these high levels are probably the consequence of  acute myo-
cardial injury, which could play a role in the pathophysiology of  acute ischemic 
stroke in young patients with COVID-197.
Among other stroke etiologies, cardioembolism represented the second most 
frequent subtype, while large vessel atherosclerosis and small artery stroke were 
less frequently reported12. In one study, no difference was found in the preva-
lence of  large-artery and lacunar stroke between patients with and those with-
out COVID-1933. 
However, any discussion of  the distribution of  stroke etiologies during the 
Covid-19 outbreak has to take into account some epidemiological bias. A high 
prevalence of  cryptogenic strokes is probably related to an underestimation 
of  the frequency of  other subtypes. This could partly be explained by some 
confounding factors such as a relatively low number of  diagnostic studies per-
formed during the outbreak and an underestimation of  mild stroke (often due 
to small vessel disease) because individuals with only mild symptoms would 
avoid going to hospital because of  fear of  contagion. 
Stroke therapy in COVID-19 patients
Acute reperfusion therapies
Safety issues related to thrombolysis have not been specifically studied in 
the setting of  COVID-19 infection. A reduction in the total number of  pa-
tients treated with Alteplase has been observed, likely related to the lockdown 
in Milan, which made it difficult for stroke patients to access medical assistance. 
A study from Italy on treated patients with thrombolysis or bridging therapy, re-
ported higher rates of  unfavorable outcomes at 1-month compared to previous 
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data from the pre-COVID-19 literature. However, there was no increase in risk 
of  symptomatic intracerebral hemorrhage46. Therefore, intravenous thrombo-
lytic therapy should be evaluated, as for any patient with acute ischemic stroke, 
according to current guidelines. A similar approach should be adopted for me-
chanical thrombectomy. However, as for thrombolysis, the number of  unfa-
vorable outcomes after endovascular therapies was also higher compared to 
previous data. A French study showed an increased risk of  reocclusion after 
initial endovascular recanalization in patients with COVID-19 that could have 
been related to hypercoagulability associated with the infection47. A European 
study investigated the efficacy and safety of  mechanical thrombectomy in pa-
tients with acute ischemic stroke and LVO associated with COVID-19 infection 
and observed a 29% rate of  30-day mortality after treatment; in more than 50%, 
the primary cause of  mortality was neurological associated with ICH or malig-
nant cerebral infarction/edema48.
Antithrombotic therapy
Up to now, no clear guidelines on antithrombotic therapy in patients with 
COVID-19 and stroke have been published. Strokes, particularly those resulting 
from large vessel occlusion, are associated with certain prothrombotic states in 
COVID-19 infection. On the other hand, anticoagulation is associated with an 
increased risk of  hemorrhagic transformation in COVID-19 patients49.
Pharmacological venous thromboembolism prophylaxis is strongly advised 
for all COVID-19 patients50. For patients with ischemic stroke with a strong 
indication for full-dose anticoagulation (atrial fibrillation, severe heart failure, 
intraventricular thrombus), early initiation is probably reasonable given the high 
thrombotic risk seen in patients with COVID-19, to be weighed up with the 
bleeding risk according to the size of  the ischemic lesion.
For other patients with cryptogenic stroke, involvement of  multiple vascular 
territories (suggesting an embolic phenomenon), presence of  other potential 
thrombotic events, an assessment of  the severity of  systemic illness assessed 
by measurement of  coagulation (fibrinogen and D-dimer) and inflammation 
markers, should all be considered when deciding between antiplatelet therapy 
or anticoagulation, always bearing in mind the higher bleeding risk in these 
patients.
Outcome
The prognosis for COVID-19-associated ischemic strokes is extremely poor. 
Patients often had severe illness requiring ICU admission and mechanical venti-
lation3,4. The prognosis was particularly bleak in those patients with high levels 
of  D-dimer5. Patients have a longer hospital stay with a greater rate of  neuro-
logical worsening during admission because of  a higher rate of  neurological 
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and cardiovascular events during hospitalization including cerebral edema, in-
tracerebral hemorrhage, myocardial infarction, or multisystem involvement32. 
In one study, up to 51% of  patients with COVID-19 had severe disability at 
discharge (median mRS 4 vs. 2) compared with patients without COVID-1933, 
and more COVID-19-positive patients suffer in-hospital death3,40,51. Friedman 
et al.7 reported that a clinical phenotype characterized by older age, a higher 
burden of  comorbid conditions, and severe COVID-19 respiratory symptoms 
was associated with the highest in-hospital mortality (58.6%) and a 3 times 
higher risk of  death than the rest of  the cohort.
COVID-19 and hemorrhagic stroke
COVID-19-related hemorrhagic strokes are much less common than ischemic 
strokes. In a recent analysis from the COVID-19 cardiovascular disease registry 
of  21,483 patients, only 48 (0.2%) had had an intraparenchymal hemorrhage9. 
Most were elderly male patients with comorbidities and more vascular risk fac-
tors, the most common being systemic hypertension9,52. Intraparenchymal hem-
orrhage was the most common variety52. A significant proportion of  patients 
with intracerebral hemorrhage were on some form (therapeutic or prophylactic 
dose) of  anticoagulation therapy, which could have predisposed them to the 
development of  the hemorrhage40,53,54. In one study, anticoagulation was as-
sociated with a 5-fold increase of  intracerebral hemorrhage in COVID-19 pa-
tients54. Patients with intracerebral hemorrhage are more likely to require ICU 
admission, mechanical ventilation, extracorporeal membranous oxygenation, 
and have a higher mortality9,31. Higher  hemorrhagic risk in COVID-19 patients 
could be explained by several hypotheses: invasion and direct damage of  cer-
ebral blood vessels by SARS-CoV-2, hypertensive effect induced by marked 
reduction in ACE-2 levels, or systemic hyperinflammatory syndrome charac-
terized by fulminant hypercytokinemia which may mediate vascular damage26,27.
Niguarda Hospital, Milan: the COVID-19 experience
A retrospective analysis was performed on 901 COVID-19 patients who at-
tended the Niguarda Hospital in Milan55. In this case series, 53 patients (5.9%) 
had a stroke. As expected, our patients with stroke were older and with more 
comorbidities, and these factors could partially explain the observed higher fa-
tality rate. It should also be noted that a mortality of  37.7% is considerably 
higher that that reported in the literature, where it ranges from 11% to 19%, 
and it is higher than previous mortality rates reported at our center (7.7% in 
2019). Our data agree with the literature in that there is a substantially higher 
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mortality in individuals with both COVID-19 and stroke than that observed in 
patients with stroke without SARS-CoV-2 infection. 
Stroke care and assisting patients with COVID-19 infection
Despite the association of  SARS-CoV-2 infection with an increased risk of  
ischemic stroke, in Spring 2020, numbers of  inpatient stroke decreased. A de-
cline in acute stroke code activations (Figure 8.1), stroke hospitalizations, and 
mechanical thrombectomy volumes have been reported in a paper by Friedlich 
et al.56 at local, regional, and national levels compared with most reports from 
comprehensive stroke centers (CSC) in high income countries (paper has been 
recently retracted because of  lack of  written consent from the American Heart Association to 
use the ‘Get with the Guidelines’ dataset). 
Primary stroke centers and centers with higher COVID-19 inpatient volumes 
experienced steeper declines. The reasons for this decrease are not completely 
understood but may relate to patients with stroke symptoms not seeking care 
due to fear of  contracting SARS-CoV-2 in the emergency room, lack of  recog-
nition of  stroke symptoms due to isolation from social distancing, misdiagnosis 
of  stroke in the setting of  SARS-CoV-2 encephalopathy, or other factors56,57.
Since the outbreak began, specific measures have been taken to contain the 
spread of  the disease, including lockdown, converting general medical wards to 
quarantine wards, and reorganizing in-hospital clinical activities for the emer-
gency management and treatment of  acute conditions. One such measure has 
been to concentrate a large proportion of  acute stroke patients in a restricted 
number of  hospitals.
The initial lull in stroke volume allowed centers to develop and implement 
new processes and protocols to care for stroke patients with SARS-CoV-2 in-
fection with the goal of  reducing the duration and frequency with which the 
staff  directly interacted with infectious patients. These changes have the dual 
benefits of  not only reducing staff  exposure to potential infection, but also 
helped to conserve personal protective equipment58. Recovery of  stroke hospi-
talization but not intravenous thrombolysis volume was noted in the later phase 
of  the initial pandemic wave and was associated with lower COVID-19 hospi-
tal burden, high volume, and higher use of  comprehensive stroke centers59-61. 
Furthermore, Rinkel et al.62 show that there was no change in the proportion of  
stroke patients treated with intravenous thrombolysis (28% vs. 30%, p = 0.58) 
or endovascular thrombectomy (11% vs. 12%, p = 0.82) or associated treatment 
times, confirming that there is no evidence for a decrease in the quality of  acute 
stroke care. In contrast, Siegler et al.63 report that evaluation for acute ischemic 
stroke during the COVID-19 period in pooled clinical data of  consecutive adult 
stroke patients from 14 US comprehensive stroke centers was associated with a 
small but significant delay in intravenous thrombolysis but no significant delay 
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in thrombectomy time metrics. The analysis in a prospective multicenter cohort 
study used data from the Thrombolysis in Ischemic Stroke Patients (TRISP) 
registry of  patients with acute ischemic stroke treated with reperfusion thera-
pies indicates the solid stability of  key quality performance measures between 
2019 and 2020 that may confirm the resilience of  acute stroke care services 
during the lockdown, at least in well-established European stroke centers64.
Several studies confirm that patients with COVID-19 have more severe 
strokes and poorer outcomes despite similar acute management to other stroke 
patients. A well-established stroke care network helps to diminish the impact 
of  such an outbreak in stroke care, reducing secondary transfers and allowing 
maintenance of  reperfusion therapies, with a minor impact on door-to-punc-
ture times, which were longer in patients who underwent chest computed to-
mography. The findings of  these studies can inform medical preparedness and 
local policies in the event of  a new COVID-19 surge or future pandemic.
Take-Home message
 – Patients with COVID-19 have higher prevalence of  moderate-severe 
stroke with large vessel occlusions, cortical and lobar location, multiterri-
torial involvement and associated brain hemorrhage (hemorrhagic trans-
formation or simultaneous hemorrhage and infarction).
 – Cryptogenic stroke is the most frequent subtype, probably related to a hy-
percoagulable state with high levels of  inflammatory and coagulation bi-
omarkers (neutrophils, C-reactive protein, IL-6, D-dimer, PT and aPTT).
 – The acute management of  ischemic or hemorrhagic stroke in COVID-19 
patients should follow the same standards of  care as for non-COVID-19 
patients, adopting the necessary precautions related to infection control.
 – Pharmacological venous thromboembolism prophylaxis should be strong-
ly considered for all COVID-19 patients.
 – In patients with cryptogenic stroke, involvement of  multiple vascular ter-
ritories (suggesting an embolic phenomenon), presence of  other arterial 
or venous thrombotic events, elevated coagulation markers should be tak-
en into consideration when deciding whether to initiate anticoagulation 
therapy, always bearing in mind the higher bleeding risk in these patients.
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Introduction
Many neurological symptoms, such as encephalopathy, seizures and status 
epilepticus, have been reported in patients with COVID-191-4. Even if  the ac-
quisition of  an Electroencephalogram (EEG) in SARS-CoV-2 positive patients 
presents some particular limitations, mainly due to the risk of  infection, many 
papers describing electroencephalographic patterns of  those patients have been 
published in the last year.
EEG findings
Although changes in mental status have been frequently reported in patients 
with COVID-195-11 together with other neurological symptoms, including clin-
ical and subclinical seizures and status epilepticus12-16, EEG studies have been 
significantly underused in these patients due to the risk of  infection. Three stud-
ies showed that EEG services have been widely disrupted by the COVID-19 
pandemic17-19. On the other hand, studies conducted using the scarce EEG 
data available showed that many of  the patients with COVID-19 and encepha-
lopathy/seizures had epileptiform discharges/seizures in their EEG examina-
tions7,20,21. In a review of  617 patients from 84 reports, Antony and Haneef22 
found that EEG abnormalities in COVID-19 patients were common, com-
prising a wide variety of  findings such as background abnormalities, periodic 
and rhythmic activity, and other epileptiform abnormalities7,23,24. Diffuse back-
ground slowing was the most frequent EEG finding, reported in two-thirds 
of  patients, indicating that a diffuse, non-specific encephalopathy is the most 
constant brain abnormality in this condition (Figure 9.1).
These findings are in line with those of  Roberto et al.25 and those of  Kubota 
et al.26 who found that the proportion of  abnormal background activity was 
even higher. These results confirm that patients infected with COVID-19 who 
required EEG may likely have encephalopathy. In fact, also in the meta-analysis 
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of  Kubota et al.26, the most common indication for EEG was altered mental 
status (68.4% of  cases). 
Figure 9.1
Male patient, aged 58, admitted for an episode of  loss of  consciousness; detection 
of  COVID-19 at swab test at admission. EEG showed diffuse background slowing 
and sporadic sharp waves. 20 sec/page, 100 µm amplitude.
 
Figure 9.2
Female patient, aged 55, admitted for confusion and altered mental status appeared 
24 hours after onset of  low-grade fever and malaise in COVID-19 infection. EEG 
showed sub-continuous rhythmic delta activity. 20 sec/page, 100 µm amplitude.
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Other EEG features suggesting diffuse encephalopathy included generalized 
rhythmic delta activity (GRDA)7,9, generalized periodic discharges (GPD) with 
triphasic morphology9,27, and discontinuous/burst suppression/background 
suppression. Kubota and colleagues found discontinuous / burst suppression 
/ background suppression and GPDs in 5.33% and 16.5% of  the patients, 
respectively26. 
Lateralized periodic and rhythmic abnormalities have also been reported, 
suggesting a co-existent focal dysfunction in some patients. Epileptiform dis-
charges were common, indicating underlying cortical irritability predisposing to 
seizures22. 
Several studies reported abnormalities in the frontal region7,22,27-29 including 
focal slowing, periodic discharges and rhythmic delta activity (Figure 9.2).
In the systematic review conducted by Antony and Henef22, half  of  all status 
epilepticus and focal slowing originated in the frontal lobe. Most of  the authors 
considered these frontal findings to be aspecific25. Others have described a spe-
cific EEG pattern characterized by continuous, slightly asymmetric, monomor-
phic, diphasic, delta slow waves with greater amplitude over both frontal areas 
and with a periodic organization22,29 proposing this pattern as a potential bio-
marker. Some authors hypothesize that the common frontal location of  focal 
abnormalities in COVID-19 patients correlates with the purported entry of  the 
virus into the brain7,27,28,30. Early clinical manifestations of  COVID-19 like anos-
mia and ageusia are thought to be due to viral entry in the nasal and oral mu-
cosa facilitated by ACE-2 receptors31. Subsequent spread to the orbitofrontal 
region31,32 via afferent nerves leads to preferential involvement of  the olfactory 
bulb and orbitofrontal/frontal regions and can explain the preponderance of  
frontal EEG findings. This theory is also corroborated by frontal hypometabo-
lism seen in PET scans in these patients33.
Technical recommendations for EEG
Although much information may be gained from an EEG, the value of  this 
information in the diagnosis and management of  the patient must be weighed 
against the risks of  infection from COVID-19 for the technologist. In this set-
ting, reduced EEG montages using single-use subdermal EEG needle elec-
trodes may be used in comatose patients. A full 10-20 EEG complement of  
electrodes with an ECG derivation remains the standard in all other cases. 
Under COVID-19 conditions, an expedited study that adequately screens for 
generalized status epilepticus, most types of  regional status epilepticus, enceph-
alopathy or sleep, may serve for most clinical questions, and using simplified 
montages may limit the risk of  infection to EEG technologists34. Carrying out 
an EEG should be assessed in accordance with clinical urgency, setting, status 
of  SARS-CoV-2 infection, and phase of  governmental restrictions. In the most 
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critical phases of  the pandemic, EEGs should be limited to patients with acute 
/ subacute neurological symptoms, and outpatient examinations should be sus-
pended. Risk of  infection could be reduced by limiting contact between staff  
through rescheduling work shifts, and the use of  disposable electrodes and 
of  dedicated EEG devices for COVID-19-positive patients35. (International 
League Against Epilepsy [ILAE]’s Guidance for EEG investigation is avail-
able online at https://www.ilae.org/patient-care/covid-19-and-epilepsy/
for-clinicians.)
Mechanisms of  seizures in SARS-CoV-2
Many case series report an association between seizures and SARS-CoV-2 
infection15,24,36-38. Three different mechanisms have been theorized by which 
seizures can develop in patients infected with SARS-CoV-2: a direct mecha-
nism, am indirect mechanism, and an exacerbation of  seizure in patients with 
epilepsy39.
Direct mechanism
SARS-CoV-2 is capable of  entering directly and infecting the central nerv-
ous system, leading to meningitis and encephalitis, and consequent seizures39-41 
through different ways. One of  them involves Angiotensin converting-en-
zyme-2 (ACE-2) receptors42, which are located on cells throughout the body, 
including the cardio-respiratory neurons of  the brainstem, glial cells, basal 
ganglia, motor cortex, raphe, and endothelial cells of  the brain. SARS-CoV-2 
can infect the endothelial cells of  the blood-brain barrier and then accumulate 
in the various previously mentioned brain regions causing direct infection with 
neurological complications40,43. Another pathway through which SARS-CoV-2 
is thought to enter the central nervous system (CNS) is the olfactory nerve via 
the nasal cavity. In fact, it has been shown that, within seven days of  infection, 
SARS-CoV-2 is able to reach the cerebrospinal fluid (CSF) and brain through 
the olfactory nerve causing inflammation and demyelinating reactions with 
potential subsequent seizures43,44.
Indirect mechanism
Downregulation of  ACE-2 expression - ACE-2 receptors may play a role 
also in an indirect mechanism. The overloading of  these receptors by SARS-
CoV-2 infection leads to a downregulation of  ACE-2 expression, dysfunction 
of  the renin-angiotensin system with overproduction of  angiotensin II result-
ing in a cascade of  biochemical events that eventually cause severe acute lung 
injury, vasoconstriction, and oxidative processes that promote brain damage 
with the possible occurrence of  seizures42,43.
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Cytokine storm - Another possible indirect mechanism derives from the im-
pairment of  natural killer and cytotoxic T-cell function which results in exces-
sive secretion of  pro-inflammatory cytokines such as tumor necrosis factor α 
(TNFα), and interleukins (IL) 1, 4, 6, 8, 10, and 18. This cytokine storm results 
in an exaggerated inflammatory response leading to vascular permeability, ede-
ma, and widespread inflammation with consequent damage to multiple organs 
with progression to multi-organ failure41,45. 
Hypoxia and hypoperfusion - Also, hypoxia can potentiate encephalopa-
thy, which can further play a role in the development of  seizures. Ischemic 
brain injury also contributes to cerebral tissue hypoperfusion and may lead to 
seizures46.
Exacerbation of  seizure in patients with epilepsy 
The effects of  COVID-19 on patients with epilepsy (PWE) are still not 
clear. The ILAE has issued a declaration that PWE are not likely to be more 
susceptible to getting COVID-19 nor are they inclined to suffer through 
severe manifestations of  SARS-CoV-2 infection47. Even if  PWE are ex-
posed to SARS-CoV-2, it is unlikely that the frequency of  seizures increases. 
Nevertheless, management of  COVID-19 in PWE requires certain precau-
tions, and guidelines need to be followed in order to avoid a worsening of  
the condition; maintaining control of  epilepsy with anti-seizure medication 
(ASM) is crucial as mortality associated with epilepsy is higher in patients with 
uncontrollable seizures. In particular, potential drug-drug interaction that may 
occur on concomitant administration of  ASM along with the drugs used to 
treat COVID-19 need to be taken into account48,49, since an increasing number 
of  medications are being considered for the management of  COVID-1950-52. 
Information about drug-drug interactions is also of  particular relevance for 
intensive care unit management of  critically ill COVID-19 patients who may 
develop acute seizures during a severe disease course. 
Some drugs currently used as anti-COVID-19 medications may increase 
the risk of  seizures, although this is rare. The mechanisms of  seizure facilita-
tion can be manifold: effects of  anti-COVID-19 drugs on seizure threshold, 
effects of  infection on ASM pharmacokinetics, and drug-drug interaction. 
Furthermore, common adverse effects of  anti-COVID-19 drugs (such as di-
arrhea) could lower plasma ASM concentration. Lastly, immunomodulation by 
ASMs has also been hypothesized53.
Moreover, COVID-19 infection could be related to impaired hepatic and 
renal function. This means that critically ill patients in particular may require 
ASM plasma concentrations to be monitored and possible dose adjustment. 
Major interactions relate to strong hepatic enzyme-inducing ASMs (pheno-
barbital, primidone, phenytoin and carbamazepine), but other mechanisms 
of  drug-drug interaction have also been reported (i.e., P-glycoprotein way)54. 
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Possible drug interactions between more common anti-COVID-19 medica-
tions and ASMs are summarized in Table 9.1.
Table 9.1: Possible interactions between anti-COVID-19 drugs  
(some of  them not currently used)  and most the commonly used ASMs,  
and recommendations for their combinations
Drug interaction Cardiac side effects Recommendations
Chloroquine/ 
Hydroxychloroquine
BRV, CBZ, ESL, 
FBM, OXC, PHT, 
PB, PRM
Possible dysrhyth-
mias if  associated 
to FBM
Avoid co-administration with 
CBZ, PHT, PB, PRM 
Lopinavir/Ritonavir BRV, CBZ, CLN, 
CLB, DZP, ESL, 
FBM, LTG, MDZ, 
OXC, PER, PHT, 
PB, PRM, VPA
Possible dysrhyth-
mias if  associated to 
ESL or LCS
Avoid co-administration with 
MDZ. If  in combination 
with CBZ, administer twice 
daily instead of  once daily. If  
co-administered with LTG, 
therapeutic monitoring of  
LTG is required. 
Tocilizumab CBZ, CLB, CLN, 
DZP, LZP, MDZ, 
PHT, PRM, VPA
Remdesivir CBZ, ESL, OXC, 
PHT, PB, PRM
Avoid co-administration with 
CBZ, PHT, PB, PRM
 Azithromycin PHT Possible dysrhyth-
mias if  associated 
to PRG
Dose adjustment and 




PB Monitor plasma concentra-
tions of  PB if  co-adminis-
tered; dose of  corticosteroids 
may have to be increased if  
administered with PB
DOACs CBZ, ESL, LEV, 
FBM, OXC, PB, 
PHT, PRM, TPM, 
VPA
If  associated with CBZ, PB, 
PHT or PRM caution and 
surveillance are needed, in 
addition to possible increases 
in DOAC dose; low molecular 
weight heparin or unfraction-
ated heparin may be used in 
these cases. 
Drug interaction Cardiac side effects Recommendations
Chloroquine/ 
Hydroxychloroquine
BRV, CBZ, ESL, 
FBM, OXC, PHT, 
PB, PRM
Possible dysrhyth-
mias if  associated 
to FBM
Avoid co-administration with 
CBZ, PHT, PB, PRM 
Lopinavir/Ritonavir BRV, CBZ, CLN, 
CLB, DZP, ESL, 
FBM, LTG, MDZ, 
OXC, PER, PHT, 
PB, PRM, VPA
Possible dysrhyth-
mias if  associated to 
ESL or LCS
Avoid co-administration with 
MDZ. If  in combination 
with CBZ, administer twice 
daily instead of  once daily. If  
co-administered with LTG, 
therapeutic monitoring of  
LTG is required. 
Tocilizumab CBZ, CLB, CLN, 
DZP, LZP, MDZ, 
PHT, PRM, VPA
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Remdesivir CBZ, ESL, OXC, 
PHT, PB, PRM
Avoid co-administration with 
CBZ, PHT, PB, PRM
 Azithromycin PHT Possible dysrhyth-
mias if  associated 
to PRG
Dose adjustment and 




PB Monitor plasma concentra-
tions of  PB if  co-adminis-
tered; dose of  corticosteroids 
may have to be increased if  
administered with PB
DOACs CBZ, ESL, LEV, 
FBM, OXC, PB, 
PHT, PRM, TPM, 
VPA
If  associated with CBZ, PB, 
PHT or PRM caution and 
surveillance are needed, in 
addition to possible increases 
in DOAC dose; low molecular 
weight heparin or unfraction-
ated heparin may be used in 
these cases. 
AMSs - BRV: brivaracetam; CBZ:  carbamazepine; CLB:  clobazam; CLN:  clonaz-
epam; DZP:  diazepam; ESL:  eslicarbaz: epine; FBM:  felbamate; LEV:  leveti-
racetam; LTG:  lamotrigine; LZP:  lorazepam; MDZ:  midazolam; OXC:  oxcarba-
zepine; PER:  perampanel; PHT:  phenytoin; PB:  phenobarbital; PRG:  pregabalin; 
PRM:  primidone; TPM:  topiramate; VPA: valproic acid.
Seizures and SARS-CoV-2
Seizures and/or status epilepticus (SE) were often recorded in patients with-
out any evidence of  acute or chronic brain injury on imaging and without any 
alteration in CSF; in those patients, seizures have been recorded mainly in the 
frontal lobe55 or in the fronto-central region15,56. Moreover, non-convulsive SE 
(NCSE) has been reported in the frontal region, unilaterally30,57, or bilaterally38 
or in the fronto-temporal region58.
Seizures and/or SE were recorded more rarely in patients with acute CNS le-
sions on brain imaging and/or significant CSF abnormalities, of  either vascular 
or inflammatory origin, and in those cases, seizures or SE were often described 
as arising from the posterior regions. Occipital focal seizures or NCSE were de-
scribed by Parauda et al.59 in patients with posterior reversible encephalopathy 
syndrome (PRES). In other cases, seizures starting from the right fronto-tem-
poral region were recorded in a patient with diffuse CNS demyelinating lesions 
on brain and spine imaging60 or multifocal and bilateral seizures were detected 
in a patient with an acute disseminated encephalomyelitis61. Finally, Bernard-
Valnet et al.62 reported the case of  a patient with lymphocytic meningitis diag-
nosed by CSF analysis, with normal brain Magnetic Resonance Imaging (MRI), 
whose EEG showed a focal anterior NCSE.
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Seizures and/or SE were also reported in patients with neurological and radi-
ological sequelae but without any acute lesions, arising from an area of  previous 
cerebral insult, for example, due to prior surgery or to remote herpes simplex 
virus1 encephalitis16,56.
Status epilepticus and SARS-CoV-2 
Hung et al. reported the first case of  status epilepticus associated with SARS, 
with the evidence of  SARS-CoV RNA in both the CSF and serum63. Since then, 
over the last few months, there has been an increased reporting of  seizures 
associated with SARS-CoV-2.
A review which analyzed published data of  SE in COVID-19 infection64 found 
that only a small proportion (6.4%) of  patients who develop SE had prior history 
of  epilepsy. Time of  onset of  SE may vary. Most of  the patients developed SE 
after COVID-19 respiratory / gastrointestinal symptoms; in a minority of  cases 
(14.9%), SE appeared before other systemic symptoms. The cause of  SE was 
unknown in the majority of  cases; acute symptomatic and multifactorial etiologies 
have been reported. Although motor symptoms represented the most frequent 
manifestation of  SE, about one-third of  the reported SE were non-convulsive 
SE. EEG abnormalities were mostly localized in the frontal lobe, followed by the 
temporal lobe. Most frequent EEG abnormalities consisted of  continuous epilep-
tiform activity, recorded in about half  the patients; EEG slow-wave continuous 
activity was also reported in some patients. Cerebral imaging (CT or MRI) detect-
ed abnormal findings in 29-42% of  patients reported having SE in the context of  
COVID-19 syndrome, including inflammatory lesions (17%), PRES (8.5%), brain 
atrophy or cerebral hemorrhage in two patients respectively (4.3%), brain tumor 
and cerebral hemorrhage in one patient (2.1%). Acute seizures and SE can arise 
from febrile status, hypoxia, or metabolic derangements. Nevertheless, according 
to the available data, such etiologies are infrequent, and are generally associated 
with a milder form of  SE, with a good response to treatment and a favorable 
outcome. In SE, the most frequently used medication was levetiracetam, probably 
for its favorable tolerance profile, few drug-drug interactions and on the whole, 
an absence of  respiratory depression, making it preferable to benzodiazepine in 
patients with COVID-19 pneumonia. Outcome was positive in the majority of  
cases reported (96%) (Table 9.2)64.
A recent epidemiological study65 has shown that the incidence of  SE during 
the pandemic was no different from the general SE incidence recorded in the 
previous five years, even if  it is probable that the real frequency of  SE, and in 
particular of  NCSE in SARS-CoV-2 infection, has been underestimated due 
to problems in using adequate diagnostic tools and in having prompt access to 
EEG recording during the pandemic.
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Table 9.2: Status epilepticus features












-GCSE evolving to NCSE 2 4.3%
-FMSE 2 4.3%
-FMSE evolving to NCSE 6 12.8%




EEG Pattern GPDs 5 10.6%
LPDs 2 4.3%




Modified from Dono et al.64. BILPDs: bilateral independent periodic discharges; 
FMSE: focal motor status epilepticus; GCSE: generalized convulsive status epilep-
ticus; GPDs: generalized periodic discharges; GRDA: generalized rhythmic delta 
activity; MSE: motor status epilepticus; NCSE: non-convulsive status epilepticus; 
LPDs: lateralized periodic discharges; NA: not available.
Treatment suggestions
In relation to the complexity of  COVID-19 disease, to the variety of  neu-
rological symptoms, and to the possible interactions between ASMs and an-
ti-COVID-19 drugs, the decision as to the best treatment for seizures should 
take into account the specific characteristics, the comorbidity, and the cur-
rent clinical condition of  the patient. As a general rule, it would be reasona-
ble to choose ASMs with less known interactions (i.e., avoiding strong hepatic 
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enzyme-inducing ASMs), and giving preference to those with an intravenous 
formulation. 
Conclusions
Neurological complications in patients with COVID-19 are common and 
may manifest as seizures. However, the underlying mechanism for development 
of  seizure in patients with COVID-19 is still unclear. 
EEG remains a crucial tool in the management of  patients with neurological 
manifestations of  COVID-19, especially encephalopathy, seizures, and status 
epilepticus. Abnormalities, when present, include slowing, periodic discharges, 
epileptiform discharges, seizures and status epilepticus, indicating the presence 
of  a localized dysfunction, non-specific encephalopathy and cortical irritability 
in this condition. Several EEG patterns have been reported in seizures and SE 
associated with COVID-19, including periodic (LPDs, LPDs ‘‘plus”, BiLPDs, 
and GPDs) and rhythmic (GRDA) patterns. However, based on the available 
evidence, no single EEG pattern appears to be specific in relation to this viral 
infection, even though a prevalent frontal lobe localization has been described. 
Seizure or SE during SARS-CoV-2 infection can occur before any other 
symptom of  respiratory and systemic involvement of  COVID-19, although 
more frequently they occur within the context of  a clinically overt respirato-
ry infection. The lack of  prompt access to EEG recordings may lead to an 
underestimation of  the incidence of  epileptic complications, particularly for 
NCSE. The etiology of  SARS-CoV-2-related SE remains mostly unknown. A 
direct role of  SARS-CoV-2 invasion in the CNS or the systemic inflammatory 
syndrome due to cytokine release has been proposed as a possible explanation.
The clinician should always prioritize identification of  any inciting factors 
(hypoxia, fever, sepsis, electrolyte derangements) and aim to manage seizures 
in patients with COVID-19 with the application of  principles of  general man-
agement of  seizures and status epilepticus. When an AED is initiated, consid-
eration should be given to the pharmacokinetics of  the drug, drug interactions, 
and medication-associated adverse effects. Patient factors such as age, along 
with any renal and/or hepatic impairment, should also be taken into account.
Further research into the relation of  the EEG findings to the clinical status 
and short- or long-term prognosis of  COVID-19 patients may be conducted 
to help clinicians identify which patients require an EEG procedure and would 
eventually require treatment, with the ultimate aim of  improving their clinical 
outcomes.
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Take-home message
 – No specific EEG pattern has been described in COVID-19 patients: dif-
fuse background slowing is the most frequent EEG finding.
 –  COVID-19 infection does not seem to increase seizure frequency in pa-
tients with epilepsy.
 – Seizures and/or status epilepticus are often recorded in patients without 
any evidence of  acute or chronic brain injury on imaging and without any 
alteration in CSF.
 – There is no specific anti-seizure medication for COVID-19 patients. 
ASMs with no/few interactions and with available intravenous formula-
tion should be preferred. 
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Background and epidemiology
Delirium, defined as a disturbance of  consciousness or cognitive function 
with acute onset and fluctuating course, is widely known to be one of  the com-
monest complications of  hospitalization in older patients also outside the con-
text of  the COVID-19 pandemic1.  
Recently, there has been an increasing recognition of  neuropsychiatric manifesta-
tions of  SARS-CoV-2 infection. Early studies indicate that 20-30% of  COVID-19 
patients will present with or develop delirium or mental status changes during their 
hospitalization, with rates of  60-70% in cases of  severe illness at all ages2-4.
The results of  a study by Mendes et al. revealed that, although COVID-19 
is not associated with a higher prevalence of  delirium than other acute illness-
es, its development is strongly associated with a higher mortality5. Recently, a 
British study has found that delirium is common and yet under-recognized in 
hospitalized patients with COVID-19. Out of  31 patients with delirium, only 19 
cases had been recognized by the clinical team. Moreover, at 4-week follow-up, 
delirium was significantly associated with worse functional outcomes inde-
pendent of  pre-morbid frailty6. Another study raised the question of  whether 
atypical symptoms of  COVID-19 could impact the quality of  care, reducing 
early recognition of  symptoms and hospitalization. Among these patients, the 
clinical presentation of  COVID-19 was mostly atypical, and the most frequent 
symptom of  onset was delirium, especially in the hypoactive form7. 
Acute encephalopathy appears to be even more common in critically ill pa-
tients. In a recent international cohort study on 2,088 patients with a SARS-
CoV-2 infection admitted to an intensive care unit (ICU), Pun et al. described 
that delirium occurred in 55%8. 
In another recent case series of  58 severe COVID patients, Helms et al. report-
ed that 84% developed neuropsychiatric symptoms3. In a cohort analysis of  140 
ICU patients described by the same group, the prevalence of  delirium was 79.5% 
in patients admitted to an ICU for acute respiratory distress syndrome (ARDS) 
due to COVID-19, with a worse prognosis than patients without delirium9. 
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Pathogenesis
A major question remains as to whether delirium in COVID-19 represents a 
primary CNS manifestation, heralding the invasion of  the brain by the virus, or 
whether it simply constitutes a symptom of  a secondary encephalopathy caused 
by inflammation or other systemic effects of  SARS-CoV-210. 
The severity of  the systemic illness in some COVID-19 patients, and the 
associated metabolic derangements and inflammatory cascades, is presumably 
sufficient to cause the toxic-metabolic encephalopathy often seen in hospital-
ized patients. However, the presentation of  patients with severe confusional 
states in the absence of  respiratory symptoms or other organ failure has raised 
questions about alternative mechanisms of  CNS injury11. 
Several investigators have proposed multiple potential mechanisms by which 
SARS-CoV-2 may induce changes in mental status, including infection spread-
ing to the CNS by retrograde transport or hematogenous route, a dysregu-
lation of  the cytokine activation leading to CNS inflammation, an induction 
of  cell-mediated CNS inflammation, postinfectious autoimmune reactions via 
molecular mimicry, and hypoxemic/thrombotic neuronal injury12.  
a. Primary neuro-invasive hypothesis: neurotropism of  coronaviridae has been 
demonstrated during SARS and MERS epidemics. During the 2002-2003 
SARS epidemic, older subjects presented not only with respiratory symptoms 
and typical febrile response, but also with decreased general well-being, poor 
feeding, and delirium. Given the fact that SARS-CoV and SARS-CoV-2 are 
similar in terms of  pathogenicity, it is quite likely that SARS-CoV-2 has a sim-
ilar ability to cause delirium13. There are two distinct proposed mechanisms 
for SARS-CoV-2 invading the CNS to cause a primary encephalopathy: entry 
route for the virus into the brain may be directly through intra-nasal access 
via olfactory nerves, or indirectly by crossing the blood-brain barrier (BBB) 
via hematogenous or lymphatic spread14. The first hypothesis would be con-
sistent with the observation of  high rates of  anosmia and ageusia, which are 
thought to be caused by the involvement of  the olfactory bulb. Given the 
anatomical positioning, one could imagine the virus travelling along the olfac-
tory bulb toward the uncinate fasciculus and reaching the anterior cingulate 
and basal forebrain directly via that pathway. Such neuro-invasive potential 
of  SARS-CoV-2 has been postulated to contribute to the respiratory failure 
observed in infected patients10. On the other hand, SARS coronaviruses enter 
human host cells mainly via the cellular receptor for the angiotensin-con-
verting enzyme 2 (ACE2), predominantly expressed in the entire respiratory 
tract, but also in the upper esophagus, by the enterocytes and in the brain. In 
particular, ACE2 receptors have been detected in both neurons and glial cells, 
which makes them vulnerable to SARS-CoV-2 invasion, but they are also 
expressed by endothelial cells, and endothelitis has also been implicated in 
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the pathology of  the virus as a result of  both direct and indirect mechanisms: 
general inflammatory response to virus infection impairs BBB integrity lead-
ing to massive infiltration of  renin-angiotensin components to the brain15.
b. Secondary-systemic mechanism hypothesis: secondary neurological effects include 
increased CNS inflammatory mediators, cerebral hypoxia, cerebrovascu-
lar involvement, multiple organ failure, pyrexia, neurotransmitter imbal-
ance, dehydration, and metabolic dysregulation. Immunologic responses 
to SARS-CoV-2 are mediated by an acute cytolytic T-cell activation which 
might also cause an autoimmune encephalopathy10. 
c. Hybrid model: a final possibility is a hybrid model, in which the virus may cause ei-
ther a primary or secondary encephalopathy, or both. This combination would 
suggest a similarity to human immunodeficiency virus (HIV). Indeed, HIV is 
known to invade the circumventricular region via two mechanisms: direct and 
indirect invasion. The circumventricular fenestrated endothelial areas represent 
the major thoroughfares for diapedesis of  HIV-infected macrophages into the 
brain, and the regions adjacent to these areas determine the neuropsychiatric 
symptoms. Invasion of  the area postrema makes the patient vulnerable to de-
pression and delirium due to selective vulnerability of  midbrain neurotransmit-
ter cell bodies, involvement of  the pineal gland disrupts the sleep-wake cycle, 
and the organum vasculosum directly abuts the pregenual anterior cingulate. 
If  SARS-CoV-2 enters the brain directly via disrupted circumventricular fenes-
trated endothelium or along an olfactory nerve track, we might expect a similar 
pathophysiological pathway to that seen in HIV encephalopathy10
Figure 10.1: Hypotheses of  encephalopathy pathogenesis in COVID-19
ARDS: acute respiratory distress syndrome; BBB: blood-brain barrier; DAD: 
diffuse alveolar damage; DIC: disseminated intravascular coagulation; MODS:  
multi-organ dysfunction syndrome.
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Clinical features and implications
Delirium is usually characterized by a disturbance of  consciousness and an 
alteration of  the cognitive state which typically develops over a short period 
of  time (over hours to days) and tends to fluctuate during the course of  the 
day. The features of  delirium are unstable, usually becoming most severe in the 
evening and at night. 
Generally, a change in the level of  awareness and in the ability to focus, 
sustain, or shift attention are often described as the earliest manifestations of  
delirium. Otherwise, in the hypoactive forms, patients could appear drowsy, 
lethargic, or even semicomatose.  
Delirium by COVID-19 may present in its hyperactive form, with agitation 
requiring sedation, or can otherwise manifest with somnolence and a decreased 
level of  consciousness4,9. It could be implied by a variety of  clinical manifes-
tations, including psychomotor agitation, sleep-wake reversals, irritability, anx-
iety, emotional lability, and hypersensitivity to lights and sounds. In a study by 
Mendes et al. on 235 patients, those who presented with delirium showed hypo-
active features in 41.6% of  cases and hyperactive or mixed traits in 35.4% and 
23.0% of  cases, respectively5.
The clinical aspects of  delirium in COVID-19 may be heterogeneous, cross-
ing over the features of  encephalitis and meningitis. Some studies show the 
concomitant presence of  pyramidal signs and/or meningeal irritation signs, 
such as enhanced deep tendon reflexes, ankle clonus, bilateral extensor plantar 
response, and neck stiffness with positive Brudzinski sign3,16. Interestingly, a 
multifocal myoclonus was found to be more frequent than would typically be 
observed in delirium10.
Unfortunately, features of  delirium in COVID-19 patients do not signifi-
cantly differ from other conditions and, especially in the hypoactive form, may 
be mistaken as secondary to respiratory or sepsis symptoms. For example, in 
our experience, many patients were diagnosed with delirium several days after 
the onset of  neuropsychiatric symptoms as they had been interpreted as be-
ing related to pneumonia or respiratory failure. This was more frequent in pa-
tients already affected by neurological diseases such as dementia or Parkinson’s 
disease. Moreover, patients who experience delirium often have cognitive and 
perceptual problems, including memory loss, disorientation, and difficulty with 
language and speech, so it is vital to understand the patient’s level of  func-
tioning prior to the onset of  delirium from reliable informants since a mild 
cognitive impairment could frequently underly delirium. However, collecting 
complete anamnestic data about previous cognitive disturbances is made diffi-
cult by restrictions put in place during hospitalization of  COVID-19 patients, 
thus delaying the diagnosis and treatment of  delirium. 
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Seizures are described along with encephalopathy in patients with COVID-19, 
just as they can occur in toxic-metabolic encephalopathy in other settings. In 
a retrospective case series by Somani et al., the authors reported 2 COVID-19 
women patients with de novo status epilepticus; in one of  them, status epilepticus 
was the initial presentation in an otherwise asymptomatic individual17. In a case 
report by Lyons et al., a young man who had tested positive for SARS-CoV-2 
presented with a generalized tonic-clonic seizure three days after complaining 
of  myalgia, lethargy and fever; in the wake of  the seizure, he was confused and 
aggressive, and required sedation18. 
Although in most cases encephalopathy develops in patients who become 
critically ill, it might also be the primary symptom of  COVID-1919-21. In a study 
of  817 older COVID-19 patients (median age 78 years) evaluated in the emer-
gency department, 37% of  patients with encephalopathy did not have typical 
COVID-19 symptoms such as fever or dyspnea19. Additionally, after a review 
of  the neurological symptoms of  COVID-19 patients, Leonardi et al. found 
that in a cohort of  2,660 hospitalized patients, 6 (0.22%) presented with acute 
encephalopathy as the first and only symptom21. 
Ticinesi et al. conducted a retrospective study on 852 patients to assess the 
incidence of  delirium in a large number of  patients hospitalized for COVID-19 
in Northern Italy. The aim of  the study was to verify its clinical correlations and 
determine its impact on in-hospital mortality. In their study, 11% of  the sample 
developed delirium during the hospital stay. These patients were usually older, 
were less likely to have common respiratory symptoms (such as cough), more 
frequently presented atypical symptoms (such as syncope, postural instability 
and thoracic pain), and had lower oxygen saturation values on room air. Patients 
who developed delirium also had a higher prevalence of  dementia and epilepsy, 
and had lower functional autonomy in daily activities22. 
Potential factors contributing to delirium during the 
COVID-19 pandemic
Studies conducted so far in the pandemic consistently show that there are 
some risk factors associated to delirium in COVID-19 patients.
 – Old age: COVID-19 is more common in older people, and this is probably 
due to the synergistic effects of  aging, frailty, and comorbidities. In par-
ticular, aging of  the immune system is characterized by a chronic systemic 
inflammatory state or ‘inflammaging’, marked by elevated inflammatory 
markers, such as IL-6 and C-reactive protein. Frailty is characterized by 
multisystem dysregulation that leads to reduced physiologic reserve and 
increased risk of  adverse health outcomes. The combined effects of  these 
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factors, added to a high rate of  comorbidities, not only increase the risk of  
severe illness but also lead to an increased risk of  delirium as a non-typical 
presentation of  COVID-1910. Mendes et al., in a study on 235 Caucasian 
patients, found that older patients with COVID-19 on admission to acute 
medical wards had a global prevalence of  delirium of  20.4% with the main 
risk factor being previous cognitive impairment5.
 – Comorbidities: comorbidities can facilitate the onset of  an acute confusion-
al state23. In a case study on ICU patients presented by Van Rompaey 
et al.24, the relative prevalence of  specific comorbidities was 16.9% for 
hypertension, 53.7% for other cardiovascular diseases, 1.9% for cere-
brovascular diseases, 8.2% for diabetes. In another study involving 509 
hospitalized COVID-19 patients, Liotta et al. found that nearly 32% de-
veloped encephalopathy. These patients were more likely to have risk fac-
tors (including a history of  any neurological disorder) than those without 
encephalopathy25. 
 – Hospitalization and isolation: long hospital stay along with hospitalization 
complications such as sleep deprivation, constipation, dehydration, urinary 
retention, and superinfections increase the risk of  delirium in COVID-19. 
Additionally, hospitals have instituted an extremely limited visitors’ policy 
and have limited interaction with hospital staff, which may increase the 
sense of  isolation and induce patients’ disorientation and reduced aware-
ness. While created to minimize contagion, policies that increase isolation 
and immobility for hospitalized patients, combined with acute illness, pro-
duce a high-risk environment for delirium26,27. This can be particularly dif-
ficult for older people, who are less likely to resort to virtual or electronic 
methods of  interpersonal communication24,28. Furthermore, this can lead 
to apathy, undermining the will to mobilize, further increasing the risk of  
delirium13. In addition, the use of  personal protective equipment by staff  
members can depersonalize them and possibly has a frightening effect on 
older people, especially those with pre-existing cognitive impairment or 
dementia. Isolation in the ICU and the need for mechanical ventilation 
may also further increase the risk of  delirium.  Earlier epidemiological 
studies have shown that up to 75% of  patients undergoing mechanical 
ventilation in ICUs suffer from delirium at some point during their hospi-
talization14. It has also been shown that medical personnel devote less time 
to isolated patients, and less frequently draw attention to the difficulties 
arising from the need to take precautionary measures, such as wearing 
personal protective equipment, which may ultimately hinder physical ex-
amination26. Therefore, respiratory isolation of  COVID-19 patients may 
decrease the frequency and quality of  delirium screening, increasing the 
risk for delirium to persist undetected in vulnerable patients13,29.
13510. Delirium
 – Psychological factors: additional factors triggering the occurrence of  deliri-
um may be related to fear, anxiety, and disorientation. Patients presenting 
to the hospital are often aware of  the high volume of  patients passing 
through in a limited period of  time and fear a risk of  contagion. They are 
conscious of  how severe the disorder can be and know that when admit-
ted to the hospital they will not be able to see their loved ones. Moreover, 
COVID-19 patients suffer from respiratory distress, and difficulties in 
breathing can trigger anxiety. Finally, uncertainty about the future and a 
sense of  disorientation may be factors associated with delirium, especially 
due to the lack of  religious or spiritual support15.
 – Iatrogenic factors: this group of  factors includes elements related to treat-
ment requirements, such as the use of  deep sedation or muscle relaxants 
to enable mechanical ventilation and the prone position30. Indeed, the use 
of  centrally acting drugs, including benzodiazepines and propofol or opi-
oids, may induce the occurrence of  sedation-related delirium31. Finally, the 
use of  medications with an anticholinergic effect predicts clinical severity 
of  delirium symptoms in older medical inpatients13. Prolonged mechanical 
ventilation and immobilization also greatly contribute to increasing the 
risk of  delirium in the ICU32 because there is no possibility of  full-scale 
physiotherapy during active infection13.
Diagnostic work-up
The main aspects of  the diagnostic evaluation of  delirium include recogni-
tion of  the disorder and uncovering the potential underlying medical illnesses. 
As previously mentioned, clinicians often fail to recognize delirium6. An early 
identification of  delirium is critical in COVID-19 patients because it could be 
an early symptom of  a worsening respiratory failure or a sign of  the spreading 
of  the infection to the CNS.  
Neurological examination should always be the first step in the diagnostic 
work-up to identify focal clinal signs and assess the severity of  the clinical pic-
ture. Clinicians must pay attention to any changes in the level of  consciousness, 
which could be the first observable clue, and to the ability of  the patient to 
focus, sustain, or shift attention during a conversation. Conversation with the 
patient may also elicit memory loss, disorientation, or tangential or incoherent 
speech. Determining whether cognitive impairment or perceptual problems are 
due to a prior or progressing dementia can be challenging and requires knowl-
edge of  the patient’s baseline level of  functioning. We thus suggest the appli-
cation of  screening tools (i.e., the 4 As Test), that are simple to administer and 
that require no formal training, to improve the diagnosis of  delirium.
Due to the heterogeneity of  predisposing factors and plausible causes of  de-
lirium in COVID-19, the diagnostic work-up for these patients should include 
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a complete assessment of  prescribed medication and relative collateral effects, 
metabolic function, hypoxemia, systemic factors (sepsis, liver and renal func-
tion, cardiac dysfunction), coagulopathy and hydration status, aiming to investi-
gate all the potential reversible causes of  delirium (Table 10.1). Indeed, success-
ful treatment of  delirium depends on the early identification of  the reversible 
contributing factors. Medications such as benzodiazepines, propofol, opioids 
or corticosteroids, commonly prescribed to COVID-19 patients, are the most 
common reversible cause of  neuropsychiatric symptoms, especially in the el-
derly. Metabolic or systemic abnormalities, such as dehydration, may also be 
associated to COVID-19-related respiratory failure.  
Table 10.1: Potential reversible causes of  delirium
Drug and toxins






Electrolyte or endocrine disturbances
Hyper/hypoglycemia
Hypoxemia
Wernicke encephalopathy, folate or B12 
deficiency
Infections and sepsis Brain disorders (See Alternative Diagnosis)
Systemic conditions
Cardiac failure
Acute or chronic liver failure
Renal failure
Coagulopathy






Once the potential reversible causes for delirium have been excluded, further 
investigations such as magnetic resonance imaging (MRI), electroencephalog-
raphy and lumbar puncture should be considered inorder to rule out a primary 
CNS involvement. Indeed, COVID-19-related neuropsychiatric symptoms may 
theoretically be associated with both acute encephalitis caused by direct SARS-
CoV-2 CNS invasion or autoimmune encephalopathy15. 
Although autoptic studies confirmed a pronounced CNS involvement with 
lymphocytic panencephalitis, diffuse petechial hemorrhages, and brainstem 
neuronal cell damage in COVID-19 patients33, in most in vivo studies, neuroim-
aging and analysis of  cerebrospinal fluid (CSF) were not performed4,9. 
Despite the fact that most patients with encephalopathy typically have no 
evidence of  brain inflammation on neuroimaging studies, a brain CT or MRI 
should be performed. A spectrum of  aspecific neuroimaging abnormalities, 
such as focal or diffuse subarachnoid abnormalities and contrast enhancement, 
bilateral fronto-temporal hypoperfusion, but also white matter abnormalities 
and microbleeds, have been found in patients with COVID-19-related neu-
ropsychiatric symptoms3,9,34. Cerebral microhemorrhages, often associated with 
concomitant leukoaraiosis, seem to be more common in patients with severe 
respiratory involvement35. Cytotoxic alterations in the splenium of  the corpus 
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callosum have also been described in adult patients with COVID-19-related 
encephalopathy as well as in multi-system inflammatory syndrome in children 
with COVID-1936. Although most of  the described radiological abnormalities 
are likely to be chronic or unrelated alterations, neuroimages may sometimes 
indicate a specific alternative diagnosis for the patient’s mental state, such as 
stroke, encephalitis, or posterior reversible encephalopathy (PRES)9,37-39, thus 
influencing patient management. For example, in a case series of  64 patients 
with COVID-19-related encephalopathy, ischemic alterations were identified in 
17 patients (27%), 10 of  whom with focal or lateralizing signs on examination, 
which suggested possible cerebrovascular accident38. 
CSF testing is suggested at least in cases of  suspected viral or autoimmune 
encephalitis. Although robust data are lacking, CSF analysis was unremarkable 
in most patients with neuropsychiatric symptoms and the RNA viral load was 
found only in a few patients9,37,39. Only a small proportion of  patients showed 
elevated intrathecal IgG and mildly elevated protein levels9.  
Patients who have undergone electroencephalography have typically demon-
strated non-specific findings which, thus far, appear to be largely consistent with 
the diffuse slowing of  background activity expected in encephalopathy9,40,41. 
However, electroencephalography should be considered in patients with unex-
plained and persistent altered consciousness to rule out Non-Convulsive Status 
Epilepticus (NCSE) or with clinical suspicion of  epileptic seizures.  





Patients with delirium/acute encephalopathy typically have no evi-
dence of  brain inflammation on neuroimaging studies. Sometimes 
MRI findings indicate a specific, alternative diagnosis. 




Electroencephalography should be considered in patients with unex-
plained and persistent altered consciousness to rule out non-convul-
sive seizures or with clinical suspicion of  epileptic seizures.  
Primary psychiatric 
illnesses 
Depression: similar to delirium could be associated with sleep 
disturbance and difficulty with concentration. However, depression 
is associated with dysphoria, and there is less fluctuation than in 
delirium.
Mania: can be confused with hyperactive delirium with agitation, 
delusions, and psychotic behavior. However, mania is usually 
associated with a positive history for psychiatric disease.
In conclusion, delirium in the COVID-19 patient is mostly a diagnosis of  
exclusion of  the potential medical reversible causes and the alternative diagno-
sis (Table 10.2). When in doubt, the most useful rule is to assume delirium and 
attempt to rule out common medical etiologies. Delirium may be mimicked by 
acute or subacute brain lesions (such as stroke, encephalitis, or PRES, which 
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must be ruled out even in the absence of  focal deficits on examination) or by 
a NCSE (facial twitching, unexplained eye movements, automatisms and acute 
aphasia or neglect without a structural lesion could imply an underlying epi-
leptic condition). Early identification of  the key features such as acute onset, 
fluctuating course, altered consciousness, and cognitive decline should help to 
distinguish delirium from other neuropsychiatric conditions, such as depres-
sion, psychotic illness, and dementia, remembering that even patients with a 
known psychiatric illness are susceptible to delirium when acutely ill.
Treatment strategies
Non-pharmacological approaches
Every patient admitted to the hospital with COVID-19 should be consid-
ered at potential risk of  developing delirium, thus prevention strategies should 
be optimized42. Unfortunately, during the COVID-19 pandemic, systematic de-
lirium monitoring using the recommended validated tests may not be put in 
place15, probably due to the fact that the main emphasis is placed on organiza-
tional issues, such as the lack of  ventilators, setting priorities, and the shortage 
of  personal protective equipment43. For this reason, it could be useful to imple-
ment easy screening tools for delirium, in order to provide prompt treatment. 
Baller et al. performed a narrative review setting out preliminary guidance for 
delirium management in COVID-19 patients. Similar to general delirium man-
agement, behavioral modifications are first line, but pharmacological options 
might be necessary for the treatment of  psycho-motor agitation and perceptual 
disturbances12. Non-pharmacological interventions, such as regular orientation 
despite social separation, are actually going to prove vitally important, given the 
new limitations and challenges related to clinical staff  and visitor restrictions in 
the hospital during the COVID-19 pandemic15.  It is essential that patients have 
supervised access to fully charged mobile phones or a tablet to communicate 
with their families and caregivers, in addition to standard environmental and 
stimulus control, early ambulation, and care clustering42.
Moreover, in ICU patients, the concomitant factors which increase the risk 
of  delirium must be managed using standard approaches towards adequate pain 
management, avoiding urinary retention and constipation, ensuring early iden-
tification and treatment of  hospital-acquired sepsis, and maintaining adequate 
oxygenation15.
Pharmacological treatment strategies
When behavioral strategies alone are not enough to guarantee control of  the 
symptoms, in particular in cases of  hyperactive delirium with important behav-
ioral issues, pharmacological management should be considered44 (Table 10.3). 
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In COVID-19 patients, the treatment of  delirium poses additional challenges 
considering that sedative agents might further compromise respiratory func-
tion, increasing the risk of  secondary infections. Furthermore, there could be a 
considerable risk of  drug interactions, particularly regarding QTc prolongation, 
as these patients are already considered to be at increased risk of  torsades de 
pointes because of  the direct effect of  the disease on the heart12.
Nevertheless, antipsychotics are to be considered first-line treatment for the 
management of  delirium in COVID-19 patients. While the National Institute for 
Health and Care Excellence (NICE) recommend haloperidol45, the COVID-19 
Delirium Workgroup at Massachusetts General Hospital12 support the prescription 
of  second-generation agents, like olanzapine and quetiapine, due to concerns about 
extrapyramidal syndrome (EPS). Baller et al. also encourage the use of  melatonin 
due to its action as a sleep regulator, its immunomodulatory role and its good safety 
profile46, and of  alpha-2 agonists due to their analgesic properties and safety.
In particular, dexmedetomidine, currently restricted to ICU settings, seems 
to improve delirium, and shorten the time to recovery47. Its administration via 
IV infusion allows for quick titration, and it could be particularly beneficial in 
ARDS patients because it does not interfere with respiratory function. Drugs 
with anti-histaminergic and anti-cholinergic profiles can effectively induce 
short-term sedation, but there may be significant long-term risks, such as day-
time sedation, respiratory distress, and further worsening of  cognitive perfor-
mance44. The use of  benzodiazepines, such as lorazepam, is recommended for 
patients who are severely agitated, in combination with antipsychotic agents45. 
However, these must be managed with extreme caution given the risk of  res-
piratory suppression in cases with pneumonia or ARDS. Other treatment, such 
as antidepressants (i.e., trazodone) and antiepileptic drugs (valproic acid) can be 
considered in patients who may not tolerate antipsychotic agents12.
Outcome and long-term complications
Delirium itself  appears to be a risk factor for poor outcome. Evidence con-
sistently shows that delirium is associated with adverse outcomes in hospitalized 
patients with COVID-19. Delirium has been associated with post-discharge 
functional and cognitive decline48, but its long-term implications in COVID-19 
are still unknown.
Liotta et al., in a study of  509 consecutive hospitalized COVID-19 patients 
with neurological manifestations, found that patients with encephalopathy had 
longer hospital stay, worse functional impairment at hospital discharge, and a 
higher mortality rate compared with those without encephalopathy. In particu-
lar, even adjusting for the severity of  the COVID-19 illness, age, and length of  
hospital stay, the occurrence of  encephalopathy remained independently asso-
ciated with a higher risk of  death at 30 days25. 
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Table 10.3: Medications for the treatment of  delirium in COVID-19 patients
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High risk Moderate 
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Haloperidol D2 antagonism ⬇ agitation 
in acute 
psychosis
Low risk Moderate 
risk
PO, IV, IM High risk of  













Low risk Fast acting Anticholiner-
gic side effects
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x 4 (25-50 
mg in 
elderly)
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High risk Low risk Low risk of  
EPS
PO only 50-150 mg
Valproic acid Sodium channel 
blocker















EPS = extrapyramidal symptoms; ICU = intensive care unit; IM = intramuscular; 
IV = intravenous; PO = per os;
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These results were confirmed by Garcez et al. in a cohort of  707 patients 
aged ≥50 years admitted consecutively to a COVID-19 hospital in Sao Paulo, 
Brazil. They found that the overall occurrence of  delirium was independently 
associated with in-hospital death, length of  hospital stay, admission to an ICU, 
and mechanical ventilation48.
As with other critically ill patients, neurological dysfunction may persist after 
acute illness symptoms have resolved. The development of  a ‘post-intensive 
care syndrome’ (PICS), a new and/or the worsening of  previous symptoms 
which lead to an impairment in any physical, cognitive, or mental domain after 
critical illness or intensive care49 has frequently been reported. In particular, a 
PICS with cognitive impairment is described in 30-80% of  ICU patients, and 
includes memory loss and a dysexecutive syndrome with difficulty in concen-
tration, comprehension, and critical thinking50.  The major risk factors for the 
development of  PICS appear to be ARDS, sepsis, delirium, prolonged mechan-
ical ventilation, and multi-organ failure51. Surviving patients with COVID-19 
treated in the ICU should be considered at higher risk for developing PICS 
given the restraints on social support, prolonged mechanical ventilation with 
exposure to greater use of  sedatives, and limited mobilization52. 
To date, the long-term neurological prognosis of  patients with COVID-19-
related encephalopathy still needs to be clarified. Prospective cognitive and neu-
rological-focused evaluations through specialized clinics dedicated to further 




 – Delirium is common and is still under-recognized in hospitalized patients 
with COVID-19.
 – 20-30% of  COVID-19 patients will present with or develop delirium or 
changes in mental status during hospitalization.
 – Although the pathogenesis remains unknown, delirium is thought to 
be related to a COVID-19 primary CNS manifestation or a secondary 
encephalopathy, caused by inflammation or other systemic effects of  
SARS-CoV-2.
 – When behavioral strategies alone are not enough to guarantee control of  
symptoms, pharmacological management should be considered.
 – Delirium itself  appears to be a risk factor for poor outcome.
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Chapter 11. Psychiatry and psychopathology 
Bernardo Dell’Osso, Benedetta Demartini, Beatrice Benatti,  
Veronica Nisticò, Nicolaja Girone, Orsola Gambini
There is a wide consensus that the current COVID-19 pandemic is affecting 
not only physical health, but also mental health and well-being, leading to con-
siderable psychosocial consequences. The aim here is to give readers an update 
on the main research findings on the impact of  COVID-19 on the principal 
psychiatric disorders. 
Mood disorders
Mood disorders, including major depressive disorder (MDD) and bipolar 
disorder (BD), are common mental disorders characterized by enhanced co-
morbidity, mortality, and risk of  suicide. Several authors suggested that people 
with a previous history of  mood disorder are at high risk of  their symptoms 
worsening during the COVID-19 pandemic, given their greater vulnerability to 
changes in daily routine due to quarantine and fear of  illnesses compared to 
the general population1-4. A study by Van Rheenen and colleagues showed that 
depressive symptoms, anxiety, stress and general distress were heightened in 
patients with affective disorders compared to healthy controls, with higher rates 
of  anxiety in patients with BD compared to those with MDD5 (Table 11.1). 
Another recent study by Fiorillo and colleagues based on an online survey con-
ducted between March and May 2020 in the Italian population highlighted that 
symptoms of  depression, anxiety and stress significantly worsened from the 
week April 9–15th to the week April 30th- May 4th. Moreover, female respond-
ents and people with pre-existing mental health problems were at higher risk 
of  developing severe depression and anxiety symptoms6. In this perspective, as 
regards patients with pre-existing affective disorders, higher levels of  depressive 
symptoms and general distress emerged in male patients with BD compared to 
females5. This latter finding is in contrast with several prior studies showing the 
opposite gender effect under non-pandemic conditions7-9, leading to the hy-
pothesis that male patients with BD could be presenting a worse clinical profile 
during the COVID-19crisis. 
In addition, specific aspects of  this pandemic, and of  the measures neces-
sary for its control, may be of  particular concern for patients with affective 
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disorders, particularly regarding risk of  relapse. More precisely, the course of  
BD is sensitive to disruption of  biological and social rhythms, an effect medi-
ated through mechanisms related to circadian rhythm regulation10; these alter-
ations are a central element of  BD and have been implicated in the genesis of  
the illness11-13. Some measures that have been adopted to curtail the spread of  
COVID-19, such as home confinement, social distancing, lockdowns and quar-
antine, may potentially disrupt both habitual sleep patterns and the number and 
quality of  social contacts and activities. This could have a deleterious influence 
on the risk of  both manic and depressive relapses3. In this regard, recent stud-
ies found that rigid lockdown was associated with specific sleep dysregulations 
in BD patients, with greater impairment in patients experiencing a depressive 
episode, suggesting that the social isolation, lockdown and consequent lack of  
emotional support might introduce biorhythm dysregulation leading to higher 
vulnerability to depression14,15. 
In addition, the close relationship between affective disorders and substance 
use, particularly alcohol use, requires consideration. During the COVID-19 
pandemic, many nations have opted to continue alcohol sales for home con-
sumption, leading to a potential increase in use in vulnerable individuals. In pa-
tients with affective disorder, this could lead to increased symptom severity, as 
well as adverse outcomes such as suicide3,16. Indeed, lifestyle behaviors are key 
mediators of  physical and cognitive health, which is typically compromised in 
BD and MDD17,18. There is evidence that increased alcohol intake, together with 
sleep loss and cessation of  exercise, could amplify cardiometabolic dysfunction 
by altering biochemical and inflammatory marker profiles19,20. Thus, the mala-
daptive lifestyle changes in response to COVID-19 might not only contribute 
to emotional decline and cognitive impairment, but may further compound the 
risk of  severe SARS-CoV-2 infection and associated medical complications21.
There is evidence of  an association between positivity for coronaviruses and 
the risk of  mood episodes. Though the significance of  this association is still 
unclear, it may be related to the neurotrophic potential of  respiratory corona-
viruses or to their ability to provoke a systemic inflammatory reaction, both of  
which may be associated with mood dysregulations3,22. In particular, the pres-
ence of  somatic symptoms prompt researchers to consider the psychoneuroim-
munological (PNI) framework of  COVID-19. COVID-19 may, indeed, cause 
acute respiratory syndrome with consequent release of  pro- inflammatory cy-
tokines, including interleukin (IL)-1β and IL-6 from the respiratory tract23; these 
cytokines were frequently found to be increased in MDD23.
Finally, other issues of  concern in patients with affective disorders in-
clude the general distress associated with a disease outbreak and the reduced 
access to treatment during an epidemic, both of  which could trigger a re-
lapse. Confinement measures considered necessary to curtail the spread of  
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SARS-CoV-2, may disrupt daily routines including reduced access to healthcare, 
therefore exacerbating affective disorders under frequent follow-up24. 
Psychotic disorders
Psychotic disorders affect 1–2% of  all adults; schizophrenia25, schizoaffec-
tive disorder26 and acute/transient psychotic disorders27 are the most common 
diagnosis. Schizophrenia involves several symptoms that differ in terms of  se-
verity of  positive, negative, and cognitive impairment and the corresponding 
risk of  the presence of  depression and hostility. In addition, individuals with 
schizophrenia are often less educated, have lower self-control and self-care than 
average and inadequate understanding of  their problem28. These elements may 
have influenced the greater difficulty shown by these patients in finding correct 
information about COVID-19 and in preventing possible contagion with ap-
propriate behaviors29 (Table 11.1).
In this regard, risk perception and adherence to protective measures in indi-
viduals diagnosed with schizophrenia should be of  particular concern for their 
caregivers. A literature review by Brown and colleagues focused on the impact 
of  successive epidemics throughout history (including SARS, MERS, Ebola, 
and swine flu) on psychosis. The research found that patients diagnosed with 
schizophrenia are less likely to be vaccinated and isolated. In addition, a positive 
correlation between psychotic symptoms and poor adherence with protective 
measures was found30.
As regards patients presenting with a first episode of  psychosis (FEP), a 
recent report on a 62-patient sample hospitalized between March and July 2020 
compared to patients with FEP hospitalized during the same timeframe in 2019 
found that the 2020 FEP patients were significantly older than patients with 
FEP in 2020 and presented with significantly less substance abuse. These find-
ings suggest a major role of  aging as a vulnerability factor to the stressful envi-
ronment during the pandemic compared to common factors such as substance 
abuse31.
From an organic perspective, people suffering from schizophrenia histori-
cally resulted more vulnerable to the adverse consequences of  new infections. 
More than 70% of  patients have experienced at least one other clinical condi-
tion, such as type-2 diabetes, chronic lung disease, or heart disease. This would 
increase the mortality rate caused by COVID-19 in individuals with schizophre-
nia32. Moreover, even the choice of  neuroleptic therapy may expose patients 
to a higher risk of  COVID-19 infection. For example, the use of  clozapine (a 
second-generation antipsychotic particularly effective in the treatment of  re-
fractory schizophrenia) has been placed among the potential contraindications 
for schizophrenic patients due to the risk of  agranulocytosis, a dangerous side 
effect32.
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The medium- and long-term social effects of  COVID-19 may disproportion-
ately impact people with psychosis or those at risk of  psychotic disorder: social 
isolation, unemployment, homelessness, relationship breakdown (divorce/sep-
aration), domestic violence, and worsened physical health may all particularly 
affect people with psychosis, given their vulnerability to social determinants 
of  health33. Moreover, the massive modifications in social networking pres-
ent a surreal scenario to which it is difficult to become accustomed. For those 
who suffer from psychotic disorders, this new reality may exacerbate feelings 
of  perplexity, anxiety, and paranoia. Furthermore, the current situation may 
be assimilated into the typical delusional contents of  patients diagnosed with 
schizophrenia29. In addition, social distancing practices could have a particu-
larly negative impact on individuals with schizophrenia. Typically, individuals 
with schizophrenia have on average smaller and poorer-quality social networks 
than the general population34. Thus, they may be more able to comply with, 
and tolerate, social distancing directives. However, social support has been as-
sociated with higher scores on recovery measures in schizophrenia and broad 
community support structures, including casual contacts at stores, have also 
been associated with improved recovery and community integration scores in 
schizophrenia35. These casual contacts have been disrupted by social distancing 
during the COVID-19 pandemic. In addition, social distancing may also dis-
proportionately impact the ability of  people with schizophrenia to satisfy their 
basic needs, given their high reliance on income support and other community 
services that have become more difficult to access36. 
Conversely, some recent studies have shown that COVID-19 distancing 
policies have not produced significant symptomatic changes for patients with 
schizophrenia or other serious mental illnesses37-39, suggesting three possible 
hypotheses: first, an unexpected demonstration of  resilience from this class 
of  patients; second, generalized social isolation may reassure patients suffering 
from persecution delusions; lastly, social isolation may be absorbed within the 
patient’s delusion28. Considering the above, the consequences of  the pandemic 
in individuals diagnosed with schizophrenia are variable and subjective, and are 
highly dependent on each patient’s symptomatology. 
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BD patients reported greater 
impact, with an increase in mood 
symptoms and a slower global 
improvement over time compared 
to healthy controls.
MDD: Major Depressive Disorder; BD: Bipolar Disorder; PANSS: Positive and 
Negative Symptom Scale.
152 Neurology of  COVID-19
Anxiety disorders
COVID-19 has been linked to increased anxiety, health anxiety, depres-
sion, stress40-42 and suicidal ideation both in the general population43-44 and 
among patients with pre-existing psychiatric disorders45-47, particularly 
due to disruptions in main routines and mental health care (Table 11.2). 
The main consequences were represented by relapse or exacerbation of  
symptoms1,4,48.
Although some studies showed that, in patients with severe/chronic men-
tal health disorders, the COVID-19 pandemic did not exacerbate pre-existing 
symptoms49-51, a study by Asmundson and colleagues focused on the impact 
of  pandemic-related stress, scored using the COVID Stress Scales (CSS), on 
patients with pre-existing anxiety disorders (e.g., generalized anxiety disor-
der, post-traumatic stress disorder, social anxiety disorder, panic disorder)52. 
These patients exhibited higher CSS total scores and higher scores on fears 
about danger and contamination, socioeconomic consequences, xenophobia, 
and traumatic stress symptoms scales. In particular, patients with pre-existing 
anxiety disorders were more likely to self-isolate and to make more active 
efforts at coping with self-isolation distress, despite there being no evidence 
of  any appreciable benefit for the methods they adopt to cope compared to 
controls. 
Obsessive-compulsive disorder 
Among patients with mental illness, those with Obsessive-Compulsive 
Disorder (OCD) showed significant clinical worsening as a result of  the 
COVID-19 pandemic. OCD is characterized by recurrent and intrusive 
thoughts or images (i.e., obsessions) associated with behavioral efforts 
aimed at neutralizing the anxiety caused by obsessions (i.e., compulsions)53. 
Moreover, among the most common OCD symptoms is the fear of  contam-
ination leading to excessive cleaning behaviors54,55; indeed, frequent compen-
satory behaviors in OCD are compulsive hand washing, avoidance behav-
ior with regard to touching objects considered contaminated, and cleansing 
rituals.
During large-scale outbreaks of  infectious disease such as transnation-
al pandemics, patients with OCD are prone to increase their dysfunc-
tional cleaning and organizing beliefs56,57. The current global outbreak of  
COVID-19 and the consequent high fear of  contamination have represent-
ed a precipitating factor for the potential increase in obsessions and com-
pulsions, also due to the reinforced cleansing habits of  patients with OCD58 
(Table 11.2). Indeed, given the high risk of  contamination, better hygiene 
habits have been encouraged by governments and the media, generating 
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plausible justifications for intensifying compulsive cleaning rituals, usually 
considered excessive or irrational, and now legitimate and socially accept-
ed59. However, this kind of  information can have drastic implications for 
individuals with OCD, since cognitive distortions and compensatory strat-
egies (cleansing rituals) generate plausible validation for the intensification 
of  compulsive cleaning rituals60, as well as excessive feelings of  responsibil-
ity, and exaggerated risk assessment61,62.
The exacerbation of  OCD symptomatology has been well-document-
ed during previous outbreaks, such as Severe Acute Respiratory Syndrome 
(SARS), Middle East Respiratory Syndrome (MERS), and Influenza63.
As expected, COVID-19-related stress has been significantly associated 
with OCD-like stress symptoms41, intrusive thoughts, reassurance-seeking64, 
intolerance of  uncertainty, OCD symptoms, health anxiety62, anxiety symp-
toms, and avoidance behaviors 65-67. The effects of  the current COVID-19 
pandemic on OCD have been shown to worsen OC symptom severity, with 
serious clinical consequences56,57,67-71 and changed the manifestation of  OC 
symptoms, leading to the development of  new and past obsessions and com-
pulsions in the context of  the pandemic. The onset of  new and past obses-
sions and compulsions could be related to the need for greater control against 
potential contamination or the increase in spare time during the lockdown, 
leading to an increase in repetitive behaviors. Moreover, high rates of  avoid-
ance behaviors, mostly related to the fear of  possible contamination, family 
accommodation, job difficulties, sleep disturbances, more psychiatric comor-
bidities and increased rates of  suicidal ideation emerged in OCD patients 
during the pandemic68.
Moreover, it is important to note that the intensification of  obsessions, a 
sense of  hopelessness, depressive symptoms and anxiety have been histori-
cally associated with high rates of  suicide in individuals with OCD72,73, and 
fear and stress related to COVID-19 may contribute to a rise in the risk of  
suicide44,74. Additional COVID-related factors that could potentially increase 
this risk include a recent increase in OCD severity, the effects of  quarantine, 
loneliness or social isolation distress68,75. Furthermore, the OC dimensions of  
responsibility for harm and unacceptable obsessional thoughts, along with 
general OCD severity, have been linked to increased suicidal ideation during 
the pandemic67. 
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61.2% of  OCD patients 
reported an increase in 
OCD severity.
Female gender, contam-
ination symptoms, and 
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were found to have a 
significant association with 
increasing OCD severity.
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contamination/washing 
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Eating disorders
Eating disorders (EDs) are characterized by persistent irregular eating be-
haviors causing a deficit in food intake or absorption, ultimately leading to a 
significant impairment of  physical health and psychosocial functioning. ano-
rexia nervosa, bulimia nervosa and binge-eating disorder are the most frequent 
EDs, and all three are characterized by irregular eating habits, along with severe 
distress or concern about body weight or shape53.
In the context of  the COVID-19 pandemic and the consequent lockdown 
measures imposed by local governments worldwide, patients both suffering and 
recovered from EDs have been considered by the scientific community to be at 
high risk of  their symptoms worsening or of  relapse. Scientific evidence suggest-
ed that during the first lockdown (March-May 2020) patients with EDs suffered 
from high levels of  anxiety, along with increased dietary restriction behaviors, 
binge eating, purging, and exercise behaviors76-78 (Table 11.3); a re-emergence of  
symptoms of  Bulimia Nervosa was also reported in patients who were recovering 
from this condition76. Several factors have been suggested to play a major role in 
the exacerbation of  ED symptoms79. First, food insecurity, defined by the Food 
and Agriculture Organization of  the United Nations in 2019 as the “scarcity, re-
duced access to, or difficulty acquiring safe, nutritionally adequate foods”79; since 
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governments worldwide recommended limiting trips to the supermarket as much 
as possible, a large part of  the population stormed stores to stockpile groceries, 
leaving shelves almost empty. Hence, even individuals from western countries, 
who have never experienced food insecurity before, for the first time had to face 
the anxiety (enhanced by media reports) of  having limited access to food80, which 
contributed to the so-called “feast or famine” pattern: periods of  food abun-
dance, hoarding, and overconsumption are alternated with compensatory behav-
iours, such as skipping meals81. Overall, food insecurity represents a risk factor 
for both the onset of  an ED, and the worsening of  pre-existing EDs symptoms, 
especially in populations from low socioeconomic backgrounds82,83.
Second, the few opportunities for physical activity due to the closure of  
fitness centers and the difficulties in training outside while maintaining physical 
distancing. On one hand, this might lead to increased anxiety about gaining 
weight even in the general population; on the other hand, individuals suffering 
from EDs (especially Anorexia Nervosa) often use compulsive physical exer-
cise both as a strategy to control their body shape, and as a coping method 
for negative emotions84. Therefore, when deprived of  physical activity, patients 
with EDs often adopt other unhealthy compensatory behaviors, such as greater 
cutting down on calories or purging79,85.
Third, the need to stay at home and the consequent disruption ofone’s own 
routine, both physiological (i.e., eating and sleeping pattern) and social need 
to be considered84. Since March 2020, all non-essential workers and students 
have been asked to work and study from home. Family members with different 
time schedules were forced to reorganize spaces that they had routinely shared, 
which were often not adequate. On one hand, the lack of  defined spaces and 
times to have one’s own meals could negatively impact the recovery of  patients 
with Eds. On the other hand, in order to meet the needs of  the entire family, 
mealtimes often had to be organized several times through the day; this inevita-
bly increased the time spent handling and speaking about food, which, in turn, 
may increase the risk for disordered eating behaviors84,86. In a psychosocial per-
spective, Castellini and colleagues76 also found that the forced confinement at 
home often led to general domestic tensions that predicted the increase in ED 
symptoms in patients known for these types of  disorder. In particular, patients 
with an insecure attachment and a history of  trauma during childhood resulted 
more vulnerable to severe COVID-19-related post-traumatic symptomatology. 
Investigating the impact of  social distancing on patients with EDs, it was sug-
gested that lockdown measures might be initially thought as a potential short-
term relief. In fact, having fewer social interactions also implies having fewer 
occasions to show in one’s own body in public79,87. However, the authors also 
highlighted that, despite the short-term mitigation of  interpersonal social trig-
gers, the risk for patients with EDs to experience a worsening of  their symp-
toms during the COVID-19 outbreak was still high, probably because social 
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support and adaptive coping strategies, known to be protective factors against 
the increase in ED symptoms, were lacking during this period84. Hence, it was 
also suggested to investigate the potential benefit of  the end of  the lockdown. 
In line with these considerations, our research group further hypothesized that 
the confinement at home might have represented a specific trigger for patients 
with EDs in terms of  having more time to think about food and to compul-
sively gaze at one’s own body in the mirror. We conducted a longitudinal study 
over two time points: 1) during the first lockdown in Italy - April 2020; and 2 a 
month after restrictions were eased - June 2020. The study aimed to assess the 
levels of  stress, anxiety, depression, and symptoms related to post-traumatic 
stress disorder (PTSD) and EDs in patients with EDs. In this context, we found 
that patients with EDs, compared to a group of  healthy controls, reported 
experiencing a heightened fear of  losing control over eating, more discomfort 
at seeing their own body, and spending more time thinking about their body 
during the lockdown than before. We also found that, at the end of  the lock-
down, PTSD-related symptoms of  patients with EDs significantly diminished 
with respect to the lockdown period, and patients reported feeling significantly 
better at the end of  lockdown, although high levels of  anxiety persisted88.
Fourth, the restricted access to healthcare84. Despite the increased need for 
social and psychological support, healthcare services worldwide had to face the 
outbreak of  a highly infectious disease, which led most of  the hospitals to con-
vert their departments into acute and subacute intensive care units and to block 
all but urgent outpatient services. In Italy, authorities were ordered to maintain 
full functionality of  mental health and substance use services, officially recog-
nizing inpatient and outpatient mental health services as being fundamental 
to the community during a global pandemic89. In our mental health depart-
ment, second-level and third-level outpatient units, including the those dealing 
with EDs, were closed and switched to telemedicine programs; phone calls and 
video conference-based visits were organized only for emergencies or specific 
patient requests, and patients were encouraged to continue psychotherapy via 
video conference89. However, telehealth visits restrict the capacity to monitor 
weight change, vital signs, and carry out other key physiological assessments79. 
Moreover, it was reported that the discomfort of  an online visit may have been 
a reason for avoiding mental healthcare services, especially for individuals who 
are at the onset of  a mental health disorder84.
In conclusion, here we have examined specific risk factors which might lead 
patients with EDs to experience a worsening of  their symptoms during the 
COVID-19 pandemic. These should be taken into account when designing 
both therapeutic interventions tailored to the single patient, and large-scale pre-
ventive interventions.
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rienced a heightened fear of  losing control 
over eating, more discomfort at seeing their 
own body, and spent  more time thinking 
about their body during the lockdown than 
before. 
At T1, in EDs patients, post-traumatic 
symptomatology diminished with respect to 
the lockdown period, and patients reported 
feeling significantly better, although high 




















Since the very beginning of  the COVID-19 
pandemic 64.5% of  the EDs patients 
reported more food restriction; 35.5% 
increased binge eating; 18.9% increased 
purging; 47.3% increased exercising. On the 
other hand, a small portion of  the sample 
also reported decreased restricting (8%) and 
binge eating (8%). EDs symptoms should 
be strictly monitored for potential long-term 
consequences.
AN: Anorexia Nervosa; BN: Bulimia Nervosa; Eds:  Eating Disorders; HC: 
Healthy Controls. 
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Autism spectrum disorders 
The diagnostic category of  autism spectrum disorders (ASDs) refers to a 
wide variety of  conditions, affecting both children and adults, sharing the com-
mon core of  “persistent deficits in social communication and social interaction 
across multiple contexts”53. These conditions can be thought of  as a contin-
uum, ranging from a severe delay in cognitive, social, and emotional develop-
ment, to where individuals show selective impairment in understanding and re-
sponding to social cues, such as the tendency to avoid eye contact and a struggle 
in picking up cues about social context and the intentions of  others, but do not 
present intellectual disabilities or cognitive impairment (Intelligence Quotient 
>70)90. The current literature aims at investigating how the COVID-19 pan-
demic and the consequent social restrictions impact on children and adults with 
autism, and with their caregivers.  
Children with ASDs
With respect to pediatric samples, a systematic review including children 
with and without ASDs recently showed that, during the pandemic, children 
with a pre-existing diagnosis of  ASDs and attention deficit hyperactivity disor-
der (ADHD) had a high probability of  their behavioral symptoms worsening, 
along with presenting anxiety, depression, irritability, boredom, inattention, and 
fear of  COVID-1991. It was also reported that, over the last year, children with 
ASDs presented symptoms resembling PTSD, in terms of  increased stereo-
types, aggression, hypersensitivity, and disturbance of  sleep patterns and appe-
tite92. However, when considering the severity of  ASDs symptoms, Lugo-Marin 
et al.93 also found that individuals with ASDs Level 1 (DSM-5-based) scored 
significantly lower in a questionnaire investigating symptoms of  withdrawal and 
depression after the lockdown started, compared to before. Since this scale 
mostly investigates shyness, withdrawal, and a preference for being alone, the 
authors hypothesized that the drastic decrease in social demands during the 
lockdown had played a major role in their findings. In other words, children and 
adolescents with ASDs Level 1 might have partially benefited from the social 
distancing measures.
With respect to therapeutic interventions, although recent studies endorsed 
the use of  video consultations for the follow-up of  children with ASDs94, 
White and colleagues showed that, in their sample of  3,502 children with ASDs 
in the United States, the majority of  them experienced significant, ongoing dis-
ruptions to their therapies during the pandemic, with a consequent worsening 
of  ASD symptoms and a heightened family distress, as reported by patients’ 
caregivers95. Along the same line, Mutluer and colleagues92 revealed that 92% 
of  their sample, consisting of  87 individuals with ASDs in Turkey, stopped 
receiving special education support during this period. The authors underlined 
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the urgent need to develop special distance learning services also for children 
with special educational needs, possibly involving professionals specialized in 
both ASDs and trauma, in order to efficiently address the trauma-related symp-
tomatology that emerged in their sample of  children with ASDs.
Adults with ASDs
As mentioned above, moving along the autism spectrum, individuals with 
different degrees of  symptom severity can be found. There is little literature 
on adult individuals with a diagnosis of  severe ASDs in the context of  the 
COVID-19 pandemic. Brondino et al. investigated the response of  a sample of  
18 adults with ASDs who attended a day-care center in Lombardy to new strict 
social routines implemented in order to keep the service running even during 
the lockdown. They increased the time spent performing individual physical ac-
tivity, split the initial laboratory group into smaller groups, and reduced non-es-
sential transfers to other facilities96. Authors assessed the patients’ daily level of  
irritability, lethargy, social withdrawal, stereotypic behavior, hyperactivity, and 
inappropriate speech, and compared their findings with pre-lockdown scores. 
Despite the restrictions, the scores were not higher than before. These results 
might suggest that, when new routines are gradually and carefully introduced, 
people with severe ASDs might be able to adapt to them96. 
Moreover, few studies investigated the psychological impact of  the pandem-
ic on adults with high functioning ASDs. On one hand, a general increase in 
symptoms of  anxiety and depression was reported; adults with autism showed 
a greater increase in worries about their work, medications and food supply, 
and their own safety/security, along with an increase in stress related to their 
loss of  routine97. In particular, Bal et al.98 showed that, among a sample of  
396 adults with ASDs, the areas of  their lives that experienced the greatest 
impact from the pandemic were, in order: i) employment ii) school; and iii) 
social life. On the other hand, a decrease in stress levels related to reduced sen-
sory and social overload was also found93,97. Lugo-Marin and colleagues found 
a general improvement in levels of  psychopathology, investigated through the 
Symptoms-Checklist-90-Revised (SCL-90-R), when comparing the scores of  
adult individuals with ASDs during the lockdown to those collected before; 
this was especially true in young adults (18- 30 years old). Adults aged over 30 
years apparently also benefited from the social distancing measures, as demon-
strated by improved scores on the SCL-90-R “Interpersonal Sensitivity”, ascale 
that refers to feelings of  inferiority and inadequacy. Only anxiety symptoms 
showed no significant improvement during the lockdown93. In fact, as reported 
by Oomen et al., the need to constantly adjust one’s own behaviors and routines 
due to continuous changes in the recommendations of  the authorities led sever-
al adults with ASDs to experience high levels of  anxiety and distress97.
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Consistent with these findings, in our clinical practice, we observed that pa-
tients with difficulties in social interaction (e.g., patients with social phobia) 
often reported an improvement in their psychological well-being in relation to 
the imposed lockdown. This observation led our research group to hypothesize 
that specific groups of  individuals might be able to handle social distancing 
better than the general population87. This might be the case of  individuals with 
ASDs without intellectual disabilities. For example, previous studies showed 
that patients with ASDs without intellectual disabilities perform better in envi-
ronments where they can work alone with a high degree of  autonomy in a clear-
ly defined and intellectually challenging job. In contrast, work settings that are 
highly variable from day-to-day and require teamwork and interaction with col-
leagues are the most challenging to secure or maintain for individuals with this 
ASD99. Preliminary results of  our research, involving a sample of  individuals 
with ASDs without intellectual disabilities and a group of  neurotypical adults as 
control group, showed that individuals with ASDs presented significantly high-
er levels of  stress, anxiety and depression than neurotypical adults in the first 
two months of  the COVID-19 lockdown in Italy. However, neurotypical adults 
reported a higher perceived change in lifestyle during the lockdown than ASD 
participants. Intriguingly, with respect to the control groups, ASD individuals 
reported feeling more comfortable during the lockdown period in relation to 
the social distancing measures adopted by the Italian authorities, and said they 
arrived at the end of  their study or working day significantly less tired during 
the lockdown than they had the month before (Nisticò et al., submitted paper, 
2020).Trying to identify risk and protective factors for individuals with ASDs, 
Bal and colleagues98 found that autistic adults who were younger, female, had a 
mental health diagnosis before the pandemic, and who knew someone directly 
infected by COVID-19, reported a greater impact of  the pandemic on their 
life, and a corresponding greater difficulty in of  coping with it. Moreover, they 
found that greater psychological distress was predicted by the feeling of  receiv-
ing little benefit from online counselling services. In fact, as in the pediatric field 
and in most aspects of  healthcare, services of  consultation and psychological 
support had to rapidly reorganize and were either cancelled (as reported by 
the 46% of  individuals interviewed by Oomen et al.97) or switched to remote 
telecommunication. Investigating the efficacy of  telecommunication, Adamou 
and colleagues100 reported that, in their sample of  117 adults with ASDs and 
ADHD in the United Kingdom, although the users subjectively found remote 
telecommunication to be useful, effective, reliable and satisfactory, almost half  
of  them stated a general preference for face-to-face consultations. 
162 Neurology of  COVID-19
Somatic symptom and related disorders
Somatic symptoms and related disorders are characterized by an intense fo-
cus on physical (somatic) symptoms that causes significant distress and/or in-
terferes with patients’ daily functioning. The DSM-5 includes in this category: 
i) somatic symptom disorders; ii) illness anxiety disorders; iii) conversion dis-
orders (also called functional neurological disorders, FNDs); iv) psychological 
factors affecting other medical conditions; and v) factitious disorders. Recent 
studies have shown that the economic impact of  somatic symptom and re-
lated disorders on national health systems is very high, both because of  the 
elevated number of  investigations that patients undergo (the so-called “doctor 
shopping” phenomenon), and because of  the level of  disability caused by the 
disorders themselves, often leading to loss of  employment and need for disa-
bility benefit payments101. In particular, FNDs are often encountered in neuro-
logical and neuropsychiatric practice101.  They are characterized by the presence 
of  neurological symptoms (e.g., motor, sensory or loss of  consciousness) that 
cannot be explained by typical neurological diseases or other medical condi-
tions, nevertheless determining clinically significant discomfort or impairment 
in patients’ social and/or occupational functioning53. FNDs encompass differ-
ent phenotypes, including functional movement disorders (FMDs), in which 
the critical symptom relates to movement (e.g., tremor, dystonia, paralysis, gait 
disorders), and psychogenic non-epileptic seizures (PNES), paroxysmal events 
resembling epileptic attacks, although not associated with abnormal electrical 
activity in the brain. Several issues concerning the impact of  the COVID-19 
pandemic and consequent lockdown on FNDs have been raised in the literature 
and these will be discussed here. 
The psychological impact of  the pandemic on patients with pre-existing 
FNDs
Few studies have investigated the state of  general physical and mental health 
in patients with pre-existing FNDs during the first lockdown (March-June 
2020)102-104 (Table 11.4). With respect to functional neurological symptoms, be-
tween 11% and 34% of  patients assessed in this period reported a worsening of  
their symptoms; between 54% and 61% of  patients reported no change in the 
frequency and intensity of  their symptoms, and between 12% and 28% of  pa-
tients felt that their symptoms had even improved during the lockdown period. 
Overall, an increase in stress, in poor quality of  sleep, and in symptoms of  anx-
iety was reported, which, in some cases, was associated with functional symp-
toms deterioration105 but not in all103 (Table 11.4). In an attempt to explain the 
stability or even the improvement of  FNDs symptoms during the COVID-19 
pandemic, several hypotheses were proposed. On one hand, Delgado and col-
leagues suggested that these findings might be caused by reduced self-moni-
toring, a phenomenon thought to play a significant role in the pathophysiology 
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of  FNDs. In other words, as in everyday life, FNDs symptoms decrease when 
patients are distracted. During the pandemic these symptoms remained sta-
ble or even improved since patients with FNDs diverted their attention from 
their body to the global health crisis. On the other hand, as mentioned above, 
our group recently hypothesized that specific populations of  patients, such as 
those with difficulties in social interactions, comorbid anxiety, or alexithymic 
personality traits, might have benefited from the lockdown, since they did not 
have to deal with external factors (e.g., comparison with colleagues or social 
relationships)105.













































94% patients were diagnosed before 
and 6% patients during the pandemic. 
PNES patients diagnosed during the 
COVID-19 pandemic less frequently 
had generalized motor seizures and had 
higher seizure frequencies than patients 







41 FMD 22 patients (54%) reported no change 
in their FMD, 5 (12%) improved and 
14 (34%) worsened during lockdown. 
General health condition was worse or 
much worse in 20 patients; 15 (37%) 
remained stable, and 6 (15%) improved. 
50% of  the patients reported increased 
anxiety, insomnia, and lower mood, but 

















20 patients completed their visits. 
At the 3-month follow up, all but 2 
patients reported improvement in event 
frequency.













2020: 550 new patients were evaluated; 
8.2% received a diagnosis of  FMD. 
2019: 665 new patients were evaluated: 
5.1% were diagnosed with FMD.












22 FND 2020: 22 patients were admitted and 
diagnosed with FND of  whom: 9 
acknowledged recent psychological 
stressors; a third was 70 years of  age or 
older. 2019: 5 patients were admitted 
and diagnosed with FND. 










Patients with FMD showed higher 
levels of  stress, anxiety, and symptoms 
related to post-traumatic stress disorder 
than healthy controls, but patients 
with PNES did not. 11.1% of  patients 
with FND reported their functional 
symptoms to have worsened or to be 
much worsened during the previous two 
months, 61.1% to have remained stable, 
and 27.8% to have improved or to be 
much improved. 27.8 % of  patients with 
FND reported their general health to 
have worsened or to be much worsened 
during the previous two months, 38.9% 
to have remained stable, and 33.3% to 
have improved or much improved.









54 PNES 28% reported increased frequency of  
PNES during the pandemic; PNES 
aggravation was predicted by higher 
levels of  stress, anxiety, depression, and 
poor sleep quality.
FND: Functional Neurological Disorders; FMS: Functional Motor Disorders; 
PNES: Psychogenic Non-Epileptic Seizures.
The incidence of  FNDs during the COVID-19 pandemic
Retrospective review of  electronic medical records of  major hospitals106,107 
showed a general increase in the incidence of  FNDs in 2020. In an adult and 
pediatric tertiary-care movement disorders clinic in Houston,Texas, USA, out 
of  550 new patients who were referred for evaluation between March and 
October 2020, 45 (8.2%) received a diagnosis of  FMDs of  whom 75.6% were 
females. This percentage is considerably higher than that of  the previous years 
(2019), when only 5.1% of  the referred patients were diagnosed with FMDs106. 
A similar increase was registered on the other side of  the globe; amongst the 
entire population who referred to the MidCentral District Health Board in New 
Zealand, 22 patients received a diagnosis of  FNDs between January and August 
2020. These numbers are remarkable, since in the same months in 2019 only 5 
patients were diagnosed with the same conditions. The authors also reported 
that a third of  these patients were over the age of  70, leading them to hypothe-
size that this incidence might reflect the increasing social isolation experienced 
by the elderly during the lockdown. Assessing the characteristics of  patients 
diagnosed with PNES during the COVID-19 pandemic, Asadi-Pooya and 
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Farazdaghi108 from the Shiraz University of  Medical Sciences,Iran, found that 
the patients diagnosed with PNES during the pandemic showed less frequently 
generalized motor seizures and had higher seizure frequency than patients diag-
nosed before the pandemic.
Interestingly, a case report of  Piscitelli and colleagues from Italy documented 
the case of  a 39-year-old woman who presented functional tremor in her lower 
limb after being diagnosed with COVID-19 and being forced into quarantine 
(Table 11.5)109. During the neuropsychiatric examination, which confirmed the 
diagnosis of  FMD, the patient recalled that she had previously experienced a 
similar sudden tremor in her legs while rock climbing. This led the authors to 
hypothesize that her FMD might be the expression of  her inability to verbally 
describe her feeling of  anxiety which was instead expressed by a physical symp-
tom. Similar cases of  somatic symptoms and related disorders in the context of  
the COVID-19 pandemic have been reported from around the world110-112 and 
are further detailed in Table 11.5. 
The efficacy of  telemedicine and online counselling services for patients 
with FNDs
So far, only one study conducted in a United States clinic has investigated the 
efficacy of  telemedicine in patients with FNDs during the pandemic. Fredwall 
and colleagues reported that, from March to June 2020, the Psychogenic 
Nonepileptic Events Clinic of  their hospital switched from the typical in-per-
son visits to a telemedicine format, including a series of  video-calls with neurol-
ogists and psychologists113 (Table 11.5). Comparing data collected in this period 
to previously published results of  in-persons visits, the authors showed that: i) 
there were just as many referrals to their clinic during the pandemic as before, 
and the rate of  patients who completed the cycle of  visits was also similar; ii) af-
ter 3 months, patients seen by telemedicine had similar acceptance rates, and the 
rate of  improvement in PNES frequency even increased. However, there was a 
decrease in connection to psychological counselling: only 63% of  the telemedi-
cine cohort was linked with counselling in comparison to the historical control 
of  73%, which might be due to additional limitations in access during the pan-
demic. Importantly, the authors noted that visits conducted only via phone (and 
not video-call) were visibly less effective in both communicating the diagnosis 
and facilitating its acceptance among the families. Overall, telemedicine (provid-
ed with a video-call) proved to be a valid alternative to in-person visits. 
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The patient (a nurse) 
presented with a history 
of  fatigue and persistent 
dysphonia. She had 
previously been infected 
with COVID-19, which 
lasted about 2 months 
with pulmonary and ex-
trapulmonary symptoms 
but, at the assessment, 
her test for SARS-
CoV-2 was negative. 
No organic alterations 









































The patient, already in 
psychological treatment 
for an emerging eating 
disorder, presented 




Despite testing negative 
for the presence of  
SARS-CoV-2, the 
patient kept presenting 
with psychomotor 
agitation and aggres-
sivity. He responded 
rapidly to a low dose 
















exacerbation of  
a pre-existing 
SSD, triggered 
by fear of  being 
infected, also 
to prevent a 
further burden 


















The patient, initially 
admitted to the ER 
in a rush, happily 
claimed to have tried 
to infect herself  with 
COVID-19 by using the 
same thermometer as 
an infected patient; no 
evidence on the hospital 
security camera footage 
in the ER to verify her 
claims were founded, 












that her feigning 




need for the 
emotional sup-
port, she would 
have received 
as a COVID-19 
patient.











The patient (a nurse), 
with no history of  
psychiatric disorder, was 
infected with SARS-
CoV-2 and, while in 
quarantine, developed 
a lower limb tremor 
with variable frequency 
and amplitude, with 
abnormal movements 
while sitting, walking 
and at rest. No tremor 
in the upper limbs or 
in the cephalic district 
emerged; neurological 
and instrumental exami-
nation were normal. She 
showed entrainment 
phenomenon and effect 
of  distractibility on the 
intensity of  movement 
disorder. After testing 
negative for COVID-19, 





Since the patient 




tremor in her 
legs while rock 
climbing, the 
authors hypoth-
esized that her 
FMD might be 
the expression of  
her inability to 
verbally describe 




by a physical 
symptom.
FND: Functional Neurological Disorders; FMS: Functional Motor Disorders; SSD: 
Somatic Symptoms Disorder.
Functional neurological symptoms and COVID-19 vaccinations
Kim and colleagues114 recently published a paper commenting on the news 
reported by newspapers and circulating on social media that at least one patient 
received the diagnosis of  Conversion Disorder after experiencing continuous 
movement of  the trunk and limbs, along with walking difficulties, after receiv-
ing the first shot of  COVID-19 vaccine. The authors reminded the readers that 
FNDs can actually be triggered by emotional and/or physical events, including 
surgical procedures and vaccinations, but these cannot be considered the direct 
cause of  FNDs. In other words, the substances contained in the vaccine cannot 
cause FNDs 114.
In conclusion, during the first year of  the COVID-19 pandemic, the inci-
dence of  FNDs significantly increased with respect to previous years. The ma-
jority of  patients with pre-existing FNDs reported no change in the frequency 
or intensity of  their symptoms, although a global increase in stress, poor qual-
ity of  sleep and symptoms of  anxiety was reported. Telemedicine appears to 
be a promising alternative to in-person initial consultation. In the near future, 
the efficacy of  online counselling for psychological distress should be further 
investigated.
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Take-home message
 – The current COVID-19 pandemic is having a major impact on mental 
health and well-being, both in the general population and in patients with 
pre-existing psychiatric symptomatology. 
 – Strict lockdown measures, leading to disruption of  individual physiologi-
cal and social routine (i.e., less social support, altered sleeping and eating 
patterns, etc.) are associated with higher risk of  worsening of  and relapse 
of  mood, eating and psychotic disorders.
 – The high fear of  contamination and reinforced cleansing habits are se-
vere precipitating factors for obsessions and compulsions. As in previous 
epidemics, individuals with obsessive-compulsive disorders showed a sig-
nificant clinical worsening during  the COVID-19 pandemic, and must be 
considered at high risk of  suicide.
 – Individuals with difficulties in social interaction (such as adults with high 
functioning autism spectrum disorders) showed, on one hand, a general 
increase in symptoms of  anxiety and depression but, on the other hand, 
a decrease in stress levels related to reduced sensory and social overload.
 – With respect to previous years, in 2020, the incidence of  somatic symptom 
disorders and functional neurological disorders significantly increased; 
this might be due to paying greater attention towards one’s own body in 
the context of  the pandemic.
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Chapter 12. Cognitive dysfunction and 
rehabilitation
Michelangelo Dini, Alberto Priori, Roberta Ferrucci
Introduction
COVID-19 is a respiratory disease which ranges from mild to severe and 
presents a wide clinical spectrum. It is primarily characterized by pneumonia 
and respiratory distress but can be accompanied by numerous other complica-
tions. Of  these, we will focus on examining the role and relevance of  cognitive 
dysfunction. Cognitive dysfunction is typically defined as the presence of  defi-
cits which affect one or more cognitive functions: memory, language, execu-
tive functions, attention, visuospatial abilities, etc. Cognitive dysfunction can 
be classified according to the severity (subjective, mild cognitive impairment, 
dementia), type of  onset (insidious, acute), and course (progressive, chronic, 
transient) of  illness. The causes may be many and diverse in nature, as cognitive 
deficits can represent the clinical manifestation of  underlying neurodegenera-
tive processes, hypoxia, hyperinflammation, cerebrovascular events, or traumat-
ic injury being the most commonly reported. 
Evidence from previous coronavirus-related respiratory diseases, such as the 
SARS and MERS epidemics in 2002 and 2012, respectively, has alerted scien-
tists all over the world about the neuroinvasive potential of  SARS-CoV-2. For 
this reason, studies aimed at assessing the incidence of  neurological symptoms 
have been conducted since the earliest phases of  the pandemic. Additionally, 
the fact that severe COVID-19 requires admission to the intensive care unit 
(ICU) and, in the most severe cases, invasive mechanical ventilation and seda-
tion, suggests that cognitive deficits might be linked to prolonged respiratory 
distress, which can cause hypoxia-related brain injury. Finally, other pathological 
processes, such as hyperinflammation and hypercoagulability, have also been 
proposed as possible causes of  cognitive dysfunction in COVID-19.
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Rationale for cognitive dysfunction in COVID-19
As outlined above, there are many different types of  pathological mechanisms 
that could determine cognitive dysfunction in COVID-19 patients (Figure 12.1)1. 
Therefore, it is difficult to establish exactly whether cognitive dysfunction in 
COVID-19 is associated with direct viral neuronal injury, or whether it results 
from the presence of  a severe systemic disorder characterized by a combination 
of  sepsis, hypoxia, hyperpyrexia, hypercoagulability and critical illness2,3.
During the SARS and MERS epidemics, studies reported the presence of  
neurological symptoms such as altered mental status in the acute phase4 and 
cognitive complaints in recovered patients5. A metanalysis of  72 studies on 
both acute and post-acute neuropsychiatric effects of  coronavirus infection6 
highlighted the presence of  delirium in the acute phase, and impaired concen-
tration and memory in the long-term (range of  follow-up from 6 weeks to 39 
months).
Evidence from studies on patients hospitalized for acute respiratory distress 
syndrome (ARDS) has highlighted a higher prevalence of  delirium in intubated 
patients with ARDS (72%) compared to intubated patients without ARDS (53%), 
and non-intubated ICU patients (21%)7. With regards to long-term cognitive out-
comes, a review of  the literature has observed that there is a high prevalence of  
ARDS-related cognitive dysfunction and that prevalence correlates inversely with 
time since recovery, ranging from 70-100% in the post-acute phase and decreas-
ing to 46-78% at 1-year follow-up, to 25-47% at two years, and to ~20% at five 
years8. The domains most affected were memory, attention, concentration, pro-
cessing speed, and executive functioning8–10. Furthermore, studies have observed 
that hypoxia is associated with neuronal atrophy and subsequent ventricular en-
largement, which are particularly associated with memory impairment11,12, likely 
due to the demonstrated sensitivity of  hippocampal neurons to hypoxic dam-
age13. However, it should be noted that other authors have also found a strong 
association between hypoxia and executive functions deficits10.
In addition to ARDS, it has been suggested that hyperinflammation plays 
a significant role in determining the severity and mortality of  COVID-193,14. 
Aberrant stress responses to acute infection have been linked to cognitive im-
pairment through the activation of  a systemic inflammation pathway associated 
with elevated interleukins serum levels15, and may represent a distinct patholog-
ical pathway. This implies  that the etiology of  COVID-19-related acute cogni-
tive dysfunction might be both inflammatory and non-inflammatory16. Indeed, 
evidence from in vitro studies shows that coronavirus-infected glial cells secrete 
large quantities of  inflammatory factors (IL-6, IL-12, IL-15 and TNF-α)17. Last 
but not least, the cases of  acute cerebrovascular disease observed in COVID-19 
may themselves be linked to cytokine storm syndromes3, but they could also 
result from increased D-dimer levels and severe platelet reduction18. 
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Notably, risk factors associated with a higher risk of  severe COVID-19 (ad-
vanced age, hypertension, obesity, diabetes)19,20 are also associated with higher risk 
of  cognitive impairment21. Finally, multiple factors related to hospital care for 
COVID-19 (i.e., prolonged mechanical ventilation, sedation, social isolation) are 
known to increase the risk of  delirium22,23, which in turn is recognized to be a 
potentially modifiable risk factor for long-term cognitive dysfunction24,25.
For these reasons, clinicians should be particularly watchful for cognitive 
dysfunction in hospitalized COVID-19 patients, both during the acute phase 
and in the long term. 
Figure 12.1: Factors contributing to long-term cognitive dysfunction  
in COVID-19 survivors
COPD: Chronic Obstructive Pulmonary Disease.
Cognitive dysfunction in COVID-19: the state of  the art
Acute cognitive impairment
Evidence regarding the presence of  cognitive impairment during the acute clin-
ical phase of  COVID-19 was provided as early as March 2020 by Chen et al.26 
who reported the presence of  delirium in 26 of  274 (9%) patients admitted for 
COVID-19. Notably, they also observed that the prevalence of  delirium was much 
higher in patients who later died (22%) compared to those who recovered (1%). 
Another study27 found that, as of  February 2020, 16 of  214 (7.5%) patients ad-
mitted to hospital for COVID-19 manifested impaired consciousness. This study 
also confirmed that the presence of  impaired consciousness was associated with 
a greater severity of  illness, as the prevalence was significantly higher in patients 
180 Neurology of  COVID-19
with severe COVID-19 compared to other patients (14.8% vs. 24%, p <0.001)27. 
Some authors have noted that the observed percentages may underestimate the 
actual incidence of  acute cognitive dysfunction, since the main clinical focus dur-
ing this period of  crisis lay in pressing organizational issues (i.e., shortages of  per-
sonal protective equipment, prioritization of  limited ventilation options), which 
may have resulted in a reduction in resources allocated to delirium prevention and 
management22. 
Between February and April 2020, as the epicenter of  the COVID-19 pan-
demic began shifting towards Europe, neurologists became ever more aware of  
the incidence of  neurological manifestations of  COVID-19. In April 2020, the 
European Academy of  Neurology (EAN) core COVID-19 Task Force28 posted 
a survey asking clinicians to report the prevalence of  neurological symptoms 
in COVID-19 patients. They collected responses from 2,343 clinicians (82% of  
which were neurologists) who reported the presence of  impaired conscious-
ness (29.3% of  patients), psychomotor agitation (26.7%), encephalopathy 
(21.3%), and cerebrovascular disease (21.0%)28. During the same period, Helms 
et al.29 reported the results of  an observational study on a series of  consecutive 
COVID-19 patients hospitalized in the ICU for ARDS. Among other neurolog-
ical symptoms, the authors observed the presence of  a dysexecutive syndrome, 
characterized by disorientation, inattention, and poorly organized behavioral 
response to commands, in over one-third of  patients (14/39; 36%)29.
In conclusion, according to studies published so far, the clinical profile of  cog-
nitive dysfunction in COVID-19 patients during the acute phase appears to be 
characterized primarily by the presence of  delirium and dysexecutive syndromes. 
(For a more detailed discussion of  delirium in COVID-19, please see the dedicat-
ed chapter.) However, to the best of  our knowledge, there have been no reports 
of  the presence of  milder and more specific cognitive deficits in the acute phase 
of  COVID-19 (i.e., during hospitalization) in the scientific literature. While there 
are many brief  neuropsychological tools designed to rapidly assess a broad range 
of  cognitive functions at the bedside (Mini-Mental State Examination – MMSE30, 
Montreal Cognitive Assessment – MoCA31, Frontal Assessment Battery – FAB32, 
to cite some of  the most widely used), several factors would have rendered their 
use challenging and often unfeasible. One of  these is the fact that hospitals faced 
enormous pressure to manage a large influx of  critical and infectious patients, and 
therefore had to prioritize pressing clinical concerns, leaving aside all those assess-
ments that were not urgently required in order to save patients’ lives. Furthermore, 
other environmental, structural, and organizational limitations could have made 
the evaluation impossible even for patients who were not being treated in the ICU 
(busy, noisy wards, impossibility of  moving patients, mandatory use of  personal 
protective equipment that made verbal communication difficult, etc.). For these 
reasons, studies that have performed formal neuropsychological assessment in 
COVID-19 patients have done so exclusively in the post-acute phase.
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Post-acute cognitive impairment
The ongoing COVID-19 pandemic continues to affect an increasing number 
of  people worldwide. Thanks to the advances in the clinical management of  
acute symptoms, there has been a parallel increase in the numbers of  patients 
who have recovered, who nevertheless often experience persisting symptoms. 
This so-called “Long-COVID” syndrome is often characterized by physical 
symptoms (fatigue, joint and bone pain), behavioral alterations (anxiety, insom-
nia), and, crucially, neurological symptoms (headache, paresthesia, cognitive im-
pairment)33,34. Therefore, during the course of  the pandemic, researchers have 
begun studying the cognitive outcomes associated with COVID-19 in order to 
establish, not only the prevalence and quality of  these deficits, but also the pres-
ence of  relevant clinical, physiological, and pathological associations.
One of  the first studies to report the presence of  cognitive deficits following 
recovery from COVID-19 symptoms was conducted by Zhou et al.35. They 
observed that, between two and three weeks after clinical recovery, patients 
exhibited slower reaction times and performed worse in a test of  continuous 
and selective attention compared to healthy controls. Interestingly, the au-
thors also found a positive correlation between C-reactive protein (CRP) levels 
and reaction times; higher CRP levels correlated with slower reaction times35. 
Researchers in Spain36 performed a complete neuropsychological assessment 
of  35 patients who recovered from COVID-19 between April and June 2020 
(aged 24-60 years; mean age: 47.6±8.9 years; 19 females). Of  these 35 patients, 
21 (60%) had required oxygen and 7 (20%) had required admission to the ICU; 
the neuropsychological assessment was conducted between two and five weeks 
after clinical recovery. The study found deficits of  memory, attention and se-
mantic fluency in 5.7%, deficits of  working memory and mental flexibility in 
8.6%, and phonemic fluency deficits in 11.4%. The authors also observed that 
patients who had required oxygen therapy (n = 21) had lower scores in memory, 
attention, and executive functions, compared to other patients (n = 14)36.
We assessed the presence of  cognitive dysfunction in recovered COVID-19 pa-
tients at approximately five months from hospital discharge, by performing a com-
plete neuropsychological assessment of  38 patients (aged 22-74 years;mean age: 
53.45±12.64 years; 11 females)37. We found that 60.5% of  our sample had deficits 
in at least one cognitive test, with attention and processing speed being the most af-
fected domains (42.1% of  patients). However,  we also observed a significant preva-
lence of  both verbal and visuospatial long-term memory deficits (26.3% and 18.4% 
of  patients, respectively)37. Interestingly, patients who suffered from ARDS showed 
significantly lower scores in tests of  verbal memory, and there was a positive corre-
lation between PaO2/FiO2 levels and verbal memory performance. After recruiting 
more patients (n = 77), we observed a general stability of  the cognitive profile, with 
an increase in the prevalence of  memory deficits, likely due to the fact that we also 
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recruited patients who had required NIV and intubation, which confirms the link 
between memory deficits and ARDS (M Dini et al., 2021, unpublished data).
Other studies have assessed cognitive dysfunction in patients who have re-
covered from COVID-19 (see Table 12.1 for a summary). Notably, Hosp et 
al.38 studied 29 patients (mean age: 65.2±14.4 years; 11 females) in the suba-
cute phase (i.e., around one month after  symptom onset) and found impaired 
global cognition in 18/26 patients (69%), as seen by MoCA scores <26; cogni-
tive dysfunction was confirmed in 15 patients via detailed neuropsychological 
testing. The authors also performed 18FDG PET scans on patients who had 
presented with at least 2 neurological symptoms, revealing a pattern of  pre-
dominant frontoparietal hypometabolism in 10/15 (66%) patients, confirmed 
by comparison with a control sample via voxel-wise principal components anal-
ysis (Figure 12.2), which showed a positive correlation (R2 = 0.62) with MoCA 
scores. Additionally, post-mortem assessment of  a patient deceased for extrac-
erebral causes revealed the presence of  pronounced microgliosis with absence 
of  neuroinflammation38. 
 
Figure 12.2: Result of  18FDG PET group analysis
Top and middle row: Transaxial sections of  group averaged and spatially normal-
ized 18FDG PET scans in patients with COVID-19 and healthy controls. Bottom 
row: COVID-19-related spatial co-variance pattern of  cerebral glucose metabo-
lism constructed by Principal component analysis of  the aforementioned groups.  
Reproduced from 38 with permission. 
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The authors conducted a follow-up study42, repeating18 FDG PET scans in 
8 patients after six months, and observed a significant reduction in the initial 
pattern of  frontoparietal hypometabolism, as well as an increase in temporal 
cortical 18FDG uptake, compared to the acute phase; these results were accom-
panied by a significant improvement in cognition. They remarked that, although 
an improvement can be observed from neurophysiological data, some patients 
still exhibit residual impairment at six months, which is confirmed by the fact 
that 5/8 (62.5%) obtained MoCA scores below the normative cut-off42. The 
studies discussed so far are characterized by small samples, mainly due to the 
limitations imposed by the pandemic. More recent studies, however, have man-
aged to collect data from larger samples. Méndez et al.41, for example, studied 
cognitive dysfunction in a sample of  179 patients at four months after clinical 
recovery. Patients (median age: 57 years; 105 males) had been hospitalized for 
COVID-19 between March and April 2020 and had required different levels of  
oxygen therapy (no support: 49.7%; nasal cannula: 11.2%; venturi mask: 21.2%; 
NIV: 4.5%; mechanical ventilation: 12.8%). The authors found that 58.7% of  
patients had impairment in at least one domain, and that the most frequently 
impaired functions were immediate verbal memory and learning (38%), and 
verbal fluency (34.6%), while they found a lower prevalence of  delayed verbal 
memory (11.8%) and working memory (6.1%) deficits. Delirium during hospi-
talization occurred in 8 (4.5%) patients, and was associated with an increased 
risk of  cognitive dysfunction (OR [95%CI] = 4.05 [1.03 – 16.4])41.
Another large sample of  patients was assessed by Cristillo et al.45 who stud-
ied a sample of  101 recovered patients at six months after discharge. Eighteen 
patients required no oxygen therapy, 68 required low-flow oxygen therapy, 13 
required NIV oxygen therapy, while only 2 required orotracheal intubation. The 
authors focused on the association between hyposmia, dysgeusia and cognitive 
dysfunction, observing that patients who reported hyposmia at six months also 
obtained lower MoCA scores (23.2 ± 3.4 vs. 25.7 ± 2.4, p < 0.001). There was 
no association between hyposmia and severity of  the disease, which suggests 
that the long-term cognitive dysfunction associated with COVID-19 might also 
have a non-respiratory component.
Mattioli et al.44 conducted a study in which they assessed 120 healthcare work-
ers who had had mild-moderate COVID-19 and 30 healthy controls, in order to 
assess cognitive dysfunction at four months from the diagnosis of  COVID-19. 
The authors found that 30% of  COVID-19 patients had at least one cognitive 
deficit at four months compared to controls (23%), although this difference 
was not significant. Notably, of  the 120 patients, only 2 had required oxygen 
therapy (one NIV and one intubation); therefore, this sample is characterized 
by significantly milder disease severity compared to the studies discussed so far.
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Methodological and practical considerations
Some key limitations need to be considered when interpreting the results of  
the studies which have been discussed so far. First and foremost, there is con-
siderable variability in terms of  sample size, with most studies characterized by 
small samples (n < 40). Additionally, most studies had an unbalanced males/fe-
male ratio, with male patients generally representing the majority of  the sample, 
mainly because COVID-19 has been shown to affect males more severely46 this 
results in higher hospitalization rates. The only exceptions were Zhou et al.35, 
who studied 16 males and 19 females, and Almeria et al.36 who studied 30 males 
and 90 females. There is also significant variability with regards to age as some 
studies assessed patients who were, on average, under 50 years of  age35,36,44, 
some assessed patients aged 50 – 60 years37,40,41, and others focused on patients 
over 60 years of  age38,39,42,43,45. Crucially, several studies differed in terms of  
the clinical characteristics of  patients. Namely, some focused on patients who 
had recovered from severe COVID-19 (i.e., had required ICU treatment and 
mechanical ventilation)39, while others focused on patients with milder illness 
severity44. The majority of  studies, however, evaluated patient populations char-
acterized by varying disease severity36,37,41,45. Crucially, some studies did not re-
port the type of  oxygen therapy patients received35,40,43.
In terms of  experimental design, most studies are observational in nature as 
they lack a control sample, and therefore they do not allow definitive conclusion 
regarding the role of  COVID-19 on the observed cognitive dysfunction to be 
reached. Some conclusions may be drawn by comparing the performance of  
recovered patients with data from published normative studies relative to the 
various neuropsychological batteries and tests; this can be done either by calcu-
lating z-scores, or by categorizing patients based on published normative cut-
offs. Another important methodological limitation is the fact that each study 
used different neuropsychological assessment batteries, which complicates the 
interpretation of  results. Some studies administered only global assessment bat-
teries (MoCA, FAB)39,42,43,45 or a very limited selection of  individual tests35,40gen-
der- and education-matched healthy controls were also recruited. The cognitive 
functions of  all subjects were evaluated by the iPad-based online neuropsycho-
logical tests, including the Trail Making Test (TMT, while others performed a 
more detailed assessment36–38,44. This, in addition to the fact that normative data 
differ across nationalities, language, and ethnicities, is likely to have contributed 
to the heterogeneity of  the results. In conclusion, while rapid global neuropsy-
chological tests (MoCA, MMSE, and FAB) should be considered for use during 
the acute phase, post-acute cognitive evaluation should be conducted using spe-
cific tests for the different cognitive domains in order to achieve greater sensi-
tivity and to better characterize the qualitative profile of  cognitive dysfunction.
Preliminary results of  our study indicate that a MoCA score ≤ 25.50 at five 
months from clinical recovery predicted the presence of  persistent cognitive 
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impairment (defined by the presence of  deficits in at least two neuropsycholog-
ical tests) at one year (sensitivity: 70.6%; scpecificity: 62.9%). Clinicians should 
be alerted to the risk of  cognitive impairment not only when faced with pa-
tients falling below the established cut-offs, but also when observing patients 
who obtain borderline normal scores, since more detailed neuropsychological 
assessments might uncover impairment of  specific cognitive domains.
Cognitive dysfunction at 1-year
As more than a year has now passed since the first peak of  the pandemic, we 
should aim to assess the long-term course of  cognitive dysfunction in recov-
ered COVID-19 patients to establish first and foremost whether the observed 
deficits do persist in the long term, and secondly, whether specific patterns 
emerge (i.e., whether certain domains improve faster than others). 
Following up on our first study37, we recruited more patients and repeated the 
neuropsychological assessment at one year from hospital discharge in order to try 
and provide an answer to the questions outlined above. Preliminary data obtained 
from follow-up assessments (n:  52, T1: 5 months, T2:  12 months) highlight that 
the majority of  patients show an improvement in all tests as time progresses, but 
it should be noted that a percentage of  patients still exhibit cognitive deficits at 
one year from hospital discharge (Dini et al., unpublished data).  
Cognitive rehabilitation
Considering what has been discussed so far, it is evident that cognitive reha-
bilitation must be included in multidisciplinary rehabilitation programs designed 
to improve the functional outcome of  recovered COVID-19 patients47,48. As of  
today, however, few studies have assessed the effects of  different cognitive re-
habilitation programs in COVID-19.
An observational study49 found that post-acute 3-week multidisciplinary reha-
bilitation improved respiratory, motor, and functional outcomes. Even though 
29% of  patients had cognitive deficits before enrolment, the authors did not 
report the results on cognitive functioning. Another study50 on the effects of  
6-week physical and educational rehabilitation interventions found that MoCA 
score significantly improved post treatment. However, since the study did not 
include formal cognitive rehabilitation, and did not include a control sample, it is 
difficult to say whether this improvement resulted from the rehabilitation inter-
vention or from a spontaneous recovery of  function. A recent study51 assessing 
the effects of  inpatient multidisciplinary rehabilitation interventions in patients 
who had recovered from COVID-19 who had required ICU treatment found 
improvements in cognition and speech, but also noted that a significant percent-
age of  patients still exhibited deficits of  attention, memory, and problem solving.
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Given the ever-increasing number of  recovered patients worldwide, rehabili-
tative interventions will play a significant role in determining the functional im-
pact of  the ongoing pandemic. As cognitive dysfunction represents a common 
symptom of  the so-called “Long-COVID” syndrome, cognitive rehabilitation 
should be included in multidisciplinaruy rehabilitation programs. Finally, as sub-
jective cognitive deficits can also significantly affect quality of  life52 and tend to 
be associated to psychological distress, anxiety and depression53, rehabilitation 
programs may also benefit from the inclusion of  techniques aimed at reducing 
psychological distress (e.g., mindfulness-based stress reduction [MBSR]).
Conclusions
Cognitive dysfunction can be observed not only during the acute phase of  
COVID-19, in the form of  delirium and dysexecutive syndrome, but also in 
the post-acute phase of  the disease, which is characterized by mild-moderate 
deficits. The qualitative profile of  cognitive dysfunction is heterogeneous, prob-
ably as a result of  differences between the various studies (socio-demograph-
ic variables, clinical variables, methodological differences) which are outlined 
above. Nevertheless, interesting results have been published linking the severity 
of  cognitive dysfunction in the months following hospital discharge to clini-
cal factors such as presence of  ARDS37, hyposmia45, and inflammation35. It is 
likely that the cognitive functioning of  these patients might improve as time 
progresses, and preliminary data seem to indicate that this is, indeed, the case. 
However, it is paramount that both clinicians and researchers be on the alert 
for the presence of  cognitive dysfunction in people who had COVID-19, as it 
could represent a key factor in determining the functional outcome of  a large 
number of  patients worldwide.
Take-home message
 – Cognitive dysfunction is common in patients with COVID-19.
 – Cognitive deficits can be observed not only in the acute phase, but also in 
the months following recovery.
 – ARDS, hyposmia/dysgeusia and hyperinflammation have all been linked 
with an increased risk of  cognitive dysfunction.
 – Cognitive deficits tend to be most severe in the first months from clinical 
recovery, and improve gradually in the long-term.
 – Brief  screening neuropsychological tests (MoCA, MMSE, FAB) may be 
unable to detect mild cognitive dysfunction in COVID-19 patients.
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Chapter 13. Disorders of  cranial and spinal 
nerves
Tommaso Bocci*, Laura Campiglio*, Alberto Priori 
* These authors equally contributed to this work
Non-length dependent neuropathies: Guillain-Barré-
Strohl syndrome and COVID-19 
Definition and epidemiology
Guillain-Barré-Strohl syndrome (GBS) is an acute, parainfectious autoim-
mune disease, either axonal or demyelinating, with rapid onset of  3-4 weeks 
following the primary infection. GBS has been described from the beginning 
of  the COVID-19 pandemic and a number of  typical features, both clinical and 
neurophysiological, have been reported1-3. GBS was reported in 0.1-0.4% of  
hospitalized patients,4-6 and GBS and variants represent about 21% of  the neu-
rological case reports7. In general, the mean age, gender and COVID-19 fea-
tures appear to reflect those of  hospitalized COVID patients, while the disease 
course is more severe than non-COVID-related GBS8,9. The causal relationship 
between GBS and COVID-19 may be classified as possible or probable. In par-
ticular, a probable association is defined when: 1) the disease onset is within 6 
weeks of  acute infection; 2) either SARS-CoV-2 RNA is detected in any sample 
or there is antibody evidence of  acute SARS-CoV-2 infection; and 3) there is no 
evidence of  other commonly associated causes10.  
Clinical, biochemical and neurophysiological features
Overall, onset of  COVID-related GBS seems to follow quickly from the pri-
mary infection, as compared to other parainfectious diseases, with neurological 
signs emerging just one week after respiratory failure. Moreover, in COVID 
patients, polyradiculoneuropathies primarily affect cranial nerves and are com-
monly related to an early and severe autonomic dysfunction11-14. In the first 
reports, axonal GBS was observed, including both acute motor axonal neu-
ropathies (AMAN) and acute motor-sensory axonal neuropathies (AMSAN11). 
As the pandemic progressed on a global scale, there have also been increas-
ing reports of  demyelinating GBS, and the current percentages of  axonal and 
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demyelinating forms are similar3,8. Nonetheless, axonal neuropathies are still 
more frequent when compared to other parainfectious GBS9. The immunolog-
ical bases are not yet fully understood, and neither are the antibodies involved 
in the pathophysiology of  the disease. However, as likely occurs for the Central 
Nervous System (CNS), we cannot rule out the possibility of  a direct viral 
invasion of  the peripheral nerves and myelin; this could explain the short de-
lay between respiratory symptoms and the early development of  neurological 
signs. As reported in some studies2,11, a direct mechanism may also be suggested 
by the absence of  serum anti-ganglioside antibodies, commonly engaged in the 
pathophysiology of  immune-related disorders. 
Putative pathophysiological mechanisms and comparison with other 
coronaviruses
As described above, the immuno-mediated nature of  COVID-related GBS 
is still a subject of  debate and we cannot exclude the possibility of  a direct viral 
invasion. In this scenario, it is worth remembering that the receptor of  the angi-
otensin-conversion enzyme (ACE), the main gate of  entry of  SARS-CoV-2 into 
the cells, is highly expressed not only on the neuronal and vascular endothelial 
surface, but also by Schwann’s cells and central oligodendrocytes15-17. Moreover, 
to further support the concept of  direct viral damage, a prion-like mechanism 
of  neuroinvasion, both at a central and a peripheral level, has been extensively 
described for other coronaviruses, both in animals and humans18-21. These data 
also fit our recent combined neurophysiological and histopathological findings 
in severe COVID-19 showing an early involvement of  the vagus nerve and 
respiratory nuclei, probably also accounting for the respiratory failure itself22,23. 
However, despite the particular abovementioned features of  COVID-related 
GBS, whether COVID patients exhibit an increased risk is still under debate. 
Recent data suggest that the incidence of  GBS in COVID is similar to that de-
scribed following other infectious diseases24, 25, while a larger multi-center study 
reports a 2.6 fold increased incidence of  GBS in Italy during the first pandemic 
outbreak 26. However, the risk of  GBS in severe COVID-19 seems to be lower 
when compared to other emerging infections, such as Zika27.       
Length-dependent neuropathies
Among other diseases affecting the Peripheral Nervous System, an increasing 
body of  literature has described “Critical Illness Polyneuropathies or Myopathies” 
(CIP/CIM) in COVID patients, during their stay in the Intensive Care Unit (ICU)28-
32.The main clinical features are difficulty in weaning the patient off  the ventilator 
and flaccid weakness, thus resulting in areflexic quadriplegia33-36. Although patho-
physiologic mechanisms still remain to be established, CIP/CIM usually follows 
a prolonged treatment of  sepsis and may represent the neural manifestation of  
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multiple organ failure (MOF). Among other causes, high and prolonged doses of  
corticosteroids and/or non-depolarizing neuromuscular blockers are thought to be 
strongly associated with these neuromuscular abnormalities34. In non-COVID pa-
tients, signs of  both neuropathy and myopathy are common, but the myopathic in-
volvement seems to be more frequent and associated to a better clinical outcome36,37. 
In comparison with non-COVID patients, a higher percentage of  CIP has 
been described in severe COVID-1931,32,38. This is of  key importance given that 
CIP/CIM may have a different  impact on the choice of  strategies to be adopted 
for functional recovery and rehabilitation, possibly delaying ICU discharge for 
patients affecting by predominant neuropathies39. Critical illness neuropathies 
are probably related to the COVID-induced MOF, but other causes should be 
taken into consideration, including a possible vasculitic involvement of  the vasa 
nervorum and a direct viral invasion of  the peripheral nerves by SARS-CoV-239.   
Figure 13.1: Neurophysiological features
The figure shows nerve conduction studies from a representative COVID-19 pa-
tient with critical illness neuropathy (CIP). Top: sensory action potentials (SAPs) 
from the right sural nerve (not recordable) and CMAP (reduced amplitude) derived 
from the right extensor digitorum brevis; at the bottom (left) F-waves from the 
left ulnar nerve are provided (with reduced amplitude and impaired representa-
tion). Bottom: (right), CMAPs obtained by either Direct Muscle Stimulation (DMS, 
top trace) or Nerve Motor Stimulation (NMS, bottom) are shown: the significant 
amplitude reduction, when NMS was compared to DMS, further confirms the pre-
dominace of  a neuropathic rather than a myopathic pattern (modified from Bocci 
et al.39, Fig. 1 p. 4).
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Although sometimes limited by the very small sample size, studies in COVID-19 
have shown that patients with high serum levels of  Interleukin-6 (IL-6) and crea-
tin-phosphokinase (CPK) are at the highest risk of  developing both muscular and 
neuropathic impairment31,40. CPK itself  is known to represent an independent 
factor associated with an overall worse clinical outcome and to the development 
of  neurological complications, both at a central and a peripheral level40. 
Isolated involvement of  the cranial nerves
Since the beginning of  the pandemic, authors around the world have report-
ed COVID-associated cranial neuropathies, detected by clinical, radiological 
and neuropathological investigation41-43. In most cases, isolated cranial nerve 
involvement consisted of  hyposmia and dysgeusia, but multiple polyneuritis 
cranialis or cranial nerves deficits in the context of  Miller Fisher Syndrome 
(MFS) have been observed in a significant number of  patients13,44. 
Smell and taste disorders
Hyposmia and/or hypogeusia are known to be the main symptoms of  SARS-
CoV-2 infection. Anosmia has been reported in about 5% of  hospitalized pa-
tients4,44,45, but its prevalence is considerably higher in dedicated studies, with a 
frequency ranging from 61% to 86%46-49. According to some studies, anosmia 
is the first symptom in about 25% of  patients50 and is nearly always associated 
with ageusia. These symptoms tend to have an unexpected onset51,52 and, be-
cause they are often not accompanied by other symptoms, these deficits could 
be the only indication of  infection in otherwise asymptomatic COVID-1953. 
Most patients report an improvement within the first week, but it is still not 
known whether some deficit could be permanent52. Some Authors propose that 
the persistence of  anosmia is related to lasting SARS-CoV-2 in the olfactory 
mucosa, while others suggest a central mechanism50,54.
The exact pathogenesis of  olfactory dysfunctions is still not fully under-
stood. Animal models have suggested an infection of  sensory neurons by 
SARS-CoV-2 or retrograde brain invasion through the olfactory nerve, but 
the sudden onset and the fast recovery do not indicate any structural sensory 
neuron damage and published data are not always in agreement about this55,56. 
Current evidence suggests an indirect mechanism (infection and inflammation) 
to non-neural supporting cells of  olfactory mucosa, particularly sustentacular 
and microvillar cells with high expression of  ACE2 receptor57.
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Figure 13.2: Olfactory disorders in SARS-COV-2 infection
1) Local inflammation due to the involvement of  supporting cells of  the olfactory 
epithelium. 2) Involvement of  endothelial cells and vascular pericytes, leading to 
hypoperfusion and inflammation. The recruitment of  inflammatory cells, cytokine 
release and generation of  neurotoxic compounds modulate the neuronal signaling 
(from Mastrangelo et al.56, Fig. 1 p. 2. Reproduced from 56 with permission).
However, the possible occurrence of  other mechanisms leading to chemosen-
sory dysfunction and a direct sensory neuron invasion have been postulated54,56. 
Interestingly, a recent study on post-mortem samples revealed the co-localization 
of  a coronavirus antigen and SARS-CoV-2 RNA in olfactory sensory neurons58.
So far, published data on the pathogenesis of  taste disorders remain limited. 
Some studies demonstrated that epithelial cells of  the tongue express ACE-2 
receptors, hypothesizing a key role for oral mucosa as an entry route for the 
virus59. For the moment there are few data available on the percentage of  taste 
and smell disorders at follow-up. Recent studies seem to suggest that many 
patients recover quickly, but about 40% of  those who experienced smell loss 
at disease onset may suffer from parosmia during the following six months60-62. 
This does not depend on the severity of  primary infection and is not related 
to the persistence of  other systemic dysfunctions during long-term follow-up.
Optic nerve disorders
Involvement of  the optic nerve during COVID-19 is unusual and optic 
neuritis has rarely been described in patients with SARS-CoV-2 infection63,64. 
Patients presented with painful vision loss, relative afferent pupillary defect and, 
in severe cases, visual field defects and optic nerve enhancement on Magnetic 
Resonance Imaging (MRI)64. 
In some other COVID-19 patients, optic neuritis was associated with mye-
lin oligodendrocyte glycoprotein (MOG) antibodies. In these cases, SARS-CoV-2 
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was not detected in the cerebrospinal fluid and researchers postulated that the 
viral infection triggered the autoimmune response 65,66.
Because SARS-CoV-2 is associated with endothelial damage, and thrombot-
ic events are a well described complication of  COVID-19, in the case of  a sud-
den visual loss, central retinal artery occlusion and retinal vein occlusion need 
to be excluded67,68.  
Oculomotor nerves 
Some cases of  oculomotor nerve palsies have been described in patients di-
agnosed with COVID-19, most often associated with areflexia and ataxia in the 
context of  Miller Fisher Syndrome (MFS)69. Case reports on isolated palsy of  
the III, IV and VI cranial nerves have also been published, and in some of  these 
patients there was no other risk factor for nerve palsy other than SARS-CoV-2 
infection70. Proposed pathogenetic mechanisms include immune response, is-
chemia or direct viral involvement of  the CNS70.
Facial and vestibulocochlear nerves 
There has been an increase in the number of  reports in the literature of  
Bell’s palsy during SARS-CoV-2 infection but whether these conditions are di-
rectly linked or just coincidental is still a matter of  debate. While some Authors 
suggest a higher occurrence of  facial palsy during the COVID-19 outbreak, 
others did not report any significant difference as compared with other infec-
tious disorders71-73.
Although rare, nystagmus, tinnitus and sudden hearing loss have been re-
ported in association with COVID-1974.
Lower cranial nerves 
Recently, the occurrence of  lower cranial neuropathy in post-intubated severe 
SARS-CoV-2 patients has been reported13,75, with asymmetric involvement of  the 
IX, X, XI and XII cranial nerves leading to dysphagia, hoarseness, weakness of  the 
soft palate, weakness of  the trapezius/ sternocleidomastoid and tongue deviation. 
Although these alterations have been previously described as the results of  
traumatic nerve involvement during prolonged intubation (e.g., stretching during 
lateral head flection in prone position or nerve compression against the cervical 
bones), recent neuropathological findings raised the hypothesis of  nerve nuclei in 
the medulla oblongata or a multiple cranial neuropathy. In a post-mortem series, 
neuroinflammatory changes in the brainstem were the most common findings, 
with SARS-CoV-2 viral proteins detected in both isolated cells of  the brainstem 
and lower cranial nerves originating from the medulla oblongata22. These data 
support the hypothesis of  an involvement of  the brainstem respiratory center in 
COVID-19 respiratory failure. According to this theory, failure to wean patients 
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off  the ventilator and the respiratory dissociation seen in some patients after re-
covery from pneumonia could be due to central respiratory drive depression. 
Practical recommendations for clinicians and personal 
experience
During the COVID-19 pandemic, the role and the guidelines for neurophys-
iological assessment changed rapidly. In particular, safety criteria have been ex-
tensively revised in terms of  the management and the response of  physicians 
and technicians, hygiene and personal protection standards, and use of  tech-
nical equipment76,77. At the same time, there has been an increasing need for 
Telemedicine, not only as a high-specialized “second opinion”.
In our experience, the main limitation was the duration of  clinical and 
electrophysiological assessment for diseases affecting the Peripheral Nervous 
System. This is because, in COVID, a neurophysiological examination usually 
takes three times longer than for non-COVID patients, mainly because of  safety 
concerns. Another limitation was the under-estimation of  cranial neuropathies, 
which may frequently complicate the disease course. Moreover, as discussed 
above, GBS in COVID-19 frequently involves the cranial nerves, even at an 
early stage, and is more severe than non-COVID-related polyradiculopathies. 
The cranial nerves are not systematically evaluated in these patients; probably 
because the attention is usually switched toward the respiratory impairment. 
Furthermore, the presence of  mechanical devices (continuous positive airway 
pressure or non-invasive ventilation devices) often makes the clinical investiga-
tion of  cranial nerves very difficult to perform. 
Take-home message
 – The involvement of  the Peripheral Nervous System (PNS) is frequent in 
severe COVID-19.
 – This involvement comprises both length- and non-length dependent dis-
eases, with particular clinical and neurophysiological features when com-
pared to other para-infectious disorders.
 – Converging histopathological, clinical and neurophysiological findings sug-
gest that PNS disorders may be due to a direct invasion by SARS-CoV-2.
 – PNS involvement can significantly impact the functional recovery and re-
habilitation strategies for COVID patients.
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Chapter 14. COVID-19-related myopathy
Gianluca Costamagna, Daniele Velardo, Giacomo Pietro Comi
Introduction
Various different viral infections can lead to muscle damage. These in-
clude influenza virus A and B, human immunodeficiency virus (HIV), cox-
sackievirus, cytomegalovirus (CMV), West Nile virus, Dengue virus, Severe 
Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1), and Severe Acute 
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)1-3
The mechanisms leading to muscle involvement in SARS-CoV-2 infection 
are still poorly understood. Possible pathogenic mechanisms may involve an 
acute cytokine release, para- or post-dysimmune dysfunctions, side effects of  
pharmacologic treatments, critical illness-associated mechanisms, or a direct vi-
ral invasion (Figure 14.1). 
Figure 14.1: Potential causes associated with SARS-CoV-2 muscle involvement 
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Different factors may play a role in SARS-CoV-2 myopathies, including iat-
rogenic effects from systemic drugs and critical illness-related muscular comor-
bidities. Systemic inflammatory responses known as “cytokine storms”, SARS-
CoV-2-triggered dysimmune reactions, or direct viral invasion may also lead to 
muscle damage.
SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) to infect 
human cells4. This receptor is expressed in different organs, including the lungs, 
the blood vessels, and the immune system5. Although there is still no evidence 
for a direct muscle invasion,skeletal muscles express ACE2 receptors4, repre-
senting a potential viral entry point to the muscle as well. In parallel, SARS-
CoV-2 can trigger an inflammatory cascade, increasing interleukin-1, interleu-
kin-6, and tumor necrosis factor release6 leading to widespread inflammation 
and possibly muscle damage. Different studies reported small arteriolar and 
venular thromboses in multiple organs with vasculopathy and vasculitis in se-
vere SARS-CoV-2 infections7 potentially linked to muscle damage. 
Muscular involvement and SARS-CoV-2 infection
Muscular involvement in the context of  SARS-CoV-2 infection includes my-
algia8,  myositis9–11 as well as critical-illness myopathies14.
Myalgia
The literature on muscular involvement in the context of  SARS-CoV-2 in-
fection is highly heterogeneous, including mainly case reports and retrospective 
analyses (Table 14.1).
Most studies report myalgia as the most frequent muscular symptom. Muscle 
involvement was first described in a retrospective study of  214 Chinese pa-
tients8 where 23 (10.7%) were reported with “skeletal muscle injury.” No spe-
cific investigations were carried out to further characterize the type and patho-
physiology of  the muscle injury. In another study involving 41 infected Chinese 
patients, 18 (44%) complained about myalgia and fatigue. In particular, all 18 
patients complained about myalgia as symptom onset; of  these, 7 patients re-
quired admission to an intensive care unit (ICU)8 for SARS-CoV-2 infection. In 
a retrospective study in a European cohort of  1,420 patients, Lechien et al. re-
ported 887 (62.5%) patients with myalgia15. In a population of  48 patients with 
neuromuscular disorders with SARS-CoV-2 infection from different Italian 
centers, 14 (29.2%) reported myalgia (G Costamagna, unpublished data, 2021).
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887 NR NR Myalgia NR NR NR 15
164 NR NR Myalgia, fatigue ≥200 U/L in 90 NR NR 16
67 NR NR Myalgia NR NR NR 17
48 NR NR Myalgia NR Normal NR 18
23 NR NR Myalgia >200 U/L in 23 NR NR 19
18 NR NR Myalgia, fatigue NR NR NR 8
11 NR NR Myalgia NR NR NR 20
6 NR NR NR NR NR Myositis 21
5 NR NR Myalgia > 200 U/l in 6 NR NR 22
5 NR NR NR > 200 U/l in 5 NR NR 23
4 8-15 2M, 
2 F
Weakness NR Myogenic NR 24
1 60 M Weakness 11,842 NR NR 12
1 58 F Weakness 700 Fibrilla-
tions
Myositis 25
1 71 M Weakness, Myalgia 8720 NR NR 26
1 16 M Weakness, fatigue 427,656 NR NR 27
1 38 M Myalgia 42,670 NR NR 28
1 NR M Weakness, Myalgia 25,384 NR NR 9
1 57 F Weakness 15,000 Myogenic Necrotizing 
myopathy
29
1 38 M Weakness 29,000 NR Type I Inter-
feronopathy
11
CK: creatine kinase; EMG: electromyography; Ref.: reference; NR: not reported.
Available studies on myalgia and creatinine kinase (CK) levels in SARS-
CoV-2 patients in different populations reported mixed results. In a cohort of  
138 infected Chinese patients, including 48 subjects presenting with myalgia, 
CK levels were normal in most cases18. In a Chinese study on 1,099 patients, 
164 (14.9%) reported myalgia. In another cohort, only 60 patients out of  657 
(13.7%) presented increased CK to > 200 U/L16. In a sample of  1,150 SARS-
CoV-2 patients in the US, 67 (26%) presented with myalgia. Increased CK was 
reported in some patients, although the exact number was not reported17. In a 
study of  351 European SARS-CoV-2 patients, 95 (27%) showed increased CK 
levels that were significantly correlated with inflammation markers and disease 
severity30.
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Altogether, these studies suggest the presence of  myalgia and variable de-
grees of  CK elevation to be associated with SARS-CoV-2 infection. However, 
the heterogeneous populations, the variable assessment of  muscle involvement, 
and the absence of  data from patient medical records on pre-infectious mus-
cular diseases limit the generalizability of  these findings. In addition, none of  
these studies prospectively investigated post-infectious muscle damage. 
Myositis and rhabdomyolysis
Single case reports and small case series have described muscular damage in 
the context of  SARS-CoV-2 infection presenting as myositis and rhabdomyol-
ysis. Manzano et al. presented the case of  a SARS-CoV-2 infected 38-year-old 
man with an acute-onset, generalized muscle weakness more severe proximally 
than distally, who was unable to walk. Laboratory testing showed markedly in-
creased CK levels (29,000 U/L). Muscle biopsy revealed some features typically 
associated with type I interferonopathies, a group of  autoinflammatory disor-
ders with prominent enhanced type I interferon signaling31. Histopathological 
alterations included abnormal expression of  major-histocompatibility-complex 
class I and abnormal myxovirus resistance protein A, suggesting a role for 
SARS-CoV-2 in causing type I interferonopathy-associated muscle damage11. 
Treatment with intravenous remdesevir and methylprednisolone followed by 
oral prednisone led to mild clinical improvement and improvement in CK levels. 
A 16-year-old female patient presented with acute rhabdomyolysis and mag-
netic resonance imaging (MRI), electromyography (EMG), and bioptic signs of  
myositis in the context of  SARS-CoV-2 infection (G Costamagna, unpublished 
observations, 2021). She was brought to the emergency department following 
a transitory loss of  consciousness, new-onset mild fever, and severe muscle 
pain. She had complained about persistent, mild muscle pain in the proximal 
lower and upper limbs two months previously; no specific tests had been car-
ried out. Upon arrival at our center, laboratory findings showed severe CK 
elevation (10,988 U/L), increased alanine aminotransferase (ALT), aspartate 
aminotransaminase (AST), troponin T and lactate dehydrogenase (LDH) levels. 
EKG and transthoracic echocardiogram ruled out acute myocardial infarction. 
Renal function was within normal limits. A nasal swab tested positive for SARS-
CoV-2. A diagnosis of  acute rhabdomyolysis associated with SARS-CoV-2 was 
made. Early aggressive fluid resuscitation with isotonic saline was initiated. A 
dermatological evaluation highlighted diffuse skin thickening and hardening on 
the neck, chest, and thighs consistent with cutaneous manifestations of  sys-
temic sclerosis (SS). Extensive autoimmune panel and comprehensive viral and 
bacterial serology showed ANA positivity (1:640) and SARS-CoV-2 IgM and 
IgG antibodies. Muscle MRI revealed diffuse muscle and fascial edema with 
mild and patchy contrast enhancement in the lower limbs. EMG documented 
diffuse fibrillation potentials with myogenic pattern in the lower limbs. Figure 
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14.2 shows muscle biopsy findings consistent with inflammatory myopathy (see 
histopathological studies). A diagnosis of  acute rhabdomyolysis associated with 
SARS-CoV-2 infection in the context of  an SS-related inflammatory myopathy 
was made. A 5-day course with intravenous methylprednisolone followed by 
high-dose oral dexamethasone led to clinical improvement.
Other reports described MRI-confirmed myositis associated with SARS-
CoV-2 infection. A previously healthy patient complained about acute-onset, 
diffuse myalgias, and proximal lower limb muscle weakness associated with falls. 
Clinical examination and early laboratory findings including CK levels were 
consistent with an acute myopathy. Work-up for polymyositis, dermatomyositis 
and necrotizing autoimmune myopathies (NAM) with comprehensive autoim-
munity screening were all negative. On day 7, lower limb MRI showed obturator 
muscle and quadricipital edema, suggesting a bilateral lower-limb myositis9. 
In another study, a 58-year-old female presented with limb and facial weak-
ness, ptosis, CK elevation, diffuse muscle edema on muscle MRI and myogenic 
alteration on EMG, with a final diagnosis of  myositis following muscle biop-
sy25. The authors reported an improvement in symptoms after a 5-day course 
of  intravenous methylprednisolone and tocilizumab. Shabbir et al. highlighted 
the case of  a middle-aged woman with a history of  chronic myopericarditis 
presenting with SARS-CoV-2 pulmonary symptoms and central chest pain. 
She developed bilateral leg weakness and elevated CK levels up to 19,000 U/L 
six days after symptom onset. Lower limb MRI revealed generalized subcuta-
neous edema and symmetrical diffuse alterations in all muscle compartments, 
pointing to myositis. Cardiac MRI showed myocardial edema and pericardial 
effusion, consistent with myopericarditis. Following treatment with colchicine, 
ibuprofen, and prednisolone, the patient showed both cardiac and muscular im-
provement upon discharge. Similar to these findings, an MRI study on 7 SARS-
CoV-2 infected patients showed intramuscular edema and/or enhancement, 
supporting the evidence of  a possible lumbar spine myositis in some patients10. 
In a case series of  10 SARS-CoV-2 patients from Brazil, minimally invasive, 
ultrasound-guided, post-mortem morphological studies highlighted features of  
myositis in 60% of  cases and necrotic muscle fibers in 80% of  patients21.
Although a thorough muscular diagnostic work-up was not performed, dif-
ferent authors have described SARS-CoV-2 patients with markedly increased 
levels of  CK, suggesting acute rhabdomyolysis. For example, Zhang et al. high-
lighted the case of  a 38-year-old man with SARS-CoV-2 pulmonary symptoms, 
muscle weakness, markedly elevated inflammatory markers, elevated ALT, 
LDH, and CK elevation up to 43,000 U/L28. Similarly, other manuscripts report 
patients with increased levels of  CK at disease onset32 or during hospital stay12.
However, since these early reports lack a full muscle diagnostic workup (e.g., 
muscle MRI, EMG, muscle biopsy), confounding factors such as iatrogenic or 
critical illness-associated effects cannot be ruled out.
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Necrotizing autoimmune myopathies
One case report described a possible association between necrotizing au-
toimmune myopathies (NAM) and SARS-CoV-2 infection. NAM refers to a 
subgroup of  inflammatory myopathies displaying necrotic muscle fibers and 
absent or minimal inflammation on muscle biopsy. While NAM cases are usu-
ally idiopathic, patients taking statins or presenting viral infections or neoplastic 
diseases may develop this condition33. Though the exact pathophysiology of  
NAM is unknown, some studies suggest a role for an exaggerated inflammatory 
response, possibly as a result of  viral infections34.
Veyseh et al. described the case of  a 57-year-old woman presenting with 
acute rhabdomyolysis, diffuse muscle weakness, and positive SARS-CoV-2 IgG 
titers one month from SARS-CoV-2-related, self-limiting, mild upper respira-
tory symptoms29.. The patient was discharged with a final diagnosis of  rhabdo-
myolysis in the setting of  SARS-CoV-2 infection. Four months later, she pre-
sented to the hospital with progressive muscle weakness over 2 weeks. Lower 
limb MRI showed bilateral, diffuse signal abnormalities in the proximal muscles 
with edema of  the myofascial layers, consistent with myositis. EMG displayed 
an irritative myogenic pattern in the tibialis anterior muscles. Muscle biopsy 
showed a few scattered necrotic myofibers with limited inflammatory cell infil-
trates, suggesting NAM. Potential confounding factors including acute viral in-
fections, electrolyte abnormalities, endocrinopathies, and statin use were ruled 
out. Serologic testing was positive for ANA (1:320, speckled pattern) and low 
titers of  anti-Smith antibodies (considered secondary to SARS-CoV-2 infec-
tion) with negative titers for anti-Jo1, anti-HMG-CoA reductase (HMGCoAR), 
and anti-signal recognition particle (SRP). High-dose prednisone (1 mg/kg) led 
to an improvement in muscle strength and decreasing CK levels. The authors 
interpreted these findings as a SARS-CoV-2 IgG-related NAM. 
Although this report suggests a possible post-SARS-CoV-2 autoimmune re-
sponse targeting the muscles, there have been no reliable reports of   viral-trig-
gered autoimmune muscular disorders.
Critical illness myopathy
Available reports have described ICU-acquired weakness (ICUAW) in severe 
SARS-CoV-2 cases. ICUAW  is typically generalized, symmetrical, affecting 
both limbs more proximally than distally, as well as respiratory muscles while 
sparing facial and ocular muscles35,36. Diaphragm dysfunction may develop 
more frequently than limb weakness37. Reduction in muscle tone and normal 
to reduced deep tendon reflexes complete the clinical presentation. Both neu-
rogenic disorders known as critical illness polyneuropathy (CIP) and myogenic 
abnormalities referred to as critical illness myopathy (CIM) can cause ICUAW36. 
Bolton’s and Lacomi’s criteria support the diagnosis of  these conditions38,39. 
21314. COVID-19-related myopathy
Table 14.2 shows the typical features of  CIP and CIM in electrophysiological 
and biopsy studies. 
Table 14.2  Features of  critical illness polyneuropathy and critical illness  
myopathy in electrophysiological and biopsy studies
Critical illness myopathy Critical illness neuropathy
CMAP amplitude Decreased Decreased
CMAP duration Increased Normal
SNAP amplitude Normal Decreased
Nerve conduction 
velocity
Normal or near normal Normal or near normal
EMG at rest Fibrillation potentials/posi-
tive sharp waves










Absence of  decremental 
response
Absence of  decremental response
Direct muscle stim-
ulation
Reduced muscle excitability Normal muscle excitability
Muscle biopsy Different abnormalities: 
myofiber atrophy, angulated 
fibers, necrosis, fatty degen-
eration, local or diffuse lack 
of  thick filaments.
Denervation atrophy of  type 1 and 2 
muscle fibers
Nerve biopsy Normal Primary distal axonal degeneration of  
sensory nerve fibers, no demyelination
CMAP: compound muscle action potential; SNAP: sensory nerve action potential; 
EMG: electromyography; MUP: muscle action potential.36,40-42.
Several risk factors can contribute to CIM onset. Among these, the severity 
of  the underlying illness, sepsis and inflammation, multiple organ failure, and 
mechanical ventilation play an important role40,43-45. In addition to these, hy-
perglycemia, parenteral nutrition, drugs such as corticosteroids, neuromuscular 
blocking agents, antibiotics (e.g., aminoglycosides and vancomycin), sedatives46, 
as well as prolonged immobilization all represent important risk factors47-49
Assessment of  weakness in patients with CIM includes mainly clinical and 
electrophysiological evaluations. The most widely used clinical approach is the 
6-grade Medical Research Council (MRC) sum score35. Other less frequently 
used tools are the hand-held dynamometry, the Scored Physical Function in 
Intensive Care Test, the Functional Status Score for the ICU, and the Chelsea 
Critical Care Physical Assessment Tool50,51. The 6-minute walking distance 
test is useful for patients’ performance at discharge or in post-ICU settings51. 
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Electrophysiological studies may be valuable tools in unconscious / non-coop-
erative patients, such as severe SARS-CoV-2 cases. EMG, single-nerve conduc-
tion studies (NCS), and direct muscle stimulation (DMS) can help to differenti-
ate CIM from CIP and other differential diagnoses41,52. 
Different case reports14,53 and small retrospective studies present severe 
SARS-CoV-2 patients with ICUAW, including CIM. Van Aerde et al. reported 
a 70% incidence of  weakness on awakening in a cohort of  50 SARS-CoV-2 
patients requiring invasive mechanical ventilation54. Among 11 patients with 
severe SARS-CoV-2 and ICUAW, 7 received a diagnosis of  CIM55. In particu-
lar, these patients presented mixed muscular electrophysiological alterations on 
EMG such as abundant spontaneous activity and short motor unit potentials 
with decreased amplitude and duration. Weak patients presented prolonged 
ventilation, higher mean morning glycemia, and higher exposure to corticos-
teroids, sedatives, and analgesics54. Madia et al. described 6 ventilator-depend-
ent SARS-induced ARDS cases with acute-onset flaccid quadriplegia noted 
when attempts were made to reduce sedation56. Physical examination showed 
quadriplegia, weak tendon reflexes, no sensory abnormalities, and preserved 
extraocular, mimic, and tongue muscles. Electrophysiological studies including 
EMG and electroneurography (ENG) revealed myopathic abnormalities with 
fibrillation potentials and rapid recruitment of  small, polyphasic motor units in 
proximal and distal limb muscles, as well as reduced compound muscle action 
potential (CMAP) amplitude. CK levels were normal or mildly elevated in all 
patients. One of  the patients died due to sepsis, while the others showed im-
provement in the neurological examination at discharge after 14-20 days.
Taken together, these findings suggest the frequent association between muscle 
involvement and SARS-CoV-2 infection, particularly in severe cases in ICU settings. 
Testing
Specific testing including imaging, electrodiagnostic and histopathological 
studies can help characterize SARS-CoV-2-associated myopathies.
Neuroimaging studies
MRI can support the diagnosis and evaluation of  muscular manifesta-
tions and iatrogenic complications associated with SARS-CoV-2 infection57. 
Myositis can present with rhabdomyolysis following damage of  the muscle 
(myonecrosis) and elevated levels of  myoglobin in the blood (myoglobinemia). 
Rhabdomyolysis can be life-threatening, potentially leading to acute kidney fail-
ure, compartment syndrome, and disseminated intravascular coagulation58.
In this context, MRI imaging is the modality of  choice for supporting the 
diagnosis and delineating the site for muscle biopsy, preferably with 1.5-T or 
3.0-T magnets, including multiplanar fluid-sensitive and anatomic sequences.
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Myositis can be associated with different alterations on muscle MRI, such as 
muscle edema. Increased signal intensity on T2-weighted or short tau inversion 
recovery (STIR) sequences identifies muscle edema59. Two different radiolog-
ical patterns define myositis, including homogeneous hyperintense signal and 
enhancement (type 1) and heterogeneous hyperintense signal and rim enhance-
ment (type 2)60. Severe disease forms may display areas of  necrosis and loss of  
muscle architecture. In particular, the “stipple sign” refers to a distinguishing 
sign of  myonecrosis, presenting with dot-like, streaky, or curvilinear enhanc-
ing foci within a muscle separated from normal tissue by an enhancing rim61. 
Intramuscular hemorrhage may be present, identified by T1 hyperintensities or 
blooming artifacts on gradient-echo sequences62. 
In addition to myositis, CIM represents the most important differential diagnosis 
for muscle edema on muscle MRI in hospitalized SARS-CoV-2 patients. CIM is 
associated with non-specific imaging findings such as multifocal muscle edema and 
atrophy59. In contrast to SARS-CoV-2-related rhabdomyolysis, there is no evidence 
of  necrosis on MRI. Clinical and imaging features of  CIM in SARS-CoV-2-infected 
patients do not appear to differ from CIM in non-SARS-CoV-2 patients. 
Imaging is also helpful to monitor diaphragm function. Patients with severe 
SARS-CoV-2 infection can present diaphragm dysfunction due to CIM, use of  
ventilators, or phrenic nerve injury, possibly from chest support devices. In addi-
tion, diaphragm impairment may be due to a direct SARS-CoV-2 involvement63. 
In an autopsy study on the human diaphragm of  ICU SARS-CoV-2 patients, 
Shi et al. demonstrated the expression of  ACE2, the presence of  SARS-CoV-2 
RNA, and the increased activity of  genes related to fibrinogenesis. The fluoros-
copy sniff  test enables the evaluation of  diaphragm excursion and ultrasound 
offers additional information on muscle atrophy, muscle thickening ratio, and 
excursion59,64. High-resolution ultrasound contributes to the assessment of  the 
phrenic nerve in the neck region, helping in the differential diagnosis between 
neuropathic versus myopathic processes.
MRI imaging allows the evaluation of  other SARS-CoV-2-associated muscu-
lar changes, such as sarcopenia and cachexia in patients with prolonged weak-
ness. Sarcopenia is defined as muscle loss typically associated with aging, though 
other contributing factors include inactivity and poor nutrition. Cachexia is as-
sociated with muscle wasting due to chronic illness. Typical MRI findings, in 
this case, encompass muscle atrophy associated with decreased muscle size and 
fat infiltration59.
Electrodiagnostic studies
Few studies have focused on the electrodiagnostic assessment of  SARS-CoV-2 
patients with muscle weakness. Most case reports / series included patients with 
severe SARS-CoV-2 infections, possibly presenting with CIM. Cabañes-Martínez 
performed electrodiagnostic assessment in a cohort of  12 ICU SARS-CoV-2 
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patients with ICUAW. Seven out of  12 patients showed some degrees of  EMG 
abnormalities, including abundant spontaneous activity, motor unit potential with 
decreased amplitude and duration. Repetitive nerve stimulation was normal in 
all cases55. Similarly, in another study, 8 SARS-CoV-2 subjects out of  23 patients 
showed increased spontaneous activity on EMG65. A 62-year-old woman with 
severe SARS-CoV-2 presented motor unit action potentials (MUAPs) with short 
duration and low amplitude as well as early recruitment, more evident in the 
quadriceps. On DMS, the post-DMS CMAP was absent in the quadriceps and 
of  reduced amplitude in the tibialis anterior. The ratio of  the amplitudes of  the 
CMAP achieved by motor nerve stimulation and DMS is useful to differentiate 
between neuropathic and myopathic processes, with values near 1 suggesting a 
myopathic disorder66. In this case, the ratio of  the CMAP amplitudes achieved by 
peroneal nerve stimulation and DMS of  the tibialis anterior was 0.96, supporting 
the diagnosis of  SARS-CoV-2-related myopathy14. A case series of  3 patients with 
post-SARS-CoV-2 infection myalgia and fatigue showed EMG alterations con-
sistent with myopathies, including MUAP with early recruitment, short duration, 
and low amplitude in proximal muscles67.
Figure 14.2: Muscle biopsy of  a 16-year-old female patient with a suspected 
systemic sclerosis-related inflammatory myopathy and SARS-CoV-2 infection
 
A (20x) and B (40x) show scattered necrotic fibers with macrophage infiltration. 
*Increased centralized nuclei and fiber splitting are also present (hematoxylin & eo-
sin stain, light microscopy). C (20x) and D (40x) display perivascular inflammatory 
cell infiltrates and slightly increased endomysial fibrosis (Gomori’s trichrome stain, 
light microscopy).
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Overall, these studies suggest no specific electrodiagnostic patterns associat-
ed with SARS-CoV-2 myopathies. However, patients with severe SARS-CoV-2 
infections may present a more abundant spontaneous activity if  compared with 
patients in the ICU for other etiologies55.
Histopathological studies 
Muscle biopsy may be useful in the differential diagnosis of  SARS-CoV-2-
associated myopathies (Figure 14.2). 
Manzano et al. performed a muscle biopsy of  the left deltoid in a patient 
with a suspected SARS-CoV-2 inflammatory myopathy, showing mild perivas-
cular inflammation in a few vessels without regenerating fibers or perifascicular 
atrophy. Immunohistochemical analysis displayed abnormal expression of  the 
major histocompatibility complex class I antigen on sarcolemma and sarco-
plasm. In addition, abnormal expression of  the myxovirus resistance protein 
A on muscle fibers and capillaries was seen with no membrane attack complex 
deposition on muscle fibers or vessels. No SARS-CoV-2 RNA was present in 
the sample11. Myxovirus resistance protein A (a type I interferon-inducible pro-
tein) can accumulate in muscle fibers and capillaries as an early sign of  dermat-
omyositis preceding muscular atrophy. However, its abnormal deposition may 
present also following viral infections, including SARS-CoV-268. In addition, 
muscle tissue lacked deposition of  membrane attack complex on capillaries, 
another sign of  dermatomyositis. The authors made a final diagnosis of  SARS-
CoV-2-associated myopathy caused by type I interferonopathy.
Severe cases of  SARS-CoV-2 infection may show consistent vascular pa-
thology on histopathological assessment. In a post-mortem evaluation of  a 
middle-aged woman with rapidly progressive and systemic SARS-CoV-2 infec-
tion, Hooper et al. detected diffuse fibrin microthrombi, perimysial microhem-
orrhages, muscle fiber vacuolar degeneration, and necrosis on muscle tissue69. 
Further analysis revealed no angulated atrophic fibers, basophilic regenerating 
fibers or increased central nuclei, and only minimal inflammatory infiltrates. 
Electron microscopy showed no clear signs of  direct viral-induced muscle dam-
age. In this case, muscle involvement was more likely due to endothelial injury 
and vascular damage rather than direct viral infection. 
Similarly, in another report on a patient with a suspected SARS-CoV-2-
associated myopathy presenting with acute proximal and bulbar weakness, 
muscle biopsy highlighted features consistent with an inflammatory etiology25. 
These included perivascular inflammatory infiltration with endomysial exten-
sion, regenerating fibers (as suggested by mild sarcoplasmic basophilia and 
enlargement of  visible nuclei), and upregulation of  human leukocyte antigen 
class ABC expression on non-necrotic fibers. Cytochrome oxidase /  succinic 
dehydrogenase enzyme histochemistry was unrevealing. 
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In a case series including 3 muscle biopsies in severe SARS-CoV-2 cases, the 
findings suggested a non-specific degenerative-regenerative process, supporting 
a diagnosis of  CIM55. In particular, 2 patients presented only occasional atroph-
ic and regenerative fibers. One patient displayed scattered necrotic and regen-
erative fibers without inflammatory infiltrates. Most of  the fibers presented an 
equal number of  degenerative-regenerative alterations and no increase in fibers 
with internal nuclei. Oxidative histochemical analysis, ATP techniques, HLA as 
well as C5b9 staining were unremarkable. No signs of  microvascular damage 
were detected.
Overall, muscle biopsies coupled with electrodiagnostic studies and imaging 
can be valuable tools in the multimodal assessment of  SARS-CoV-2 patients 
with suspected myopathies.
Treatment
There are no specific treatments for SARS-CoV-2-associated myopathies. As 
a rule of  thumb, inflammatory myopathies associated with SARS-CoV-2 infec-
tion should be treated with corticosteroids (e.g., intravenous methylpredniso-
lone 1 g/die for 3-5 days followed by oral prednisone 1 mg/kg/die for 4 weeks 
with slow tapering)11,25,70. Although there is no high-quality evidence available, 
another report suggests the use of  tocilizumab25.
In the context of  CIM, controlling risk factors and providing support ther-
apies remain the mainstay of  treatment. Avoiding hyperglycemia, certain drugs 
(vasoactive medications, corticosteroids, neuromuscular blocking agents, sed-
atives aminoglycosides, vancomycin), and limiting parenteral nutrition, as well 
as prolonged bed immobilization and mechanical ventilation reduce the risk 
of  ICU-acquired CIM71. Intensive insulin therapy and early rehabilitation seem 
the most useful approaches for preventing CIM. There is no high-quality ev-
idence supporting the use of  corticosteroids or electric muscle stimulation in 
this setting72.
Patients presenting with rhabdomyolysis are at increased risk for heme-in-
duced acute kidney injury73-75. Early and aggressive fluid resuscitation is the 
major preventative measure. Patients presenting CK levels > 5,000 U/L or in-
creasing values regardless of  baseline values should receive intravenous fluids76. 
Isotonic fluids with an initial volume repletion at a rate of  1- 2 L/hour may be 
preferred over alternatives, such as colloids. There are some limited data to sup-
port the use of  urine alkalinization with bicarbonate, loop diuretics, mannitol, 
and routine renal replacement therapy in severe rhabdomyolysis76. 
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Take-home message
 – Muscle involvement in the context of  SARS-CoV-2 infection includes 
myalgia,  myositis, rhabdomyolysis, as well as critical-illness myopathies14.
 – Rare SARS-CoV-2 cases with muscle involvement presented an inflam-
matory-like phenotype with some features of  type I interferonopathies, 
a group of  autoinflammatory disorders with prominent enhanced type I 
interferon signaling.
 – Muscle MRI is valuable for assessing SARS-CoV-2-associated muscu-
lar changes, such as sarcopenia and cachexia in patients with prolonged 
weakness.
 – Histopathological analysis of  muscle biopsies from SARS-CoV-2 patients 
with muscle involvement may show inflammatory and/or chronic illness 
myopathy-related changes.
 – There are no specific treatments for SARS-CoV-2-associated myopathies. 
Inflammatory-like forms should be treated similarly to inflammatory my-
ositis, whereas critical illness myopathies require ICU-related risk factors 
to be controlled and the provision of  support therapy.
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Chapter 15. Teleneurology in the COVID-19 
era
Elena Moro, Sara Meoni
Introduction
Telemedicine is defined as the delivery of  medical care by electronic commu-
nication between a health care professional (i.e., a physician or advanced prac-
tice provider) and a patient, each at different locations1. It has the potential to 
overcome geographical, physical, and biological barriers to health care access. 
Telemedicine has been shown to be a safe, efficient, timely, and convenient proce-
dure1,2 . For decades, it has provided medical care to rural and underserved areas3, 
but only more recently has this field undergone an accelerated development. This 
has been due to advances in technologies and a broader Internet access. 
The application of  telemedicine to neurology (teleneurology) allows deliv-
ery of  or additional neurological care to remote locations. It reflects the gap 
existing between the growing demand of  neurological expertise and the lack of  
neurologists4,5.
Over the last decades, teleneurology has been successfully applied in acute 
care, mostly for stroke (“telestroke”)6, in outpatient evaluation and in telecon-
sultations for chronic diseases such as movement disorders7, epilepsy8, multiple 
sclerosis9, dementia10 and headache11.
However, before the advent of  COVID-19, there were considerable limita-
tions to the use of  telemedicine: technological, regulatory, political and clinical 
considerations, reimbursement issues, and social barriers.  
Since 2020, the COVID-19 pandemic and the new related challenges in 
health care have greatly pushed teleneurology forward12. 
Most of  the hospitals and health systems around the world have modified 
their standard practices in telemedicine in order to assure care management of  
non-COVID neurological disorders13. The main objective of  the adoption of  
telehealth during the pandemic is the safety of  all the participants in their clin-
ical encounters, including patients, family members, caregivers and health care 
teams. Several reimbursement and licenses issues which had limited teleneurol-
ogy in the pre-COVID era, have been suspended or removed in order to deal 
with the worldwide health emergency. Most of  the hospital consultations have 
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been replaced by teleconsultations using tablets, smartphones, mobile telehealth 
carts or cameras at patients’ homes. New telemedicine tools have emerged to 
reduce the exposure to COVID-19 infection13,14. 
All the pandemic-related changes in neurology clinical practice have hap-
pened very quickly, in days or weeks, requiring the availability of  adequate 
equipment and the rapid development of  technology infrastructure to support 
the large expansion in the use of  teleneurology. For example, at the epicenter 
of  the pandemic, at NYU Langone Health, teleconsultations grew from a typ-
ical 50 visits per day to >7,000 daily visits within 10 days15. At the University 
of  Pennsylvania Health System, nearly 400,000 telemedicine meetings across 
thousands of  providers occurred in less than three months, requiring imple-
mentation of  videoconferencing platforms, training, and development of  new 
procedures for outpatient and inpatient management16.
Figure 15.1: Teleneurology applications in the COVID-19 era
ICU: Intensive Care Unit.
Moreover, the pandemic has greatly impacted the scientific community and 
academic activities, as all the congresses, and educational training and teaching 
courses have been turned into virtual conferences and webinars, requiring a 
huge effort to change the routine practices in place up to the pre-COVID era.
In this chapter, we provide a summary of  the available literature on tele-
neurology during the COVID-19 pandemic, its advantages and limitations, clin-
ical implications, and future challenges.
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Telestroke 
Since the earliest stages of  the pandemic, the risk of  underestimating and 
undertreating several potentially treatable strokes emerged, leading health au-
thorities to generate an appeal to the general population not to stay at home in 
case of  onset of  acute neurological symptoms17. However, studies in European 
countries18,19, China20 and the USA21 reported a significant  global reduction 
in admissions to the emergency department or stroke units for acute ischemic 
stroke in the first period of  the emergency. This contraction has likely been sec-
ondary to policies minimizing provider-patient interactions as well as patients’ 
reticence to come to the emergency departments during the pandemic. 
At the same time, the COVID-19 crisis has required implementation of  the 
use of  telemedicine in the field of  stroke at all treatment stages22,23, and it could 
be the starting point for its large-scale use24,25.
The continuum of  care via telestroke has broadened to include prehospital, 
inter-facility and intra-facility hospital-based services, stroke telerehabilitation, 
and ambulatory telestroke26.
Alternative stroke care models have been developed including protected 
stroke codes and streamlined triage for endovascular therapy27-29 in order to 
maintain patient care in this pandemic setting. 
Prehospital telestroke offers many advantages for acute stroke care in this 
context, such as the use of  mobile systems limiting person-to-person contact in 
the prehospital stroke assessment, and ambulance-based telestroke. Emergency 
service providers can focus on personal protective equipment (PPE) and res-
piratory management, in parallel with a remote emergency provider or stroke 
specialist, who can assist with screening during ambulance transport30. The 
prehospital evaluation by the remote provider potentially reduces PPE usage 
limiting the need for multiple re-evaluations prior to acute treatment deci-
sions. Prehospital triage with telestroke could further limit unnecessary expo-
sures and PPE usage by identifying the appropriate hospital for the patient’s 
needs. However, additional research is needed in order to optimize tele-triage 
protocols. 
Inter-facility telestroke may also help during the pandemic, in order to limit 
unnecessary transfers of  patients with mild stroke syndromes or stroke mim-
ics in their local facilities and to reduce potential exposure to the patient and 
treatment teams. This is a key point, considering the higher risk of  infection 
in stroke patients31. This model can also preserve bed availability at the hub 
for patients needing a higher level of  care. Moreover, ambulance-based mobile 
systems can be used to support long distance transfers, particularly for “drip-
and-ship” post-thrombolysis management, and for critically ill stroke patients32.
During the COVID-19 crisis, several hospitals and stroke centers have devel-
oped intra-facility telestroke to help reduce provider and patient exposure and 
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PPE usage, and to cover workforce shortages due to COVID-19 related illness 
and quarantining of  staff13,14. A new framework for COVID-19 screening and 
proper usage of  PPE incorporated with stroke assessment, called “protected 
stroke code”28 has emerged during the pandemic, which has also been applied at 
an intra-facility level. This model allows several team members to participate in 
the patient evaluation remotely, while preserving PPE and limiting staff-patient 
interactions. Moreover, some academic centers have also switched to virtual 
rounds using a teleconferencing platform13, with table rounds first completed 
via teleconferencing, and with only one team member moving the workstation 
to each patient’s room to carry out the examination, functioning as tele-present-
er for the remote team. The virtual round model allows health-care providers to 
guarantee patients care even during therapeutic or prophylactic quarantine. In 
addition, this allows for a rotating schedule which can be used to address staff  
shortages.
Tele-ICU
Telemedicine enables remote monitoring of  patients in intensive care units 
(ICUs) without continuous availability of  critical care expertise, in order to 
expand coverage, similar to telestroke coverage of  emergency departments. 
Management of  neurological emergencies, such as status epilepticus, may be 
facilitated by telemedicine, thanks to remote access to subspecialty expertise. 
In the pre-COVID-19 era, a metanalysis reported on a reduction in mortality 
and hospital lengths of  stay with tele-ICU33. The neurological ICU population 
is not specifically addressed in most studies, although one report demonstrated 
reduced response times and shorter lengths of  stay34. 
The pandemic has been the turning point for digital transformation also 
in neurocritical care. The tele-ICU solution can triage and manage patients in 
isolation, conserving PPE, avoiding infection, and optimizing human resources 
with constant remote monitoring. Close range telemedicine called ‘ePPE’ has 
evolved and wireless monitoring has been developed35.  Mobile devices are used 
to communicate with patients who can be physically attended to immediately if  
needed. Workforce sustainability, fewer burnout episodes, and lower incidence 
of  specialists having to quarantine are consequences of  tele- ICUs. Video con-
ferencing helps decrease infection risk during the pandemic. Moreover, tele-
EEG monitoring can be used for diagnosing non-convulsive status epilepticus 
as a cause of  unexplained consciousness in COVID-19 patients36. The remote 
reading of  EEG helps reduce the risk of  infection. Furthermore, telemedicine 
may also help to establish a dedicated command unit for critical care support by 
linking ICUs of  COVID hospitals on a single platform37. 
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Outpatient teleneurology
Studies across multiple neurological subspecialties report non-inferiority of  
outpatient evaluations by telemedicine compared with in-person evaluations in 
terms of  patient and caregiver satisfaction and diagnostic accuracy38. 
Telemedicine has the potential to address challenges in the transition be-
tween hospital and home. In the pre-COVID-19 era, transitional care mod-
els had showed the potential to improve outpatient management, mostly for 
post-stroke patients39. However, these models were not really incorporated into 
global routine practice until today. Pre-pandemic barriers to widespread use of  
telemedicine for outpatient care have mostly been due to reimbursement chal-
lenges and lack of  infrastructures40.  
With the pandemic, social distancing requirements and restrictions on 
non-essential visits to the clinic created an urgent need for outpatient telemed-
icine in the stroke population25,41,42 and in several chronic neurological diseases, 
such as Parkinson’s disease7,4349, and other movement disorders2,50-53, epilep-
sy54-68, Alzheimer’s disease69-73, multiple sclerosis74-81 and migraine82–84.
The integration of  telemedicine into outpatient practice has required a rapid 
adaptation of  the standard clinic practice85. In the US, for example, a policy of  
expansion of  Centers for Medicare and reimbursement for Medicaid Services 
in March 2020 led to the implementation of  telestroke services38. Institutional 
support is strongly required for widespread adoption and sustainability of  tech-
nology, such as hardware, audiovisual platforms, Electronic Health Records in-
tegration, and server support. Scheduling, billing and coding integration have 
also to be considered in any staffing changes. Training for providers and staff, 
patient education, and on-call technology assistance for both patients and pro-
viders must also be guaranteed. The main limitation of  the application of  tele-
neurology in outpatient care concerns its feasibility in elderly patients, frequent-
ly with motor and cognitive issues, and having little contact with the younger 
generation who are more experienced with technology.
Preliminary experience suggests positive results of  telemedicine use during 
the pandemic, both via video and phone. However, disparities in health care de-
livery emerged, and these were exacerbated by inequalities in access to technol-
ogy in socially or economically disadvantaged populations86.  Lack of  adequate 
access to technology, high-speed internet services and increased need for tech-
nology support will need to be addressed to achieve widespread improvements 
in access to care. 
Teleneurology for long-term care facilities
Telemedicine can be applied to patients in long-term care and correctional 
facilities which have limited access to specialty care87. The COVID-19 pandemic 
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has raised a major concern in terms of  a higher risk and exposure for this vul-
nerable population of  patients and staff  due to close living quarters and the 
need for frequent in-person assessments of  healthcare needs. The use of  tele-
medicine for post-acute care in long-term care settings has the advantage of  
staff  support, which reduces the technological burden on patients, and on-site 
assistance with the physical examination. Telemedicine can also be useful to 
assess patients with stroke symptoms in these environments and to guide neces-
sary triage decisions88,89. Telestroke could inform appropriate hospital destina-
tion choices for both thrombolytics and thrombectomy, minimizing the activa-
tion of  emergency medical services and exposure of  health care providers, and 
avoiding unnecessary transfer to the emergency room for high-risk patients.
Telerehabilitation
Telemedicine is important in rehabilitation90. During the pandemic, the 
standard model of  in-person stroke rehabilitation, including physical, occupa-
tional, and speech and language therapies, has been reassessed. The drastic re-
duction in the availablity of  rehabilitation facilities, due to their conversion to 
host COVID-19 patients, makes the telerehabilitation a key tool in this phase. 
On the Google trend engine, searches for the term “telerehab” grew by about 
400% in the first week of  March 2020.91 Indeed, for COVID-19 patients with 
ischemic stroke, telerehabilitation has been shown to be beneficial92 and it can 
dramatically lower the risk of  infection without compromising post-stroke 
recovery. 
Telerehabilitation has been performed with benefit in other neurological dis-
eases such as Parkinson’s disease93-98 and multiple sclerosis74,99,100.
Telerehabilitation might also have a role in achieving an adequate cognitive 
stimulation in several neurological diseases with associated cognitive issues in 
the era of  social distancing due to the pandemic101.
Terehabilitation is useful even for non-infected patients, reducing PPE con-
sumption and the exposure of  therapists and providers, and helping maintain 
patient safety in a fragile population102. The application of  telerehabilitation may 
equally help patients in densely populated urban areas where the infection risk is 
higher, and for patients living in rural areas, with geographic barriers and shel-
ter-at-home orders limiting their access to therapy and healthcare services103. 
New digital technologies 
In parallel with the dramatic and far-reaching health crisis, the COVID-19 
pandemic has boosted the integration of  new digital technologies into our 
medical armamentarium for the management of  several neurological disorders, 
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including stroke104,105, Parkinson’s disease,106-108, epilepsy109,110,  multiple sclero-
sis80,81 and dementia73. 
Novel applications for remote monitoring via e-diaries, sensors, vital sign 
monitoring, or even cardiac monitoring via smart watches have been applied 
for diagnostic, rehabilitation and research purposes and regular follow-up visits.
Stroke is the field which has probably seen a larger use of  digital technologies 
compared to other neurological disciplines. Accelerometers and gyroscopes in 
smartphones have been shown to be effective in recording mechanical cardiac 
activity to support the diagnosis of  atrial fibrillation (AF)111. 
Photoplethysmography with a smartphone camera has been applied for 
AF screening112. Apps specifically designed to record a rhythm strip using 
smartwatches have been seen to be accurate in differentiating AF from sinus 
rhythm113. More recently, an app for detecting AF has been applied in the Apple 
Heart Study114. 
Depending on the availability of  the users, the telerehabilitation sessions can 
be performed by phone, via videoconferencing software or through dedicated 
apps (i.e., “REHABmyPatient,” “myRehab,” or “RehabPal”)91.
This pandemic might be the key moment in which to introduce a more 
widespread use of  new technologies to improve management of  neurological 
disorders.
Training and educational teleneurology
The COVID-19 pandemic greatly impacted neurology education and training, 
including lectures, grand rounds and international congresses.115,116 With social 
distancing and closure of  lecture halls, in-person teaching and lessons moved to 
on-line platforms, such as WebEx™, Zoom™ and Microsoft Teams™, requir-
ing a rapid availablility for millions of  people, the development of  technology 
resources, and teachers and students had to adapt to these changes117-119.
The advantages of  this new educational delivery are the access to live/on 
demand lectures from any location or from different educational centers via 
virtual platforms120 with no need to travel. The limitations include the reduction 
of  trainees’ exposure to elective procedures and bed-side teaching, resulting in 
a poorer clinical experience. Moreover, remote education for some neurological 
skills such as neurological examination may not be ideal. 
The experience from the pandemic may be utilized to further improve neu-
rology education and training, as current and future neurology education will 
likely consist of  a mixture of  in-person and virtual learning.
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Practical implications and future directions 
In the post-pandemic era, the major limitations to the widespread use of  
teleneurology might be the lack of  evidence for its efficacy, and understanding 
its proper place when in-person care is also available. Although randomized 
trials are challenging in teleneurology121, the high volume of  virtual visits dur-
ing the COVID-19 crisis should allow patients’ outcomes using telemedicine 
and in-person visits to be compared. Moreover, the role of  evaluation through 
physical examination, provider-patient interaction, and workflow changes using 
telemedicine will need to be established.
In some ways, we might use teleneurology after the pandemic to improve on 
in-person visits. Indeed, telemedicine promotes a team approach by virtually 
bringing together providers from various disciplines in different locations with-
out traveling and saving time. Similarly, teleneurology can allow family members 
to take part in tele-vists; they can provide medical history and receive counseling, 
and can be included in the decision-making process even if  the medical team is 
working in remote, far from the patient and provider. For neurological patients in 
rural areas and those with limited mobility, telemedicine might have an important 
role when an in-person visit is not practical or the alternative is reduced care or 
no care at all. Teleneurology consultations in such situations has the potential to 
improve outcomes and reduce costs while saving time for busy clinicians. 
Today teleneurology is still in its infancy. Along with digital transformation 
in other industries, teleneurology has considerable possibilities for further im-
provement122. The COVID-19 experience will lead to the development of  new 
applications in large networks with analytics and big data. Moreover, artificial 
intelligence may automate some of  the processes now requiring training and 
proficiency, improving teleneurology, diagnosis and outcomes. The integrat-
ed use of  the electronic medical records and wearable devices adds important 
new information to increase teleneurology capabilities. Although teleneurol-
ogy has limitations in terms of  the physical examination, it may be enhanced 
through observational aids or in some cases the assistance of  family members 
on site123,124. The integration of  digital sensors and activity monitors into rou-
tine practice might provide additional information on patient characteristics not 
available during an in-person visit. With the growing use of  home monitoring 
and wearable devices, health providers will need to learn how to monitor and 
to manage patient-generated data. Consequently, hospitals and health services 
need to develop new, more powerful informatics systems to manage a large 
inflow of  data and to integrate it into electronic health records. 
The pandemic has highlighted the problems of  access to health care for 
those patients living in underserved areas125. The efforts of  health systems, in-
cluding community and long-term care facilities should be scrutinized to ensure 
an equal distribution of  services, keeping patients in their own environment 
and optimizing the use of  high-technology tools. 
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Moreover, telemedicine could provide specialist support for patients with 
neurological diseases needing a high level of  expertise, such as movement dis-
orders, epilepsy or stroke, avoiding the need to direct them to hub hospitals for 
lower-acuity problems. The goal should be to guarantee to all patients within 
any single system the same level of  excellent care. This could consolidate sub-
specialty centers, reducing costs and avoiding duplication of  valuable resources. 
The use of  telemedicine in the COVID-19 crisis has also changed the ap-
proach of  the medical system to the patient, which was provider-based in the 
pre-pandemic era; this has now become patient-focused. The patient remains in 
his environment, saving time spent on transfers and visits. Moreover, tele-con-
sultations with videos allow the provider to obtain important information about 
the patients’ home environment, improving their overall care.
In conclusion, teleneurology expands access and availability across the spec-
trum from outpatient to acute care and rehabilitation1. The temporary enabling 
policies that expire with the public health emergency will hopefully translate 
into lasting changes. Private payers are increasing the coverage, and countries 
are considering new approaches to telemedicine licensing. These advances 
could dramatically improve the landscape for telemedicine and teleneurology. 
Hopefully, national, regional, private, and public entities will join forces to keep 
the development of  telemedicine moving forward. 
Take home message
 – The COVID-19 pandemic has greatly pushed the development of  tele-
neurology forward, reducing or removing technological, regulatory, polit-
ical and clinical considerations, reimbursement issues, and social barriers.
 – Teleneurology has been successfully applied in the COVID-19 era to man-
age outpatients, inpatients, and for rehabilitation purposes in several neu-
rological disorders.
 – The COVID-19 pandemic has boosted the integration of  new digital 
technologies into the medical armamentarium for the management of  
neurological disesases.
 – The pandemic has greatly impacted the scientific community and the aca-
demic activities, as all the congresses, and educational training and teach-
ing courses have been turned into virtual conferences and webinars.
 – After the pandemic, teleneurology could be used to improve on in-person 
visits and in academic activities, and to integrate the new technologies into 
our clinical practice. 
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Paola Alberti, Simone Beretta, Laura Brighina,  
Valeria Isella, Carlo Ferrarese
Introduction
Neurological sequelae and complications have been reported as being related 
to COVID-191-3. Yet light should still be shed on the exact impact of  COVID-19 
on neurological diseases as well as on patients with an underlying neurological 
condition. To solve this unmet clinical and scientific need, large observational 
multicenter studies are warranted; one good example is the NEUROCOVID 
study proposed by Members of  the Italian Society for Neurology (Società 
Italiana di Neurologia, SIN)4.
In this chapter we address some potentially highly interesting topics related 
to COVID-19 and neurological patients. 
Neuroinflammatory and neuro-oncological diseases
In this section we discuss issues related to some categories of  frail neuro-
logical patients: those affected by neuroinflammatory and neuro-oncological 
conditions. As a general indication, basic safety rules apply. Social distancing is 
crucial, and given these are mainly chronic patients, appropriate logistic solu-
tions should be put in place by the treating physician/center: minimizing trips 
to pharmacies, relying on telemedicine if  appropriate and switching to home in-
fusion of  selected drugs (e.g., home-base intravenous immunoglobulin subcu-
taneous administration). In the next section we will examine the specific issues 
related to COVID-19 in categories of  fragile patients. 
Multiple sclerosis
Epidemiological studies are addressing the potential effects of  COVID-19 
in multiple sclerosis (MS) patients. A European multicenter trial reported 
21.8% of  399 MS patients suffered from an infection clinically suggestive of  
COVID-19, and reported major symptoms of  COVID-195. MS is a chronic 
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immune-mediated demyelinating disease of  the central nervous system which 
involves inflammation, blood-brain-barrier disruption, and autoreactive lym-
phocytes. Its treatment relies on disease-modifying therapies (DMTs) aiming 
at immunomodulation, immunosuppression, or cell depletion and/or altera-
tion of  inflammatory cell trafficking6. Relapse treatment is based on glucocor-
ticoids and, occasionally, plasmapheresis cases of  corticosteroid failures, with, 
of  course, only short-term administration. Instead, DMTs are administered 
chronically to help prevent relapse and to slow progression. In basic terms, 
DMTs can be divided into6: immunomodulatory drugs, such as interferon-beta-1 
(IFN-β1), glatiramer acetate (GA), and fumarates (i.e., dimethyl fumarate); cell 
trafficking alterations molecules, like S1P receptor modulators (i.e., fingolimod), and 
natalizumab, an anti-α4-integrin antibody; cell depletion (anti-CD20 antibodies 
[i.e., ocrelizumab, rituximab, ofatumumab], cladribine, and anti-CD52 antibodies 
[i.e., alemtuzumab]); systemic immunosuppressants (i.e., teriflunomide). The immu-
nocompetence status of  patients might play an important role in COVID-19 as-
sociated risks. It has been suggested that MS patients not receiving DMTs have 
the same risk of  suffering from COVID-19 as the general population7 and that 
the greatest risk of  contracting the disease can be related to dosage and med-
ication administered, in particular for second-generation therapies8. However, 
these observations were conducted on a relatively small cohort possibly biasing 
the results8, 9. From case series studies, immunosuppression has emerged as a 
risk factor for severe forms of  COVID-1910. Dimethyl fumarate, for example, 
could potentially induce lymphopenia, mainly in the early treatment course11, 
eventually increasing susceptibility to SARS-CoV-2 in case of  moderate-to-se-
vere lymphopenia, but it is considered likely to be safe in patients with no or 
mild lymphopenia (absolute lymphocyte count > 800/mm3)12. Another drug, 
natalizumab, is considered to be low risk for severe forms of  COVID-1913 since 
it does not interfere with lymphocyte function. Other drugs with, however, a 
possible moderate risk for COVID-19 are those with a modulatory effect of  
the S1P receptor (fingolimod, siponimod, and ozanimod) and anti-CD20 monoclonal 
antibodies (ocrelizumab and rituximab)13. S1P modulators are capable of  reducing 
peripheral lymphocytes, increasing susceptibility to coronavirus infection, as 
evidenced by the increased predisposition to other viral infections13. Anti-CD20 
monoclonal antibodies could impair the anti-viral long-term immunity and in-
crease the risk of  reinfection13. For the same reasons, the greatest infection risk 
might be suggested for treatments acting on the lymphocyte population, such 
as alemtuzumab or cladribine; moreover, they potentially affect the early and 
long-term immunity against SARS-CoV-2, increasing infection susceptibility 
and re-infection rate13.
Given these reflections, caution should be exercised when managing each 
individual patient both for acute relapse treatment, and management of  con-
firmed COVID-19 cases. In case of  acute relapse, single cases should be carefully 
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evaluated given that corticosteroids are associated with an increased risk of  in-
fections, including (of  course) SARS-CoV-2 infection, and these accelerate the 
onset of  relapses11. In patients with a relapsed MS and, at the same time, an 
ongoing COVID-19, the use of  plasmapheresis was suggested13. However, in 
case of  COVID-19 in a MS patient without an active neuroinflammatory status, 
it is generally suggested to continue DMTs if  infection is mild. Suspension is 
to be evaluated in those with greater immunosuppressive effects or in patients 
with other risk factors for development of  a more severe form of  COVID-19. 
Careful risk assessment of  rebound activity should always be considered in case 
of  suspension of  S1P modulators and natalizumab11. However, it should be 
noted that we are still gaining inferences on COVID-19 and MS patients as well 
as DMTs, therefore, it should be strongly encouraged to stay carefully updated 
on the indications of  regulatory agencies and scientific societies on these prod-
ucts (see as an example those released by Associazione Italiana Sclerosi Multipla 
[AISM]14).
Myasthenia gravis
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by 
fluctuating muscle weakness affecting ocular, bulbar and limb skeletal muscles15. 
The onset of  MG has been related to several triggering factors including hepati-
tis B and C, herpes simplex, HIV, Epstein-Barr virus, West Nile and Zika virus. 
SARS-CoV-2 virus has given rise to some possible challenges in MG patients 
since it can lead to variable symptoms, ranging from mild to severe pneumo-
nia, subsequently leading to acute respiratory distress syndrome (ARDS) and 
death in many cases16. The risk can be higher in MG patients for many reasons: 
a potential immunocompromised state related to MG therapies and possible 
respiratory muscle weakness16. Several reports in literature are available on MG 
patients suffering from COVID-19; Camelo-Filho et al.17 published a large se-
ries of  patients, revealing a rather severe disease course, requiring intensive care 
admission in 87% of  cases, mechanical ventilation in 73%, and with a fatal out-
come in 30%. However, clinical response of  MG patients to COVID-19 repre-
sents a major challenge and outcome predictors are still lacking. Most notably, 
it has been pointed out that Treg/Th17 imbalance in the course of  COVID-19 
might increase or even trigger an excessive autoimmune response, and a pos-
sible role for hyper-inflammatory responses in COVID-19 might be crucial in 
respiratory failure16. Therefore, respiratory muscle function evaluation is crucial 
in deciding the timing of  endotracheal intubation in MG patients affected by 
COVID-19. A non-invasive ventilation trial can be indicated and could avoid 
endotracheal intubation. But, in cases of  excessive distress in breathing, or in 
case of  the development of  bulbar dysfunction or ARDS, early intubation and 
mechanical ventilation could be required. The current state of  knowledge on 
the interaction between MG and COVID-19 is changing rapidly due to growing 
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experience with patients. The ongoing international registries will soon provide 
greater insight on this matter18, 19. For the moment, the best approach is for 
MG patients to continue their current treatment, unless specifically discussed 
with and approved by the treating physician; when deciding whether altering or 
stopping an existing immunosuppressive therapy, the increased disease activity 
and/or MG exacerbation or crisis, should be considered.
Inflammatory neuropathy
The relationship between COVID-19 and inflammatory neuropathies is 
quite complex. On one hand, patients affected by inflammatory neuropathies 
might be undergoing an immunomodulatory treatment, raising the same con-
cerns discussed for other diseases so far; on the other hand, COVID-19 itself  
might trigger an immune reaction resulting in potential damage to the peripher-
al nervous system. Regarding chronic conditions, such as chronic inflammato-
ry demyelinating polyneuropathy, a reflection is in order. Some standard treat-
ments are not expected to increase the risk of  COVID-19 or severe disease: 
immunoglobulin (either intravenous or subcutaneous), complement inhibitor 
therapy (e.g., eculizumab), therapeutic plasma exchange. 
Notably, the inflammatory response driven by COVID-19 has started to raise 
concerns related to acute polyradiculoneuritis occurrence. Case reports and 
case series were reported at the beginning of  the first COVID-19 outbreak20,21. 
As pointed out by Sheikh and co-authors22 in a recent systematic review, acute 
polyradiculoneuritis could be considered one of  the many presentations of  
COVID-19. However, there is no definite agreement on the robustness of  the 
association between COVID-19 and acute polyradiculoneuritis. A recently pub-
lished study by Keddie and collaborators23 argues against SARS-CoV-2 as being 
causative. They based this statement comparing cases in the UK from 2016 to 
2019 and cases reported during the COVID-19 outbreak. Nevertheless, authors 
recognized it is not possible to entirely rule out the possibility of  a link, since 
acute polyradiculoneuritis incidence has fallen during the pandemic, probably 
due to lockdown measures reducing transmission of  other pathogens associat-
ed with this condition. In general, despite the reported conflicting studies, it is 
highly important not to underestimate a diagnosis of  acute polyradiculoneuritis 
related to COVID-19; acute polyradiculoneuritis raises specific challenges the 
treating physician should be aware of, especially in an intensive care setting. 
Neuro-oncological patients
The COVID-19 pandemic has created major issues for cancer diagnosis and 
treatment, as well as in access to care; this is particularly true in the field of  neu-
ro-oncology. In the case of  brain tumors, the perceived benefit of  therapeutic 
interventions is often low, although this view is not always correct. As a conse-
quence of  the pandemic, the risk/benefit ratio has altered and major challenges 
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have been posed to health-care providers. In order to reduce risks to patients, 
different responses were evaluated: brain scans intervals were increased and 
radiotherapy schedules were adapted to hypofractionation. Another issue was 
raised by systemic chemotherapy given its immunosuppressive potential, rais-
ing some concerns, for example, on proposing temozolomide to glioblastoma 
patients lacking MGMT promoter methylation, given the risk of  lymphopenia 
and repeated access to the hospital facilities (e.g., for blood tests), thus increas-
ing the risk of  developing COVID-1924. For brain cancer patients symptomatic 
for COVID-19, withholding systemic chemotherapy, unless entirely non-im-
munosuppressive, could be suggested until full recovery from COVID-1924. A 
careful evaluation of  risk/benefit is needed, and moderate delays of  systemic 
chemotherapy may be a preferred option, in case of  patients positive for SARS-
CoV-2, as part of  a screening program, but asymptomatic. In any case, there is 
an urgent need to ensure treatment of  neuro-oncological patients is not signif-
icantly delayed and initiating therapy should not be outweighed by COVID-19. 
Therefore, multidisciplinary initiatives are being undertaken to better navigate 
through pandemics and learn/adapt practice. As an example, Bernhardt and 
collaborators25 proposed detailed consensus-based practice recommendations 
based on experts’ opinion, including neuro-oncologists, neurosurgeons, radia-
tion oncologists, and medical physicists. They suggest adapting treatments, pro-
posing hypofractionated radiotherapy, and modifying chemotherapy to mini-
mize immunosuppression. 
Cerebrovascular diseases
COVID-19 patients with pre-existing cerebrovascular disease have been 
shown to have a significantly higher risk of  in-hospital death, compared to 
COVID-19 patients without cerebrovascular comorbidity (relative risk 2.18)26. 
Moreover, patients with previous cerebrovascular disease had higher risk of  
severe COVID-19 than those without (relative risk 2.07) and requiring inten-
sive care (relative risk 2.79). Both pharmacological and non-pharmacological 
therapies used for COVID-19 have increased risks or are less practicable in 
patients with previous stroke. Dexamethasone and tocilizumab increase the risk 
of  bacterial infections,27 hydroxychloroquine has a potential cardiac toxicity28 
and prone positioning is difficult to apply in conscious patients with previous 
motor disability.
The risk of  first or recurrent stroke associated with COVID-19 is a matter 
of  debate. The first studies during the early phase of  the pandemic indicated 
an apparent increase in the number of  stroke patients who were younger and 
with a lower vascular risk factor burden, as well as an apparent increase in stroke 
severity, but other cohorts did not identify this different patient profile.29-34 
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For patients with pre-existing cerebrovascular disease, who are more vulner-
able to secondary events as a result of  their poor vascular condition, the risk 
of  recurrent stroke among individuals with COVID-19 remains to be deter-
mined. This issue is even more difficult to ascertain due to the approximately 
30% decrease in the volume of  stroke patients accessing hospitals during the 
COVID-19 pandemic, with an even larger decrease (up to 40-60%) for patients 
with transient ischemic attacks (TIA) and mild strokes.35-37 Despite a true decline 
in stroke incidence that may be related to a reduced exposure to common virus-
es (well-known triggers of  acute cerebrovascular events), during the lockdown 
periods,38 the most likely explanation is that the reduced stroke presentation is a 
direct consequence of  social distancing, decreasing early identification of  stroke 
and patients’ fears about coming to the hospital in the midst of  a pandemic.39 
Hospital avoidance may have created a cohort of  untreated stroke patients at 
risk of  poorer outcomes and recurrent events. Notably, an alarming increase in 
lifestyle risk factors for cerebrovascular diseases, such as smoking, alcohol and 
physical inactivity was noticed during the months of  confinement.40, 41 
COVID-19 highlighted the long road that still has to be run towards a satis-
factory education of  the population for stroke. The World Stroke Organization 
issued an important campaign highlighting the importance of  not wasting time 
in suspected first or recurrent stroke during the COVID pandemic.42
In particular, for patients who had already suffered a stroke and were likely to 
have reduced access to secondary prevention clinics and neurological rehabili-
tation therapies, the pandemic has highlighted the enormous potential of  tele-
medicine in stroke care. Although still in their early stages, novel models of  care 
have been implemented for telemedicine neurological consultations of  TIA pa-
tients43 and for video-guided telerehabilitation using home exercise programs.44
Epilepsy
Epilepsy is one of  the most common chronic neurological conditions, with a 
prevalence of  approximately 1% and a high incidence among elderly individuals 
and children45. Various factors surrounding epilepsy and epilepsy care may be 
affected by COVID-19.
A systematic review article showed that the rate of  COVID-19 severity in 
people with epilepsy is lower than other neurological disorders such as demen-
tia, cerebrovascular disease, and multiple sclerosis46. However, epilepsy is not 
a single disease; it has many causes and associations, some of  which may de-
bilitate the patient and increase the risk of  respiratory impairment. Notably, 
patients with epilepsy associated with learning and developmental disabilities 
are exposed to a significantly higher risk of  death due to a severe form of  
COVID-19 compared to other epilepsy patients47. 
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Current evidence indicates that the incidence of  acute symptomatic seizures 
due to COVID-19 is less than 1%,48 suggesting that acute symptomatic seizures 
caused by COVID-19 are not particularly common compared with other viral 
diseases. However, a change in seizure frequency among patients with chronic 
epilepsy during the COVID-19 crisis has been reported, regardless of  wheth-
er these patients were infected with COVID-1949. The proportion of  patients 
experiencing increased seizures varied from 8% to up to 30%, and may re-
flect several contributing factors, besides COVID-19 infection itself: reduced 
compliance to antiepileptic drug schedule, difficulty in obtaining medicine due 
to lockdown or reduction in income, increased psychological stress and sleep 
problems. Indeed, the impact of  the COVID-19 pandemic on psychological 
effects in epilepsy patients showed a high prevalence of  depression (29%), anx-
iety (38%) and insomnia (29%)50.
The social impact of  COVID-19 has been seen also in epilepsy care facilities. 
Patient access to healthcare facilities has been greatly restricted because of  the 
potential for patient-to-patient or healthcare provider-to-patient transmission 
of  SARS-CoV-2. In a survey from 49 countries, more than 90% of  physicians 
responding stated that in-person outpatient visits had decreased and use of  
telemedicine had increased51.
The use of  virtual epilepsy appointments became the standard of  care in the 
lockdown periods in most countries and allowed an unprecedented assessment 
of  this new care system, from both the patient’s and the physician’s perspective. 
Two large studies enrolling over 1,300 patients showed no backlog of  appoint-
ments or loss of  care continuity and strong levels of  satisfaction expressed by 
clinicians for routing follow-up appointments, including adjustment of  antie-
pileptic drugs and prescriptions of  diagnostic testing52, 53. On the other hand, 
most physicians doubted the suitability of  telemedicine for patients with newly 
diagnosed epilepsy and drug-resistant epilepsy. Up to 75% of  patients reported 
positive experiences of  telephone appointments comparing them favorably to 
face-to-face encounters. Beyond the pandemic, most patients reported a pref-
erence for continuing telemedicine if  their epilepsy symptoms remained stable, 
while only 44.4% chose telemedicine should their symptoms worsen. 
Dementia and movement disorders
Coexistence of  coronavirus disease with degenerative cognitive and movement 
disorders has represented the crossroad of  two pandemics. Neurodegenerative 
diseases like Parkinson’s disease (PD) or, and above all, Alzheimer’s disease 
(AD), are extremely frequent in older people, who were also the main target 
of  COVID-19 infection. The impact of  the virus in these clinical populations 
has been massive and diverse: during the quarantine these patients have shown 
a higher risk of  contagion and a worse outcome of  the infection, have suffered 
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the consequences of  physical confinement and social deprivation, and also of  
greater caregiver burnout, and have experienced discontinuity in assistance due 
to overload or lockdown of  medical and support services.
Results from meta-analyses and systematic reviews have shown that, com-
pared with individuals with no dementia, dementia patients were at higher risk 
of  COVID-19 infection, showed a more severe disease course, and had a higher 
mortality rate (with ORs ranging from 1.54 to 5.17)46, 54-62. Various elements 
have been indicated as causes of  this increased vulnerability63, 64. Some were 
related to age (increased viral shedding, atypical presentations, such as lack of  
fever, that delay the diagnosis, or heavy comorbidity), while others were more 
specific to dementia. A case in point was delirium, which is particularly fre-
quent in patients with a neurodegenerative disease in the course of  an infection; 
this is a serious, potentially lethal condition. A second element was the fact 
that measures to prevent contagion, like wearing masks, frequent handwashing 
or avoiding social contact, are difficult to introduce to individuals with cogni-
tive impairment. Third, potential biological mediators of  major vulnerability 
to COVID-19 in AD were hypothesized61, 62, 64-66. For instance, Apolipoprotein 
E allele ɛ4, a known risk factor for AD, has been associated with increased 
COVID-19 severity, and expression of  the ACE2gene, coronavirus binding 
protein for cell entry, has been found to be upregulated in the brain tissues of  
AD subjects. Moreover, and more importantly, cytokine-mediated neuroinflam-
mation plays a central role in the pathogenesis of  AD, and COVID-19 is known 
for causing a ‘cytokine storm’ that affects multiple organs, including the central 
and peripheral nervous system. These observations on biological common links 
between coronavirus and AD, however, are for the moment highly speculative, 
and will need to be verified empirically.
As far as PD is concerned, it remains unclear whether there was a major 
incidence of  coronavirus disease in this disorder. Reports on prevalence of  the 
infection varied greatly (according to geographical area, inclusion criteria, etc.), 
ranging from 0.6% to 8.5%67, but in most studies it was below 1%, therefore 
equivalent to that of  the general population. Risk factors for COVID-19 infec-
tion in PD were also similar to those seen in control populations, i.e., age, male 
gender, smoking, cardiovascular and chronic obstructive pulmonary diseases67. 
However, data are still insufficient to establish whether the similar prevalence 
was related to the same predisposition for COVID-19 infection, or to a higher 
level of  attention and self-isolation in PD patients as an at-risk population68, 
69. Interestingly, a few studies have actually reported that a subgroup of  PD 
patients were less likely to be infected by COVID-19, namely those receiving 
amantadine70, 71. This finding has also received support from an in vitro drug 
screen gene expression study showing that amantadine decreased the virus rate 
of  replication and degree of  infectivity72.
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With regard to the prognosis, mortality rates were also highly variable (from 
5% to 75%) according to sample size, and patients’ socio-demographic and 
clinical characteristics (e.g., disease stage, involvement of  community-dwelling, 
hospital-based or long-term care facilities series). However, they were gener-
ally higher in PD patients than in age-matched non-PD individuals73, mostly 
because of  restricted pulmonary capacity due to axial akinesia, and impaired 
cough reflex74. Interestingly in PD the detrimental interaction between corona-
virus infection and neurodegeneration has appeared to be bi-directional, in the 
sense that the virus also seemed to have a negative impact on the course of  the 
motor disorder, through various mechanisms. Dopamine neurons have in fact 
been shown to highly express the ACE2 receptor, which mediates COVID-19 
entry to cells, and immune activation in the olfactory system, targeted by the 
virus, has been shown to eventually lead to the misfolding of  α-synuclein in the 
central nervous system, possibly causing the development and/or progression 
of  PD. In support of  this hypothesis, four cases of  parkinsonism have been 
reported, which manifested between five to 32 days from coronavirus infection 
and showed asymmetric decrease of  dopamine uptake in the putamina and 
good response to dopamine replacement therapy75, 76. These cases of  new-onset 
parkinsonism might have been related to unmasking subclinical PD. Large co-
hort studies will be needed to determine whether COVID-19 will also increase 
the incidence of  PD in the long term.
The pandemic has had heavy consequences on patients with dementia and 
movement disorders also indirectly, through quarantine and isolation. During 
the lockdown declared in Italy as a containment measure of  the first wave of  
the coronavirus pandemic, the COVID-19 Study Group of  the Italian Society 
of  Neurology for Dementia (SINdem) carried out a nation-wide survey on the 
impact of  quarantine on cognitive, neuropsychiatric and motor symptoms of  
dementia, using a telephone interview with patients’ family caregivers. Clinical 
worsening was reported in approximately two patients in three for behavioral 
aspects (mainly irritability and apathy), in one patient in two for cognitive func-
tions (especially memory), and in one patient in three for motor disturbances 
(above all, in walking)77, 78. These findings are in line with a large bulk of  lit-
erature also showing exacerbation of  pre-existing neurological symptoms of  
dementia during and after quarantine78. Such an exacerbation appeared to be 
linked to multiple factors: movement restriction, reduced social interaction and 
activities that usually stimulate cognition and have a beneficial effect on mood 
and behavior, disruption of  daily routine. A negative effect was also observed 
in terms of  greater caregiver burnout, which has been reported repeatedly in 
the pandemic literature79, 80, and quarantine due to the coronavirus disease 2019 
(COVID-19, and this set off  a vicious cycle with worsening of  the patient’s 
clinical condition. 
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Very similar findings have been reported for PD patients. Worsening of  
motor and non-motor symptoms has also been described in these patients, 
and attributed mainly to psychological distress, depression and anxiety, a re-
duction in physical activity, and social isolation, besides fear of  being infect-
ed by COVID-1981, 82. A behavioral disturbance very typical of  PD, Impulse 
Control Disorder (ICD), has also been found to increase during the COVID-19 
lockdown82.
The SINdem COVID-19 Study Group’s report on the impact of  quarantine 
on family caregivers of  patients with dementia identified discontinuity in assis-
tance as one of  the main determinants of  caregiver stress, causing a three-fold 
increase in feelings of  isolation and abandonment and a two-fold increase in a 
sense of  being overwhelmed and helpless83. This element has in fact emerged 
as one of  the main causes of  the extra burden resulting from the pandemic on 
patients with dementia83, mostly on patients with PD81, 82. Redeployment of  hos-
pital units and lockdown of  medical and assistance services (outpatient clinics, 
diagnostic departments, cognitive and motor rehabilitation centers, elderly day-
care facilities, social support services) created a real emergency, with problems 
in the supply of  medications and postponement of  appointments for follow 
ups and for new referrals, leading to delays in diagnosis and initiation of  appro-
priate management. PD patients seem to have been the most heavily penalized 
by this situation, due to the fact that, unlike other neurological groups, they 
need routine visits to the hospital for physical assessment and medication ad-
justments by movement disorder specialists. In particular, during the peak phas-
es of  the COVID-19 pandemic a significant decline was observed globally for 
PD Multimodal Complex Treatments (MCT), including levodopa/carbidopa 
intestinal gel, continuous subcutaneous apomorphine infusion and Deep Brain 
Stimulation (DBS). Patients treated by MCT require regular follow-up visits in 
highly specialized and multidisciplinary clinical settings, which appear to have 
been massively affected by social distancing and lockdown measures84. Beside 
reporting concern about problems of  hospital access and the interruption of  
pharmacological and non-pharmacological treatments, patients treated with 
MCT were also worried specifically about management of  stimulation devices. 
First of  all, PD patients with implanted DBS systems require replacements of  
the Implantable Pulse Generator (IPG), especially if  not rechargeable, every 
three to five years. More crucially, battery malfunction due to exhaustion or oth-
er device-related issues may occur unexpectedly and become an emergency re-
quiring surgical intervention to avoid the risk of  life-threatening complications 
such as malignant subthalamic nucleus-DBS withdrawal syndrome (similar to 
a neuroleptic malignant syndrome), acute dystonic crisis, and the reappearance 
of  disabling PD symptoms, which can be refractory to medication. During the 
pandemic, both pre-planned and urgent hospitalizations for interventions on 
the device were extremely problematic.
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Possible role of  telemedicine
These issues lead straight to reflections about the need to identify and im-
plement interventions aimed at providing care in current and future situations 
of  physical distancing. Telehealth must represent a very promising solution, as 
it helps in limiting virus circulation by decreasing person-to-person contact, 
while allowing remote delivery of  a full spectrum of  services to patients and 
caregivers85, 86. Indeed, a recent study showed that telemedicine was as effica-
cious as in-office visits, and PD patients even expressed an increased likeli-
hood of  participating in future clinical research studies if  some visits could 
be conducted remotely87. Along these lines, the International Parkinson and 
Movement Disorder Society has developed a guide on how to set up telemedi-
cine practice as a valid alternative method for consultations and remote assess-
ments of  PD patients88. History-taking, aspects of  the neurological examina-
tion, a brief  cognitive assessment, and medication reviews can be performed 
via videoconferencing. Virtual cognitive and also physical stimulation programs 
may also be arranged, and counseling or psychological support may be pro-
vided to patients, caregivers and family members through telephone or web 
meetings. Furthermore, PD patients may efficiently be assessed with wearable 
devices to complement remote MDS-UPDRS scores. However, telehealth has 
some limitations: the impossibility of  performing a complete neuropsycholog-
ical evaluation or physical examination (e.g., to assess rigidity, or to perform 
balance-related maneuvers, especially without the supervision/assistance of  
a trained caregiver); the lack of  validation and norms for neuropsychological 
tools; the inability to conduct ‘difficult conversations’ (e.g., on palliative care) on 
the screen, or to check in with the caregiver without the presence of  the patient; 
the problems in using audio-visual devices for older people and for subjects 
with major neurocognitive disorders or severe neurosensory deficits, or even 
the unavailability of  such devices.
Patient and caregiver education programs
When and where telehealth is not a feasible or efficient solution, other inter-
ventions might help reduce the overall impact of  coronavirus disease on neuro-
logical disorders, and particularly on dementia and PD populations64, 89. Patients 
and caregivers should first of  all be educated to keep home a “clean zone” 
(e.g., contacts should receive an anti-COVID vaccine, have regular COVID-19 
testing, wear appropriate personal protective equipment, strictly follow rec-
ommended prevention rules). Family members and caregivers should also be 
encouraged to monitor patients’ clinical changes (including, for instance, wors-
ening or onset of  ICD in PD patients), and be advised on how to organize 
home-based activities like cognitive stimulating tasks (including arts and crafts 
or games) or simple exercise (e.g., walking, stretching). In fact, although the ma-
jority of  physical rehabilitation programs for PD patients are conducted outside 
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the home in supervised settings (e.g., non-contact boxing programs, assisted 
aerobic or functional strength activities, yoga), many activities can be done at 
home90. Most of  them have been shown to effectively reduce off-state motor 
signs even with minimal remote supervision, at least in patients with mild dis-
ease severity91. For PD patients, web-based exercise initiatives such as online 
singing and exercise or dancing classes have indeed been implemented during 
the pandemic, often initiated or supported by large patient associations.
Pharmacological interactions
On their part, clinicians should keep on the alert for atypical presentations of  
coronavirus infection, to promote timely diagnosis of  the disease, and be able 
to adopt a targeted approach in those patients who do become infected. Special 
efforts should be made to monitor and prevent delirium, given the high preva-
lence and poor outcome of  this condition in patients with a neurodegenerative 
disorder, and close attention should be paid to possible pharmacological inter-
actions. Patients with dementia are often on a cocktail of  cholinesterase inhibi-
tors/memantine, antidepressants and antipsychotics that interact with liver en-
zymes and cause adverse events similar to those of  antirheumatic (chloroquine 
and hydroxychloroquine), antiviral (ritonavir in particular) or antibiotic (e.g., 
azithromycin) drugs used for treating COVID-1962. Pharmacological choices 
should be guided by these observations. As an example, cholinesterase inhibitors 
might require adjusting, or replacing with memantine (which has lower hepatic 
interaction) if  used in conjunction with antirheumatics, and ribavirin or favip-
iravir should be preferred to other antivirals as they can be administered more 
safely alongside treatments for AD. As to patients with PD, several case series 
and observational studies have reported a worsening of  motor and non-motor 
symptoms during COVID-19 infection, which may be linked to acute systemic 
inflammatory response, or to changes in pharmacokinetics of  oral therapy (e.g., 
reduced absorption due to diarrhea)92. Clinicians should be prepared to increase 
levodopa dose in these circumstances92. For patients treated with MCT, it is 
recommended to gradually reduce stimulation amplitude and increase levodopa 
dosage accordingly to avoid acute cessation when end of  IPG life is approach-
ing. Routine management of  the device should also be reorganized, for instance 
through supplementation of  programming-related follow ups with video tele-
consultations, and with the use of  patient-controlled programmers. Decision 
algorithms for patients with advanced therapies are available in the literature to 
improve PD work up in these difficult circumstances93.
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Reflections on COVID-19 vaccination in frail neurologi-
cal patients 
The ultimate defense against coronavirus infection is, of  course, represented 
by vaccines. 
Specialists managing patients with dementia should be aware that vaccination 
against COVID-19 is recommended to these patients above and beyond the gen-
eral elderly population. Participation of  patients with cognitive impairment or 
dementia in clinical trials on anti-COVID vaccines was probably null or negli-
gible, since such conditions were explicit reasons for exclusion in the Oxford-
AstraZeneca trial, and could be reasons for exclusion upon investigator’s judgment 
in the Pfizer/BioNTech and Moderna trials94, but without a doubt the risk-benefit 
ratio favors vaccination of  patients with dementia against coronavirus. This has 
also been clearly confirmed in PD patients (see MDS/MDS COVID-19 Vaccine 
Statement for Patients95) since the benefits and risks of  approved COVID-19 
vaccinations do not appear to differ in individuals with this disorder from those 
observed in the general population, while the risks of  life-threatening complica-
tions of  the infection do appear to be higher for persons living with advanced PD. 
Moreover, no changes in PD symptoms or responses to PD treatments following 
COVID-19 vaccination have been reported, whereas PD symptoms may worsen 
after COVID-19 infection. Finally, although longitudinal studies are warranted to 
explore the impact of  vaccines on PD progression, no evidence has been found 
thus far suggesting a direct interaction of  vaccine-induced immune response with 
the neurodegenerative process and, in particular, with inflammation associated 
with the pathogenesis of  PD96.
Some concern might arise in patients with underlying neuroinflammatory 
conditions when it comes to COVID-19 vaccines; the fear is that vaccination 
would trigger the immune system and lead to neurological adverse events. One 
of  the main concerns is related to the possible onset of  an acute polyradicu-
loneuritis following vaccination. Weighing the evidence to date, the potential 
COVID-19 specific consequences outweigh the risks of  vaccination. The gen-
eral recommendation is that patients with inflammatory neuropathies should 
be encouraged to have the vaccination97 and, as stated by such experts as Lunn 
and co-authors98, although an association of  any vaccination to acute polyradic-
uloneuritis cannot be ruled out and we should stay vigilant, it is not necessarily 
to be expected. On the other hand, regarding those patients who are actively 
receiving an immunosuppressive/immunomodulatory treatment, such as, for 
example, MS patients, some concerns might arise as to the effect of  these treat-
ments on vaccine efficacy, reducing the ability of  the individual patient to have 
an adequate immune response99, especially for those which interfere with B-cell 
activity and antibody production. This gave rise to some indications by differ-
ent scientific societies, for example the SIN, suggesting to wait 4-6 weeks after 
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the completion of  the whole vaccination cycle before starting drugs such as 
alemtuzumab, rituximab, ocrelizumab, ofatumumab, cyclophosphamide, mitox-
antrone100. However, this is just an example, and given that we are still obtaining 
evidence on COVID-19 and COVID-19 vaccination management (taking into 
account novel vaccines might be soon available), the best course of  action is to 
rely on indications given by regulatory agencies, such as the European Medicine 
Agency (EMA) in Europe and the Food and Drug Administration (FDA) in the 
US, and to keep constantly updated on changes on data reported in the techni-
cal description of  both DMTs and COVID-19 vaccine. 
Take-home message
 – SARS-CoV-2 virus, known to cause COVID-19, is having a dramatic im-
pact on neurological patients, highlighting older and new frailties.
 – Careful updates on growing evidence should be recommended for pa-
tients undergoing immunomodulatory/immunosuppressive treatments, 
relying on indications that continue to be released by regulatory agencies 
and scientific societies.
 – There have been problems in treatment/care/follow up of  frail patients 
(e.g., dementia patients) suggesting a possible role for telemedicine.
 – COVID-19 should be carefully monitored for potential neurological com-
plications and their exact impact will only be evaluated through large ob-
servational trails, such as the NEUROCOVID study proposed by the SIN.
 – The ultimate defense against coronavirus infection is represented by vac-
cines. Considering the evidence so far, the potential COVID-19 specific 
consequences outweigh the risks of  vaccination. Careful planning of  vac-
cine administration should be undertaken for patients undergoing immu-
nomodulant and/or immunosuppressive treatments.
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Chapter 17. Neurological complications  
of  vaccines for COVID-19
Laura Bertolasi, Maria Donata Benedetti
On January 30 2020, the World Health Organization (WHO) declared the 
outbreak of  the novel severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) (COVID-19) a public health emergency of  international concern, 
reaching a pandemic status on March 11 20201. In less than 12 months, several 
research teams rapidly developed candidate vaccines to prevent COVID-19, 
assessing their efficacy and safety in phases I, II, and, later, in phase III clin-
ical trials2-10. Pfizer-BioNTech COVID-19, Moderna COVID-19, and J&J/
Janssen COVID-19 vaccines were authorized for emergency use in rapid suc-
cession in the US (Food and Drug Administration [FDA]: December 11 202011, 
December 18 202012, and February 27 202113, respectively) and in Europe 
(European Medicines Agency [EMA]: December 21 202014, January 6 202115, 
and March 11 202116), where a fourth vaccine, AstraZeneca COVID-19, was 
also authorized on January 29 202117. The WHO recently authorized two vac-
cines developed in China: Sinopharm COVID-1918 and Sinovac COVID-1919; 
authorization by the FDA and the EMA is still awaited. Overall, more than 
100 candidate vaccines are currently under clinical development, while another 
three vaccines have been authorized and are used in several parts of  the world 
(Sputnik V, Russia20,21; CanSino, China; Bharat Biotech, India22). As of  June 18 
2021, the worldwide cumulative number of  COVID-19 cases was 177,108,695, 
the cumulative deaths 3,840,223, and a total of  2,378,482,776 vaccine doses had 
been administered worldwide23. Currently authorized COVID-19 vaccines are 
summarized in Table 17.1.
Despite the urgency related to the pandemic state, the safety profiles of  
candidate vaccine resulting from available clinical trials and all documents 
and product information submitted by companies, were rigorously and thor-
oughly evaluated by the WHO and regulatory agencies before authorization24. 
Nevertheless, clinical trials have a limited follow-up time and insufficient power 
to detect rare adverse events (AEs), or those occurring at a later time, or those 
emerging after large populations have been vaccinated. Post-marketing safety 
surveillance and monitoring allow recommendations and advice to be updated 
and modified.
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According to the WHO criteria for causality assessment, an AE following 
immunization (AEFI) is any untoward medical occurrence which follows vac-
cination and which does not necessarily have a causal relationship with the 
usage of  the vaccine25. The AE may be any unfavorable or unintended sign, 
abnormal laboratory finding, symptom or disease. Serious adverse events 
(SAE) are untoward events that at any dose result in death, are life-threat-
ening, require hospitalization or prolongation of  existing hospitalization, or 
result in persistent or significant disability/incapacity or birth defect, or AEs 
requiring medical attention, or leading to withdrawal from the trial. The AE 
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severity grading scale ranges from grade 1 (mild), grade 2 (moderate), and 
grade 3 (severe), to grade 4 (life-threatening). Reactogenicity is evaluated in 
terms of  solicited local (injection site pain / tenderness / swelling) and sys-
temic (fatigue, headache, myalgia, nausea, fever) AEs during the 7 days after 
vaccination, and unsolicited AEs over the 28 days post vaccination. AEs are 
further classified as AEs of  Special Interest (AESI) or according to MedDRA 
(Medical Dictionary for Regulatory Activities) by system organ classes (SOC), 
e.g., nervous system disorders. Finally, investigators, independent committees 
of  neurological experts, and regulatory agencies evaluated whether it is plau-
sible that the reported AEs are or are not related to the vaccine under study. 
For the purpose of  this discussion, AEs were searched in published trials and 
Supplementary Appendices, and FDA and EMA assessment reports.
Neurological complications of  COVID-19 vaccines in 
clinical trials
1. BNT162b2 COVID-19 mRNA-based vaccine
The safety and efficacy of  the BNT162b2 candidate vaccine (Pfizer and 
BioNTech) were assessed in phase I and II/III randomized, placebo-con-
trolled clinical trials2,7, where local and systemic events were generally milder 
in older than in younger participants and were greater after the second than 
after the first dose. The phase III trial enrolled 43,448 subjects aged 16 years 
and over from July to November 2020, randomized to receive BNT162b2 
(n=21,720) or placebo (n=21,728) two doses, 21 days apart7. The safety pop-
ulation, followed for a median of  2 months after the second dose, included 
37,706 subjects, median age 52 years, while reactogenicity was evaluated in a 
subgroup of  8,183 subjects. Related AEs were reported more frequently in 
vaccine recipients (20.7%) than in placebo (5.1%), largely due to reactogenic-
ity events during the 7 days after vaccination. Among them, headache was 
reported more often after the second dose (52% vs 24% in placebo [16-55 
years], and 39% vs 14% in placebo [>55 years]) than after the first dose (42% 
vs 34% in placebo [16-55 years], and 25% vs 18% in placebo [>55 years]). 
No severe AEs/SAEs of  neurological interest occurred in the safety popula-
tion. The investigators concluded that no deaths were to be considered to be 
related to the study interventions. In the FDA and EMA assessment reports 
(not in the published paper7), four cases of  Bell’s palsy were reported in the 
vaccine arm versus 0 in placebo, three occurring 3, 9 and 48 days after dose 
2, and one 37 days after dose 1; the study investigators considered all four to 
be related to vaccination11,14. Sleep disturbances (insomnia/sleep disorder/
abnormal dreams) were more frequent in the vaccine than in the placebo arm, 
possibly due to local/systemic reactogenicity11,14. Overall, systemic reactions 
268 Neurology of  COVID-19
were transient and of  short duration, mostly of  mild or moderate intensity, 
and reported more often by younger subjects. The frequency of  severe AEs, 
SAEs and AEs leading to trial discontinuation was low and equally distributed 
in both study arms. 
Comment: the efficacy of  Pfizer-BioNTech COVID-19 vaccine (Comirnaty 
in Europe) was considered high (95%) and the observed safety profile favora-
ble, with a positive benefit-risk balance. The frequency of  Bell’s palsy in the 
vaccine group was consistent with the expected rate in the general popula-
tion11, with a possible relation to the vaccine14. Surveillance for cases of  Bell’s 
palsy and allergic (anaphylactic) reactions with deployment of  the vaccine 
into larger populations was recommended.
2. mRNA-1273 MODERNA COVID-19 -based vaccine 
This vaccine was evaluated in two small phase I studies3,4 and in a large 
phase III, placebo-controlled clinical trial enrolling 30,420 subjects between 
July 2020 and October 2020, randomized to receive mRNA-1273 (n=15,185) 
two doses, 28 days apart, or placebo (n=15,166)8. The median follow-up after 
the second injection was 63 days; 25% of  participants were ≥65 years of  age. 
Reactogenicity was pronounced for both local and systemic adverse reactions, 
in particular after the second dose of  vaccine, with mostly mild or moderate 
transient events12,15. Headache was more frequently reported in younger than 
in older persons, and after the second dose: 65.8% versus 25.3% in place-
bo (18-64 years) and 46.2% versus 17.5% in placebo (≥65 years), than after 
the first dose: 35.3% versus 29% in placebo (18-64 years) and 24.5% versus 
19.3% in placebo  (≥65 years). Unsolicited nervous system disorders during 
the 28 days after vaccination were reported by 4.5% in the vaccine arm (3.1% 
headache) and 4.1% in the placebo group (3% headache) (Supplementary 
Appendix: Tables S9-S11)8. Moreover, three cases of  Bell’s palsy were ob-
served in the mRNA-group compared to one case in the placebo group, with 
timing suggesting a possible causal relationship to vaccination15. Treatment-
related sensory disturbances (paresthesia, hypoesthesia, hyperesthesia) were 
more frequent in the vaccine than in the placebo arm (20 vs 7) as well as 
sleep disorders (insomnia abnormal dreams, nightmare) (30 vs 15). Finally, 
in vaccine recipients, three SAEs of  cerebrovascular accident (1 placebo), 2 
SAEs of  embolic stroke (none in the placebo group), and 1 SAE of  transient 
ischemic attack (none in the placebo group) were reported; the investigators 
did not consider any of  them to be related to vaccination.
Comments: the efficacy of  mRNA-1273 MODERNA COVID-19-based 
vaccine was high, and the safety profile was favorable, although this vaccine 
appeared more reactogenic than many of  the standard vaccines in use. As 
for the COVID-19 vaccines, long-term safety data, interaction with other 
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vaccines, data on use in pregnancy and other subgroups require updates and 
surveillance for AEs26.
3. ChAdOx1 nCoV-19 vaccine (AZD1222)
The safety and efficacy of  the AstraZeneca COVID-19 vaccine, now called 
Vaxzevira, were evaluated in a phase I/II trial5 and in the pooled interim 
analysis of  four ongoing randomized, blinded, controlled trials carried out 
across the UK, Brazil, and South Africa between April 23 and Nov 4 20209. 
The safety analysis included 23,745 participants randomly assigned to receive 
two doses of  AZD1222 (n=12,021) or vaccine/placebo (n=11,724). Overall, 
in the safety population, 91.1% were aged 18-64 years, 8.9% were 65 years or 
over, 55.8% were female. The median follow-up from the first dose was 105 
days in the AZD1222 treatment and 104 days in the control groups. Local 
and systemic AEs, generally mild or moderate, were reported more frequently 
in AZD1222 than in controls, and after the first dose than after the second. 
Headache was the second most frequently reported solicited systemic AE 
(57.5% vs 42.4% in control) after fatigue (62.3% vs 48% in control)17, while 
among the unsolicited AEs, the frequency of  nervous system disorders was 
higher in the vaccine group (9.3%, mostly of  grade 1-2) than in controls 
(5.5%), including headache, lethargy, migraines, somnolence, dizzines17. In 
the category of  AESI, five ‘potential immune mediated conditions-neuroin-
flammatory disorders’ are reported in the AZD1222 group (three Bell’s palsy, 
one transverse myelitis, one multiple sclerosis) and four in controls (three 
Bell’s palsy, one myelitis), while ‘other neurologic events’ reported in both 
vaccinated and control groups, although with a very low  frequency (range 
<0.1 - <0.5%) included paresthesia, hypoesthesia, muscular weakness, visual 
impairment, followed by sensory disturbance (sensory loss, dysesthesia, hy-
peresthesia), gait disturbance, neuralgia (Supplementary Appendix Table S7)9. 
Of  the six cases of  Bell’s palsy, only one in the vaccine and one in the control 
group were considered to be at least possibly related to vaccination based 
on the timing. Again, among the seven SAEs of  neurological interest in the 
vaccine recipients (facial spasm, ischemic stroke, migraine, multiple sclero-
sis, transverse myelitis, presyncope, serotonin syndrome; one case each), and 
the four in controls (myelitis, subarachnoid hemorrhage, syncope, transient 
ischemic attack; one case each) (Supplementary Appendix Table S6), only 
the case of  transverse myelitis in the AZD1222 group was reported as be-
ing possibly related to vaccination, resulting in temporarily pausing the trial, 
while multiple sclerosis was considered unrelated to study treatment as the 
MRI showed new and pre-existent brain lesions9. One case in each group 
had generalized convulsion, while a case of  neuritis and a case of  peripheral 
neuropathy were reported in the AZD1222 group. 
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Comment: in this trial the subjects in the control group were administered 
Meningococcus ACWY vaccine or saline, which complicates the comparison 
of  data17. Only 3 of  175 SAEs were considered to be related to the vaccine 
or control. Thrombotic and neurovascular events were more frequent in con-
trols (8 cases) than in the AZD1222 group. 
4. Ad26.COV2.S COVID-19 vaccine
Immunogenicity was studied in a very small phase I trial6, while the safety 
and efficacy of  a single dose of  Ad26.COV2.S (Janssen/Johnson & Johnson) 
vaccine were evaluated in a multicenter, placebo-controlled, phase III trial, 
enrolling 43,783 subjects aged 18 years and over from September 2020 to 
January 2021, randomized to receive a single dose of  either Ad26.COV2.S 
(n=21,895) or saline placebo (n=21,888)10. The median follow-up was 58 days 
(range 1- 124), 66.5% of  subjects were aged 18-59 years, 33.5% were 60 years 
or over. In the safety population (3,356 vaccine recipients and 3,380 place-
bo recipients), systemic solicited AEs were more frequent in Ad26.COV2.S 
(55.2%) than in placebo recipients (35.1%), and in the class of  study partici-
pants aged 18 to 59 years than in those aged 60 years or over. Headache was 
the most frequently reported solicited AE (39% vs 23.8% in placebo). Among 
7 SAEs that the investigators considered to be related to vaccination, 4 were 
neurological disorders: two Bell’s palsy, one brachial radiculitis, one Guillain–
Barré syndrome versus 0 in control (Supplementary Appendix Tables S6 and 
S7)10. One case of  Guillain-Barré syndrome and two cases of  Bell’s palsy in 
the placebo group, as well as another case of  Bell’s palsy in the vaccine group, 
were, however, considered to be unrelated. Moreover, four cases of  headache 
in the vaccine group (vs 2 in control) and 1 syncope (vs 0 in control) were 
reported as AEs of  grade ≥3 (Supplementary Appendix Table S6)10. One case 
of  transverse sinus thrombosis with cerebral hemorrhage occurring 21 days 
after the vaccination in a male of  25 years of  age was considered unrelated to 
vaccination; the patient recovered. Finally, six cases of  tinnitus were reported 
in the vaccine arm and none in the placebo group, while seizures occurred in 
4 vaccine recipients and 1 placebo recipient. The causal relationship between 
these events and the vaccine remains undetermined10.
Comments: EMA recommendations were updated in April and June 2021 
with evolving experience of  thrombosis with thrombocytopenia syndrome 
(TTS) following vaccination with Vaxzevria and the Janssen COVID-19 vac-
cine in people under 60 years of  age within three weeks after vaccination, the 
majority in women27,28. On April 23 2021, the FDA recommended resuming 
the use of  the Janssen COVID-19 vaccine in the US after the pause deter-
mined by the reports of  six cases of  a rare and severe type of  blood clot 
following administration29.
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5. Sinovac and Sinopharm inactivated vaccine against COVID-19 
Safety, efficacy and immunogenicity data for WHO Sinovac-CoronaVac au-
thorization19 came from several trials of  phase I/II in China30,31 and ongoing 
phase III trials in Brazil32, Turkey, Indonesia and Chile. In the available safety 
population (n=8,840) who received any dose/schedule of  Sinovac, AEs were 
mild/moderate, and there was no imbalance between vaccine and control 
group in SAEs, all classified as unrelated/unlikely related to vaccine, or AEs 
grade 3+19. In older subjects, reactogenicity was lower compared to younger 
adults, while the safety profile was similar. Post-authorization, two neurolog-
ical SAEs were reported in China (one cerebral hemorrhage and one demy-
elination) out of  over 35.8 million doses19. Vaccine efficacy was evaluated to 
be 51% for symptomatic disease and 100% for severe disease and hospital-
ization19. The WHO authorized Sinopharm BBIBP-CorV COVID-1918 after 
assessment of  efficacy and safety reported in phase I/II trials in China33 and 
an ongoing phase III trial in Bahrain, Egypt, Jordan, and the United Arab 
Emirates34. The available safety population included 16,671 participants who 
received any dose/schedule of  BBIBP-CorV vaccine. Most AEs were mild to 
moderate, without any imbalance in the number of  reported SAEs, AEs of  
special interest (neurological diseases) or grade 3+ AEs between the BBIBP-
CorV and placebo groups. One SAE initially reported as being possibly linked 
to vaccination was inflammatory demyelination syndrome/acute disseminat-
ed encephalomyelitis, later not confirmed. In terms of  quality of  evidence, 
the WHO concluded, with a moderate level of  confidence, that the risk of  
SAEs following one or two doses of  BBIBP-CorV in adults (age 18-59 years) 
is low, while for older adults (age ≥60 years) the level of  confidence was very 
low. Vaccine efficacy for symptomatic and hospitalized disease was estimated 
to be 79% in all age groups combined18. No AEs of  neurological interest were 
reported in Sputnik V20,21 and Covaxin22 trials. 
In summary, neurological AEs were extremely rare in clinical trials of  
COVID-19 vaccines, and vaccine-induced immune thrombotic thrombocy-
topenia (VITT) was observed only in a small number of  persons receiving 
AZD1222 and Ad26.COV2.S. However, with mass vaccination, several hun-
dred patients were reported with this syndrome, which is caused by platelet 
activation and subsequent stimulation of  the coagulation system, resulting in 
thromboembolic complications, as discussed below.
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*3 Serious adverse events (SAEs) of  cerebrovascular accident (1 in placebo), 2 
SAEs of  embolic stroke (none in placebo), and 1 SAE of  transient ischemic attack 
(none in placebo).
** Headache was analyzed in 8,183 participants (reactogenicity subset). 
§One case of  transverse myelitis 14 days after AZD1222 vaccination was judged to 
be related (the most likely diagnosis to be of  an idiopathic, short segment, spinal 
cord demyelination), resulting in temporarily pausing the trial. The other case of  
transverse myelitis 10 days after AZD1222 vaccination, initially considered to be 
related, was later judged as pre-existing, but previously unrecognised, multiple scle-
rosis. The transverse myelitis in control was judged to be unrelated.
§§ Seven cases in vaccine recipients: facial spasm, ischemic stroke, migraine, mul-
tiple sclerosis, transverse myelitis (related), presyncope, serotonin syndrome (one 
each); 4 cases in controls: myelitis, SAE, syncope, transient ischemic attack. All 
considered unrelated (multiple sclerosis was considered unrelated to study treat-
ment as the MRI showed new and pre-existent brain lesions).
° From Supplementary Appendix Table 8S: in the text it was instead specified that 
a man aged 30 years was diagnosed with possible demyelinating myelitis after re-
ceiving the first dose, but later pathophysiological tests excluded the possibility of  
multiple sclerosis and identified that the man was heterozygous for very long-chain 
acyl-CoA dehydrogenase deficiency variant.
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# Palacios Ricardo et al.32 Efficacy and safety of  a COVID-19 inactivated vac-
cine in healthcare 2 professionals in Brazil: The PROFISCOV study (submitted) 
https://dx.doi.org/10.2139/ssrn.3822780
^ In two small, previous open, non-randomized phase I/II trials with two vaccine 
formulations in 76 volunteers, no SAEs were reported.21
^^ A phase III placebo-controlled, double-blind trial is ongoing on 25,800 rand-
omized subjects.
Post-marketing surveillance of  neurological complica-
tions of  COVID-19 vaccines 
Several countries have mandatory reporting systems of  AEs following immu-
nization used for post-marketing vaccine monitoring and surveillance. While at 
the population level there are several criteria to establish causality, temporal re-
lationship (the only criterion necessary), strength of  association, dose-response 
relationship, consistency of  evidence, specificity, biological plausibility and coher-
ence, at the individual level it is often impossible to achieve certainty about the 
cause-and-effect link between a reported AE and the vaccine22. After considering 
all other possible explanations, including coincidence, vaccine-quality defect, and 
error, the conclusions of  systematic assessment establish whether the evidence 
is consistent with the vaccine being a cause, or is inconsistent, or indeterminate.
The US
The Centers for Disease Control and Prevention (CDC) and the FDA use 
the Vaccine Adverse Event Reporting System (VAERS) to monitor the safe-
ty of  vaccines licensed for use in the US. According to the last CDC report 
(June 14 2021), results from VAERS are reassuring as to the safety and effec-
tiveness of  COVID-19 vaccines35. Anaphylaxis is rare (2-5 people per million 
vaccinated). After more than 11.7 million doses of  the J&J/Janssen COVID-19 
vaccine injected, 36 confirmed TTS have been reported (more than half  with 
cerebral venous sinus thrombosis), nearly all in adult women under 50 years 
of  age, and one confirmed case of  TTS following mRNA COVID-19 vacci-
nation (Moderna) after more than 310 million doses of  mRNA COVID-19 
vaccines administered in US. The clinical features of  TTS following vaccina-
tion with the Janssen COVID-19 vaccine appear to be similar to those being 
observed following AstraZeneca COVID-19 vaccination in Europe. However, 
based on available data, there is no an increased risk for TTS after mRNA 
COVID-19 vaccination. No other neurological AEs of  special interest have 
been reported. Myocarditis and pericarditis after COVID-19 vaccination are 
27517. Neurological complications of  vaccines for COVID-19
rare. As of  June 14 2021, VAERS has received 511 reports of  myocarditis or 
pericarditis (323 confirmed by the CDC and the FDA) among people aged 
30 years and under who received a COVID-19 vaccine, most cases being re-
ported after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna), 
particularly in male adolescents and young adults; investigation into the rela-
tionship to vaccination is ongoing. From December 14 2020 through June 14 
2021, VAERS received 5,343 reports of  death (0.0017%) among recipients of  
COVID-19 vaccines (more than 310 million doses administered in the US), but 
a review of  available clinical information (death certificates, autopsy, medical 
records) has not established a causal link to COVID-19 vaccines, even if  there 
is a plausible causal relationship between the J&J/Janssen COVID-19 vaccine 
and TTS, which has led to deaths. 
Europe
According to the EMA/EudraVigilance (the system monitoring all suspect-
ed AEs to medicines authorized in the European Economic Area [EEA]), as 
of  April 2021, 169 cases of  cerebral venous thrombosis, often associated to 
thrombocytopenia, were reported in the EEA and the UK after the first dose 
of  Vaxzevria vaccination out 34 million of  doses injected (4.9 cases per mil-
lion)36. As occurred with the J&J/Janssen COVID-19 vaccine in the US, also 
AstraZeneca was paused in several European countries in March, to be restart-
ed (in some countries only in persons over 55-60 years of  age) when the EMA 
concluded that the AE had not increased beyond the expected incidence rate36. 
However, the incidence of  all cases of  TTS seems to be 1/100,000 vaccinated 
with Vaxzevria (lower in Italy, at around 0.45 cases)37. This thrombotic throm-
bocytopenia, which is immune in origin, seems to be due to the activation of  
antibodies against platelet factor PF4 and is clinically similar to the autoimmune 
heparin-induced thrombocytopenia37. Similar findings, with more thrombo-
sis and intracerebral hemorrhage, are described after J&J/Janssen COVID19 
vaccine with a frequency of  presentation comparable to that described for 
Vaxzevria38. The diagnosis of  cerebral venous sinus thrombosis (CVST) is sug-
gested by persistent, worsening headache or blurred vision, focal neurological 
signs, or subacute encephalopathy. Thrombocytopenia is present, brain comput-
ed tomography (CT) or magnetic resonance imaging (MRI) detect CVST, PF4 
antibody testing is positive. Therapeutic recommendations include intravenous 
immunoglobulin, oral anticoagulation or anticoagulants other than heparin.
In the European database there are 122 reported cases of  myocarditis in Pfizer 
(Comirnaty) recipients, 16 in the Moderna COVID-19 vaccine, 38 in Vaxzevria) 
and 0 for the Janssen COVID-19 vaccine39. The reported cases of  pericarditis 
were 126 (Comirnaty), 18 (Moderna COVID-19 vaccine), 47 (Vaxzevria) and 1 
(Janssen COVID-19 vaccine). The exposure in the EEA for each vaccine was 
276 Neurology of  COVID-19
around 160 million doses for Comirnaty, 19 million doses for Moderna, 40 mil-
lion for Vaxzevria, and 2 million for Janssen. Most of  these cases were mild, re-
solving within a few days, mainly affecting males under 30 years of  age, and after 
the second dose of  vaccination39. Six cases of  capillary leak syndrome in people 
who had received Vaxzevria were reported mostly in women within 4 days of  
vaccination (one of  the 3 with history of  capillary leak syndrome died)40. 
Overall, cerebral venous thrombosis is the most relevant neurological SAE 
reported in the post-marketing findings for the two viral vector vaccines, even 
if  its frequency is not considered to be higher than expected in the general 
population, and both the FDA (J&J/Janssen) and the EMA (J&J/Janssen and 
Vaxzevria) concluded that the benefits outweigh the risks. However, especially 
women under 50 years of  age should be aware of  the rare but increased risk of  
this adverse event and that there are other COVID-19 vaccine options available 
for which this risk has not been seen.
There is no evidence at the present time to suggest that any of  the vaccines 
is associated with AEs of  neurological interest in any significant numbers. The 
only consistent neurological AE clearly associated to COVID-19 vaccines in 
clinical trials is headache, mostly occurring in mRNA vaccines, in younger peo-
ple, and after the second dose. However, headache is very common after any 
vaccination (e.g., against Influenza virus and Hepatitis B virus) and probably re-
flects reactogenicity, with or without other symptoms such as fever and myalgia, 
and local reactions. Bell’s palsy in clinical trials was rare, but investigators and 
the EMA considered it to be related to mRNA-vaccines, and even if  it usually 
resolved by itself, surveillance is recommended as part of  post-marketing pro-
cedures. As for influenza, the risk of  Guillain-Barré syndrome after COVID-19 
is probably higher than the risk after vaccination.
Take-home message
 – The most frequent neurological AE associated with COVID-19 vaccines 
is headache, which is, however, common after any vaccination. 
 – Other AEs are rare events and are comparable to those of  the usual 
vaccines.
 – Occasional reports concerning extremely serious neurological AEs, such 
as cerebral venous thrombosis, require careful surveillance and the choice 
of  the safest vaccine for a specific class of  age and gender.
 – Final considerations are limited by the continuing evolution of  this unique 
global vaccination campaign. But it is evident that, despite the fact that ex-
tremely serious but very rare AEs are probably attributable to the vaccines, 
the benefits far outweigh the risks.
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Introduction
Since the first cases identified in December 2019 in Wuhan, China, 
COVID-19 (COronaVIrus Disease 19), caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), has rapidly progressed into a global 
pandemic. As of  17th May 2021, there have been 162,704,139 confirmed cases 
of  COVID-19 worldwide, including 3,374,052 deaths reported to the World 
Health Organization (WHO)1. 
Presentations of  SARS-CoV-2 vary widely and range from asymptomatic to 
mild or moderate respiratory symptoms, to severe COVID-19 pneumonia, acute 
respiratory distress syndrome (ARDS), and multiorgan failure. Furthermore, 
many non-respiratory symptoms and manifestations have been reported, includ-
ing variable long-lasting effects (the post-COVID syndrome or Long COVID)2,3. 
COVID-19 may affect individuals of  all ages, but the pediatric population 
seems to be less susceptible to SARS-CoV-2 infection.  Moreover, reports of  
severe COVID-19 manifestations in children and adolescents are rare. The most 
common presenting manifestations of  COVID-19 in children are non-specific 
symptoms, such as fever and cough; most children experienced asymptomatic, 
mild or moderate illness4,5. Furthermore, compared to adult populations, chil-
dren were more likely to have normal leukocyte counts, while lymphopenia or 
lymphocytosis were infrequent5. Currently, few data regarding COVID-19 in 
the pediatric population are available and there has been no systematic descrip-
tion of  the clinical spectrum of  the disease in this group.
Although the pulmonary manifestations in COVID-19 are the most com-
mon, neurological symptoms are being recognized in an increasing number of  
patients, especially in severe disease. The first retrospective series published by 
Mao et al. reported neurological manifestations on 36% of  214 patients hos-
pitalized for COVID-19, including non-specific symptoms such as headache, 
myalgia, weakness, dizziness and specific neurological signs such as cerebrovas-
cular disease, altered state of  consciousness and encephalopathy6. 
Neurological disease in children has already been reported in association with 
six of  the seven human coronaviruses (HCoV), including SARS-CoV-2, while the 
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seventh, the Middle East respiratory syndrome coronavirus (MERS-CoV), has 
been described with neurological involvement in adults7-11.  Neurological man-
ifestations in children with HCoV are relatively rare, therefore there is little in-
formation about neurodevelopmental sequelae. However, cases of  neurological 
disease associated with SARS-CoV-2 infections in children are rapidly emerging, 
suggesting a possible greater neurological involvement in the pediatric population 
affected by this virus than in other HCoVs. Only a small fraction of  children 
affected by SARS-CoV-2 showed neurological manifestations such as seizures, 
encephalitis, stroke or neuropathies12. In most cases, severe neurological manifes-
tations in the pediatric population appeared to be associated with the presence of  
Multisystem Inflammatory Syndrome (MIS-C). A review conducted by Chen in 
2020 considering 187 children from the six latest reports of  MIS-C cases showed 
that 34% suffered from neurological manifestations13-19. Of  the 187 children stud-
ied, 64 had different neurological symptoms, most of  which were headaches, pos-
itive meningeal signs (meningism), and altered mental status; taken together, most 
manifestations represent a central, rather than a peripheral involvement.
Neurological symptoms are thought to be secondary to a combination of  
different mechanisms, including the direct viral effect on the nervous system, 
the para- and post-infectious inflammation, and the neurological complications 
of  the systemic effects of  COVID-1920. 
Neurological manifestations of  COVID-19 in children
Headache
Headache is the most common neurological symptom related to COVID-19 
and has been described as one of  the presenting symptoms also in children5,21. 
From January 22nd to May 30th 2020, according to case surveillance in the US, 
headache was reported in 15% of  subjects in a cohort of  5,188 children with 
COVID-19 aged 0-9 years, and in 42% of  12,689 children aged 10-19 years22. 
According to another recent review, headache, together with myalgia and fatigue, 
were predominant non-specific neurological manifestations, being reported in 
16.7% of  3,707 patients aged 18 years12. Although headache is frequently report-
ed by patients, this symptom appears to be in most cases non-specific or related to 
an inflammatory systemic process, fever or migraine exacerbation23,24. Headache 
could be secondary to meningeal irritation, encephalitis and encephalopathy only 
in a minority of  patients. In these cases, headache is only one of  a cluster of  
symptoms indicating an infectious and inflammatory process within the central 
nervous system (CNS), like seizures, impairment of  consciousness, nausea and 
vomiting, neck stiffness, irritability, and others. Headache is also frequently re-
ported in children with MIS-C, a recently recognized but uncommon Kawasaki 
syndrome-like hyperinflammatory childhood disorder related to SARS-CoV-2 
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infection (see below). In a series of  58 hospitalized children from 8 different hos-
pitals in England, headache was the most common symptom in MIS-C affecting 
26% of  patients25. Finally, headache could be one of  the symptoms to persist after 
the resolution of  the SARS-CoV-2 infection, also in children26. 
Seizures
Over the past years, betacoronaviruses SARS-CoV and MERS-CoV have 
been associated with neuropathological alterations and neurological symptoms. 
The most common neurological manifestations of  HCoV infections were sei-
zures; in particular, simple febrile seizures.
Data about a possible neuro-invasiveness of  SARS-CoV-2 as well as patho-
physiological mechanisms give rise to the hypothesis that the infection could be 
associated with an increased risk of  seizure recurrence or with the development 
of  new onset and acute symptomatic seizures. 
Up to now, there have been no important evidence in literature that SARS-
CoV-2 infection can cause worsening of  the seizure in people with epilepsy. 
However, it is possible that the infection could favor the onset of  seizures trig-
gered by fever. Moreover, a severe disease course and advanced disease stage 
can result in hypoxic encephalopathy, cerebrovascular events, and the so-called 
“cytokine storm”, which may trigger the development of  acute seizures. 
Different case reports regarding SARS-CoV-2 infections have suggested a neu-
ro-invasive potential, with occurrence of  neurological symptoms such as general-
ized tonic-clonic seizures, loss of  consciousness, headache, and dizziness27. 
Some case series reported the predominance of  HCoV-associated simple fe-
brile seizures in children under one year of  age28. In addition to febrile seizures, 
some cases of  afebrile seizures associated to HCoV were reported. Esper et 
al. reported new-onset seizures in a patient affected by HCoV-HKU1. Central 
nervous system infections were ruled out; lumbar puncture, brain magnetic res-
onance imaging (MRI) were negative29. In 2020, Garcia-Howard et al. presented 
the case of  a 3-month-old girl with a mildly symptomatic SARS-CoV-2 infec-
tion characterized by 2 days of  fever and cough, which developed into two focal 
motor seizures with impaired awareness. Signs of  meningo-encephalitis, oth-
er infections or active epilepsy were ruled out, and electroencephalogram and 
brain MRI were unremarkable. After 3 days, the child presented another afebrile 
motor seizure, and treatment with levetiracetam was started, with a favorable 
response. Whole exome sequencing was performed and revealed a pathogenic 
frameshift mutation in the PRRT2 gene in both the child and the mother, who 
had a history of  late infantile febrile seizures30.
Moreover, 4 cases of  status epilepticus associated with SARS-CoV-2 infec-
tion were described.
Swarz et al. described the case of  a healthy 9-year-old child who test-
ed positive for SARS-CoV-2, and who developed an acute-onset focal status 
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epilepticus. EEG showed a continuous delta slowing throughout the right hem-
isphere without epileptiform features. Head CT and brain MRI were normal. 
After the acute event, the patient recovered without reported deficits31.
Another case of  status epilepticus associated to encephalitis in a patient af-
fected by SARS-CoV-2 was reported by McAbee et al. (see below)32.
Farley et al. described the case of  status epilepticus in an 8-year old patient 
with SARS-CoV-2 infection who remained afebrile throughout the entire course 
of  his illness; the patient had an underlying tic disorder without a previous history 
of  epilepsy33. Saeed et al. reported the case of  a previously healthy 3-year-old boy 
with SARS-CoV-2 infection who presented with repeated fever-induced seizure 
and status epilepticus. Brain CT scan revealed brain edema and 5 days later brain 
MRI showed intracerebral hemorrhage in the right occipital lobe34.
In all the cases reported, the patients had a complete recovery without neu-
rological sequelae; however, long-term neurodevelopmental outcome is not yet 
evaluable due to short follow-up. 
Encephalitis 
Encephalitis is the inflammation of  cerebral parenchyma caused by an in-
fectious agent or aberrant reaction of  the immune system against nervous sys-
tem epitopes. For the diagnosis of  infective encephalitis, the evidence of  brain 
inflammation and the detection of  the pathogen in cerebrospinal fluid (CSF) 
are necessary.  Table 18.1 reports criteria for the diagnosis of  SARS-CoV-2 en-
cephalitis, according to the definition provided in a rapid review by Ellul et al.20.
Up to now, only a few reports of  SARS-CoV-2 infection-associated enceph-
alitis in children are available and virus has not been recovered from CSF in 
these few cases. McAbee et al. described a previously healthy 11-year-old boy 
who was admitted to the hospital with status epilepticus. The CSF analysis was 
compatible with a viral infection and the EEG registered frontal intermittent 
delta activity. The presence of  SARS-CoV-2 was confirmed by nasopharyngeal 
swab; however, the detection of  SARS-CoV-2 in the CSF is not reported. This 
case did not require specific treatment and the boy had a complete recovery in 
a few days32. Another case, described by Freij et al., was a previously healthy 
5-year-old girl, presenting fever and severe headache for 7-10 days, subsequent 
confusion and seizure, and after another few days, lethargia and asymmetric 
pupils. Brain MRI showed an extensive meningoencephalitis involving cerebel-
lum and corpus callosum with leptomeningeal enhancement over the surface 
of  the brainstem and into the auditory canal. CSF was suggestive for viral en-
cephalitis but negative for infection. The child died at day 32 of  illness. The 
brain biopsy evidenced the presence of  SARS-CoV-2 RNA and Mycobacterium 
tuberculosis complex DNA. In this case, the author hypothesized that the patient 
was asymptomatically infected with M. tuberculosis and the host immune system 
could not concurrently respond to the SARS-CoV-2 virus35. The pathophys-
iology of  SARS-CoV-2-associated encephalitis is still not completely under-
stood, but some mechanisms have been hypothesized. The dysregulation of  
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the immune system, cell edema secondary to neuroinflammatory injury, im-
mune-mediated neuronal damage due to “cytokine storm” syndrome, and the 
direct invasion of  SARS-CoV-2 to the CNS could all be mechanisms contribut-
ing to the encephalitis process13. 
Table 18.1: Diagnostic criteria for encephalitis associated  
with SARS-CoV-2 infection (Reproduced from 20 with permission)
SARS-CoV-2 meningitis, encephalitis, myelitis, or CNS vasculitis
Confirmed 
(1) SARS-CoV-2 detected in CSF or brain tissue or evidence of  SARS-CoV-2-specific in-
trathecal antibody
(2) no other explanatory pathogen or cause found 
Probable 
(1) SARS-CoV-2 detected in respiratory or other non-CNS sample, or evidence of  SARS-
CoV-2-specific antibody in serum indicating acute infection
(2) no other explanatory pathogen or cause found 
Possible 
Patient meets suspected case definition of  COVID-19 according to national or WHO guid-
ance on the basis of  clinical symptoms and epidemiological risk factors; in the context of  
known community SARS-CoV-2 transmission, supportive features include the following: 
the new onset of  at least one of  cough, fever, muscle aches, loss of  smell, or loss of  taste; 
lymphopenia or raised D-dimer level; and radiological evidence of  abnormalities consistent 
with infection or inflammation (eg, ground glass changes)
In conclusion, a surprisingly small number of  COVID-19 children devel-
op classic encephalitic symptoms and data demonstrating SARS-CoV-2 in CSF 
are inconsistent. Clearly, more data are needed to clarify the potential role of  
SARS-CoV-2 in determining encephalitis. 
Stroke and cerebrovascular disease
As regards cerebrovascular involvement, different reports of  strokes and 
other types of  cerebrovascular diseases in association with SARS-CoV-2 infec-
tions are available, whereas they were not previously described in association 
with other HCoVs. In Table 18.2 diagnostic criteria for stroke associated to 
SARS-CoV-2 infection are reported.
Regev et al. reported a case of  a 16-year-old boy with unremarkable medical 
history who, after exposure to a COVID-19 patient, developed fever, sore throat, 
fatigue, abdominal pain, headache, and nuchal rigidity. After hospitalization, the 
patient developed septic shock requiring intubation. Diagnostic workup, including 
CSF and brain MRI documented the presence of  a cerebrovascular disease involving 
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microvascular structures, probably due to an inflammatory process. The patient re-
covered within 2 weeks after discharge, although muscular weakness persisted36.
Table 18.2: Diagnostic criteria for stroke associated with SARS-CoV-2 infection 
(Reproduced from 20 with permission)
Stroke associated with SARS-CoV-2 infection 
Probable association 
(1) Either SARS-CoV-2 detected in CSF or other sample, or evidence of  SARS-CoV-2-
specific antibody in serum indicating acute infection;
(2) no other known traditional cardiovascular risk factors
Possible association 
(1) Either SARS-CoV-2 detected in CSF or other sample, or evidence of  SARS-CoV-2-
specific antibody indicating acute infection;
(2) other traditional cardiovascular risk factors 
Schupper et al. described 2 cases of  cerebrovascular events in a 2-month-old 
infant and a 5-year-old child. The first had a medical history of  tracheomalacia 
with tracheostomy and presented with respiratory failure requiring Extra Corporeal 
Membrane Oxygenation (ECMO). Head CT showed bilateral middle and posterior 
cerebral artery infarctions with hemorrhagic transformation, and brain MRI doc-
umented the presence of  evolving hemorrhagic infarctions of  bilateral occipito-
parietal lobes, left temporal and frontal lobes; EEG showed non-convulsive status 
epilepticus. At time of  publication, the patient was still on mechanical ventilation. 
The second case was a healthy 5-year-old child who was admitted to hospital af-
ter several days of  fever, cough, and abdominal pain, with cardiogenic shock and 
cardiopulmonary failure requiring ECMO. Head CT showed right middle cerebral 
artery infarction, cerebral edema, and diffuse contralateral subarachnoid hemor-
rhage. After 5 days on ECMO, the child developed bilateral fixed and dilated pupils 
followed by loss of  brainstem reflexes37. A similar case was reported by Kihira et al. 
describing a healthy 5-year-old child who after 3 days of  fever, cough and abdomi-
nal pain presented deterioration and cardiogenic shock requiring ECMO; the child 
died. A large right anterior and middle cerebral artery infarction with subarachnoid 
hemorrhage in the left hemisphere was documented by head CT38. 
Another case of  stroke in a patient with SARS-CoV-2 infection was reported by 
Tiwari et al. The patient, a 9-year-old child, presented with fever, frontal headache, 
vomiting and progressive right hemisome weakness that evolved to complete hemi-
plegia. CT angiography was performed and documented a multifocal smooth stenosis 
of  both intracranial internal carotid arteries, right middle cerebral artery, and segments 
of  the anterior cerebral arteries. The patient partially recovered and was on rehabil-
itation at time of  publication39. Furthermore, Freij et al. and Essajee et al. reported 
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cerebrovascular involvement in 2 patients with concurrence of  active M. tuberculosis 
infection and SARS-CoV-2 infection. (See above for the case described by Freij et al35).
The case described by Essajee et al. was a healthy two and a half  year old girl who 
presented with an acute onset lethargy, right mydriasis and ptosis, and left-sided 
hemiparesis. She also had progressively enlarging cervical lymphadenopathy and 
decreased appetite. Head CT showed pan-hydrocephalus, basal meningeal enhance-
ment and infarction involving the anterior limb of  the right internal capsule, lenti-
form nucleus, and thalamus. Cerebral sinus venous thrombosis was documented. 
Both the authors postulated that the hyperinflammatory status caused by the 
overlapping infections resulted in endothelial damage, which exacerbated coag-
ulopathy and stroke risk40. Two more case reports described focal cerebral arte-
riopathy involving the left middle cerebral artery with acute infarctions of  the 
left insula and basal ganglia in children who tested positive for SARS-CoV-241,42. 
The most accredited hypothesis up to now, based on the evidence from adult 
patients, is that cerebrovascular events resulted from the SARS-CoV-2 “cy-
tokine storm” causing inflammation-induced focal vasculitis.
Acute disseminated encephalomyelitis 
Acute disseminated encephalomyelitis (ADEM) is a syndrome characterized 
by multifocal demyelination and presenting with focal neurological symptoms, 
typically occurring weeks after an infection. A provisional definition of  ADEM 
related to SARS-CoV-2 infection is shown in Table 18.3.
Table 18.3: Diagnostic criteria for ADEM associated  
with SARS-CoV-2 infection (Reproduced from 20 with permission)
Acute disseminated encephalomyelitis associated with SARS-CoV-2 infection, Guillain-
Barré syndrome, and other acute neuropathies associated with SARS-CoV-2 infection
Probable association 
(1) Neurological disease onset within 6 weeks of  acute infection
(2) either SARS-CoV-2 RNA detected in any sample or antibody evidence of  acute SARS-CoV-2 
infection
(3) no evidence of  other commonly associated causes 
Possible association 
(1) Neurological disease onset within 6 weeks of  acute infection
(2) either SARS-CoV-2 RNA detected in any sample or antibody evidence of  acute SARS-CoV-2 
infection
(3) evidence of  other commonly associated causes 
ADEM has already been reported in association with infections by oth-
er HCoVs. In 2004, Ye et al. described the case of  a 15-year-old boy who 
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developed ADEM during HCoV-OC43 infection43. De Miranda Henriques-
Souza et al. reported the case of  a previously healthy 12-year-old female who 
presented with skin rash lasting 6 days, and headache and fever for 1 day. 
After 5 days she presented acute, progressive, bilateral, symmetrical motor 
weakness with inability to stand, walk, or handle objects. On the second day 
of  hospitalization, she developed respiratory failure requiring intubation, 
quadriparesis, and absence of  deep tendon reflexes. CSF analysis was negative 
for infections but nasopharyngeal swab was positive for SARS-CoV-2; brain 
MRI revealed a neuroradiological pattern consistent with ADEM.
The patient underwent 5-day therapy with methylprednisolone, which was re-
peated due to little improvement of  her weakness after first pulse therapy. More 
than two months after the onset, this patient had still not completely recovered 
and was still unable to sit without support, had persistent spastic quadriparesis 
with global hyperreflexia, and did not have complete sphincter control44.  
Another recently reported case was a 17-month-old girl who presented with 
irritability, neck stiffness, right-sided nasolabial fold flattening, left upper ex-
tremity rigidity, right upper extremity paresis, lower limb hyper-reflexia, and 
truncal ataxia. During hospitalization, the patient developed autonomic insta-
bility and impairment of  consciousness, and was moved to the intensive care 
unit (ICU). Brain MRI revealed multifocal hyperintense T2 fluid-attenuated in-
version recovery signals in subcortical and periventricular white matter. CSF 
analysis was unrevealing but nasopharyngeal SARS-CoV-2 PCR was positive, as 
was serum antibody testing. This patient had a complete recovery in 2 months 
after high-dose methylprednisolone and intravenous immunoglobulin thera-
py followed by rehabilitation45. ADEM has been reported also in a 6-year-old 
patient with Fisher-Evans syndrome (autoimmune hemolytic anemia, immune 
thrombocytopenia and/or autoimmune neutropenia), who was given sirolimus 
and thalidomide. She had positive nasopharyngeal swab for SARS-CoV-2 but 
no symptoms suggestive of  COVID-19.  After 10 days, the patient presented 
a generalized tonic-clonic seizure with spontaneous resolution. A brain MRI 
showed a pattern consistent with ADEM. The patient received methylpredni-
solone and had a favorable clinical course46. These cases suggest that clinicians 
should consider ADEM when evaluating a child with encephalopathy and neu-
rological signs together with a recent diagnosis of  COVID-19. 
Guillain-Barrè syndrome and other neuropathies
Guillain-Barré syndrome (GBS) is an acute polyradiculopathy clinically charac-
terized by rapidly evolving ascending limb weakness, areflexia and sensory symp-
toms20. GBS has already been reported in children with HCoV infections. A case 
of  acute flaccid paralysis was reported by Turgay et al., describing a case of  a 
healthy 3-year-old child who presented with fever and cough, followed, after a few 
days, by dyspnea, inability to chew, swallow or speak, reduced muscular strength 
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and absent deep tendon reflexes. The patient developed respiratory failure that 
required intubation. CSF pressure, glucose, and protein were normal, and blood, 
urine, and CSF cultures were negative. Electromyography and brain and spine 
MRI were normal. A nasopharyngeal swab revealed the presence of  HCoV-229E 
and HCoV-OC43 co-infection. Treatment with intravenous immunoglobulin was 
effective and after 2 weeks the patient could walk with support47.
Another case of  acute flaccid paralysis associated with HCoV-OC43 was re-
ported by Sharma et al. The patient is a 5-year-old healthy male presenting with a 
left Bell palsy, reduced muscular strength, generalized hypotonia, inability to walk 
or to raise his arms above the shoulders, dysmetria, ataxia, dysphagia with drool-
ing. CSF showed albumin-cytologic dissociation with no cells, and elevated CSF 
total protein, elevated albumin index (39.8; reference ≤9) and IgG index (0.89; 
reference ≤0.66), normal myelin basic protein, no oligoclonal bands. MRI showed 
brain and spine enhancement of  the left bulbar nerve complex and anterior and 
posterior cervical nerve roots. Clinical and instrumental examinations suggested 
GBS diagnosis. The patient was treated with non-invasive ventilation for acute 
respiratory failure, and intravenous immunoglobulin, with a partial recovery after 
2 weeks48. Khalifa et al. reported a case of  GBS associated with SARS-CoV-2 in-
fection in a previously healthy 11-year-old male who, a month after upper respira-
tory infection and fever, developed acute symmetrical muscular weakness of  the 
lower extremities and loss of  deep tendon reflexes, tingling, impaired sensitivity. 
CSF and brain and spine MRI showing, respectively, albumin-cytologic dissocia-
tion and enhancement of  the cauda equina nerve roots, in addition to evidence 
of  a demyelinating process at nerve conduction studies, were consistent with a 
diagnosis of  GBS. The patient was treated with intravenous immunoglobulin and 
after 2 weeks showed improved strength and sensory symptoms49. Gaur et al. 
described the case of  a 3-year-old healthy child with asymptomatic SARS-CoV-2 
infection, who developed transverse myelitis presenting with progressive extrem-
ity weakness resulting in flaccid tetraparesis, areflexia, and impaired sensitivity. 
Spine MRI showed swelling of  cervical spinal cord with a lesion involving most 
of  the transverse spinal cord from the lower medulla to the midthoracic level. 
CSF studies revealed pleocytosis and mildly elevated proteins50. 
There is no direct evidence of  a causative relationship between GBS or 
other acute flaccid paralysis and SARS-CoV-2 infection but the reports of  
similar cases and the data available about adult patients can raise the hypoth-
esis that SARS-CoV-2 virus may be a possible trigger.
Other viruses such as Epstein-Barr virus (EBV), cytomegalovirus (CMV) 
and human immunodeficiency virus (HIV) had previously been implicated 
in the pathogenesis of  GBS. The suggested mechanism is an autoimmune 
reaction secondary to molecular mimicry between the surface glycoproteins 
of  the offending pathogen and the structures on peripheral nerves causing 
the antibodies to attack the nerves and cause neurological symptom. It is, 
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therefore, possible to hypothesize that SARS-CoV-2 could be a trigger for a 
neurological process as the basis of  GBS51,52.
Furthermore, before the recent pandemic, few cases of  GBS secondary to 
coronavirus infections had been reported, whereas a recent systematic review 
documented a significant increase in the number of  patients with GBS during 
the COVID-19 pandemic53.
Table 18.4: Diagnostic criteria for MIS-C associated with SARS-CoV-2 infection 
according to Centers for Disease Control and Prevention definition  
(Reproduced from 55  with permission)
CDC case definition
All 4 criteria must be met:
1. Age <21 years 
2. Clinical presentation consistent with MIS-C, including all of  the following: 
• Fever: Documented fever >38.0°C (100.4°F) for ≥24 hours or Report of  
subjective fever lasting ≥24 hours 
• Laboratory evidence of  inflammation, Including, but not limited to, any of  the 
following: 
• Elevated CRP 
• Elevated ESR 
• Elevated fibrinogen 
• Elevated procalcitonin 
• Elevated D-dimer 
• Elevated ferritin 
• Elevated LDH 




• Multisystem involvement (2 or more organ systems involved): 
• Cardiovascular (eg, shock, elevated troponin, elevated BNP, abnormal 
echocardiogram, arrhythmia) 
• Respiratory (eg, pneumonia, ARDS, pulmonary embolism) 
• Renal (eg, AKI, renal failure) 
• Neurologic (eg, seizure, stroke, aseptic meningitis) 
• Hematologic (eg, coagulopathy) 
• Gastrointestinal (eg, abdominal pain, vomiting, diarrhea, elevated liver enzymes, 
ileus, gastrointestinal bleeding) 
• Dermatologic (eg, erythroderma, mucositis, other rash)  
• Severe illness requiring hospitalization
No alternative plausible diagnoses 
Recent or current SARS-CoV-2 infection or exposure (any of  the following):
• Positive SARS-CoV-2 RT-PCR 
• Positive serology 
• Positive antigen test 
• COVID-19 exposure within the 4 weeks prior to the onset of  symptoms
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Neurological manifestations in Multisystem Inflamma-
tory Syndrome in Children 
In contrast to most children with SARS-CoV-2 who develop only mild 
symptoms which usually do not require medical intervention, in April 2020, 
a group of  clinicians from the UK described 8 previously healthy children 
presenting with fever, cardiovascular shock, and hyperinflammation54. In May 
2020, the Centers for Disease Control and Prevention (CDC) defined the cri-
teria for MIS-C and published a health advisory requesting health care prac-
titioners to report suspected MIS-C cases to local, state, and territorial public 
health authorities. Criteria for MIS-C according to the CDC and the WHO 
definition are reported in Tables 18.4 and 18.5.
Table 18.5: Diagnostic criteria for MIS-C associated with SARS-CoV-2 infection 
according to World Health Organization definition56
WHO case definition
All 6 criteria must be met:
Age 0 to 19 years 
Fever for ≥3 days 
Clinical signs of  multisystem involvement (at least 2 of  the following): 
• Rash, bilateral nonpurulent conjunctivitis, or mucocutaneous inflammation signs (oral, hands, or 
feet) 
• Hypotension or shock 
• Cardiac dysfunction, pericarditis, valvulitis, or coronary abnormalities (including 
echocardiographic findings or elevated troponin/BNP)
• Evidence of  coagulopathy (prolonged PT or PTT; elevated D-dimer) 
• Acute gastrointestinal symptoms (diarrhea, vomiting, or abdominal pain) 
Elevated markers of  inflammation (eg, ESR, CRP, or procalcitonin) 
No other obvious microbial cause of  inflammation, including bacterial sepsis and staphylococcal/
streptococcal toxic shock syndromes 
Evidence of  SARS-CoV-2 infection. Any of  the following: 
• Positive SARS-CoV-2 RT-PCR 
• Positive serology 
• Positive antigen test 
• Contact with an individual with COVID-19
MIS-C is a Kawasaki-like syndrome with hyperinflammation presenting 
with acute hypotension and cardiogenic shock. This syndrome is thought to 
be a post-infection inflammatory phenomenon due to an immune reaction 
following asymptomatic or pauci-symptomatic COVID-19. Children can de-
velop toxic shock-like symptoms, hypoxia-ischemia, and damage to the heart, 
kidneys, and other organs57,58. Neurological manifestations are frequently 
described in MIS-C. In New York, 31-47% of  affected children reported 
neurological symptoms like headache, altered mental status, and encephalop-
athy19. A recent systematic review including eight studies reported neurolog-
ical symptoms in 25-50% of  children with MIS-C59. A multicenter study on 
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children with MIS-C in the US described neurological complications such as 
altered mental status, seizures and encephalitis in 5-11% of  cases57. Headache 
was the most common symptom also in patients with MIS-C, affecting 26% 
of  a series of  58 patients25. In another series of  27 children with MIS-C, 
4 patients developed encephalopathy, headache, dysarthria, dysphagia, weak-
ness, ataxia, and peripheral neuropathy. In 2 patients, lumbar puncture was 
performed, and CSF was negative for SARS-CoV-2.  Three patients showed 
diffuse slowing at EEG. For all children, brain MRI showed signal abnormal-
ities of  the splenium of  the corpus callosum60. Another series of  21 children 
from France reported irritability in 57% and “other neurological features” not 
further specified in 29% of  children studied61. In a recent case series of  inpa-
tients aged <21 years with positive test for SARS-CoV-2 in 61 US hospitals, 
MIS-C was diagnosed in 36% of  patients and in 35% of  patients with neuro-
logical involvement. Twenty patients with MIS-C who developed life-threat-
ening COVID-19-related neurological conditions had an MIS-C diagnosis. 
Among these, 8 had severe encephalopathy, 3 had ischemic or hemorrhagic 
stroke, 6 had acute CNS infection or ADEM, 2 had acute fulminant cerebral 
edema, and one developed GBS62. Patients with neurological manifestations 
in MIS-C could frequently present with symptoms such as altered mental 
status or headache, which suggest a CNS infection. However, in the reported 
cases, no demonstration of  SARS-CoV-2 was evident. These data seem to in-
dicate that neurological symptoms of  MIS-C could be secondary to a post-in-
fectious immune response. The over-reaction of  monocytes, macrophages, 
and T cells which produces the “cytokine storm” syndrome may contribute 
to the neuronal damage, further aggravated by the release of  interleukin-6 
(IL-6)13. In conclusion, the impact of  SARS-CoV-2 on the developing CNS, 
the immature immune system, and the neural-immune maturation have to be 
considered, and further data are needed to understand the pathophysiological 
characteristics of  SARS-CoV-2 neurological involvement in MIS-C.
Conclusions and clinical work-up  
Neurological manifestations associated with SARS-CoV-2 infection are rare 
in children but include a wide variety of  central and peripheral insults. Most 
common symptoms are non-specific (headache, weakness), but severe manifes-
tations such as encephalopathy, seizures, demyelinating disorders, and cerebro-
vascular events are possible. Furthermore, the pathophysiological mechanism 
at the basis of  neurological manifestations is still under investigation, due to the 
relatively brief  period of  observation of  the COVID-19 pandemic. 
While for unspecific symptoms most cases require no further investigation, 
when symptoms suggesting a neurological involvement are present, other tests 
are needed. In particular, clinicians should be guided by signs observed during 
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the neurological examinations and the symptoms reported by patients them-
selves. If  altered mental status, meningism and neurological signs are detected, 
the clinical work-up should include brain MRI, EEG, and, if  the suspicion of  
meningoencephalitis is still not clarified, a lumbar puncture with CSF analysis, 
including SARS-CoV-2 PCR is indicated. If  weakness and paresis are present 
and GBS is suspected, an electromyography with electroneurography should 
be considered and a CSF examination showing albuminocytologic dissociation 
could be supportive for the diagnosis. 
In conclusion, the diagnostic process should be personalized, based on the 
diagnostic hypothesis, and addressed by the symptoms reported and signs de-
tected in patients. 
Therapeutic recommendation and prognosis
The therapeutic approach in SARS-CoV-2 should follow guidelines for each 
suspected disorder. 
Patients with headache usually benefit from commonly used analgesic drugs 
like non-steroidal anti-inflammatory drugs (NSAIDs), as no specific treatment 
options for COVID-19-related headache have been reported. When treating 
seizures, clinicians should always consider the interactions between anti-sei-
zure medication and drugs used for COVID-19. Caution is needed in particular 
for carbamazepine, phenytoin, phenobarbital and primidone, enzyme induc-
ers. A list of  drug interactions is reported at the web page: https://www.cov-
id19-druginteractions.org.63
Clinicians should be guided by conventional inclusion and exclusion criteria 
for stroke treatment such as systemic fibrinolysis and mechanical thrombecto-
my, even during SARS-CoV-2 infection. 
In addition, the treatment of  SARS-CoV-2 infection-related GBS and acute 
neuropathies does not differ from the conventional treatment, even if  per-
forming plasma exchange could present some organizational problems when 
patients are infectious64. According to a recent cohort study reporting on neu-
rological symptoms in SARS-CoV-2 infection in hospitalized children and ad-
olescents in the UK, immunomodulation was used as treatment in 86% of  
patients with ADEM, 80% of  patients with GBS, and in the only patient with 
limbic encephalitis. Admission to a pediatric ICU admission was necessary in 
29% of  patients with ADEM, 20% of  patients with GBS, and 56% of  patients 
with severe encephalopathy65.
Prognosis is frequently good but cases with neurological sequelae have been 
reported.  
As regards short-term prognosis, disability was the outcome in 57% of  chil-
dren with ADEM, 40% of  patients with GBS, 11% of  patients with severe 
encephalopathy in the previously cited cohort of  hospitalized children; in these 
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groups, no death was reported65. Data on long-term outcome of  pediatric pa-
tients with COVID-19-related neurological involvement are still lacking and 
should be collected in such a way as to allow effects on cognition and develop-
ment to be evaluated.
Take home message
 – Neurological involvement in SARS-CoV-2 infection in children is rare 
but has to be considered when symptoms suggesting central or peripheral 
nervous system disease are present. 
 – The pathophysiology of  neurological diseases in SARS-CoV-2 infection is 
still not completely clear but probably includes neuroinflammatory injury, 
a dysregulation of  the immune system, immune-mediated neuronal dam-
age due to “cytokine storm” syndrome, and the potential direct invasion 
of  SARS-CoV-2 to the CNS.
 – The most common symptom is headache, but cases of  encephalopa-
thy, seizures, demyelinating disorders, and cerebrovascular events during 
SARS-CoV-2 infection in children have been reported.
 – Neurological symptoms are more frequent and could be serious in pa-
tients with MIS-C. 
 – Treatment should follow guidelines for each disorder.
29518. Neuro-COVID in children
References 
1. https://covid19.who.int
2. Carfì A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care 
Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 
2020;324:603-605.
3. Osuchowski MF, Winkler MS, Skirecki T, et al. COVID-19: Pathophysiology of  
Acute Disease 1. The COVID-19 puzzle: deciphering pathophysiology and phe-
notypes of  a new disease entity. Lancet. 2021;9(6):622-642. 
4. Mantovani A, Rinaldi E, Zusi C, et al. Coronavirus disease 2019 (COVID-19) in 
children and/or adolescents: a meta-analysis. Pediatr Res. 2021;89(4):733-737. 
5. Cui X, Zhao Z, Zhang T, et al. A systematic review and meta-analysis of  children 
with coronavirus disease 2019 (COVID-19). J Med Virol. 2021;93(2):1057-1069.
6. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of  hospitalized patients 
With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020;77(6):683-
690.
7. Desforges M, Favreau DJ, Brison A, et al. Human coronaviruses: respiratory pathogens 
revisited as infectious neuroinvasive, neurotropic, and neuro- virulent agents. In: Neuroviral 
Infections: RNA Viruses and Retroviruses. Boca Raton, FL: CRC Press; 2013.
8. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of  SARS-CoV2 may 
be at least partially responsible for the respiratory failure of  COVID-19 patients. 
J Med Virol. 2020;92:552e555.
9. Barmore J. 5-year-old with rare complication becomes first Michigan child to die 
of  COVID-19. The Detroit News, April 19, 2020. Accessed: April 30, 2020.
10. Molteni M. What does Covid-19 do to your brain? Available from: www.wired.
com, April 15, 2020. Accessed: April 30, 2020.
11. Algahtani H, Subahi A, Shirah B. Neurological complications of  Middle East re-
spiratory syndrome coronavirus: a report of  two cases and review of  the literature. 
Case Rep Neurol Med. 2016;2016.3502683. doi:10.1155/2016/3502683.
12. Panda PK, Sharawat IK, Panda P, et al. Neurological Complications of  SARS-
CoV-2 Infection in Children: A Systematic Review and Meta-Analysis. J Trop Pedi-
atr. 2021;67(3):fmaa070. doi:10.1093/tropej/fmaa070.
13. Chen TH. Neurological involvement associated with COVID-19 infection in chil-
dren. J Neurol Sci. 2020;418:117096.
14. Belhadjer Z, Meot M, Bajolle F, et al. Acute heart failure in multisystem inflamma-
tory syndrome in children (MIS-C) in the context of  global SARS-CoV-2 pandem-
ic. Circulation. 2020;142:429-436.
15. Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory 
syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease 
(Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020;79(8):999-1006. 
16. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory 
syndrome in children during the covid-19 pandemic in Paris, France: prospective 
observational study, BMJ. 2020;369:m2094. 
296 Neurology of  COVID-19
17. Chiotos K, Bassiri H, Behrens EM, et al., Multisystem inflammatory syndrome 
in children during the COVID-19 pandemic: a case series. J Pediatric Infect Dis Soc. 
2020;9(3):393-398. 
18. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of  severe Kawasaki-like dis-
ease at the Italian epicentre of  the SARS-CoV-2 epidemic: an observational cohort 
study. Lancet. 2020;395(10239):1771-1778. 
19. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome 
in children in New York state. N Engl J Med. 2020;383(4):347-358.
20. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of  COVID-19. 
Lancet Neurol. 2020;19:767-783.
21. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of  children and 
young people admitted to hospital with covid-19 in United Kingdom: prospective 
multicentre observational cohort study. BMJ. 2020;370:m3249.
22. Stokes EK, Zambrano LD, Anderson KN, et al.  Coronavirus Disease 2019 Case 
Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly 
Rep. 2020;69(24):759. 
23. Poncet-Megemont L, Paris,ì P, Tronchere  A, et al. High Prevalence of  Headaches 
During Covid-19 Infection: A Retrospective Cohort Study. Headache J Head Face 
Pain. 2020;60(10):2578-2582. 
24. Stafstrom CE and Jantzie LL. COVID-19: Neurological Considerations in Neo-
nates and Children. Children. 2020;7:133.
25. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of  58 Children 
With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated 
With SARS-CoV-2. JAMA. 2020;324(3):259-269.
26. Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID 
in children. Acta Paediatr. 2021;110(7):2208-2211.
27. Lau KK, Yu WC, Chu CM, et al. Possible central nervous system infection by 
SARS coronavirus. Emerg Infect Dis. 2004;10:342-344.
28. Singer TG, Evankovich KD, Fisher K, et al. Coronavirus Infections in the Ner-
vous System of  Children: A Scoping Review Making the Case for Long-Term 
Neurodevelopmental Surveillance. Pediatr Neurol. 2021;117:47-63. 
29. Esper F, Weibel C, Ferguson D, et al. Coronavirus HKU1 infection in the United 
States. Emerg Infect Dis. 2006;12:775-779.
30. García-Howard M, Herranz-Aguirre M, Moreno-Galarraga L, et al. Case report: 
benign infantile seizures temporally associated with COVID-19. Front Pediatr. 
2020;8:507.
31. Swarz JA, Daily S, Niemi E, et al. COVID-19 infection presenting as acute-onset 
focal status epilepticus. Pediatr Neurol. 2020;112:7.
32. McAbee GN, Brosgol Y, Pavlakis S, et al. Encephalitis associated with COVID-19 
infection in an 11-year-old child. Pediatr Neurol. 2020;109:94.
33. Farley M, Zuberi J. COVID-19 precipitating status epilepticus in a pediatric pa-
tient. Am J Case Rep. 2020;21:e925776-1-e925776-4.
29718. Neuro-COVID in children
34. Saeed A, Shorafa E. Status epilepticus as a first presentation of  COVID-19 in-
fection in a 3 years old boy; case report and review the literature. IDCases. 
2020;22:e00942.
35. Freij BJ, Gebara BM, Tariq R, et al. Fatal central nervous system co-infection with 
SARS-CoV-2 and tuberculosis in a healthy child. BMC Pediatr. 2020;20:429.
36. Regev T, Antebi M, Eytan D, et al. Pediatric inflammatory multisystem syndrome 
with central nervous system involvement and hypocomplementemia following 
SARS-COV-2 infection. Pediatr Infect Dis J. 2020;39:E206-eE207.
37. Schupper AJ, Yaeger KA, Morgenstern PF. Neurological manifestations of  pedi-
atric multi-system inflammatory syndrome potentially associated with COVID-19. 
Childs Nerv Syst. 2020;36:1579e1580.
38. Kihira S, Morgenstern PF, Raynes H, et al. Fatal cerebral infarct in a child with 
COVID-19. Pediatr Radiol. 2020;50:1479e1480.
39. Tiwari L, Shekhar S, Bansal A, et al. COVID-19 associated arterial ischaemic 
stroke and multisystem inflammatory syndrome in children: a case report. Lancet 
Child Adolesc Heal. 2021;5:88e90.
40. Essajee F, Solomons R, Goussard P, et al. Child with tuberculous meningitis and 
COVID-19 coinfection complicated by extensive cerebral sinus venous thrombo-
sis. BMJ Case Rep. 2020;13:e238597.
41. Gulko E, Overby P, Ali S, et al. Vessel Wall Enhancement and Focal Cerebral Arte-
riopathy in a Pediatric Patient with Acute Infarct and COVID-19 Infection. AJNR 
Am J Neuroradiol. 2020;41(12):2348-2350. 
42. Mirzaee SMM, Gonçalves FG, Mohammadifard M, et al. Focal Cerebral Arteri-
opathy in a Pediatric Patient with COVID-19. Radiology. 2020;297(2):E274-E275. 
43. Yeh EA, Collins A, Cohen M, et al. Detection of  coronavirus in the central 
nervous system of  a child with acute disseminated encephalomyelitis. Pediatrics. 
2004;113:e73ee76.
44. de Miranda Henriques-Souza AM, de Melo ACMG, de Aguiar Coelho Silva Madei-
ro B, et al. Acute disseminated encephalomyelitis in a COVID-19 pediatric patient. 
Neuroradiology. 2020;63:141e145.
45. McLendon LA, Rao CK, Da Hora CC, et al. Post-COVID-19 Acute Disseminated 
Encephalomyelitis in a 17-Month-Old. Pediatrics. 2021;147(6):e2020049678. 
46. Manzo ML, Galati C, Gallo C, et al. ADEM post-Sars-CoV-2 infection in a pediat-
ric patient with Fisher-Evans syndrome. Neurol Sci. 2021;12:1-4. 
47. Turgay C, Emine T, Ozlem K, et al. A rare cause of  acute flaccid paralysis: human 
coronaviruses. J Pediatr Neurosci. 2015;10:280.
48. Sharma K, Tengsupakul S, Sanchez O, et al. Guillain-Barre syndrome with unilat-
eral peripheral facial and bulbar palsy in a child: a case report. SAGE Open Med 
Case Rep. 2019;7:2050313X19838750.
49. Khalifa M, Zakaria F, Ragab Y, et al. Guillain-Barre syndrome associated with se-
vere acute respiratory syndrome coronavirus 2 detection and coronavirus disease 
2019 in a child. J Pediatr Infect Dis Soc. 2020;9:510e513.
298 Neurology of  COVID-19
50. Gaur P, Dixon L, Jones B, et al. COVID-19-associated cytotoxic lesions of  the 
corpus callosum. AJNR Am J Neuroradiol. 2020;41:1905e1907.
51. Pritchard J. Guillain-Barré syndrome. Clin Med (Lond). 2010;10(4):399-401. 
52. Yuki N, Hartung H-P. Guillain-Barré Syndrome. N Engl J Med. 2012;366(24):2294-
2304.
53. Gittermann LMT, Feris SNV, von Oetinger Giacoman A. Relation Between 
COVID-19 and Guillain-Barré Syndrome in Adults: A Systematic Review. Neu-
rologıá (English Edition) 2020;35(9):646-654. 
54. Riphagen S, Gomez X, Gonzalez-Martinez C. Hyperinflammatory shock in chil-
dren during COVID-19 pandemic. Lancet. 2020;395:1607-1608. 
55. Centers for Disease Control and Prevention Health Alert Network (HAN). Mul-
tisystem Inflammatory Syndrome in Children (MIS-C) Associated with Corona-
virus Disease 2019 (COVID-19). 2020. Available at: https://emergency.cdc.gov/
han/2020/han00432.asp
56. World Health Organization. Multisystem inflammatory syndrome in children 
and adolescents with COVID-19: Scientific Brief. 2020. Available at: https://
www.who.int/publications-detail/multisystem-inflammatory-syndrome-in-chil-
dren-and-adolescents-with-covid-19 
57. 57 Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syn-
drome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334-346. 
58. Nakra NA, Blumberg DA, Herrera-Guerra A, et al. Multi-System Inflammatory 
Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of  Clin-
ical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children. 
2020;7:69. 
59. Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem Inflammatory Syn-
drome in Children (MIS-C) Associated with SARS-CoV-2: A Systematic Review. J 
Pediatr. 2020;5;226:45-54.e1.
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